Agenda: 2018 National Rx Drug Abuse & Heroin Summit

Terrace Foyer

Monday, April 2, 2018

2018-04-02

Conference Registration

9:00 AM - 6:00 PM

9:00 AM

6:00 PM

Conference registration

Centennial Ballroom

Monday, April 2, 2018

2018-04-02

Stimulants and Opioids: An Emerging Drug Threat in the Midst of the Opioid Epidemic

1:00 PM - 2:00 PM

1:00 PM

2:00 PM

Moderator: Doug Edwards, MBA, Director, Institute for the Advancement of Behavioral Healthcare CE Certified By: AMA,ADA,ACPE,ANCC,NAADAC,APA,NASW,NBCC Based on analysis of data from law enforcement, prescription drug monitoring programs (PDMPs), monitoring of non-medical and illicit drug uses, and public health sources, a leading U.S. expert will demonstrate that supplies of Rx stimulants and illicit stimulants are increasing at faster rate than opioids. Topics will include: 1. Drug Supply. From 2010 through 2016 there were increasing seizures by High Intensity Drug Trafficking Area task forces of illicit opioids and illicit stimulants, but the quantities of seized stimulants exceeded seized heroin. Data from 11 PDMPs show that prescribing of opioids and other, non-stimulant drugs finally peaked between 2011 and 2015 and have declined since. However, prescriptions of stimulants have steadily increased each year. 2. Drug Demand. Demand for drugs of abuse are changing, according to the Substance Abuse and Mental Health Services Administration National Survey on Drug Use and Health. The number of people abusing Rx opioids decreased somewhat during the period 2010 through 2015, while those abusing heroin increased. At the same time, the number of people abusing Rx stimulants and illicit stimulants increased more rapidly. 3. Deaths. Cocaine-related deaths involving opioids more than doubled between 2010 and 2015, while cocaine deaths not involving opioids were stable. This links the opioid epidemic and the increasing supply of and demand for stimulants. With the goal of launching responses in time to prevent a repetition of the opioid epidemic, this workshop will serve as an early warning that changes are needed in prevention, treatment, emergency responses to drug overdoses, clinical prescribing behavior, pharmacy practice, public policy and statutes, law enforcement, PDMPs, third-party payer policies, education and advocacy. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Discuss evidence that the supplies of Rx stimulants and illicit stimulants are increasing and are increasing at a faster rate than opioids. - Identify methods available to monitor what is going on with multiple types of drug abuse, including non-medical use of stimulants and use of illicit stimulants, even while primary attention is focused on just one type, i.e. opioids. - Explain how available tools can be used to establish an early warning system to alert all professions and concerned national, state and local groups to emerging threats so prevention and other responses can be launched in time to prevent a repetition of the opioid epidemic.

John Eadie, MPA

Coordinator, Public Health and Prescription Drug Monitoring Program Project

National Emerging Threat Initiative, A National HIDTA Initiative

John Eadie is the Public Health & Prescription Drug Monitoring Program project coordinator for the National Emerging Threat Initiative of the National HIDTA Assistance Center. He previously served as director of the Prescription Drug Monitoring Program (PDMP) Center of Excellence at Brandeis University (2010-2015). For 44 years, Eadie has served in management, executive and consulting capacities in the field of public health. As director of the Division of Public Health Protection in the New York State Department of Health (1985-1995), he directed the state’s pharmaceutical diversion program, including the PDMP. He co-founded both the Alliance of States with Prescription Monitoring Programs and the National Association of State Controlled Substances Authorities, served as president for both organizations and held other posts. Since leaving New York state service in 2001, Eadie has served as a consultant on PDMPs, including serving as the administrative reviewer for the Massachusetts PDMP.

Hanover FG

Monday, April 2, 2018

2018-04-02

A Public, Private Payer Partnership to Prevent Opioid Abuse and Transform Acute Care Pain Management

2:15 PM - 4:15 PM

2:15 PM

4:15 PM

Moderator: Greg Hamlin, Director of Claims, Kentucky Employers’ Mutual Insurance CE Certified By: AMA,AAFP,ACPE,ADA,ANCC This workshop will explain the unique platform and approach of the Michigan Opioid Prescribing Engagement Network (OPEN) from the perspective of physicians, private payers and Medicaid. The presenters will describe the program’s approach to understanding the impact of acute care prescribing in the opioid epidemic, as well as successes in changing practices and the challenges ahead. Three University of Michigan (UM) physicians launched Michigan OPEN with support from the Michigan Department of Health and Human Services, Blue Cross Blue Shield of Michigan Value Partnerships, and the Institute for Healthcare Policy and Innovation at UM. Their goal was to develop a preventive approach to the state’s opioid epidemic through a focus on reducing acute care prescribing (surgery, dentistry, emergency medicine and trauma). Addressing opioid prescribing during the acute care period among those patients not using opioids has the greatest potential to reduce the number of new chronic opioid users and minimize unintended distribution of Rx opioids into communities. Through a partnership with statewide, physician-led networks, Michigan OPEN is collecting data and identifying and disseminating best practices in acute care opioid prescribing to providers around the state. The Michigan OPEN initiative also has partnered with communities, hospitals and law enforcement around the state to hold opioid recovery drives in locations throughout the state. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe Michigan OPEN, a partnership that is targeting opioid naïve surgical and dental patients prior to opioid dependence. - Explain the Michigan OPEN model for creating change and disseminating best practices in opioid prescribing and disposal for application in other communities across the country. - Describe the effect of specific Michigan OPEN initiatives on clinical care and healthcare policy for opioid prescribing in the acute care setting, and understand their role in mitigating against the opioid epidemic in the United States.

Chad Brummett

MD, Associate Professor of Anesthesiology and Director of the Division of Pain Research

University of Michigan

Dr. Chad Brummett co-directs the Michigan Opioid Prescribing Engagement Network, or Michigan-OPEN, an initiative that seeks to transform pain management and curb opioid abuse in the state of Michigan. Based at the University of Michigan Medical School and Institute for Healthcare Policy and Innovation, it is a five-year initiative funded by the Michigan Department of Health and Human Services. Brummett is an Associate Professor of Anesthesiology at the University of Michigan, the director of the Division of Pain Research and, more broadly, is the Director of Clinical Research in the Department of Anesthesiology. He studies perioperative opioid use and opioid-related outcomes, informing his work with Michigan-OPEN. In addition, his research interests include predictors of acute and chronic post-surgical pain and failure to derive benefit for interventions and surgeries done primarily for pain. Brummett earned his undergraduate and medical degrees at Indiana University followed by anesthesiology residency at the University of Michigan and a pain medicine fellowship at Johns Hopkins University.

Chris Priest

MPP, Vice President, Medicaid Solutions

Centene Corporation

Chris Priest is Vice President of Medicaid Solutions for Centene Corporation. Previously, he was Deputy Director for Medical Services with the Michigan Department of Health and Human Services (MDHHS). In that role, he also served as Michigan’s Medicaid director, overseeing several healthcare programs, including MIChild and the Healthy Michigan Plan. Before joining MDHHS, Priest worked as Gov. Rick Snyder’s Deputy Director of Strategy, where he advised the governor on various issues, including healthcare and insurance. Previously, Priest served as Director of the Bureau of Medicaid Policy and Health System Innovation in the former Michigan Department of Community Health, which was responsible for many aspects of the Medicaid program and several health reform issues, and as the Project Manager involved with the health insurance exchange in the Michigan Department of Licensing and Regulatory Affairs. Prior to these appointments, Priest served in the State of Michigan’s Washington, D.C., office under former Gov. Jennifer M. Granholm, served governors from the State of Indiana, worked with private sector clients on health policy, and worked in the Indiana Family and Social Services Administration. Priest holds a master’s degree in public policy from George Mason University and bachelor's degree in public affairs from Indiana University.

Jennifer Waljee

MD, MS, Associate Professor of Plastic and Reconstructive Surgery

University of Michigan

Dr. Jennifer Waljee co-directs the Michigan Opioid Prescribing Engagement Network, or Michigan-OPEN, an initiative that seeks to transform pain management and curb opioid abuse in Michigan. Based at the University of Michigan Medical School and Institute for Healthcare Policy and Innovation, it is a five-year initiative funded by the Michigan Department of Health and Human Services. Waljee is an Associate Professor of Surgery in the Section of Plastic Surgery at the University of Michigan. Her research focuses on improving patient-centered outcomes following surgery across a variety of patient populations. Frequent topics include the efficacy of patient-reported outcomes as quality metrics in surgical collaborative quality improvement programs and variation in postoperative patient outcomes. Waljee earned her undergraduate and master’s degrees in public health and science at the University of Michigan and her medical degree at Emory University. She completed her general surgery residency training in 2009, and she spent an additional two years completing training in plastic and reconstructive surgery at the University of Michigan. In 2012, she completed a fellowship in hand surgery also at the University of Michigan.

Tom Leyden

MBA, Director II, Value Partnerships Program

Blue Cross Blue Shield of Michigan

Tom Leyden has over 20 years of healthcare practice transformation experience in a variety of areas, including clinical program development, value-based reimbursement, performance improvement consulting, market research, planning and business development, and marketing and communications. As Director of the Value Partnerships Program for Blue Cross Blue Shield of Michigan (BCBSM), he oversees a portfolio of 50-plus statewide comprehensive partnerships with physicians, physician groups and hospitals. Prior to joining Blue Cross, Leyden served as Vice President at MPRO (Michigan’s federally designated quality improvement organization), where he oversaw performance on its statewide Medicare contract, headed many of its programs and product lines, and oversaw its marketing, community outreach, and business development functions. Prior to MPRO, Leyden worked in a variety of capacities in healthcare in Chicago and Detroit. He has presented across America and internationally on a variety of healthcare topics for forums. Leyden received his bachelor's degree from Michigan State University and his master's degree in business administration from Wayne State University.

Dunwoody

Monday, April 2, 2018

2018-04-02

Drug Checking: A Novel Evidence-Based Strategy for Preventing Overdose

2:15 PM - 4:15 PM

2:15 PM

4:15 PM

Moderator: Grant T. Baldwin, PhD, MPH, Director, Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,APA,MCHES,GA Bar,GA POST,NAADAC,NASW,NBCC Unprecedented increases in opioid overdose deaths throughout the United States are largely driven by illicitly-made fentanyl (IMF) and other potent, rapid-acting synthetic opioids. Federal, state and community-based organizations are searching for pre-overdose interventions to avert poisonings involving IMF, but an effective technique has yet to be discovered. In this workshop, two teams of researchers will consider several evidence-based interventions. Field-based fentanyl detection is being employed in several community-based settings, but there are little data on the validity of field-based testing modalities as well as an understanding of how testing could be scaled up. The first presentation team will reveal novel findings from a multi-site study (Baltimore, Boston and Providence) that tested the validity, practical implementation and likely uptake of three field-based methods of fentanyl checking: off-label use of fentanyl test strips (FTS), Fourier-transform infrared spectroscopy and Raman spectroscopy. They will share reflections from stakeholders on their interest in drug-checking services for improving consumer safety. The second presentation team will reveal findings from the first scientific study in the United States to systematically measure behavioral outcomes associated with the use of FTS by people who inject drugs (PWID), in addition to describing how FTS can be used as a harm reduction tool. Topics will include self-efficacy, consumption patterns, injecting mechanics, product identification, product discernment by physical effects and overdose prevention. Findings on how PWID seek and exchange information on the Internet about IMF also will be presented. The implications of using FTS in public health practice as a novel approach to overdose prevention will be deliberated in the context of program integration and population-based approaches for delivering care to PWID. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the role of heroin, fentanyl and synthetic opioids in the U.S. overdose epidemic. - Summarize cutting-edge research findings on drug checking for public health applications. - Recognize the need to generate discussion to create novel solutions to address the national opioid overdose crisis. - Describe changes in street opioid markets and the risks posed by market unpredictability. - Explain findings on behavioral outcomes associated with the use of fentanyl test strips and implications for overdose prevention. - Describe strategies to incorporate fentanyl test strips into existing overdose education and naloxone programs and other harm reduction efforts (e.g., syringe service programs).

Brandon Marshall

PhD, Associate Professor

Brown University

Dr. Brandon Marshall is an Associate Professor of Epidemiology at the Brown University School of Public Health. Broadly, his research focuses on HIV/AIDS, substance use epidemiology, and the social, environmental, and structural determinants of health of urban populations. He is the inaugural recipient of the National Institute on Drug Abuse "Avenir" award, which supports a research program using agent-based modeling to investigate HIV transmssion dynamics among people who use drugs and involved in a number of other NIH and CIHR-funded cohort studies of people who use drugs, street-involved youth and men who have sex with men. Marshall is also the Associate Public Health & Epidemiology Editor of the International Journal of Drug Policy.

Susan Sherman

PhD, MPH, Professor

Johns Hopkins University

Dr. Susan Sherman is a behavioral scientist who conducts research on the structural determinants of drug use, HIV and overdose risk. She is Professor of Health, Behavior and Society at Johns Hopkins Bloomberg School of Public Health, Co-Lead of the Addiction and Overdose workgroup of the Bloomberg American Health Initiative, and Co-Director of the Johns Hopkins Center for AIDS Research Baltimore HIV Collaboratory. She leads several studies funded by the National Institute of Health (NIH) in Baltimore and previously led several NIH-funded intervention studies in India, Pakistan and Thailand. Sherman serves on several Baltimore and Maryland commissions on syringe exchange programs and overdose prevention.

Jon Zibbell

PhD, Senior Public Health Scientist

RTI International

Jon E. Zibbell, PhD, is a Senior Public Health Scientist in the Behavioral and Urban Health Program at the RTI International, where he conducts behavioral epidemiological research on risk factors and health outcomes associated with the opioid epidemic and injection drug use. He is a medical anthropologist with two decades of field experience in the areas of injection drug use, opioid use disorder, drug overdose and injection-related infectious disease. Before coming to RTI, Zibbell worked as a Centers for Disease Control and Prevention Health Scientist in the Divisions of Viral Hepatitis and Unintentional Injury Prevention, conducting epidemiological and surveillance research on viral hepatitis and drug overdose while assisting states during outbreak investigations to respond to injuries and infections caused by drug use behaviors. In addition to research, he has conducted rapid ethnographic needs assessments for community-based syringe service and overdose prevention programs and continues to assist states and community organizations to develop evidence-based approaches to reduce morbidity and mortality associated with the opioid epidemic. His work has appeared in both academic and professional journals and he holds a joint, adjunct appointment in the Center for the Study of Human Health and the Department of Anthropology at Emory University.

Nick Peiper

PhD, MPH, Behavioral Epidemiologist

RTI International

Nicholas C. Peiper, PhD, MPH, is a Behavioral Scientist in RTI International's Behavioral and Urban Health Program, with 10 years of experience in substance use, mental health and clinical epidemiology. His current work with the Centers for Disease Control and Prevention (CDC) evaluates prescription drug monitoring programs, opioid overdose policies and medication assisted treatment programs. Through the Substance Abuse and Mental Health Services Administration (SAMHSA), he also investigates psychiatric comorbidity and service utilization among adults with serious mental illness. In a similar line of research, Peiper concentrates on the application of emergent computational methods to understand the epidemiology of cannabis use, including the intersection with opioids. As part of this work, he currently conducts Internet-mediated surveys to better understand quality of life outcomes among medical cannabis patients who substitute cannabis for Rx opioids and heroin. In addition, he holds an adjunct appointment in the Department of Epidemiology and Population Health at the University of Louisville, where he teaches online doctoral courses in behavioral epidemiology and applied research methodologies; directs practicum and internship programs; and mentors graduate students in public health and the social sciences.

Louise Vincent

MPH, Executive Director

Urban Survivors' Union

Louise Vincent, MPH, is a harm reductionist who has worked in the substance use and harm reduction fields for the last 10 years. She intimately understands the consequences of ineffective traditional drug treatment programs. She was treated in 2005 for HCV and has worked in a number of roles and capacities, including Program Director, Outreach specialist, Naloxone Consultant, Health Education Facilitator and Counselor. She assisted in the development and implementation of North Carolina's first harm reduction, hepatitis education, testing and linkage-to-care program and is a North Carolina certified HIV and Hepatitis C Counselor. She has been at the forefront of the harm reduction response to illicit drug use in North Carolina and is committed to preventing blood-borne virus transmission and drug-related deaths and improving the health of people who use drugs.

Traci Green

PhD, MSc, Deputy Director, Boston Medical Center Injury Prevention Center

Associate Professor of Emergency Medicine and Epidemiology, Warren Alpert School of Medicine, Brown University

Dr. Traci Green is an epidemiologist whose research focuses on drug abuse, addiction and injury. She earned a master's degree in epidemiology and biostatistics from McGill University and a doctorate in epidemiology from Yale University. She helped design the ASI-MV®, a real-time illicit and Rx drug abuse surveillance system developed by Inflexxion, Inc. Currently, she is Deputy Director of the Boston Medical Center Injury Prevention Center and Associate Professor of Emergency Medicine and Epidemiology at the Warren Alpert School of Medicine at Brown University. Green helped co-found www.prescribetoprevent.org, chairs the Drug Overdose Prevention and Rescue Coalition for the Rhode Island Department of Health, and serves as an advisor to the Rhode Island Governor on addiction and overdose. Her research is supported by the Centers for Disease Control and Prevention, the National Institute on Drug Abuse, the Agency for Healthcare Research and Quality, the Patient Centered Outcomes Research Institute, and the Department of Justice.

Hanover AB

Monday, April 2, 2018

2018-04-02

Drug-Endangered Children: How Law Enforcement, Child Protection Agencies and Schools Can Help

2:15 PM - 4:15 PM

2:15 PM

4:15 PM

Moderator: Jackie L. Steele, Jr., JD, Commonwealth Attorney, Kentucky 27th Judicial Circuit, and Member, Operation UNITE Board of Directors CE Certified By: AAFP,ANCC,APA,GA Bar,GA POST,NASW Drug-endangered children are the silent victims of the opioid crisis. This workshop will equip the professionals who interact with children on the scenes of drug-related crimes and who support them during the aftermath. A national expert in drug-endangered children will set the stage with an overview of how the Rx drug abuse and heroin epidemic is impacting children and families. Based on her experience working with communities across the country, she will recommend collaborative, multidisciplinary response strategies for law enforcement. Incorporating a multifaceted team response can address suspected abuse or neglect that has occurred, as well as address potential future abuse. In fact, the response to the child can be as important as the enforcement action itself. From Plymouth County, Massachusetts, representatives of the District Attorney’s Office will demonstrate a trauma-informed approach for law enforcement and schools to help drug-endangered children. Previously, the office collaborated with the Trauma and Policy Learning Initiative at Harvard Law School to develop a trauma-informed approach for law enforcement and school systems to handle children exposed to violence. The office is now using the same approach to serve children exposed to family drug use, overdoses and drug-seeking behavior. Presenters will explore the Adverse Childhood Experiences (ACES) Study as it relates to exposure to drugs. It is necessary for police officers to communicate effectively with school personnel, and schools need to have trauma-informed staff and policies to provide the appropriate response. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the national concern created when children are exposed to illicit drug use, manufacturing, distribution and cultivation and the non-medical use of Rx drugs. - Explain the importance of collaboration and a multidisciplinary response to children identified in drug environments. - Explain the basic premises of the Adverse Childhood Experiences Study. - Design their own process to identify drug-endangered children. - Plan the communication process between police and schools to help drug-endangered children.

Deborah Augustine

National Program Manager

U.S. Drug Enforcement Administration

Deborah Augustine is the National Program Manager, Victim Witness Assistance Program, U.S. Drug Enforcement Administration (DEA). She provides training, case support and guidance to DEA global domestic and international offices; coordinates victim issues with federal, state and local law enforcement; collaborates with crime victim organizations and gives presentations focused on the risks to children exposed to drug environments. She represents DEA on the Federal Task Force on Missing and Exploited Children, and the International Association of Chiefs of Police (IACP), Victim Services Committee, and she worked on the Safeguarding Children of Arrested Parents Advisory Working Group, an initiative of IACP, the White House Domestic Policy Council and Bureau of Justice Assistance.

Edward Jacoubs, MSW

Director of Grants and Sponsored Projects

Plymouth County District Attorney's Office

Edward Jacoubs is director of grants and special projects for the Plymouth County District Attorney’s Office. He brings to the board experience designing and implementing programs for off-track youth, and he has authored and received numerous grants focused on supporting Map Academy’s target population. Jacoubs will help facilitate change for high-risk youth through his deep connections to local organizations that can provide resources and supports to Map Academy students and families. Additionally, he is the chair of the Map Academy Board of Trustees.

Timothy Cruz

District Attorney

Plymouth County District Attorney's Office

Timothy J. Cruz has served as the Plymouth County District Attorney since November, 2001. During his tenure he has aggressively prosecuted crime in Plymouth County. Most recently, Cruz has focused his office’s efforts on battling the opioid crisis at all levels. His office also works collaboratively with local law enforcement, social service agencies, healthcare professionals, the faith community and educators on crime prevention initiatives throughout the county. Cruz has served as a member of the Massachusetts Office for Victim Assistance; Department of Corrections Advisory Council; Governor’s Council on Capital Punishment; and the Forensic Technology Subcommittee of the Governor’s Commission on Criminal Justice Innovation. He has also served two terms as the President of the Massachusetts District Attorneys Association. Previously, he worked in private practice, and as an Assistant District Attorney in Plymouth County. He is a graduate of Boston College and Suffolk University Law School and is admitted to both the Massachusetts and the United States District Court bars, as well as the United States Court of Appeals and the Supreme Court of the United States.

Regency V

Monday, April 2, 2018

2018-04-02

Real Costs of Rx Pain Meds, Opioids and Substance Use in the Workplace: What Employers and Communities Can Do

2:15 PM - 4:15 PM

2:15 PM

4:15 PM

Moderator: Gary Enos, MS, Editor, Addiction Professional CE Certified By: AMA,AAFP,ANCC More than 75% of adults with a substance use disorder and 60% with an opioid use disorder work. Yet few employers, government policymakers, treatment programs or anti-drug coalitions are doing much for them. In this session, presenters will demonstrate the Real Cost of Substance Use to Employers calculator — a new, free online tool that can help businesses and public employers understand how untreated substance use impacts their bottom lines. The tool shows costs avoided if workers get treatment and recover, as well as evidence-based policies and practices that could be implemented to avoid lost productivity and absenteeism, excessive turn-over, healthcare expenses, disability and workers’ compensation costs associated with untreated substance use. The Real Costs tool provides authoritative estimates of substance use costs and costs avoided based on large government epidemiologic surveys and research. Presenters will share examples of approaches that employers are taking to address the opioid epidemic among workers and their families. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Explain how untreated Rx pain medication misuse and substance use disorders impact employers’ bottom lines and apply it to employers in their community. - Describe the costs avoided when workers with a substance use disorder get treatment and recover from their addiction. - Identify promising practices that employers and others are taking to address opioid and substance use among the workforce. - Use the Real Cost of Substance Use to Employers calculator in their own workforce or with employers in their communities.

Eric Goplerud

PhD, MA, Vice President and Senior Fellow Public Health

NORC at the University of Chicago

Eric Goplerud, PhD, Vice President and Senior Fellow at NORC at the University of Chicago, has more than 25 years in senior federal and non-governmental leadership directing numerous studies and task forces on behavioral health. At the Substance Abuse and Mental Health Services Administration (SAMHSA), he led the agency’s policy and planning office, directed the agency’s managed care, quality and finance office, and served as first director of SAMHSA’s science to service program to speed transmission of evidence-based practices into everyday clinical practice. In the 15 years since leaving federal service, he has directed major government and foundation-supported programs to integrate behavioral health into acute and primary care settings, including hospitals, Federally Qualified Health Centers, and workplace programs. Goplerud led the successful effort to secure new substance use screening and brief intervention CPT codes from AMA and new SBI HCPCS II codes from Centers for Medicare and Medicaid Services, and was instrumental in getting Medicare to cover primary care SA screening and brief intervention as a preventive service.

Shannon Hartley

Chief Marketing Officer

Shatterproof

Shannon Hartley is the Chief Marketing Officer for Shatterproof. She leads the teams responsible for delivering the programs focused on ending the stigma associated with addiction and the educational resources to support families seeking information on prevention, evidence-based treatment and recovery support. Her team leads the program, fundraising and volunteerism activities for Shatterproof. She has more than 20 years of marketing and strategy experience. Hartley is a founding member of FORCE (Female Opioid Research & Clinical Experts). She began her career at Procter & Gamble in customer insights and sales roles. She led neuroscience/mental health customer insight and global strategy at Bristol-Myers Squibb. Most recently, Hartley was the Managing Director of Razorfish Health, a customer engagement agency that is part of Publicis Healthcare, the largest healthcare marketing and communications network in the world. She is a graduate of Miami University and lives in Princeton, New Jersey.

Jenny Burke

JD, Senior Director, Advocacy

National Safety Council

Jenny Burke advances the National Safety Council (NSC) mission of eliminating preventable deaths in our lifetime by leading various NSC initiatives. These programs raise awareness and educate audiences to keep each other safe, involving safety on the road and in homes and communities, fatigue and Rx drug overdose. Burke previously served as a Senior Legal Analyst at the law firm of Wolters Kluwer, specializing in Medicare, Medicaid, food and drug law and healthcare compliance. She is a licensed attorney in Illinois since 2002 and clerked for two years in the Illinois Appellate Court, First Division. A graduate of DePaul University College of Law, Burke also holds a master's degree in health law and policy from DePaul’s Public Services graduate program and a certificate in health law. She received her bachelor's degree in English literature from the University of Illinois, Urbana-Champaign. Burke has served on her local school board and the nature center board.

Regency VI

Monday, April 2, 2018

2018-04-02

Addressing Gaps in the Addiction Specialty Workforce

2:15 PM - 4:15 PM

2:15 PM

4:15 PM

Moderator: Kelly Clark, MD, MBA, DFAPA, DFASAM, Chief Medical Officer, Clean Slate Centers, President, American Society of Addiction Medicine, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ANCC,NAADAC,NBCC The growing opioid epidemic in the United States has exposed a significant shortfall among healthcare professionals with regard to limited confidence and expertise in identifying and treating patients with substance use disorders. Few healthcare professionals have received adequate training in the areas of identification of risky substance use, treatment of substance use disorders or harm reduction techniques. In many states, the addiction treatment system has been kept separate from medical care, with limited coordination or integration of physical health services and addiction treatment services. Many health professionals working in addiction treatment systems have not received adequate training on current evidence-based practices, including but not limited to the evidence base of medication assisted treatment for opioid use disorder. To address this gap, many communities, including city and state governments, have developed innovative programs and strategies to educate, support and incentivize clinicians to offer addiction treatment services consistent with current medical knowledge. In this presentation, members of the American Society of Addiction Medicine will discuss a range of strategies currently being implemented on municipal and state levels to improve training of the addiction medicine workforce and increase the number of professionals working in the field of addiction. Challenges in building systems to provide evidence-based care at the population level will be identified and examples of innovative solutions presented. Participants should leave with knowledge of how to identify their local resources (e.g., financial, workforce, stakeholder groups) and work with their local resources to increase and leverage the specialty workforce to help build a more clinically effective and cost-effective approach to the epidemic. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Explain the gap between the current needs of addiction treatment and the current state of addiction treatment resources. - Identify the challenges to increasing access to appropriate treatment. - Describe strategies to maximize available resources.

Hillary Kunins

MD, MPH, MS, Assistant Commissioner

New York City Department of Health and Mental Hygiene

Dr. Hillary Kunins is an Assistant Commissioner at the New York City Department of Health and Mental Hygiene, where she leads the Department's Bureau of Alcohol and Drug Use - Prevention, Care and Treatment. She previously served as the Residency Director for the programs in Primary Care and Social Internal Medicine at Montefiore Medical Center. Kunins received her bachelor's degree in religion from Swarthmore College and her medical degree and master's degree in public health from Columbia University. She completed her residency training in the primary care internal medicine program at Montefiore Medical Center, followed by her Chief Residency. Following residency training, Kunins joined the Division of Substance Abuse at Einstein as the Medical Director of a substance abuse treatment clinic and also served as the Division's Director of Women's Health. In that role, she developed an innovative women's HIV prevention and reproductive health program. Kunins completed the CARE fellowship in substance abuse research and a master's degree in clinical research at AECOM/Montefiore in 2005. She has been the recipient of several grant awards, including an Einstein K12 Career Development Award in Substance Abuse and Health Disparities (2005-2007) and an HIV Prevention Program Grant from New York State AIDS Institute (2003-present).

Elizabeth Salisbury-Afshar

MD, MPH, FAAFP, FASAM, FACPM, Medical Director of Behavioral Health

Chicago Department of Public Health

Elizabeth Salisbury-Afshar, MD, MPH, serves as the Medical Director of Behavioral Health for the Chicago Department of Public Health, where she contributes to the department’s work in substance use prevention and treatment, mental health and violence prevention. She is a physician certified in family medicine, addiction medicine and preventive medicine (public health). She previously served as Medical Director of Behavioral Health Systems Baltimore, a quasi-public entity that oversees all publicly funded addiction and mental health treatment. In this role, she oversaw the Baltimore City Overdose Prevention Plan. Salisbury-Afshar came back to Chicago in 2014 and served as Medical Director at Heartland Health Outreach (HHO), the healthcare for the homeless provider in Chicago. While at HHO, she helped expand their addiction treatment services and develop a medication assisted treatment program. Salisbury-Afshar has been working with the Chicago Department of Public Health since September of 2016 and continues to volunteer in the medication assisted treatment program at HHO.

Hanover CDE

Monday, April 2, 2018

2018-04-02

Data-Driven Initiatives to End Overdoses

2:15 PM - 4:15 PM

2:15 PM

4:15 PM

Moderator: Chauncey Parker, JD, Director, New York/New Jersey HIDTA, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ANCC,GA Bar,GA POST,NASW If you normally tune out when you hear “data,” then this workshop may convince you to tune in. Presenters will showcase three data-driven initiatives that are guiding immediate and ongoing efforts to save lives. The New York City RxStat, led by the New York City Department of Health and Mental Hygiene and the New York Police Department, is a public health/public safety partnership initiative is a multi-agency collaborative with the goal of reducing overdose mortality. RxStat includes representatives of more than 40 federal, state and city agencies that share data and coordinate strategies. Additionally, it has expanded to include RxStat Operations, which drills down into individual mortality cases to identify points of intervention. RxStat and RxOperations complement each other by utilizing both population-level and case-level analyses to implement actionable change to save lives. The presentation will identify challenges and methods for other jurisdictions to consider. From North Carolina, presenters will describe a project assessing the availability of statewide drug seizure data through the National Seizure System (NSS), National Forensic Advantage Information System (NFLIS) and Atlanta-Carolinas HIDTA. Data sources were compared and mapped to evaluate access, accuracy and timeliness of drug seizure data to inform both public health and public safety partners of emerging threats. Objectives of this presentation include the abilities to assess availability, access and timeliness of statewide drug seizure data; use maps to identify gaps in decentralized drug seizure data; and address the need to improve access, accuracy and timeliness of statewide drug seizure data to better track emerging threats relating to the opioid epidemic The Overdose Detection Mapping Application Program (ODMAP), a web-based tool created by the Washington/Baltimore HIDTA, provides real-time overdose surveillance data to public health and safety partners. The system links first responders on scene to a mapping tool to track overdoses to stimulate real-time response and strategic analysis across jurisdictions. The tool was released just over a year ago and is now live in 27 states supporting over 300 agencies nationally. The presenter will explore the use of ODMAP to respond to the nation’s growing overdose crisis by discussing lessons learned and the benefits of data sharing. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe differences and tensions that exist between public health and public safety partner agencies. - Explain how data sharing can be used to identify mutual policy goals. - Define strategies to build and strengthen health/safety partnerships within participants' jurisdictions. - Evaluate availability, access and timeliness of statewide drug seizure data. - Use maps to identify gaps in decentralized drug seizure data. - Discuss the need to improve access, accuracy and timeliness of statewide drug seizure data to better track emerging threats relating to the opioid epidemic. - Describe the Overdose Detection Mapping Application Program and how it is being used in the field. - Recognize how the Overdose Detection Mapping Application Program tool can stimulate a public health response across multiple jurisdictions. - Discuss the need to bridge the gap between how public health and safety entities share information beyond their own jurisdiction to better address the opioid epidemic.

Sherani Jagroep

MPH, Public Health Analyst

Atlanta-Carolinas HIDTA

Sherani Jagroep is a Public Health Analyst with the Atlanta Carolinas High Intensity Drug Trafficking Areas (HIDTA), based in the North Carolina Division of Public Health. In the four years since receiving her Master of Public Health in evaluative sciences from Stony Brook University, Jagroep has worked as a Research Co-Investigator on a reproductive health study in Buenos Aires, Argentina, and as a Data Analyst with Physicians for Reproductive Health and Ipas. She joined the Injury and Violence Prevention Branch in February 2017 as a Public Health Analyst, supporting both the public health and public safety sector with data requests and surveillance of the opioid epidemic in North Carolina.

Jeff Beeson

MS, Deputy Director

Washington/Baltimore HIDTA

Jeff Beeson serves as the Deputy Director and Chief of Staff for the Washington/Baltimore High Intensity Drug Trafficking Area (W/B HIDTA) program. His responsibilities include the overall administration of the HIDTA program, including the budget, annual report, and Threat Assessment and Strategy, as well as direct oversight of the treatment, prevention and training initiatives. Additionally, he is responsible for managing the non-HIDTA grants and contracts that support new and existing law enforcement, criminal justice, drug treatment and prevention, homeland security, technology and information sharing initiatives. Prior to joining the W/B HIDTA, Beeson served as Assistant Vice President for the Division of Innovation and Applied Research at Towson University, responsible for a portfolio of state and federal grants and contracts valued at $5 million to support workforce and public safety initiatives throughout Maryland. He also served as Deputy Assistant Secretary for the Maryland Department of Labor, Licensing and Regulation, overseeing correctional and adult education, apprenticeship, and workforce training programs. He served under two administrations within the Maryland Department of Public Safety and Correctional Services managing reentry programs and supporting progressive criminal justice policies. Beeson began his career as a senate staffer working for U.S. Senator Barbara A. Mikulski of Maryland.

Chauncey Parker

JD, Director

New York/New Jersey HIDTA, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board

Chauncey Parker, JD, serves as the Director of the New York/New Jersey High Intensity Drug Trafficking Area (HIDTA), a federally-funded program that invests in public safety and public health partnerships designed to reduce drug abuse and its consequences. He also serves as Executive Assistant District Attorney for Crime Strategies in the Manhattan District Attorney’s Office. A veteran of more than 27 years in criminal justice, Parker began his career in the District Attorney’s Office in 1986, where he served for five years. He next served for 10 years as an Assistant U.S. Attorney for the Southern District of New York. In 2002, Gov. George Pataki appointed him to serve as the Director of Criminal Justice for New York State, where for five years he oversaw all state criminal justice agencies. Parker is a member of the National Rx Drug Abuse & Heroin Summit Advisory Board.

Scott Proescholdbell

MPH, Head of Injury Epidemiology and Surveillance Unit

Injury and Violence Prevention Branch, North Carolina Division of Public Health

Scott Proescholdbell joined the Injury and Violence Prevention Branch at the North Carolina Division of Public Health in June 2008 to head the Injury Epidemiology and Surveillance Unit, where he is the Principle Investigator of the North Carolina Violent Death Reporting System and North Carolina Prescription Drug Overdose project, and he is working to build capacity for a general injury surveillance system. He serves on several state and national groups working to reduce drug overdose deaths. He has an Adjunct Faculty appointment with the Department of Epidemiology at the University of North Carolina Gilling’s School of Global Public Health.

Courtland

Monday, April 2, 2018

2018-04-02

VA Best Practices: S.T.O.P. P.A.I.N Initiative and Practice Guidelines

2:15 PM - 4:15 PM

2:15 PM

4:15 PM

Moderator: Elizabeth Oliva, PhD, VA National Opioid Overdose Education and Naloxone Distribution Coordinator, Department of Veterans Affairs, Veterans Health Administration CE Certified By: AMA,AAFP,ACPE,ADA,ANCC The Department of Veterans Affairs (VA) recently launched a S.T.O.P. P.A.I.N. initiative to highlight VA’s eight best practices to help stem the opioid crisis. This workshop will describe these practices with the goal of equipping attendees with actionable approaches to integrate into their healthcare system or clinical practice. Presenters will drill deeper into the topic of practice guidelines to address the opioid prescriber’s dilemma: how to translate evidence to provide safe, patient-centered care. Increased understanding of the risks associated with opioid prescribing has led to significant changes in guidelines for prescribing opioids (e.g., Centers for Disease Control and Prevention, 2016; VA/Department of Defense, 2017), calling for tools and resources to help translate these guidelines into practice, particularly for practitioners who may not be specialists. There is some concern that adherence to guideline recommendations (e.g., recommended doses) without proper training/guidance in tapering may increase risk of overdose, cause inadvertent pain and suffering for patients, and damage provider-patient relationships. Drawing from the VA’s extensive experience, the presenters’ goals are to provide: 1. VA tools and resources based on recent guidelines and the evidence base to help opioid prescribers and their treatment teams implement guideline-concordant care in a safe and humane patient-centered fashion. 2. Examples and models of implementation in different clinical settings (e.g., primary care, emergency department), including such tools as the “Acute Pain Clinician’s Guide,” “Chronic Pain Clinician’s Guide,” and “Opioid Taper Tool.” UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Recognize the need to take a comprehensive, multifaceted and multidisciplinary approach to address the opioid crisis. - Describe elements of VA’s S.T.O.P. P.A.I.N. initiative — comprised of eight best practices that reflect VA’s comprehensive, multidisciplinary healthcare system approach to addressing the opioid crisis. - Identify tools and resources to support integration of S.T.O.P. P.A.I.N. best practices into diverse clinical practices and healthcare settings. - Identify tools and resources to help opioid prescribers and their treatment teams implement guideline-concordant care in a safe and humane patient-centered fashion. - Explain examples and models of guideline implementation in different clinical settings. - Apply information and tools from the workshop to help implement guideline-concordant care in a safe and humane patient-centered manner into participants’ clinical practice.

A. Lucile Burgo-Black

MD, FACP, ABIHM, National Co-Director Post Deployment Integrated Care Initiative

Veterans Health Administration, Patient Care Services, VA Connecticut Health Care System

Dr. Lucile Burgo-Black is a general internist and assistant clinical professor at Yale University. For 31 years she has provided primary care at the West Haven, Connecticut VA Medical Center to all cohorts of veterans and works with medical students and residents. She has served in local and regional primary care leadership positions and is now the National Co-Director of the Post Deployment Integrated Care Initiative with Patient Care Services. She is involved in national opioid safety, pain, military culture and PACT (patient aligned care team) initiatives and training of both VA and community providers. Her interests are the integration of mental health services into primary care, integrative medicine, collaborative care models for patients with complex chronic comorbidities especially involving chronic pain, as well as, improving our healthcare care systems for veterans leveraging virtual care and social media.

Julianne Himstreet

PharmD, BCPS, VA Academic Detailing Service National Program Manager

VA Eugene VA Healthcare Center

Dr. Julianne Himstreet graduated from Oregon State University with a bachelor’s degrees in pharmacy and microbiology in 1995 and completed a Doctor of Pharmacy at Oregon State University/Oregon Health Sciences University in 1997. She then completed a PGY2 Residency in Ambulatory Care at the University of Colorado Health Sciences Center. She worked for two years as a Pharmacy Supervisor at the U.S. Army Medical Clinic in Hohenfels, Germany, and then transitioned to the VA Roseburg Healthcare System-Eugene Healthcare Clinic, where she worked for 15 years as a Clinical Pharmacy Specialist in Primary Care. During this time, she also worked for VA Central Office's Office of Public Health as the Senior Clinical Advisor, providing tobacco cessation education for clinical staff at VA medical facilities. She is now an Education and Training National Program Manager for VA Pharmacy Benefits Management Service's Academic Detailing Service and works out of Eugene, Oregon.

Elizabeth Oliva

PhD, VA National Opioid Overdose Education and Naloxone Distribution Coordinator

Department of Veterans Affairs, Veterans Health Administration

Elizabeth Oliva, PhD, received her bachelor's degree in psychology and sociology from UCLA. She received her doctorate in clinical and developmental psychology from University of Minnesota, where her graduate work was funded by a National Science Foundation Graduate Fellowship. Oliva completed her pre-doctoral clinical psychology internship at UCSD/VA San Diego and, since then, has worked for the VA Office of Mental Health and Suicide Prevention. She is currently the VA National Opioid Overdose Education and Naloxone Distribution (OEND) Coordinator and is also a Core Investigator at the VA Center for Innovation to Implementation. Oliva chairs the VA workgroup that developed the national OEND implementation and evaluation plan, was Principal Investigator on a VA grant that evaluated initial implementation of OEND within two Veterans Integrated Service Networks, and was recently awarded another VA grant to evaluate the effectiveness of naloxone distribution within VA. She was also a Co-Investigator on a VA grant that developed and evaluated a multi-faceted intervention to improve access to pharmacological treatments for alcohol dependence. Oliva also serves as an Associate Editor for the journal Substance Abuse.

Friedhelm Sandbrink

MD, VA Acting National Director for Pain Management

Department of Veterans Affairs, Veterans Health Administration

Dr. Friedhelm Sandbrink completed his residency in neurology at Georgetown University in Washington D.C., and fellowship in clinical neurophysiology at the National Institutes of Health, Bethesda, Maryland. He is board-certified in neurology, clinical neurophysiology and pain medicine. Since he joined the VA in 2001, he has been leading the Pain Management Program at the Washington VA Medical Center. The program is located within the Neurology Department and provides comprehensive interdisciplinary evaluation and treatment of patients with chronic pain conditions. He became the VA Deputy National Program Director for Pain Management in May 2014. Since October 2016, he has been leading the Pain Program for VHA as the Acting National Director for Pain Management. He is Clinical Associate Professor in Neurology at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. He also has academic appointments at Georgetown University and George Washington University.

Karen Drexler

MD, National Mental Health Program Director - Substance Use Disorders, VACO

Veterans Health Administration, field-based at the Atlanta VA Medical Center

Dr. Karen Drexler serves as National Mental Health Program Director for Substance Use Disorders in the Office of Mental Health and Suicide Prevention in VA Central Office. She graduated from Duke University School of Medicine and completed her psychiatry residency at Wilford Hall U.S. Air Force Medical Center in San Antonio, Texas. She served four years as a psychiatrist and Medical Director of the Alcohol Rehabilitation Center at Wright-Patterson Air Force Base and on the faculty at Wright State University School of Medicine in Dayton, Ohio. She is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine, where she was Addiction Psychiatry Residency Training Director from 2002 to 2014. Her research interests include clinical trials in addiction treatment and translational research on the neurobiology of addiction. She serves as a member of the Board of Directors of the American Academy of Addiction Psychiatry, and as a member of the Board of Directors of the Community Anti-Drug Coalitions of America. She continues to actively practice addiction psychiatry at the Atlanta VA Medical Center.

Regency VII

Monday, April 2, 2018

2018-04-02

Marijuana: Reading Between the Lines and Understanding the Impact

2:15 PM - 4:15 PM

2:15 PM

4:15 PM

Thomas Gorman

Director

Rocky Mountain HIDTA

In 1968, Tom Gorman graduated from San Jose State University and joined the California Bureau of Narcotic Enforcement. He served 10 years as an undercover agent. He made 1,000 undercover purchases and received two Purple Hearts from being shot and later stabbed. He was promoted in 1990 to Deputy Chief in charge of statewide drug enforcement operations. In 1997, he retired to become the director of the Rocky Mountain High Intensity Drug Trafficking Area (HIDTA). Gorman is a graduate of the FBI National Academy and is past President of the California Narcotic Officers Association and the National Alliance of State Drug Enforcement Agencies. He is President of the National HIDTA Directors Association. He authored "The Myths of Drug Legalization and Marijuana Legalization: The Issues." He authored a recently published book titled "To Believe or not Believe, That is the Question - An Undercover Agent’s Quest for the Truth."

Sue Thau

MCRP, Public Policy Consultant

Community Anti-Drug Coalitions of America

Sue Thau is a Public Policy Consultant representing Community Anti-Drug Coalitions of America (CADCA). She is nationally recognized for her advocacy and legislative accomplishments on behalf of the substance abuse prevention field. She has an extensive background in public policy and has held high positions at the federal, state and local levels. She was a Budget Examiner and Legislative Analyst at the Office of Management and Budget, in the Executive Office of the President for over 10 years. Thau was a driving force behind the passage, reauthorization and full funding of the Drug-Free Communities Act. In addition, she has worked to save and enhance funding for all federal substance abuse prevention and treatment programs over the last two decades. She is highly respected as an expert on demand reduction issues by members of Congress and staff on both sides of the aisle on Capitol Hill. Thau has an undergraduate degree from Cornell University in human development and family studies and a master's degree in city and regional planning from Rutgers University.

Centennial Ballroom

Monday, April 2, 2018

2018-04-02

Welcome and Opening Plenary Session

4:30 PM - 6:30 PM

4:30 PM

6:30 PM

Welcome and Opening

Doug Edwards

Director

Institute for the Advancement of Behavioral Healthcare

Doug Edwards is Director of the Institute for the Advancement of Behavioral Healthcare, which produces the National Conference on Addiction Disorders, the National Rx Drug Abuse & Heroin Summit, the Summits for Clinical Excellence, and other conferences for behavioral healthcare professionals and allied stakeholders. He previously was the Editor-in-Chief and Publisher of both Addiction Professional and Behavioral Healthcare magazines. Edwards has been serving the mental health and addiction treatment community for more than 17 years. Noted for his behavioral healthcare market expertise, Edwards presents at conferences and moderates expert panel discussions around the country. He earned his master's degree in business administration from Franklin University and his bachelor's degree from The University of Akron.

Nancy Hale

MA, President and Chief Executive Officer

Operation UNITE, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board

Following 34 years as a teacher, career counselor and administrative coordinator, Nancy Hale retired from public education in 2012 and joined Operation UNITE (Unlawful Narcotics Investigations, Treatment and Education) as Co-Program Director for the UNITE Service Corps (AmeriCorps) Program. In February 2015, she was named UNITE’s third President and CEO. Very involved in her community, Hale has served as an Executive Board Member and volunteer with the Rockcastle County (Ky.) UNITE Coalition for the last 11 years, with the Kentucky YMCA Youth Association for 26 years, as well as a current board member and twice-elected President of the Kentucky Association of Professional Educators. As a member of the Delta Kappa Gamma Society, Pi Chapter, Hale was named Kentucky Volunteer of the Year four times. She received the Golden Apple Achiever Award from Ashland Oil, Inc. in 2000 as one of Kentucky's outstanding educators. In 2001, she was chosen as the Kentucky YMCA Champion and was the first inductee into the Kentucky YMCA Youth Advisor Hall of Fame in 2010. She and her husband, John, also an educator and principal for 43 years, are the parents of two grown sons and have two granddaughters and a grandson. Hale is a member of the National Rx Drug Abuse & Heroin Summit Advisory Board.

Harold Rogers

U.S. Representative

(R-KY, 5th District)

Serving Kentucky's 5th Congressional District since 1981, Hal Rogers is currently in his 19th term representing the people of southern and eastern Kentucky, and is the longest serving Kentucky Republican ever elected to federal office. Focused on economic development, job creation, fighting illegal drug use and preserving the natural treasures of Appalachia, Rogers has a reputation for listening to his constituents and fighting for the interests of the region where he was raised. Born in rural Kentucky and representing one of the poorest Congressional Districts in the nation, Rogers' vision for a stronger region spurred some of the greatest success stories in southern and eastern Kentucky. Organizations such as PRIDE, Operation UNITE, Southeast Kentucky Economic Development (SKED), The Center for Rural Development and Shaping Our Appalachian Region (SOAR) have brought local communities together by revitalizing the environment, providing hope in the fight against drugs, building small businesses, and creating jobs by increasing tourism in one of the most beautiful regions of the country. Nationally, as Chairman of the powerful House Appropriations Committee from 2011 to 2016, he reduced the size and scope of the government by reining in federal spending, conducting rigorous but thoughtful oversight of federal agencies, and restoring fiscal discipline and transparency to our budget process. Rogers led the Congress to reduce discretionary spending by a historic amount, cutting $126 billion in discretionary spending since 2010. Rogers also restored regular order and a culture on the Committee for serious budget oversight and transparency in process, including 2122 amendments considered to appropriations bills on the floor and 650 oversight hearings conducted during his tenure as Chairman. With more than 30-years of experience on the Appropriations Committee, he has served on eight different subcommittees, including leadership roles as Chairman or Ranking Member of three. Rogers was tapped in 2003 to lead the newly established Subcommittee on Homeland Security. Through this important role, Rogers fought to ensure our first responders received the funds necessary to protect against terrorist threats; demanded tough answers from FEMA in the wake of federal responses to wildfires, hurricanes and flash floods; and insisted on enforcement of our country's immigration laws and stronger border security. Whether Rogers is on Capitol Hill ensuring the appropriate use of taxpayer dollars, fighting to secure the homeland, scrutinizing federal government agencies, or home in southern and eastern Kentucky working to make a difference in the lives of the individuals he represents, Rogers remains committed to being a strong voice in Congress for fiscal responsibility, economic development, a strong national defense, and a prosperous future for America.

Grand Hall

Monday, April 2, 2018

2018-04-02

Opening Reception in the Exhibit Hall

6:30 PM - 8:00 PM

6:30 PM

8:00 PM

Opening Reception in the Exhibit Hall

Grand Hall

Tuesday, April 3, 2018

2018-04-03

Coffee in the Exhibit Hall

7:00 AM - 8:00 AM

7:00 AM

8:00 AM

Coffee in the Exhibit Hall

Terrace Foyer

Tuesday, April 3, 2018

2018-04-03

Conference Registration

7:00 AM - 6:00 PM

7:00 AM

6:00 PM

Conference Registration

Baker

Tuesday, April 3, 2018

2018-04-03

Using Clinical Expertise and the Latest Evidence to Build Effective Solutions for Opioid Use Disorder Treatment and to Reduce Associated Costs - Hosted by axialHealthcare

8:00 AM - 8:45 AM

8:00 AM

8:45 AM

A 2015 review of the available literature regarding healthcare costs for opioid users suggested that the average increased costs attributable to opioid use disorder (OUD) are approximately $15,000 per patient annually. Presenters will propose a solution that employs a summary of widely recognized guidelines of clinically-validated best practices for OUD treatment alongside a data management and solutions approach capable of driving high quality outcomes and lowering healthcare costs among individuals with OUD. By culling the shared elements across a number of guidelines, presenters will focus on aspects that are measurable and actionable for a health system that desires an evidence-based, consistent approach to managing OUD. Presenters will describe a strategy for linking relevant medical billing and pharmacy claims data to the measurable components of consolidated shared elements in order to correlate health plan member treatment with outcomes. This presentation will provide an overview of the solutions put in place in collaboration with partners and give the audience a glimpse into the methodology designed to impact outcomes associated with interventions. Discussion will include lessons learned and challenges faced along the way. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe a strategy by which health plan claims data can be analyzed to identify patients at-risk for OUD. - Connect patients identified as at-risk for OUD with appropriate treatment resources, prioritizing early intervention. - Build patient-centered solutions to support sustained recovery beyond a clinician’s office.

Brooke DeFosse

PharmD, BCPS, CPE, Clinical Product Specialist

axialHealthcare

Brooke DeFosse is a clinical product specialist with axialHealthcare, a national pain management solutions company based in Nashville. As an axial clinician, she serves as a clinical resource for internal multifunctional teams and applies her pharmaceutical and substance abuse knowledge to analytics methodology and product development. DeFosse received her Bachelor of Science degree from Middle Tennessee State University in 2011 and her PharmD from the University of Tennessee College of Pharmacy in 2015. After graduation, she completed a managed care residency with the Tennessee Department of Mental Health and Substance Abuse Services and the University of Tennessee.

Amber Watson

PharmD, BCPS, CPE, Clinical Product Specialist

axialHealthcare

Amber Watson is a clinical product specialist at axialHealthcare. Watson received her PharmD from the University of Tennessee College of Pharmacy in 2015 and completed her fellowship in academia, drug information and toxicology with Aegis Sciences Corporation and Belmont University College of Pharmacy. She uses her clinical expertise to guide the development of axialHealthcare's analytics methodology and evidence-based products for pain management and opioid therapy.

Tim Atkinson

PharmD, BCPS, CPE, Clinical Pharmacy Specialist, Pain Management

VA Tennessee Valley Healthcare System

Tim Atkinson, PharmD, BCPS, CPE, is currently a clinical pharmacy specialist in pain management at the VA Tennessee Valley Healthcare System (TVHS). Atkinson specializes in complex and high risk pain medication management through direct patient care and electronic consult services within the regional referral pain clinic. He is the residency director for the PGY-2 Pain and Palliative Care Residency program at TVHS. Additionally, Atkinson is a clinical product advisor and consultant for axialHealthcare where he develops evidence-based methods for monitoring opioid use.

Hanover G

Tuesday, April 3, 2018

2018-04-03

Implementing SAMHSA TIP 63: Accessing Pharmacotherapy Across the Care Continuum - Hosted by CleanSlate

8:00 AM - 8:45 AM

8:00 AM

8:45 AM

The recently released Treatment Improvement Protocol (TIP 63) from the U.S. Department of Health and Human Services is clear in the need to provide people suffering from opioid use disorder (OUD) with evidence-based treatment. Discussing medications that can treat OUD with patients who have this disorder is the clinical standard of care͟. Medication is an effective treatment for OUD, and people with OUD should be referred for an assessment for pharmacotherapy unless they decline͟. It is inappropriate to refuse evidence-based treatment with medications for a patient with OUD, when that may be the most clinically appropriate course of treatment͟. Still, many patients with OUD do not have access to appropriate medication therapy. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Discuss the role of medications in the abstinence-based treatment of OUD. - Describe some current models for delivering medication treatment through the continuum of care. - Identify the elements of quality medication management programs with buprenorphine and naltrexone.

Kelly Clark

MD, MBA, DFAPA, DFASAM, Chief Medical Officer, Clean Slate Centers

President, American Society of Addiction Medicine, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board

Dr. Kelly Clark has focused her career on issues of addictive disease, evidence-informed behavioral healthcare and payment reform. She is Chief Medical Officer of CleanSlate Centers, a multi-state medical group currently treating over 7,000 patients with opioid addiction in office based settings in eight states. Clark is the President of the American Society of Addiction Medicine and has served as expert to the National Safety Council, the U.S. Comptroller General and the U.S. Attorney General’s office in Kentucky, where she is past President of the Kentucky Society of Addiction Medicine, and she led the workgroup on Health Systems and Reimbursement at Substance Abuse and Mental Health Services Administration’s Buprenorphine Summit. Clark continues her work as a founding member of the Advisory Board of the National Rx Drug Abuse and Heroin Summit.

Gregory C. Marotta

President and CEO

CleanSlate

As president and CEO of CleanSlate, Marotta leads a multi-state medical group that has been a pioneer in outpatient addiction medicine and a significant partner on the front lines of the opioid epidemic. Marotta has overseen the continued rapid expansion of CleanSlate to meet the urgent demand for its medication-assisted treatment services in communities across the country. CleanSlate currently treats nearly 8,000 active patients monthly at 39 centers in eight states. In 2017, Marotta relocated CleanSlate to Nashville. His focus at CleanSlate is not only on expanding the company's own capacity to save lives but also in leading the company's public policy and information efforts to drive legislative change, increase access to care and break down the stigma around the chronic disease of addiction. Marotta brings leadership in all areas of management within startup/high-growth operations, including mergers and acquisitions, change management and strategic reorganizations. As senior vice president of national operations at U.S. Healthworks, the second-largest provider of occupational medical care, Marotta oversaw a national network of more than 230 healthcare facilities in 20 states. Prior to serving in a national capacity at U.S. Healthworks, Marotta served as senior vice president of operations in the east division and as vice president of operations at the company. Earlier in his career, Marotta served as vice president of outpatient services at the Kessler Institute for Rehabilitation, ranked by U.S. News & World Report as one of the top three rehabilitation hospitals in the country. Marotta obtained his bachelor of arts degree from Kean University and is a graduate of the Advanced Management Program at Harvard Business School.

Dunwoody

Tuesday, April 3, 2018

2018-04-03

Neuroscience for Non-Scientists - Hosted by Ideal Option

8:00 AM - 8:45 AM

8:00 AM

8:45 AM

The U.S. is in the throes of an unrelenting opioid epidemic and the individuals suffering from Opioid Use Disorder (OUD) are meeting a tepid response from policy-makers and practitioners. We are witnessing overdose deaths from opioids, or opioids in combination with other substances, at rates that are unprecedented. This change in morbidity and mortality is occurring at a time when psychosocial and pharmacological therapies are being developed at an amazing pace and systems of care are responding with expansion and employing disruptive technologies to overcome barriers of remote access and an inadequate number of people in the workforce to respond to the growing need. Additionally, polices to limit the individuals who can employ medication therapy are changing, but not at a pace equal to the expansion of the epidemic. Andrea G. Barthwell, MD, DFASAM, former Deputy Director of Demand Reduction, White House Office of National Drug Control Policy, is uniquely placed to review the environment of care and recommend strategies to expand access that can be employed by policy makers, communities, practitioners, and individuals who are trying to save lives and provide access to individualized care. Her presentation will review our current understanding of neuroscience underlying substance use disorders (SUD) as understood through the American Society of Addiction Medicine (ASAM) definition of SUD; outline current treatment approaches to SUD based upon the neuroscience of addiction; list the existing responses to SUD including psycho-social therapies, medication therapies, and combination therapies; and explore the basis of selection bias in developing and promoting therapeutic response to SUD from a review of societal and cultural considerations versus individual considerations. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe scientific understanding of substance use disorders (SUD), particularly Opioid Use Disorders (OUD). - Apply understanding of SUD to predicting therapeutic approaches, including medications, to treat SUD, and OUD. - Evaluate the impact of existing responses on outcomes in substance use disorders, particularly OUD.

Andrea Barthwell

MD, DFASAM, Founder and Director

Two Dreams Treatment Centers

Dr. Andrea Grubb Barthwell is Founder and CEO of Two Dreams, a comprehensive wellness center for the treatment of alcoholism and substance use disorders. She is also the Founder and Chief Executive Officer of the Washington, D.C.-based global healthcare and policy-consulting firm EMGlobal LLC. Barthwell served as Deputy Director for Demand Reduction in the Office of National Drug Control Policy under President George W. Bush from 2002 to 2004. Her current work is focused on developing strategies to expand access to treatment for opioid dependence disorder, expanding practitioner knowledge of urine drug testing in the identification and treatment of substance use disorders, and helping individuals and families prevent substance use disorders with the lecture series, “The Parents Academy.” Barthwell received a bachelor's degree in psychology from Wesleyan University and a medical degree from the University of Michigan Medical School. In 2003, she received the Betty Ford Award from the Association for Medical Education and Research in Substance Abuse. In 1997, her peers named her one of the "Best Doctors in America" in addiction medicine.

Hanover AB

Tuesday, April 3, 2018

2018-04-03

Not All Messages Are Worth Promoting: Developing the Right Prevention Communications for Different Opioid Risk Populations - Hosted by Rescue | The Behavior Change Agency

8:00 AM - 8:45 AM

8:00 AM

8:45 AM

Opioid prevention is not a straightforward problem. While overdoses are plaguing our communities, current opioid users and potential future users may not respond to overdose-focused messaging for multiple reasons. These barriers include a lack of knowledge of what opioids are, an assumption that doctor’s prescriptions are safe, and drug addict stigmas, amongst others. This session will explore the differences between messaging strategies for recreational users, parents, potential users, and prescribed users, including samples from different populations and states. Then, the session will review message testing research with various opioid risk audiences and present a messaging framework to build an understanding of opioid risk. The speaker will touch on critical communications concepts, including message tailoring, cultural competency, and segmentation, and how they apply to opioids prevention. This framework will help those developing opioid prevention campaigns and communications ensure their messages are effectively and efficiently reaching their specific audience segments. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the barriers to effective opioids communications with distinct audiences. - Explain the building blocks of knowledge necessary to for the public to understand opioids risk. - Explore how message tailoring, cultural competency, and segmentation apply to opioid communications.

Jeffrey Jordan

President and Executive Creative Director

Rescue Agency

Jeffrey is President and Executive Creative Director of Rescue, a health behavior change marketing agency focused on making healthy behaviors easier and more appealing. Jeff studied Marketing for his undergraduate degree and received a Master's in Experimental Psychology. Since founding Rescue in 2001, he has led its growth to include dozens health behavior change programs across North America, tackling issues such as tobacco, sexual health, obesity, and substance use. Rescue's campaigns include the FDA's national tobacco prevention campaigns for multicultural teens and LGBT young adults, as well as active contracts with over a dozen state and local health departments. Over the past 2 years, Rescue has been applying its health behavior change expertise to opioid prevention, including the state of Vermont's new opioid prevention campaign, Over The Dose.

Hanover F

Tuesday, April 3, 2018

2018-04-03

Helping Our Most Vulnerable Populations Impacted by the Opioid Crisis: Pregnant Women, Their Infants and Those Receiving Child Welfare Services - Hosted by JBS International

8:00 AM - 8:45 AM

8:00 AM

8:45 AM

In this session, presenters will describe the current landscape of opioid use disorder among pregnant and parenting women in the United States and subsequent trends. This session will highlight uses of the Substance Abuse and Mental Health Services Administration’s “Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants” guide. It also will demonstrate a model of intervention with child welfare and family court staff to mitigate escalation. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify approaches for transforming the clinical into tools for patients, providers and researchers. - Illustrate methodology for assessing community needs and developing individualized micro-training modules for child welfare and family court. - Highlight a decision support tool created to support family court judges in dependency cases.

Jennifer Kasten

PhD, MSW, President

JBS International

Jennifer Kasten, PhD, MSW, is chief strategy officer and a vice president of JBS International. She is a former clinician with 25 years of experience in the behavioral health field, specifically focused on substance abuse and mental health disorders. She leads JBS strategies to address the opioid epidemic, and has led the Center for Substance Abuse Treatment (CSAT) Clinical TA Project since 2009. Kasten is co-author of "Methadone Maintenance Treatment in the United States: A Practical Question and Answer Guide."

Pamela Baston

MPA, MCAP, CPP, Technical Expert Lead

JBS International, Inc.

Pamela Baston, MPA, MCAP, CPP, is a technical expert lead at JBS International. She leads an innovative state project with Florida's child welfare system to identify and engage opioid-using parents and align treatment and family court strategies. She has 35 years of experience in the prevention and treatment of behavioral health disorders and previously served as director of Florida's substance abuse agency. She is an expert in evidence-based treatment practices for women and mothers with behavioral health disorders and HIV/AIDS.

Regency V

Tuesday, April 3, 2018

2018-04-03

What You Say Says It All: Federal Perspectives on Effective Opioid Epidemic Messaging and Engagement Strategies - Hosted by ICF

8:00 AM - 8:45 AM

8:00 AM

8:45 AM

Everyone, it seems, is talking about opioids. Whether it’s about prescription misuse or illicit use; prevention or treatment approaches; public health or law enforcement sectors, this epidemic has myriad dimensions, stakeholders, and audiences. But how do we decide what we’re going to say to those we’re trying to reach? How are we addressing notions of stigma, addiction, access, poly drug use, cultural sensitivity, and evidence-based approaches in our communications? And how do we determine the impact of these efforts on our communities? Join us for an interactive and dynamic panel discussion featuring leaders from across federal agencies involved in the nation’s opioid response, such as the CDC, DEA, and SAMHSA. Moderated by ICF Senior Vice President, Kris Tremaine, you’ll hear perspectives and ideas for effectively communicating to the public; innovative approaches for programming and evaluation; and guiding principles for ensuring that outreach efforts, whether to individuals, communities, or the nation at-large, don’t have unintended consequences. Bring your questions, we’ll reserve time for Q&A. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Understand the messaging and communications nuances for talking with disparate and diverse populations of all ages about opioids - Hear and discuss strategies for effectively engaging audiences in programming, communications, and evaluation efforts, including vulnerable populations, youth, and those in high intensity drug trafficking areas - Discuss novel approaches that reflect culturally and linguistically appropriate must-haves for reaching those most in need

Kris Tremaine

Senior Vice President

ICF

Kris Tremaine has 25 years of experience providing strategic communications, public relations, marketing and digital solutions to government, nonprofit, and private sector clients. She served in chief operating officer and executive vice president roles at Washington-based PR agencies prior to coming to ICF, where she now leads an integrated team of more than 600 professionals focused on marketing and communications; digital transformation; IT modernization; and organizational research, learning and performance. Her team's largest clients include various Government agencies, including the U.S. Department of Health and Human Services (HHS), the U.S. Department of Transportation, U.S. Department of Homeland Security (DHS), the U.S. Environmental Protection Agency (EPA), the U. S. Department of Energy, and many other Federal agencies.

Piedmont

Tuesday, April 3, 2018

2018-04-03

The Intersection of Health IT and Opioid Misuse: Implementing a Real-Time Patient Safety System - Hosted by Health IT Now

8:00 AM - 8:45 AM

8:00 AM

8:45 AM

A critical component to fighting the opioid epidemic is arming those on the front lines — providers and pharmacists — with complete, accurate and timely data regarding the Rx history of the patient in front of them. To accomplish that goal, however, a real-time patient safety system needs to be implemented. In this session, presenters will describe challenges faced by current systems that provide patient Rx information, how to address those challenges and details on how common-sense solutions can be implemented at the federal level with a data-enabled element. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify challenges in the current Rx monitoring system. - Understand how a patient safety system solution addresses shortcomings in the current system. - Learn how and through what authorities this type of solution can be implemented at the federal level.

Joel White

Executive Director

Health IT Now

Joel White is executive director of Health IT Now, a broad-based coalition of patient groups, provider organizations, employers and payers that supports incentives to deploy heath information technology to improve quality, outcomes and patient safety, and to lower costs. White spent 12 years on Capitol Hill as professional staff, during which he helped enact nine healthcare laws. He also was instrumental in developing the Medicare e-prescribing law and in developing legislation that passed the House to promote the adoption and use of health information technology. White was the staff director of the Ways and Means Health Subcommittee with responsibility for advising members of Congress and directing staff on policy issues.

Steve Mullenix

Senior Vice President

National Council for Prescription Drug Programs

Steve Mullenix joined the National Council for Prescription Drug Programs in June 2009 and currently serves as senior vice president of public policy and industry relations. Previously, Mullenix served as director of professional and trade relations for Covidien/Mallinckrodt Pharmaceuticals. He also served as vice president of managed care and professional services with Medicap Pharmacies, Inc., a national pharmacy franchise organization. He is the former executive vice president of Q-A, Inc., a national drug utilization review and pharmacy consulting company. Mullenix also served as vice president and chief operating officer for the Iowa Pharmacy Association and its for-profit subsidiary.

Kelly Wygal

Vice President, Business Development

McKesson Specialty Health

For the past eight years, Kelly Wygal has served as the national leader for REMS business development at McKesson, focused on both individual and class-wide shared system REMS programs. She is the primary point of contact for advancing the portfolio of REMS services for manufacturer sponsors across McKesson Specialty Health and RelayHealth. Wygal brings business development experience as both an individual performer and sales leader. She has an extensive sales and marketing background with more than 20 years' experience in healthcare, working on both the pharmaceutical manufacturer and supplier sides of industry. Having joined McKesson in 2001, Wygal represented the manufacturer-focused businesses for specialty products. Wygal also served as executive director of client relationships and filled a role as the primary point of contact across McKesson's portfolio of services for strategic accounts including: reimbursement services, patient assistance programs, copay assistance, managed distribution and specialty pharmacy services. Additionally, Wygal leads the business development teams for health informatics, health economics outcomes research, clinical education and site management research services for manufacturers as an extension of McKesson's US Oncology business.

Courtland

Tuesday, April 3, 2018

2018-04-03

Treating Co-Occurring Disorders in the Substance Use Disorder Patient: Depression, Anxiety and Sometimes Pain - Hosted by Pathway Healthcare

8:00 AM - 8:45 AM

8:00 AM

8:45 AM

Co-occurring psychiatric disorders and physical pain are two of the most common diagnoses alongside a substance use disorder. As access to care for substance use disorders is steadily increasing, it is equally important to provide treatment that completes the spectrum of care for each individual patient. Understanding the characteristics of psychopathology in the opioid-addicted patient, using psychosocial interventions, and providing appropriate and effective alternatives to the treatment of physical pain in the opioid-addicted patient are key components to a holistic, evidence-based approach. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Understand the characteristics of psychopathology in the opioid-addicted patient. - Understand the use of psychosocial interventions in the treatment of patients with opioid use disorders. - Recognize appropriate treatments for pain in buprenorphine patients.

Brent Boyett

CMO, Clinician

Pathway Healthcare

Brent Boyett, DMD, DO, DFASAM, was trained as a general dentist and is board certified in family medicine as a physician. He practiced both dentistry and primary care medicine until discovering his passion in the field of addiction medicine in 2008. Boyett became board certified in addiction medicine and is a speaker, researcher and leader in addiction medicine. As a researcher, Boyett has served as principal investigator in several clinical trials and as a clinical advisor in the development of new treatment options for addictive disorders. Boyett is a former president of the Alabama Osteopathic Medical Association and the current president of the Alabama Society of Addiction Medicine (ALSAM). In 2017, he was appointed by Alabama Gov. Robert Bentley to serve on the Governor's Task Force on Opioid Addiction and Abuse.

Stephen Taylor

MD, MPH, FASAM, Chief Medical Officer, Behavioral

Pathway Healthcare, LLC

Stephen Taylor, MD, MPH, FASAM, is a quadruple-board-certified psychiatrist, educator and presenter who provides education and specialized care to adolescents and young adult patients and their families afflicted with drug and alcohol addictions and general psychiatric disorders. Taylor is board certified in general psychiatry, child/adolescent psychiatry and addiction psychiatry, has a master of public health degree, and is a certified medical review officer. Taylor is a fellow of the American Society of Addiction Medicine (ASAM), and a member of the American Academy of Addiction Psychiatry, the American Academy of Child and Adolescent Psychiatry, and the International Society of Sports Psychiatry. Currently, he is completing his 11th year as the medical director of the Player Assistance/Anti-Drug Program of the National Basketball Association (NBA) and the National Basketball Players Association (NBPA).

Learning Center

Tuesday, April 3, 2018

2018-04-03

Physician Anesthesiologists’ Role in Addressing the Opioid Epidemic: Optimizing Acute Pain Management - Hosted by American Society of Anesthesiologists

8:00 AM - 8:45 AM

8:00 AM

8:45 AM

Physician anesthesiologists play a major role in managing pain. They can ensure patients undergoing surgery have a pain management plan tailored to their needs, including patients with prior opioid exposure who are opioid tolerant and pose unique challenges for surgery. Physicians must also manage patients after surgery and provide care to those suffering from chronic pain. Over decades, physician anesthesiologists have acquired specialized knowledge in minimizing opioid use for surgical patients to speed recovery. These approaches reduce or eliminate opioid exposure and the attendant risks, and are generally transferable to many settings in which acute pain management is required. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Explain the role of physician anesthesiologists and how they can have an impact on the opioid epidemic. - Describe techniques physician anesthesiologists are using to reduce opioid use during and after surgery, including multimodal, opioid-sparing analgesic regimens and regional anesthesia and analgesia for the benefit of both opioid-naïve and -tolerant patients. - List interventional therapies physician anesthesiologists can recommend for chronic pain patients.

James Grant

MD, MBA, FASA, President

American Society of Anesthesiologists; Chair, Department of Anesthesiology, Beaumont Hospital

James Grant is chair of the Department of Anesthesiology at Beaumont Hospital-Royal Oak in Michigan and the 100th president of the American Society of Anesthesiologists (ASA). He graduated from Wayne State University School of Medicine and completed his post graduate training at Northwestern University Medical Center in Chicago and his MBA at Indiana University. He is a diplomate and associate examiner of the American Board of Anesthesiology. A past president of the Michigan State Medical Society (MSMS) and Michigan Society of Anesthesiologists (MSA), Grant received the MSA President's Award in 2012 and the MSMS Presidential Citation in 2014. He was twice appointed to the Michigan Board of Medicine and served as chair from 2004 to 2006. Grant is on the board of directors of the Anesthesia Foundation, Foundation for Anesthesia Education and Research, and Blue Cross Blue Shield of Michigan. He also serves as the chair of the Michigan delegation to the American Medical Association.

Alexander Hannenberg

MD, Chief Quality Officer

American Society of Anesthesiologists; Clinical Professor of Anesthesiology, Tufts University School of Medicine, Boston

Alexander Hannenberg served as president of the American Society of Anesthesiologists (ASA) in 2010. He attended Vassar College and Tufts University School of Medicine before completing his anesthesia training at Harvard's Beth Israel Hospital. He practiced anesthesiology for more than 25 years in suburban Boston. Additionally, he is clinical professor of anesthesiology at Tufts University School of Medicine in Boston. He is a faculty member at Ariadne Labs, a joint center for health system innovation at the Harvard T.H. Chan School of Public Health and Brigham & Women's Hospital. He earned the ASA's highest honor, the Distinguished Service Award, in 2015. Also in 2017, he was named the inaugural chief quality officer for the American Society of Anesthesiologists.

Regency VII

Tuesday, April 3, 2018

2018-04-03

State Leadership on the Opioid Epidemic - Hosted by National Association of Attorneys General (NAAG)

8:00 AM - 8:45 AM

8:00 AM

8:45 AM

Massachusetts Attorney General Maura Healey will discuss her approach to disrupting the opioid crisis.

Maura Healey

Attorney General

Massachusetts

Since January 2015, Maura Healey has served as the Attorney General of Massachusetts, leading the People's Law Firm in the fight for fairness and equality. Since assuming office, Healey has focused on expanding economic opportunity by addressing rising energy and health care costs, tackling student loan debt, and ensuring fair treatment for workers and a level playing field for businesses. Healey has also gained national prominence for her leadership in combatting the state's opioid epidemic, including expanding addiction prevention training for young people. Healey is a graduate of Harvard College and Northeastern University School of Law.

Regency VI

Tuesday, April 3, 2018

2018-04-03

EMS Response to Opioid Overdose and Fire Fighter Behavioral Health Center of Excellence - Hosted by International Association of Fire Fighters (IAFF)

8:00 AM - 8:45 AM

8:00 AM

8:45 AM

Firefighters and EMS providers are often called to respond to situations involving opioid-related emergencies. They are not immune to the effects of constantly witnessing these situations or of using opioids themselves. The International Association of Fire Fighters (IAFF) has opened the first behavioral health center of excellence exclusively for firefighters. The IAFF Center of Excellence for Behavioral Health Treatment and Recovery is a one-of-a-kind facility specializing in treating IAFF members who are struggling with addiction, PTSD and other related behavioral health challenges, offering the help they need in taking the first steps toward recovery. It is a safe haven for members to talk with other members who have faced or overcome similar challenges. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the depth and breadth of the prehospital response to opioid overdoses in North America. - Describe how first responders are handling these recurring overdose calls. - Describe the significance of the ARS IAFF Behavioral Health Center of Excellence.

Patrick Morrison

Assistant to the General President for Occupational Health, Safety and Medicine

International Association of Fire Fighters

Patrick Morrison is the assistant to the general president for occupational health, safety and medicine at the International Association of Fire Fighters. Morrison's expertise is in the design and implementation of health, safety and wellness programs to improve firefighters' overall physical and mental health, address their medical needs and increase protections from the hazardous elements of firefighting. Prior to joining the IAFF, Morrison was a career firefighter for 21 years with the Fairfax County Fire and Rescue Department in Fairfax, Va.

Lori Moore-Merrell

DrPH, MPH, EMT-P, Assistant to the President

International Association of Fire Fighters

Lori Moore-Merrell is the assistant to the president of the International Association of Fire Fighters (IAFF) in charge of data, research and technical assistance. The IAFF represents more than 310,000 professional firefighters and paramedics throughout North America. Moore-Merrell's expertise is in community risk assessment, emergency response system design, staffing and deployment of mobile resources, and system performance measurement and evaluation. She has managed emergency response system evaluation project teams, including data procurement, geographic information systems analysis, and workload analysis in hundreds of fire departments throughout North America.

Hanover CDE

Tuesday, April 3, 2018

2018-04-03

Coordinating a Community Response: The Northern Kentucky Story - Hosted by Northern Kentucky University

8:00 AM - 8:45 AM

8:00 AM

8:45 AM

Opioid overdoses and deaths have hit Kentucky’s three northernmost counties, which represent the second largest metropolitan area in the state. As the crisis unfolded, the community rallied to respond. The goal was to tear down silos and rethink how existing services might be repurposed. A leading player in the realignment is the Kenton County Detention Center, where a 125-bed unit was redesigned as a treatment center for inmates addicted to heroin and other drugs. Early findings show impressive results, as highlighted in a New York Times op-ed column in June 2017, “Addicts Need Help. Jails Could Have the Answer.” The criminal justice, medical and social work professionals who collaborated on the inmate treatment unit are now designing a Quick Response Team to keep people who overdose out of jail and get them into treatment. It’s an evidence-based approach that will be monitored and evaluated in real time, with support from Northern Kentucky University. It’s also an approach that can be replicated elsewhere in America. Our panelists will offer guidance on how to adopt the approach.

Jason Merrick

MSW, CADC, Director of Addiction Services

Kenton County (Kentucky) Detention Center

Jason Merrick is the Director of Addiction Services with Kenton County Detention Center in Covington, Kentucky. He and his team developed, implemented and manage a 125-bed residential treatment program for men and women who are involved with the criminal justice system. A Northern Kentucky University graduate with a master's degree in social work and a Certified Alcohol and Other Drug Abuse Counselor, Merrick is at the forefront of the heroin crisis and addiction-related issues in the Northern Kentucky region. He is a co-author of "Northern Kentucky’s Collective Response to the Heroin Epidemic." He and Kenton County Jailer Terry Carl are committed to changing the way we respond to addiction-related issues in Northern Kentucky and beyond.

Suk-hee Kim

PhD, Assistant Professor, Department of Counseling, Social Work and Leadership

Northern Kentucky University

Suk-hee Kim, PhD, is an assistant professor in the Department of Counseling, Social Work and Leadership at Northern Kentucky University in Highland Heights, Kentucky. Kim teaches both undergraduate and graduate courses. Her expertise is in neuroscience and social work, global social work education and aging in social work. She received her BA from Han-il University and Presbyterian Theological Seminary in social welfare and a Master's of Social Work from Boston University. She earned her joint doctorate from the University of Louisville and University of Kentucky in social work. She has designed and taught online courses and is a nationally certified online instructor. Previously, she was an assistant professor at Norfolk State University and was a first social work doctoral research fellow of the Department of Family and Geriatric Medicine in the School of Medicine at the University of Louisville.

Mina "Mike" Kalfas

MD, Primary Care Physician

The Christ Hospital Health Network, Cincinnati

Mina Kalfas, MD, is a primary care physician with The Christ Hospital Health Network in Cincinnati, Ohio. A drug treatment clinic opened up near his primary care practice, and in time, Kalfas was pressed into service. The "accidental addiction doc" became a certified addiction specialist and an ally of advocacy groups bringing attention to the heroin epidemic. Kalfas received his medical degree at the University Of Kentucky College of Medicine and completed his residency at Bethesda Family Practice Program in Cincinnati. He consults with the Kenton County Detention Center and its addiction services programming.

Centennial Ballroom

Tuesday, April 3, 2018

2018-04-03

Plenary Session: Congressional Leaders Update

9:00 AM - 11:00 AM

9:00 AM

11:00 AM

Congressional leaders will provide updates.

Harold Rogers

U.S. Representative

(R-KY, 5th District)

Edward J. Markey

U.S. Senator

(D-MA)

Senator Edward J. Markey, a consumer champion and national leader on energy, environmental protection and telecommunications policy, has a prolific legislative record on major issues across the policy spectrum and a deep commitment to improving the lives of the people of Massachusetts and our country. Whether the issue is climate change, clean energy, safeguarding privacy, nuclear non-proliferation, investor protection or preserving an open Internet that spurs competition and consumer choice, Senator Markey stands up for the priorities and values of Massachusetts. Markey Headshot High Resolution While serving for 37 years in the U.S. House of Representatives, Senator Markey fought for his constituents throughout his Congressional District. When he was Dean of the Massachusetts delegation in the House, he worked to harness the energy and influence of his colleagues on behalf of the entire Commonwealth. Elected to the Senate in a special election in June 2013, Senator Markey is bringing his experience, energy and expertise to fight for all the people of Massachusetts. Senator Markey has amassed an unparalleled record of energy and environmental legislative achievements. He has consistently fought to create new jobs in American clean energy and served as a leading consumer champion against rising gas prices and foreign oil. He is the principal House author of the 2007 fuel economy law, which will increase fuel economy standards to 54.5 miles per gallon by 2025, the first increase in a generation. He also is the author of the appliance efficiency act of 1987, which stopped the construction of hundreds of coal-fired plants. Senator Markey authored the law that established the Northeast Home Heating Oil Reserve, ensuring that New England families won't be left out in the cold when oil prices spike. And he is the author of the revolutionary law that requires electricity regulators to open up the wholesale electric power market for the first time. In 2009, Congressman Markey was the co-author of the landmark Waxman-Markey bill, the only comprehensive climate legislation ever to pass a chamber of Congress. It gave hope to the world that the United States was serious about addressing climate change and helped America effectively negotiate with the international community. Senator Markey was a leading voice in the investigation into the BP oil spill. He insisted that the company reveal the true size of the spill's flow rate, raised concerns about the use of toxic chemical dispersants into the environment and forced BP to make live video footage of the oil spill available to the public on the "Spillcam" website he created. BP ultimately pled guilty to 14 counts, including one count of Obstruction of Congress for making false and misleading statements and withholding information and documents from then-Rep. Markey about the true size of the spill. In the House of Representatives, Congressman Markey served as the Ranking Member of the Natural Resources Committee. From 2007 to 2010, he served as Chairman of the Select Committee on Energy Independence and Global Warming, a signature committee established by then-Speaker Nancy Pelosi. He also served on the Energy and Commerce Committee, where he was Chairman of the Subcommittee on Energy and the Environment. A member of the Commerce, Science and Transportation Committee, Senator Markey is a national leader on telecommunications policy, technology and privacy. In the House, he served for 20 years as Chair or Ranking Member of the Subcommittee on Telecommunications and the Internet, where he fostered the growth of new information technologies and was the principal author of many of the laws now governing our nation's telephone, broadcasting, cable television, wireless, and broadband communications systems. He is the House author of the 1992 Cable Act, which increased choices for millions of consumers and enabled satellite-delivered programming to be more widely offered. He also authored the law in 1993 that moved over 200 MHz of spectrum from government to commercial use, creating the 3rd, 4th, 5th, and 6th wireless phone companies. New companies entered the market with digital technology, forcing the incumbents to innovate and invest and pushing mobile phone prices down. Congressman Markey authored the landmark Telecommunications Act of 1996, ushering competition into the telecommunications marketplace and unleashing private sector investment. Competition remains Senator Markey's economic mantra, in his words, "ruthless Darwinian competition that would bring a smile to Adam Smith." He has been instrumental in breaking up anti-consumer, anti-innovative monopolies in electricity, long-distance and local telephone service, cable television, and international satellite services. He was one of the only members of the House Commerce Committee to fight AT&T's monopoly in the early 1980s and is a principal author of the requirement that the Bell Operating companies accept local telephone service in the 1990s. His pro-competition policies have directly benefited job creation in Massachusetts and throughout the country. While in the House, Congressman Markey introduced the Internet Freedom Preservation Act, the first net neutrality bill introduced in Congress, to ensure that as the Internet continues to evolve, it remains a level playing field guided by the principles of openness, competition and innovation. He also has been a key leader on providing privacy protections for personal information such as medical records, financial records, and on-line purchases. He has championed strengthening privacy protections for children and is the House author of the Children's Online Privacy and Protection Act (COPPA), the primary law that safeguards children's privacy online. From 2003 to 2009 in the House of Representatives, Senator Markey also served as a senior member of the Homeland Security Committee. In that capacity, he focused on closing gaps in our homeland defenses, particularly in the areas of nuclear, aviation, maritime, liquefied natural gas and chemical security. In the wake of the 9-11 attacks, he authored the first-ever mandate in the law that 100% of cargo on passenger planes is screened, and 100% of all maritime cargo is scanned before entering America's ports. Senator Markey also was the leader of the national Nuclear Freeze movement and has been a Congressional champion on nuclear nonproliferation. His amendment to ban all underground nuclear testing passed in 1986, and in the 1990s, he fought to tighten controls on global trafficking in nuclear technology. Since then, Senator Markey has continued his work on nuclear nonproliferation, successfully enacting new restrictions on exports of nuclear and dual-use technologies to Iran, North Korea, and other countries designated as state sponsors of terrorism and pressing for stronger nuclear nonproliferation conditions on all future nuclear trade cooperation agreements As founder of the Nonproliferation Caucus, Senator Markey continues to spearhead efforts to prevent the spread of nuclear weapons to safeguard the future for generations to come. He is the author of some of the most important Wall Street reform laws since the Great Depression, including statutes that strengthened penalties against insider trading, improved federal oversight over the stock and futures markets, and reformed regulation of the government securities market. Senator Markey was born in Malden, Massachusetts, on July 11, 1946. He attended Boston College (B.A., 1968) and Boston College Law School (J.D., 1972). He served in the U.S. Army Reserve and was elected to the Massachusetts State House where he served two terms representing Malden and Melrose. He is married to Dr. Susan Blumenthal.

Maggie Hassan

U.S. Senator

(D-NH)

United States Senator Maggie Hassan is committed to working with members of both parties to represent New Hampshire values and to solve problems in order to expand middle class opportunity, support small businesses, and keep America safe, secure, and free. She is the second woman in American history to be elected both Governor and United States Senator, along with fellow New Hampshire Senator Jeanne Shaheen. Elected to the U.S. Senate in 2016, Senator Hassan is working to combat the heroin, fentanyl, and opioid crisis; expand access to job training and make college more affordable for our students and families; help innovative businesses grow and create good jobs; and build a more inclusive economic future where all people who work hard to get ahead can stay ahead. She is also focused on strengthening national security; protecting Social Security and Medicare; ensuring that veterans get the services that they need and deserve; combating climate change and preserving our natural resources; and protecting a woman's right to make her own health care decisions. Senator Hassan's committee assignments allow her to focus on these as well as other critical priorities facing New Hampshire's families, small businesses, and economy. She is a member of the Senate Committee on Homeland Security and Governmental Affairs; the Committee on Health, Education, Labor, and Pensions (HELP); the Committee on Commerce, Science, and Transportation; and the Joint Economic Committee. Senator Hassan was drawn to public service as an advocate fighting to ensure that children like her son Ben, who experiences severe disabilities, would be fully included in their communities and have the same opportunities that all parents want for their children. In 1999, then-Governor Shaheen asked her to serve on the Advisory Committee to the Adequacy in Education and Finance Commission. Her experience as a business attorney and as a parent of a child who experiences disabilities enabled her to provide a unique perspective as the commission did its work. Senator Hassan was first elected to the New Hampshire Senate in 2004, serving the people of the 23rd District, which included ten Seacoast towns. During her six years in office, she was selected by her colleagues to serve as President Pro Tempore and Majority Leader of the State Senate. In 2013, she was sworn in as the 81st Governor of New Hampshire. Throughout her two terms as Governor, she responsibly balanced the state budget; created a business-friendly environment that encouraged innovation and saw New Hampshire's unemployment rate drop to among the lowest in the nation; worked to implement a comprehensive, hands-on approach to the heroin, fentanyl and opioid crisis; and froze in-state tuition at state universities for the first time in 25 years while lowering tuition at community colleges. Maggie Hassan earned her B.A. from Brown University and her J.D. from the Northeastern School of Law. She and her husband, Tom, who serves as the President of School Year Abroad, live in Newfields and are the proud parents of two children, Ben (29) and Meg (24).

Earl "Buddy" Carter

U.S. Representative

(R-GA, 1st District)

Earl L. "Buddy" Carter is an experienced businessman, health care professional and faithful public servant. As the owner of Carter's Pharmacy, Inc., South Georgians have trusted Buddy with their most valuable assets: their health, lives and families for more than thirty years. While running his business, he learned how to balance a budget and create jobs. He also saw firsthand the devastating impacts of government overregulation which drives his commitment to ensuring that the federal government creates policies to empower business instead of increasing burdens on America's job creators. A committed public servant, Buddy previously served as the Mayor of Pooler, Georgia and in the Georgia General Assembly where he used his business experience to make government more efficient and responsive to the people. Buddy is serving his second term in the United States House of Representatives and is a member of the Committee on Energy and Commerce. As the only pharmacist serving in Congress, Buddy is the co-chair of the Community Pharmacy Caucus and is dedicated to working towards a health care system that provides more choices, less costs and better services. A lifelong resident of the First District, Buddy was born and raised in Port Wentworth, Georgia and is a proud graduate of Young Harris College and the University of Georgia where he earned his Bachelor of Science in Pharmacy. Buddy married his college sweetheart, Amy, 39 years ago. Buddy and Amy now reside in Pooler, Georgia and have three sons, two daughters-in-law and three grandchildren.

Katherine Clark

U.S. Representative

(D-MA, 5th District)

Katherine Clark proudly serves the Fifth District of Massachusetts. She was first elected in a special election in December of 2013. Katherine's career in public service is driven by her commitment to helping children and families succeed. She is a vocal advocate for ending wage discrimination, protecting women's health care, access to affordable, high-quality child care, paid family leave, safer schools, and other reforms to address the challenges women and families face. She believes that Congress must work to end the glaring disconnect between the needs of families at home and priorities in Washington. In Congress, she brings her experience as a state senator, state representative, general counsel for the Massachusetts Office of Child Care Services, and policy chief for the state attorney general. Katherine represents a diverse district comprised of 24 cities and towns that stretch from the coastal communities of Revere and Winthrop through the economic engine of MetroWest. Katherine serves on the U.S. House Committee on Appropriations. In the House Democratic Caucus she serves as a Senior Whip, and is a member of the Steering and Policy Committee. Katherine is a member of several caucuses in Congress, including the Congressional Progressive Caucus and the Women's Caucus.

Grand Hall

Tuesday, April 3, 2018

2018-04-03

Lunch in the Exhibit Hall

11:00 AM - 2:00 PM

11:00 AM

2:00 PM

Lunch in the Exhibit Hall

Piedmont

Tuesday, April 3, 2018

2018-04-03

Ending the Opioid Crisis: Solutions for State Policymakers

11:15 AM - 12:30 PM

11:15 AM

12:30 PM

Moderator: Karen H. Perry, Co-Founder and Executive Director, Narcotics Overdose Prevention and Education (NOPE) Task Force, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,APA,MCHES,GA Bar,NASW State policymakers are fervently pursuing a variety of approaches to stem the tide of the nation’s opioid epidemic. Some states are further along the learning curve than others. In this session, two national nonprofit organizations will present lessons learned from state responses across the country. Participants will take home proven strategies to implement in their states. The National Center on Addiction and Substance Abuse (CASA) published "Ending the Opioid Crisis: A Practical Guide for State Policymakers" in October 2017 to help state policymakers address the opioid epidemic — and the larger public health crisis of addiction. CASA recognized policymakers’ need for solutions that bridge the profound gap between what research demonstrates to be effective and the practices currently in use. In response, the guide culls proven and promising strategies from evidence-based resources to offer a clear and concise set of actions states can take. Based on the guide, presenters will explain how to implement a public health approach — equipping policymakers to replace misinformation and stigma with research-based facts and practical, health-based solutions. They will offer examples of data-informed and treatment-focused programs and initiatives on the state and local levels that can serve as models for states seeking to implement evidence-based prevention, early intervention, treatment, disease management and recovery support. Presenters will identify key objectives and fundamental steps that states must take to change the course of the opioid epidemic. From Shatterproof, the presenter will draw from the organization’s experience advocating for state policies to respond to the opioid epidemic. Using evidence-based and scientifically verified data, the presenter will recommend legislative action for states to implement immediately to prevent overdoses and addiction related fatalities. Using scorecards developed from a consensus of experts in the field, states will be evaluated on their existing policies and policy outcomes. Case studies will illustrate which state policies are effective and why. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Explain the key elements of a public health approach to addiction prevention and treatment. - Recognize state policies, programs and initiatives that are consistent with a public health approach and are informed by data and evidence. - Evaluate whether data-informed and treatment-focused programs and initiatives being employed by other states would benefit residents of their state. - Identify state policies that could be implemented immediately to prevent overdoses and addiction-related fatalities. - Describe successes and shortfalls in existing state policies and policy outcomes related to combating the opioid epidemic.

Linda Richter

PhD, Director of Policy Research and Analysis

The National Center on Addiction and Substance Abuse

Dr. Linda Richter is the Director of Policy Research and Analysis at The National Center on Addiction and Substance Abuse. She oversees the policy-oriented research projects at the center. Her work focuses on understanding the nature and scope of substance use and other addictive behaviors among youth and adults and the public’s substance-related attitudes, beliefs and behaviors; informing the public, policymakers, health professionals and educators about addiction science and best practices in addiction prevention and care; and identifying and promoting effective measures for improving substance use and addiction prevention and treatment. Richter received her doctorate in social psychology from the University of Maryland.

Lindsey Vuolo

JD, MPH, Associate Director of Health Law and Policy

The National Center on Addiction and Substance Abuse

Lindsey Vuolo is the Associate Director of Health Law and Policy at The National Center on Addiction and Substance Abuse and does legal, regulatory and policy work related to addiction prevention and treatment with a focus on healthcare system reform. Prior to joining the center, Vuolo worked in regulatory affairs for a managed care organization. She received a Juris Doctor from Northeastern University School of Law and Master of Public Health from Tufts Medical School. She graduated from Boston College.

Samantha Arsenault

MA, Manager of National Treatment Quality Initiatives

Shatterproof

Samantha Arsenault is the Manager of National Treatment Quality Initiatives for Shatterproof. In this role, she manages the Substance Use Disorder Treatment Task Force and provides strategic guidance and support to critical stakeholders across sectors to improve the quality of addiction treatment nationally. Prior to joining Shatterproof, Arsenault worked on the Substance Use Prevention and Treatment Initiative at The Pew Charitable Trusts. She worked to advance programs and policies that improve access and quality of substance use disorder treatment at the state and federal levels, with a focus on medication assisted treatment for opioid use disorder, and changes to infrastructure and payment systems. In addition, Arsenault worked on research and policy-based initiatives to reduce the inappropriate use of Rx drugs, while ensuring that patients have access to effective pain management. Arsenault holds a master's degree in community development and planning and bachelor's degree in economics, summa cum laude, both from Clark University.

Hanover AB

Tuesday, April 3, 2018

2018-04-03

CDC Guideline: Implementing Clinical and Practice-Level Strategies

11:15 AM - 12:30 PM

11:15 AM

12:30 PM

Moderator: Jan Losby, PhD, MSW, Team Lead, Prescription Drug Overdose Health Systems Team, Centers for Disease Control and Prevention CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,APA,NASW The Centers for Disease Control and Prevention (CDC) developed and published the CDC Guideline for Prescribing Opioids for Chronic Pain (March 2016). To encourage careful and selective use of long-term opioid therapy, a coordinated care plan was created for practices to implement systems-level clinical strategies. The presenters will share results of a mixed-methods evaluation of the implementation of the recommended strategies in primary care clinics, which measured the effects on opioid prescribing and other outcomes (e.g., reducing opioid use, high-dose opioids, co-prescribing of benzodiazepines and opioids, provider behavior, clinic policies). Their findings will include the use of the recommended strategies, effectiveness of the strategies on outcomes, and the implementation experiences of clinicians. They will highlight real-world implementation experiences from primary care clinics and provide insight into the potential effectiveness of the recommended strategies to inform future health system’s efforts to implement CDC’s guideline. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the experiences of clinics with implementation of the CDC Guideline for Prescribing Opioids for Chronic Pain. - Analyze the outcomes of implementing the strategies compared to comparison clinics. - Identify how to effectively implement recommended strategies in clinical settings.

Wesley M. Sargent, Jr.

EdD, EdS, MA, Health Scientist

Centers for Disease Control and Prevention

Wesley Sargent, EdD, LPC, is a Health Scientist on the Prescription Drug Overdose Health Systems Team in Center for Disease Control and Prevention (CDC) Division of Unintentional Injury Prevention (DUIP). He first joined DUIP in 2014 as an Evaluation Fellow, working on multiple Rx drug overdose projects, which included the CDC Guideline for Prescribing Opioids for Chronic Pain and the evaluation of the Substance Abuse and Mental Health Administration's Prescription Drug Monitoring Program (PDMP) Electronic Health Records Integration and Interoperability Expansion Program. Sargent’s current responsibilities include working with CDC-funded states to enhance PDMPs, implement community or insurer/health system interventions identifying, evaluate policy/legislative initiatives provide scientific and technical assistance. He also assists with Rx drug overdose projects that are designed to address the opioid overdose epidemic at both the health systems and state level. Sargent obtained his Doctor of Education in professional counseling and supervision with an emphasis in program evaluation at the University of West Georgia.

Jan Losby

PhD, MSW, Team Lead, Prescription Drug Overdose Health Systems Team

Centers for Disease Control and Prevention

Jan Losby, PhD, MSW, is the Team Lead for the Prescription Drug Overdose Health Systems Team in Center for Disease Control and Prevention (CDC) Division of Unintentional Injury Prevention. This team is responsible for implementing the CDC prescribing guideline in clinical settings, conducting applied health systems research, and providing scientific support to state public health departments. Prior to joining CDC, Dr. Losby managed the evaluation arm of a nonprofit evaluation organization where she designed and conducted evaluations of social service and public health programs in welfare reform, asset development, refugee services, mental health, substance abuse and employment.

Sarah J. Shoemaker

PhD, PharmD, Health Services Researcher

Abt Associates

Sarah J. Shoemaker, PhD, PharmD, a Senior Associates with Abt Associates, Inc., is a health services researcher and implementation scientist who conducts research on opioid prescribing and management, medication management and safety, primary care transformation, and quality improvement. Shoemaker is a strong methodologist with deep experience in qualitative and mixed-methods for health services, evaluation and implementation research. Shoemaker has led several studies and evaluations for the Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC), the Centers for Medicare and Medicaid Services and other clients. She currently serves as Principal Investigator/Co-Principal Investigator on a trio of projects for the CDC to develop resources in support of implementing the CDC Guideline for Prescribing Opioids for Chronic Pain through coordinated care, implementation, clinical decision support, quality improvement (QI) and QI measures for systems to monitor progress implementing the Guideline recommendations. Shoemaker’s work has been widely disseminated in peer-reviewed publications, conference presentations and posters, and in evidence-based resources available from AHRQ and CDC. Shoemaker serves on the quality and compliance committee of a Boston-based federally qualified health center, as well as the editorial advisory board of several journals. She also has served as a guest editor for journal supplements on implementation science and primary care practice improvement. Shoemaker is a registered pharmacist with experience practicing in a clinic-based practice (providing direct patient care) and several retail pharmacies (independent, chain and specialty). She received her doctorate in pharmacy degree from Creighton University and her doctorate degree from the University of Minnesota.

Douglas McDonald

PhD, Principal Associate

Abt Associates

Douglas McDonald, PhD, a Principal Associate at Abt Associates, has been conducting research and evaluation projects on prevention, treatment, and control of substance use and abuse (including both illegal and Rx drugs), opioid prescribing, healthcare, and criminal justice policies and practices, among other topics. Most of his work in the past decade has focused on the opioid epidemic. This includes National Institute on Drug Abuse-funded epidemiological research on the prevalence of opioid prescribing and of opioid diversion; providing research support to the Center for Disease Control and Prevention's development of opioid prescribing guidelines; two other projects for CDC to improve safety of opioid prescribing; Centers for Medicare and Medicaid Services-funded studies of opioid use and high-risk use by Medicare beneficiaries; and studies of prescription drug monitoring programs to identify high-risk opioid patients. He has also conducted many studies of criminal justice processing of persons charged with illegal drug use or distribution, and evaluations of drug treatment programs in prisons and in community-based probation and parole agencies.

Regency V

Tuesday, April 3, 2018

2018-04-03

Federal Efforts to Combat Synthetic Opioids

11:15 AM - 12:30 PM

11:15 AM

12:30 PM

Moderator: CeCe Spitznas, PhD, Senior Science Policy Advisor, Office of National Drug Control Policy, and Member, National Rx Drug Abuse & Heroin Summit CE Certified By: AMA,AAFP,ACPE,APA,GA Bar,GA POST The rate of drug overdose deaths involving synthetic opioids increased by 72.2% between 2014 and 2015, According to the most recent national data available from the Centers for Disease Control and Prevention, and a substantial portion of this increase appears to be related to the availability of illicit fentanyl. This session will provide an overview of the U.S. Government Accountability Office’s (GAO) 2018 report on federal efforts to combat synthetic opioids, which focused on federal actions to: 1) limit the international production and export of illicit synthetic opioids; 2) counteract the smuggling and domestic distribution of illicit synthetic opioids; and 3) prevent and treat addiction in light of the threat of synthetic opioids. This presentation will discuss the various initiatives in these arenas, many of which are cross-cutting and involve federal, state and local stakeholders across sectors, including law enforcement, public health, international relations and public policy. The discussion will outline areas of progress as well as persistent challenges that stakeholders face. Further, this presentation will discuss opportunities for improvement GAO identified during the course of the work that, if implemented, may better position federal agencies to understand and respond to the growing issue of illicit synthetic opioids. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe ways in which the federal government is responding to the threat of illicit synthetic opioids and engaging with state and local counterparts. - Identify examples of efforts where progress is being made. - Discuss the challenges that impede progress and opportunities for agencies to better understand and respond to the issue.

Julia Vieweg

MPA, Senior Analyst

U.S. Government Accountability Office

Julia Vieweg is a Senior Analyst at the Government Accountability Office (GAO). Starting at GAO in 2009, she has worked on a number of different issues spanning the federal government and currently works in GAO’s Homeland Security and Justice team on a project that is assessing U.S. efforts to combat illicit synthetic opioids. In addition to her current work, she has contributed to a number of projects on the federal prison system, border security and management of the Department of Homeland Security, among others. Prior to joining GAO, Vieweg worked as a teacher in Fairfax County (Virginia) Public Schools, an intern at the State Department’s Office of International Religious Freedom and as an AmeriCorps member serving in areas affected by Hurricane Katrina. She graduated with a bachelor's degree in politics and government, with an emphasis in international relations from the University of Puget Sound in 2005, and a master's degree in public administration, with a concentration in human rights and social justice from Cornell University in 2008.

Diana Maurer

Director, Homeland Security and Justice

U.S. Government Accountability Office

Diana Maurer has been a Director in the U.S. Government Accountability Office’s (GAO) Homeland Security and Justice team since 2009, where she currently leads GAO’s work reviewing justice and law enforcement issues. Her recent work includes reports and testimonies on the federal prison system, the Secret Service, combating violent extremism, the FBI’s use of facial recognition technology and audio-video policies at the Supreme Court. She has testified more than two dozen times before Congressional committees on several issues, including national drug control policy, FBI whistleblower protection, U.S. Department of Justice oversight and nuclear smuggling. From 2008-9, Maurer worked as an Acting Director in GAO’s Natural Resource and Environment team, where she managed work assessing U.S. global nuclear detection programs and enforcement of federal environmental law. From 1993-2007, she managed and led work in GAO’s International Affairs and Trade team, where she reviewed U.S. efforts to combat international terrorism and proliferation of weapons of mass destruction, U.S. assistance to the former Soviet Union, peacekeeping in the Balkans, and several other international issues. Maurer began her GAO career in 1990 in GAO’s Detroit Regional Office, where she worked on military and environmental issues.

Regency VI

Tuesday, April 3, 2018

2018-04-03

America's Hidden Drug Epidemic: It's More than Opioids

11:15 AM - 12:30 PM

11:15 AM

12:30 PM

Moderator: Mark Birdwhistell, MPA, Vice President for Administration and External Affairs, University of Kentucky HealthCare CE Certified By: AAFP,ACPE,APA,GA Bar,GA POST,NASW Opioids and other drugs are now increasingly cut with multiple, highly toxic adulterants, in some cases as many as 10 adulterants, in addition to fentanyl. These toxic adulterants can cause numerous medical consequences including death. Unfortunately, these adulterants are not routinely tested by forensic laboratories on seized materials or in testing for individuals undergoing treatment. Failure to identify these “hidden” toxic adulterants can hinder accurate clinical diagnosis. This presentation will provide an overview of several U.S. State Department-funded projects using state-of-the-art technologies to test street drugs and urine of individuals internationally and domestically, uncovering this unprecedented trend. It will identify the toxic adulterants driving this “hidden” epidemic, their specific health-related effects, and provide guidance to enable health professionals to accurately diagnose adulterant exposure. The presenters' novel data suggest that absent fentanyl, overdose and severe near-term health problems, even death, could occur due to a synergistic effect of multiple toxic adulterants. This information will assist law enforcement and public health officials nationally and internationally, as the toxic adulteration of street drugs is only at the beginning stage. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify the major toxic adulterants appearing in heroin. - Explain the health-related effects of individual toxic adulterants. - Recognize the importance of evaluating overdose victims for exposure to adulterants.

Thom Browne, Jr.

MA, Chief Executive Officer

Colombo Plan Secretariat

Thom Browne, Jr., who has a master's degree in criminal justice, is the President and Chief Executive Officer of the global criminal justice and demand reduction consulting firm Rubicon Global Enterprises and CEO of the international organization Colombo Plan. Browne is an internationally recognized expert in the demand reduction and criminal justice fields, having created substance use treatment systems and prevention programs in over 70 countries and international law enforcement academies on five continents during his 25-year career at the U.S. Department of State/Bureau of International Narcotics and Law Enforcement Affairs (INL). Earlier in his federal career, Browne served at the U.S. Drug Enforcement Administration (DEA), where he developed strategies, designed programs and authored research/intelligence reports addressing the original fentanyl analog/synthetic heroin and crack cocaine epidemics in the 1980s. He finished his DEA service as Chief of the Latin American Intelligence section where he authored the Reagan Administration’s cocaine suppression strategy. At INL, Browne supported the formation of the International Society of Substance Use Professionals and International Society of Addiction Medicine. In 2014, he was a finalist for the prestigious Service to America Medal for Career Achievement in the federal government. Upon his retirement from INL in 2015, he was given the Career Achievement Award by the Secretary of State.

David Martin

PhD, Science Team Director

JMJ Technologies

Dr. David Martin is a pioneer in the drug testing industry. Over the past 40 years, he has built several drug testing laboratories, including one of the first laboratories specifically to monitor impaired professionals and certified to test federal employees. He is the former Chairman of the Drug and Alcohol Testing Industry Association, Drug Testing Administrator for the International Tennis Federation, member of the IOC Medical Commission, professor at University of Florida Department of Psychiatry, Lead Scientist on the U.S. State Department Afghanistan National Drug Survey, and is currently the Science Team Director of the Colombo Plan's Global Study on Toxic Adulterants in Street Drugs.

Mark Gold, MD

Cocaine and Addiction Researcher

Mark S. Gold, MD, is a teacher, translational researcher, author, mentor and inventor best known for his work on the brain systems underlying the effects of opiate drugs, cocaine and food. He has worked as an advisor to several White House drug czars, National Institute on Drug Abuse directors and National Institute of Mental Health directors over his more than 40-year career. Gold was co-inventor of the use of clonidine in opioid withdrawal and the dopamine hypothesis for cocaine addiction and anhedonic withdrawal. He pioneered the use of clonidine and lofexidine in the late 1970s and early 1980s. Gold has earned a number of national awards for his research, including the Foundations Fund Prize, the McGovern Award for Lifetime Achievement, the National Leadership Award from the National Association of Addiction Treatment Providers, the DARE Lifetime Achievement Award and the PATH Foundation’s Lifetime Achievement Award--presented to him by drug czar Michael Botticelli. He was awarded distinguished alumni awards from Yale University and Washington University.

Hanover CDE

Tuesday, April 3, 2018

2018-04-03

Takeaways from the HIDTA/CDC Heroin Response Strategy and an Assessment of 911 Good Samaritan Laws

11:15 AM - 12:30 PM

11:15 AM

12:30 PM

Moderator: Chauncey Parker, JD, Director, New York/New Jersey HIDTA, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified by: GA Bar, GA POST This session will provide take-home lessons for all U.S. communities based on the Heroin Response Strategy (HRS) — an unprecedented public health-public safety partnership between the High Intensity Drug Trafficking Area (HIDTA) program and the Centers for Disease Control and Prevention (CDC), focused on the ultimate goal of reducing fatal and non-fatal opioid overdoses. HRS leverages a network of Public Health Analysts (PHAs) and Drug Intelligence Officers (DIOs) in 22 states. In addition to daily data and intelligence sharing, PHAs and DIOs engage in HRS Cornerstone Projects — collaborative efforts that provide a comprehensive understanding of the strengths and weaknesses in each state’s prevention, treatment and response efforts. The presenters will discuss key findings from the Cornerstone Projects, which seek to illuminate gaps in resources and create recommendations. The session will also present findings from a survey conducted among patrol officers in eight of the regional HRS HIDTAs of law enforcement perceptions of 911 Good Samaritan Laws and experiences responding to an overdose. Forty-two states have enacted such laws, which provide limited criminal immunity to those experiencing an opioid overdose or seeking medical assistance for someone else experiencing an opioid overdose. Presenters will detail the major findings, describe current patterns in overdose response activities and provide a comprehensive assessment of factors shaping the implementation of Good Samaritan laws across the 20 contiguous states represented by participating HRS HIDTAs. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Explain the HIDTA Heroin Response Strategy. - Outline two examples of the HIDTA Heroin Response Strategy Cornerstone Projects (process, findings, actions). - Evaluate the possibility of implementing a Cornerstone Project in your region. - Identify regional and environmental (i.e. urban/rural) patterns in law enforcement knowledge, attitudes and behaviors related to 911 Good Samaritan Laws. - Describe patterns and variations in the implementation of law enforcement policies and procedures related to 911 Good Samaritan Laws. - Identify patterns in the effect of 911 Good Samaritan Laws on patterns of opioid overdose and overdose related 911 calls.

Jennifer J. Carroll

PhD, MPH, Science to Action Coordinator, HIDTA/CDC Heroin Response Strategy

Centers for Disease Control and Prevention

Dr. Jennifer J. Carroll is a medical anthropologist who specializes in drug use and overdose prevention. She is an Adjunct Assistant Professor of Medicine at Brown University and a scientific consultant for the Centers for Disease Control and Prevention/High Intensity Drug Trafficking Area Heroin Response Strategy. She holds a doctorate in anthropology and a Master in Public Health in epidemiology from the University of Washington. She has been conducting research on harm reduction and drug treatment efforts in Ukraine since 2007 and is currently writing a book on drug use and global health in Ukraine before, during and after the country’s recent political revolution.

Jessica Wolff

MPH, Evaluator/Program Manager

Centers for Disease Control and Prevention

Jessica Wolff has six years of program evaluation and project management experience in a variety of public health fields, including global HIV/AIDS prevention, youth suicide prevention and children’s mental health services. She currently serves as project manager for the Heroin Response Strategy, a 20-state collaborative between public health (Centers for Disease Control and Prevention) and public safety (High Intensity Drug Trafficking Areas) to address the opioid epidemic. Prior to her work with the Heroin Response Strategy, Jessica was a Senior Research Associate at a public health consulting firm, providing evaluation training and technical assistance to federally funded grantees.

Chauncey Parker

JD, Director

New York/New Jersey HIDTA, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board

Rita Noonan

PhD, Branch Chief, Division of Unintentional Injury Prevention

Centers for Disease Control and Prevention

Rita K. Noonan, PhD, is a sociologist and Branch Chief in the Centers for Disease Control and Prevention's Division of Unintentional Injury Prevention. Noonan and her staff oversee the $125 million Overdose Prevention in States (OPIS) initiative, a combination of prevention, intervention and public health surveillance programs to reduce opioid-related overdose across the United States. She works closely with several High Intensity Drug Trafficking Areas (HIDTAs), managing the public health component of Office of National Drug Control Policy's Heroin Response Strategy, which links public health and public safety across 22 states. She has been the recipient of several prestigious awards, including a Fulbright Scholarship and a MacArthur Fellowship. She received her doctorate degree from Indiana University.

Hanover FG

Tuesday, April 3, 2018

2018-04-03

What We Wish We Had Known: Lessons Learned in Establishing a MAT Program for Pregnant Women

12:30 PM - 1:45 PM

12:30 PM

1:45 PM

Moderator: Carla S. Saunders, DNP, APRN, NNP-BC, Advance Practice Coordinator, Pediatrix Medical Group, Neonatal Nurse Practitioner, East Tennessee Children’s Hospital, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,ACPE,ANCC,NAADAC,NASW,NBCC Pregnant women with opioid use disorder often are more motivated for recovery compared to other populations. Prioritizing their care has the potential to have a substantial impact on generational addiction as well as the opioid epidemic. In this session, presenters will allow a platform for those in the trenches caring for pregnant women to share ideas, examine solutions, and show stakeholders the hardships faced. Additionally, presenters intend to impart advice, mentorship and knowledge that will urge medication assisted treatment (MAT) providers not currently caring for pregnant women to do so. Experienced high-risk pregnancy providers will describe their lessons learned while developing and instituting a MAT program for pregnant women. Presenters will demonstrate their response to barriers including: protocol development and implementation; ancillary service procurement and collaboration; education attainment and dispersal; and peripartum management. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Provide a platform to cultivate critical thought and dialogue among those who care for pregnant women with opioid use disorder. - Encourage medication assisted treatment providers to care for pregnant women and increase awareness of the adversities encountered in providing care for pregnant women. - Prevent other practitioners from reinventing the wheel in developing medication assisted treatment programs for pregnant women.

Catherine "Bizz" Grimes

MEd, ASN, RN, Ambulatory Nurse Clinician

Indiana University School of Medicine

Catherine "Bizz" Grimes obtained her nursing degree in 2003 from the School of Nursing at Indiana University-Purdue University Indianapolis. Upon receipt of her degree, she worked with the high-risk obstetric population on the Obstetric Intensive Care Unit at Indiana University Health, University Hospital for ten years. After a three-month respite, she returned to work as an Ambulatory Nurse Clinician in the Prenatal Diagnosis Clinic at Indiana University Health, University Hospital. She naturally gravitated toward the opioid use disorder population within the first year of working as an outpatient nurse. Prior to obtaining her nursing degree, she spent 10years working as a Reference Assistant and Interlibrary Loan Coordinator at the Roy O. West Library at DePauw University in Greencastle, Indiana.

Brandi Brinkerhoff

MSN, RN, WHNP-BC, Women's Health Nurse Practitioner and Maternal-Fetal Medicine Ambassador

Indiana University School of Medicine

Brandi Brinkerhoff is a board-certified Nurse Practitioner in Women’s Health Care. She obtained her Associates of Science in Nursing in 2010, her Bachelors of Science in Nursing in 2011, and her Masters of Science in Nursing in 2015, all from the University of Indianapolis. Brinkerhoff started her nursing career as a bedside nurse on a Pulmonary Medical-Surgical unit, before spending four years as a Labor and Delivery Nurse on the Obstetric Intensive Care Unit at Indiana University Health, University Hospital. Upon obtaining her master's degree, she transitioned into the advanced provider role with Maternal Fetal Medicine in 2015. Brinkerhoff has a DEA waiver to prescribe buprenorphine for up to 30 patients. She works both in the inpatient setting to help pregnant women with opioid use disorder initiate onto buprenorphine and the outpatient setting to monitor those women during their pregnancies.

Tara Benjamin

MD, MS, FACOG, Assistant Clinical Professor, Department of Obstetrics and Gynecology, Indiana University School of Medicine

Director, Maternal Recovery Program, Riley Maternity and Newborn Health

Tara Benjamin, MD, MS, is a native of New Iberia, Louisiana. She is board certified in Obstetrics and Gynecology and Maternal-Fetal Medicine. Her bachelor's degree was obtained from Xavier University of Louisiana and her medical degree from Harvard Medical School. Her residency was completed at Tulane University and her fellowship at Indiana University School of Medicine, where she also received a master's degree in clinical research. She is the Director of the Maternal Recovery Program for Riley Maternity and Newborn Health and an Assistant Professor in the Department of Obstetrics and Gynecology at Indiana University School of Medicine (IUSM). Benjamin has a special interest in opioid use disorder in pregnancy and has a DEA waiver to prescribe buprenorphine for up to 100 patients. Since becoming faculty at IUSM in August 2015, she and her team have managed almost 300 pregnant women with opioid use disorder.

Courtland

Tuesday, April 3, 2018

2018-04-03

PDMP Innovations: Washington’s Prescriber Feedback and Wisconsin’s Data Analytics

12:30 PM - 1:45 PM

12:30 PM

1:45 PM

Moderator: Grant T. Baldwin, PhD, MPH, Director, Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ADA,ANCC States continually improve their prescription drug monitoring programs (PDMPs) to respond more effectively to Rx drug abuse. In this session, two states will report on developments in their PDMP programs. From Washington, the presenter will explore using PDMP data to change prescribing practices and overdose notifications. In 2017, Washington passed new legislation that allows PDMP data to be shared with healthcare systems at the prescriber level for prescribing quality improvement work that provides for prescriber feedback reports, and that creates an overdose notification system using the state Emergency Department Information Exchange. This new authority provides new avenues to positively impact the epidemic. From Wisconsin, the presenter will detail how the Wisconsin Enhanced Prescription Drug Monitoring Program (WI ePDMP) leverages data analytics and data visualizations. First, WI ePDMP’s publicly available data dashboard provides the public with dynamic de-identified data visualizations about PDMP utilization, controlled substance dispensing and law enforcement PDMP alerts. The presentation will examine each type of data visualization, including how the underlying data was chosen. Second, the WI ePDMP uses an entirely electronic method to receive requests and prepare and disclose de-identified data sets for academic and research purposes. Finally, the functionality enables chief medical officers, medical directors and other authorized people to review prescribing practice metrics reports that contain data analytics about the prescribing practices and patient populations of an individual prescriber. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Explain how Washington uses facility-level prescribing reports to change prescribing behavior. - Explain Washington’s use of prescriber feedback reports. - Describe how Washington uses the PDMP and Emergency Department Information Exchange systems to create an overdose notification system. - Identify the ways in which the Wisconsin Enhanced Prescription Drug Monitoring Program uniquely leverages data analytics to maximize its benefits. - Recognize the importance of effective data visualization to convey complex sets of information. - Prepare to implement functionalities similar to those of the Wisconsin Enhanced Prescription Drug Monitoring Program in their own states.

Chris Baumgartner

Drug Systems Director

Washington State Department of Health

Chris Baumgartner is the Drug Systems Director at the Washington State Department of Health. Prior to his appointment in 2015, he served in various capacities for 10 years, including working for the department as the Prescription Monitoring Program Director and owning a consulting firm that provided training and technical services to federal and state governments. He also worked for the Washington State Department of Social and Health Services as an IT Portfolio Analyst and managed the Prescription Monitoring Program for the State of Maine while with the Office of Substance Abuse.

Andrea Magermans

Prescription Drug Monitoring Program Managing Director

Wisconsin Department of Safety and Professional Services

Andrea Magermans is currently the Managing Director of the Wisconsin Prescription Drug Monitoring Program (WI PDMP) at the Wisconsin Department of Safety and Professional Services. She joined the department in December 2012 as a Program and Policy Analyst to oversee the training and outreach efforts for the launch of the WI PDMP in 2013. Since then, she collaborated as Deputy Managing Director on all aspects of the operations and enhancement of the WI PDMP, including the development of the Wisconsin Enhanced Prescription Drug Monitoring Program in 2017. She became Managing Director in September 2017.

Baker

Tuesday, April 3, 2018

2018-04-03

Interprofessional Excellence: Integrating Pharmacists into the MAT Team

12:30 PM - 1:45 PM

12:30 PM

1:45 PM

Moderator: Daniel Blaney-Koen, JD, Senior Legislative Attorney, American Medical Association, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ANCC,APA,NAADAC,NASW,NBCC Pharmacists are often an underutilized healthcare resource despite their medication expertise and accessibility. Pharmacists are essential healthcare providers who are trained to recognize opioid overdose, opioid use disorder and withdrawal syndromes. Integration of the pharmacist into medication assisted treatment (MAT) teams for opioid use disorders can help improve access and outcomes, while reducing the risk of relapse. When pharmacists partner with prescribers to provide MAT, pharmacists are able to take the lead in developing treatment plans, communicating with patients, improving adherence, monitoring patients, identifying treatment options and performing tasks to alleviate prescriber burden. This session will demonstrate three different practice settings where psychiatric pharmacists partner with prescribers to provide care collaboratively for patients with substance use disorders. Participants will gain knowledge of innovative ways to include pharmacists on the MAT interprofessional team and how to design and execute effective practice protocols. This presentation is provided in collaboration with the College of Psychiatric and Neurologic Pharmacists. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify the unique training and traits pharmacists bring to the interprofessional treatment team caring for patients with substance use disorders. - Describe the barriers and benefits encountered in establishing a collaborative practice agreement with prescribers to provide medication assisted treatment. - Compare outcomes from collaborations integrating pharmacists in the medication assisted treatment care team in different practice settings across the United States.

Bethany DiPaula

PharmD, BCPP, Associate Professor, School of Pharmacy

University of Maryland - Baltimore

Bethany A. DiPaula, PharmD, BCPP, is an Associate Professor at the University of Maryland School of Pharmacy, Baltimore, Director of Pharmacy at Springfield Hospital Center, and Clinical Pharmacist at Helping Up Mission. DiPaula completed her Doctor in Pharmacy and psychiatric residency training at the University Of Maryland School Of Pharmacy, Baltimore. She became a Board Certified Psychiatric Pharmacist in 1997. DiPaula has been active in shaping state collaborative drug therapy management legislation and in developing physician-pharmacist collaborative practices. She currently practices collaboratively providing medication management services for psychiatric and opioid use disorder patients at Helping Up Mission. She previously created a collaborative buprenorphine/naloxone-maintenance program at a federally funded community health clinic and a local health department. She received state approval for her physician-pharmacist opioid use disorder and psychiatric disorders drug therapy management protocols. DiPaula has worked on a state committee, which legislatively advocated for expanded access to naloxone through greater pharmacist involvement. She has served as an instructor and supervisor for Maryland’s opioid overdose response program curriculum at a local health department. DiPaula has mentored addicted pharmacists while volunteering with the Pharmacist Education and Assistance Committee.

Sarah Melton

PharmD, BCPP, BCACP, FASCP, Professor of Pharmacy Practice

Gatton College of Pharmacy, East Tennessee State University

Dr. Sarah T. Melton is Professor of Pharmacy Practice at the Gatton College of Pharmacy at East Tennessee State University (ETSU). She is the Clinical Pharmacist at the Johnson City Community Health Center, the ETSU Center of Excellence for HIV/AIDS, and Highpower, PC. Melton received her bachelor's degree in pharmacy (1991) and doctorate in pharmacy (1994) from Virginia Commonwealth University/Medical College of Virginia School of Pharmacy (VCU). She completed a Fellowship in Psychiatric Pharmacy at VCU in 1996. She has been a board-certified psychiatric pharmacist (Board of Pharmaceutical Specialties) since 1997 and a board-certified ambulatory care pharmacist since 2011. She is a Fellow of the American Society of Consultant Pharmacists. She performs comprehensive medication management in the areas of psychiatric and neurologic pharmacy, addiction, and other primary care disorders.

Troy A. Moore

PharmD, MS, BCPP, Clinical Pharmacy Specialist- Psychiatry

South Texas Veterans Health Care System

Troy A. Moore received his doctorate of pharmacy degree from the University of New Mexico College of Pharmacy in 2003. He subsequently attended the University of Texas at Austin College of Pharmacy, receiving his master's degree in pharmacy in 2005 while completing a two-year Psychiatric Pharmacy Residency at the San Antonio State Hospital and the South Texas Veterans Health Care System (STVHCS). He joined the University of Texas Health Science Center at San Antonio Department of Psychiatry, Division of Schizophrenia and Related Disorders in 2005 and became Assistant Professor in 2007. He joined the STVHCS as Clinical Pharmacy Specialist in Psychiatry in 2010, where he serves the Substance Abuse and Domiciliary Programs. He is the author of numerous publications, including the Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. He is a reviewer for multiple psychiatric and pharmacy journals. He is the Director of the ASHP accredited PGY-2 Psychiatric Pharmacy Residency at STVHCS, serves as the Chair of the STVHCS Pharmacy Professional Standards Board, and serves as one of the handling editors for the Mental Health Clinician. Moore previously served as Co-Director of the Advanced Fellowship in Addiction Treatment at STVHCS, Chair of the Board of Pharmacy Specialties Specialty Council on Psychiatric Pharmacy, and the Member-at-Large on the Board of Director for the College of Psychiatric and Neurologic.

Regency VII

Tuesday, April 3, 2018

2018-04-03

Stop Them Before They Start

12:30 PM - 1:45 PM

12:30 PM

1:45 PM

Moderator: Tina Messer, MA, Manager, Department of Specialty Courts, Kentucky Administrative Office of the Courts, and Member, Operation UNITE Board of Directors CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,MCHES,NASW What are our communities doing to help prevent that initial misuse of Rx drugs, which too often leads to serious addiction? This session will highlight best practices related to preventing substance misuse in a data-driven, communitywide, comprehensive manner. From the Community Anti-Drug Coalitions of America (CADCA), the presenter will identify national best practices for community prevention coalitions to plan, implement and evaluate across CADCA’s Seven Strategies for Community Change to specifically impact population-level reductions in medicine misuse and abuse. Discussion will cover the tools and resources developed by CADCA to address the Rx drug issue with scale and scope in diverse communities. From Carter County, Kentucky, which was at the epicenter of the opioid epidemic, the presenter will describe the organization of and funding for a plan to implement evidence-based, data-driven, comprehensive strategies. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify best practices for comprehensively reducing Rx misuse and abuse at the community level. - Describe the strategic process and comprehensive implementation/evaluation methods used by the Carter County Drug-Free Coalition to reduce Rx misuse and abuse rates from among the highest in the nation to below national averages. - Explain the types and mix of comprehensive strategy options a community can implement to prevent the misuse of Rx drugs, especially opioids.

Sue Thau

MCRP, Public Policy Consultant

Community Anti-Drug Coalitions of America

Shelly Steiner

DFC Grant Coordinator

Carter County (Kentucky) Drug Free Coalition

Shelly Steiner is the DFC Grant Coordinator for the Carter County (Kentucky) Drug Free Coalition. She earned her Certified Prevention Specialist in 2012 and has been working in the prevention field for the past eight years. She has presented at the Community Anti-Drug Coalitions of America (CADCA) National Leadership Forum, CADCA Mid-Year Training Institute, and the National Rx Drug Abuse and Heroin Summit. She earned a bachelor's degree in secondary education, majoring in Spanish and minoring in speech and communications, from Morehead State University, and she is working towards her master's degree in counseling. She worked in the public school system for 17 years, four as a Spanish teacher, before coming into the prevention field.

Learning Center

Tuesday, April 3, 2018

2018-04-03

Health Plans Address America’s Opioid Epidemic with Evidence-Based Strategies

12:30 PM - 1:45 PM

12:30 PM

1:45 PM

Moderator: J. Kevin Massey, Health Administrator, Correct Care Solutions, Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ANCC,NAADAC,NASW,NBCC Clinical leaders from health plans will discuss programs and strategies to engage patients, providers, and communities to combat the opioid epidemic. The panel will describe how education, prevention, early intervention, behavioral healthcare and evidence-based treatment are critical components of a multi-faceted, multi-stakeholder approach to effectively caring for pain while also reducing the risk of addiction. Panelists will consider the following questions: 1. Have any policies been implemented for reducing inappropriate opioid prescribing? 2. What are those policies and what methods of communication have been utilized to disseminate information about the policies to patients and physicians, pharmacists and other healthcare practitioners, especially for situations where opioid thresholds might be exceeded? 3. Have non-opioid pharmacologic and non-pharmacologic pain care coverage options been added, or have other changes been implemented to facilitate access to other pain care options for patients? 4. Are measures being implemented or explored that would increase access to medication assisted treatment for opioid use disorder? 5. Are measures being implemented or explored that would increase access to mental health, behavioral health and other modalities to help treat opioid use disorder? 6. Are other measures being implemented or explored that would enhance the overdose prevention efforts of your members? 7. What role does naloxone play? 8. Are you tracking the impact of these policies, not only on opioid utilization, but also on overall health outcomes? UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe health plan programs and strategies to address the opioid epidemic. - Reconize the importance of collaboration across all stakeholders. - Identify ongoing challenges and strategies to address those challenges to curtail the opioid crisis.

Eric Bailly

LPC, LADC, CM Business Solutions Director

Anthem, Inc.

Eric Bailly is a Business Solutions Director at Anthem, Inc. In his tenth year at Anthem, his role is focused on the Commercial and Specialty Business Division’s substance use disorder strategy, with an emphasis on the enterprise opioid strategy. Bailly earned a bachelor’s degree in psychology from Concordia College in Moorhead, Minnesota, in 1993, and a master’s degree in counseling psychology from the University of Colorado at Denver in 1996. He is a Licensed Professional Counselor in the states of North Dakota and Colorado, and is a Licensed Alcohol and Drug Counselor in the state of Minnesota. Bailly has worked as a behavioral health clinician in several settings, including Outpatient Substance Use Disorder treatment services at both Kaiser Permanente and the Jefferson County Department of Health and Environment, both in the Denver, Colorado, metro area.

Barbara Henry

RPh, Clinical Pharmacy Coordinator

Harvard Pilgrim Health Care

Barbara Henry has nearly 30 years of managed care experience and is currently a Lead Pharmacy Specialist at Harvard Pilgrim Health Care (HPHC) serving members in Massachusetts, Maine, New Hampshire and Connecticut. In this role her responsibilities focus on the development and management of multiple formularies, and the creation of quality programs with a patient-centric and value-based approach. She also provides leadership in the execution of pharmacy strategy including comprehensive drug cost management initiatives and monitoring medical and pharmacy drug trends. Her areas of professional interest focus on appropriate opioid prescribing, substance use disorder, and adolescent behavioral health. She leads HPHC’s cross functional team addressing the opioid crisis and participates in her local coalition and the Norfolk County Prescription Drug Task Force lead by the District Attorney.

Douglas (Doug) Nemecek

Chief Medical Officer

Cigna

Doug Nemecek, MD, MBA is the chief medical liaison for behavioral health integration, quality and clinical operations. He helps ensure network access and availability, patient safety, compliance with clinical guidelines, customer and provider satisfaction, and utilization management. Additionally, he works directly with customers and clients to mold operations and provides clinical expertise in new and existing behavioral health and integrated program development. Nemecek also leads Cigna’s national Coverage Policy team, responsible for developing policies and tools that are used to interpret standard medical, behavioral, and pharmacy benefit plan provisions. Additionally, he helps to coordinate Cigna’s national medical cost trend analysis and initiatives to address major medical cost drivers for our clients.

Dunwoody

Tuesday, April 3, 2018

2018-04-03

The National Opioid Overdose Epidemic: It’s Not Just Opioids

12:30 PM - 1:45 PM

12:30 PM

1:45 PM

Moderator: Christopher M. Jones, PharmD, MPH, Director, National Mental Health and Substance Use Policy Laboratory, Substance Abuse and Mental Health Services Administration, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,APA,MCHES,GA Bar,GA POST,NAADAC,NASW,NBCC A common misconception about the opioid overdose epidemic is that it is limited to opioids. Glaringly overlooked is the fact that there are few people addicted to opioids that do not also, and usually simultaneously, use many other drugs. The national data on opioid overdose deaths collected by the Center for Disease Control and Prevention is limited because it is based on death reports from medical examiners, which substantially underreport the presence of additional drugs. In contrast, the Florida Drug-Related Outcomes Surveillance and Tracking System (FROST) collects the statewide systematic, extensive toxicological testing done on all drug overdose cases. This presentation will present FROST data to elucidate the role of other drugs — alcohol, Rx drugs and illicit drugs — in the opioid overdose epidemic. About 95% of deaths involve other drugs — averaging two to four additional non-opioid drugs, but reaching as many as 11 other drugs. Patterns of drug use among overdose death victims will be presented along with recommendations for changes in data collection and testing. Recommendations will be made for policy changes to improve prevention and treatment as part of a national response to reduce the overdose epidemic. These changes are necessary to reflect the ubiquity of polydrug use among opioid addicted people. A clear picture of the drug use of opioid dependent people is needed not only to treat this epidemic but also to prevent it. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the ubiquity of alcohol, Rx drugs and illegal drugs in the opioid epidemic. - Identify procedures to improve data collection for overdose deaths. - Define new goals for prevention and treatment of opioid use disorders based on polysubstance use in overdoses.

Robert DuPont

MD, President

Institute for Behavior and Health, Inc., and Member, National Rx Drug Abuse & Heroin Summit Advisory Board

For over 40 years, Dr. Robert L. DuPont has been a leader in drug abuse prevention and treatment. He was the first Director of the National Institute on Drug Abuse (1973-1978) and the second White House Drug Chief (1973-1977). From 1968-1970, he was Director of Community Services for the District of Columbia Department of Corrections. From 1970-1973, he served as Administrator of the District of Columbia Narcotics Treatment Administration. In 1978, he became the founding President of the Institute for Behavior and Health, Inc. He has been Clinical Professor of Psychiatry at the Georgetown University School of Medicine since 1980. He is a Distinguished Fellow of the American Society of Addiction Medicine and Life Fellow of the American Psychiatric Association. DuPont's signature role throughout his career has been to focus on the public health goal of reducing the use of illegal drugs.

Bruce A. Goldberger

PhD, Professor and Chief, Division of Forensic Medicine, Department of Pathology, Immunology and Laboratory Medicine

University of Florida College of Medicine

Dr. Bruce Goldberger is a Professor and the Chief of the Division of Forensic Medicine in the Department of Pathology, Immunology and Laboratory Medicine in the College of Medicine at the University of Florida in Gainesville. Goldberger is the Editor-in-Chief of the Journal of Analytical Toxicology, is a past-President of the American Academy of Forensic Sciences and the President of the American Board of Forensic Toxicology and Society of Forensic Toxicologists. Goldberger received a Bachelor of Arts Degree in Zoology from Drew University and Master of Science and Doctor of Philosophy in Forensic Toxicology from the University of Maryland School of Medicine in Baltimore. He is a Fellow of the American Board of Forensic Toxicology and the National Academy of Clinical Biochemistry. He has published numerous articles, reviews and chapters related to forensic toxicology and is co-editor of the "Handbook of Workplace Drug Testing, On-Site Drug Testing and Garriott’s Medicolegal Aspects of Alcohol, 6th Edition."

Piedmont

Tuesday, April 3, 2018

2018-04-03

More PDMPs, More CME, Fewer Opioids — So Why Is the Epidemic Worse?

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: J. Kevin Massey, Health Administrator, Correct Care Solutions, Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ADA,ANCC This presentation will begin with a retrospective look at state and national directives and mandates governing physician behaviors, including use of prescription drug monitoring programs (PDMPs), opioid prescribing, continuing medical education (CME) and access to naloxone. Legislative efforts in these areas began in earnest in the 2013-2014 state legislative sessions, with mandates largely being enacted in the 2015-2016 session years. Prior to the mandates, however, physicians began to show progress on each measure. The first question, therefore, is what effect have the mandates had on physician practices? The second issue is the fact that despite the new state policies, the number of people dying from opioid-related causes continues to increase. In addition, the factors that fueled the epidemic (Rx opioid supply and diversion) have begun to shift. That is, as opioid prescribing has decreased — in total prescriptions, dose and quantity — opioid-related mortality from heroin and illicit fentanyl has increased by staggering proportions. While the data is inconclusive as to a direct correlation (let alone causation) for this shift, the second question is what policy interventions, if any, can help address the shifting mortality dynamics? The third issue is the most intractable, yet perhaps the most important. Specifically, how do we — as physicians, payers, policymakers — help the millions suffering from chronic pain and/or a substance use disorder access affordable, comprehensive treatment? Without increased care, what are the likely implications for the opioid epidemic? UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify the top state legislative and national policy trends that have occurred as a result of increased opioid-related mortality. - Explain the results of those policies on physician practices and opioid-related mortality. - Outline what policymakers must do now to reverse the nation’s opioid epidemic.

Patrice Harris

MD, MA, Member, AMA Board of Trustees; Chair AMA Opioid Task Force

American Medical Association

Patrice A. Harris, MD, MA, a psychiatrist from Atlanta, has diverse experience as a private practicing physician, public health administrator, patient advocate and medical society lobbyist. She was elected to the American Medical Association (AMA) Board of Trustees in June 2011. Active in organized medicine her entire career, Harris has served on the board of the American Psychiatric Association, the governing council of the AMA Women Physicians Congress, the AMA reference committees, and AMA work groups on health information technology, sustainable growth rate and private contracting. She has held many leadership positions at the state level, including serving on the board and as President of the Georgia Psychiatric Physicians Association and on the Medical Association of Georgia’s Council on Legislation, its Committee on Constitution and Bylaws, and its Membership Task Force. She was the founding President of the Georgia Psychiatry Political Action Committee. In 2001, she was selected Psychiatrist of the Year by the Georgia Psychiatric Physicians Association. Starting with medical school at West Virginia University, followed by a psychiatry residency and child psychiatry and forensics fellowships at Emory University, and then as the Barton Senior Policy Fellow at the Emory University School of Law, she has worked for children both clinically and in the advocacy arena. As past director of Health Services for Fulton County, which includes Atlanta, Harris was the county's chief health officer. She continues in private practice and consults with both public and private organizations on health service delivery and emerging trends in practice and health policy. She is an Adjunct Assistant Professor in the Emory Department of Psychiatry and Behavioral Sciences.

Hanover AB

Tuesday, April 3, 2018

2018-04-03

Integrating Peer Support Service in the ED: Benefits and Challenges

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: John J. Dreyzehner, MD, MPH, FACOEM, Commissioner, Tennessee Department of Health, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ANCC,APA,NAADAC,NASW,NBCC Project POINT is an emergency department (ED) based outreach program designed to support survivors of opioid overdoses and bridge them to ongoing care. POINT has revealed that there are far more patients in need of/seeking treatment than there are professionals equipped to provide high quality, interdisciplinary, evidenced-based care. Incorporating peer recovery coach support is an evidenced-based way to expand the quantity and quality of the care available to patients with opioid misuse disorders. Presenters will share their experience integrating recovery coaching services into their ED outreach program. The benefits include: 1. Increased patient engagement with the outreach team. 2. Increased cooperation and engagement in the ED assessment and referral process. 3. Longer engagement and increased success of treatment after ED discharge. Their challenges have been: 1. Lack of structure for hiring and incorporating new roles in a busy, high acuity clinical setting. 2. Creating a plan for recovery coaching supervision, continuing education and wellness. 3. Prioritizing responsibilities, managing expectations and setting boundaries for clinical staff, recovery coaches and patients. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the role of a peer recovery coach in the emergency department setting. - Identify ways to address barriers to incorporating this service into their own clinical setting. - Explain how to design support for this role in the team through ongoing professional development.

Krista Brucker

MD, Assistant Professor of Emergency Medicine

Indiana University School of Medicine Department of Emergency Medicine

Dr. Krista Brucker is a faculty member at the Indiana University School of Medicine’s Department of Emergency Medicine and works clinically in the Emergency Department at Eskenazi Health. Her research focuses on mental health and substance abuse treatment in the Emergency Department setting. Her current work includes the design and implementation of Project POINT, a collaborative effort aimed at identifying, treating and linking patients with opioid use disorders to outpatient treatment services. She also runs an observational study assessing a new risk stratification tool for emergency department patients with suicidal ideation. Brucker completed her emergency medicine residency at the Northwestern University Feinberg School of Medicine in Chicago. She is a graduate of Harvard Medical School and earned her undergraduate degree in biochemistry from DePauw University. Born and raised in Minnesota, she currently resides in Indianapolis.

Emily Zarse

MD, Medical Director of Addiction Psychiatry

Eskenazi Health

Emily Zarse, MD, is the Medical Director of Addiction Psychiatry at Eskenazi Health and is Assistant Professor at Indiana University School of Medicine. In addition to working in a dual diagnosis clinic treating patients with comorbid mental illness and substance use disorders, Zarse is the addictions expert on the Eskenazi Health Opioid Collaborative to improve access to care for opioid dependent patients in a primary care setting. She is training primary care doctors on identifying patients with opioid use disorders and treating appropriate patients with buprenorphine. She is also collaborating with the Emergency Department on Project POINT with an aim to improve access to care for opiate overdose patients.

Hanover FG

Tuesday, April 3, 2018

2018-04-03

Kentucky’s Comprehensive System of Care Model for Pregnant and Parenting Women with SUD

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: Carla S. Saunders, DNP, APRN, NNP-BC, Advance Practice Coordinator, Pediatrix Medical Group, Neonatal Nurse Practitioner, East Tennessee Children’s Hospital, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ANCC,APA,NAADAC,NASW,NBCC Over the past three years Kentucky has been working to develop a new system of care that is evidence-based, comprehensive, integrated, and includes community coordinated service delivery elements for pregnant and parenting women diagnosed with substance use disorder (SUD). The purpose of this project is to expand treatment services and increase capacity for evidence-based treatment including medication assisted treatment (MAT) and other recovery support services to pregnant and postpartum women with SUD for up to 2 years after the birth of the child. Elements of the project address many factors from early identification and screening to specialized services for pregnant women to promoting community partnerships and more. Expected outcomes include: - Increased access to MAT, wrap around services and treatment supports - Increased number of individuals receiving comprehensive, integrated, community coordinated care - Reduction in adverse childhood experiences (ACE) and intergenerational substance abuse patterns - Decreased illicit drug use among target population at 6 months’ follow-up - Formation of a comprehensive and sustainable system of care that can be replicated. The session will present the process and components of Kentucky’s Comprehensive System of Care Model for Pregnant and Parenting Women with Substance Use Disorder. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify the components of a comprehensive system of care for pregnant and parenting women. - Identify the components of a Plan of Safe Care. - Identify the importance of promoting community partnerships for this population.

Maggie Schroeder

MA, LCADC, Adult Substance Use Treatment and Recovery Services Branch Manager, Division of Behavioral Health

Kentucky Cabinet for Health and Family Services

Maggie Schroeder is the Branch Manager for the Adult Substance Use Treatment and Recovery Services Branch at the Kentucky Division of Behavioral Health, Developmental and Intellectual Disabilities. She has master's degrees in clinical psychology and political science and is a licensed clinical alcohol and drug counselor. She has over 30 years of experience in providing behavioral health and substance abuse services to individuals and their families including case management and therapeutic interventions services, as well as providing clinical and administrative supervision.

Regency V

Tuesday, April 3, 2018

2018-04-03

Faster Data: The CDC-Funded Enhanced State Opioid Overdose Surveillance Program

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: Puja Seth, PhD, Lead, Overdose Epidemiology and Surveillance Team, Centers for Disease Control and Prevention CE Certified By: AMA,AAFP,ACPE,ANCC,APA,GA Bar,GA POST Current surveillance systems have delays in data availability exceeding a year, highlighting the need for timely and comprehensive nonfatal and fatal overdose surveillance. This session will describe goals, components and preliminary findings of the Enhanced State Opioid Overdose Surveillance Program (ESOOS), funded by the Centers for Disease Control and Prevention (CDC). Through ESOOS, CDC is able to report morbidity data on opioid overdoses by states on a quarterly basis and mortality data bi-annually by specific drug(s) because of enhanced toxicology. The increased timeliness of these data will inform the strategic planning around CDC-funded prevention efforts, facilitate a more rapid, targeted response effort at the local level, and disseminate data to key stakeholders and policymakers. The goals of ESOOS are as follows: 1) increase the timeliness of reporting of nonfatal opioid overdoses and help detect sharp increases or decreases; 2) increase the timeliness of reporting of fatal opioid overdoses and associated risk factors; and 3) disseminate surveillance findings to key stakeholders working to prevent or respond to the opioid overdose epidemic. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the CDC’s new opioid overdose surveillance program. - Discuss how rapidly available data can be used to inform overdose response and prevention efforts. - Overview emergency department and emergency medical services data for use in tracking opioid overdose trends. - Describe the development of case definitions for opioid and heroin overdose in emergency department and emergency medical services data. - Overview data available for fatal opioid overdoses and associated risk factors and its use in informing prevention and response recommendations.

Puja Seth

PhD, Lead, Overdose Epidemiology and Surveillance Team

Centers for Disease Control and Prevention

Dr. Puja Seth is the Team Lead for the Overdose Epidemiology and Surveillance Team in the Division of Unintentional Injury Prevention (DUIP) at the Centers for Disease Control and Prevention (CDC). Her team is responsible for the Enhanced State Opioid Overdose Surveillance (ESOOS) program. She has served in this capacity since February 2016 and has been at CDC since 2009. Prior to joining DUIP, Seth worked internationally and domestically on programmatic and research efforts on HIV testing and HIV service delivery, prevention with HIV-positive persons, program evaluation, national-level HIV data and data quality issues, capacity building, and providing technical assistance to states and countries. She is an adjunct faculty member in the Rollins School of Public Health at Emory University. Seth has her doctorate in clinical psychology from the University of Georgia and her master's degree from the University of North Carolina at Wilmington. She has over 55 publications in peer-reviewed journals, book chapters and government reports, and she has given over 85 presentations.

Alana Vivolo-Kantor

PhD, MPH, Behavioral Scientist

Centers for Disease Control and Prevention

Dr. Alana Vivolo-Kantor is a Behavioral Scientist on the Overdose Epidemiology and Surveillance Team in the Division of Unintentional Injury Prevention at the Centers for Disease Control and Prevention (CDC) working on the Enhanced State Opioid Overdose Surveillance (ESOOS) grant. She serves as a Science Officer for several funded state health departments; manages the Emergency Department data delivery (including coordination and partnership with CDC’s NSSP/ESSENCE); and leads ESOOS dissemination efforts. Prior to coming to DUIP, she was a Behavioral Scientist in CDC’s Division of Violence Prevention in the Research and Evaluation Branch, where she focused on measurement, surveillance, etiologic research, and program evaluation activities for youth violence, bullying and teen dating violence.

Julie O'Donnell

PhD, MPH, Epidemiologist

Centers for Disease Control and Prevention

Dr. Julie O’Donnell is an Epidemiologist on the Epidemiology and Surveillance Team in the Division of Unintentional Injury Prevention (DUIP) at the National Center for Injury Prevention and Control in the Centers for Disease Control and Prevention, working on the Enhanced State Opioid Overdose Surveillance (ESOOS) program. She is a subject matter expert working on the mortality data component of ESOOS and serves as the Science Officer for several funded states. O’Donnell served as an Epidemic Intelligence Service Officer at the Substance Abuse and Mental Health Services Administration prior to joining DUIP. As an Epidemic Intelligence Service Officer, she conducted field investigations and epidemiologic studies of behavioral health issues, including opioid overdose.

Regency VI

Tuesday, April 3, 2018

2018-04-03

It's More Than Opioids: Polysubstance Use in North Carolina

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Sherani Jagroep

MPH, Public Health Analyst

Atlanta-Carolinas HIDTA

Mary Beth Cox

MPH, Substance Use Epidemiologist

North Carolina Division of Public Health

Mary Beth Cox is an Epidemiologist with the North Carolina Division of Public Health. In the six years since receiving her Master of Public Health in epidemiology and global health from New York Medical College, she has served as a Peace Corps Volunteer in Malawi and worked in communicable disease surveillance in New York and North Carolina. She joined the Injury and Violence Prevention Branch in January 2016 as a Substance Use Epidemiologist. Cox serves on several state and national work groups that aim to reduce alcohol and other drug morbidity and mortality.

Scott Proescholdbell

MPH, Head of Injury Epidemiology and Surveillance Unit

Injury and Violence Prevention Branch, North Carolina Division of Public Health

Hanover CDE

Tuesday, April 3, 2018

2018-04-03

Law Enforcement and Harm Reduction: Merging Public Safety and Public Health Roles

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: Rita Noonan, PhD, Branch Chief, Division of Unintentional Injury Prevention, Centers for Disease Control and Prevention CE Certified by: GA Bar, GA POST State and local jurisdictions across the country have implemented a number of innovative policing strategies - such as arrest diversion programs - that reflect the principles of harm reduction. These strategies prioritize: 1) reducing drug use harms; 2) engaging with offenders in a non-punitive manner; 3) linking offenders to rehabilitative services; 4) reducing recidivism; and 5) increasing community health, safety and wellness. Some jurisdictions are implementing data-driven, front-end responses that utilize public health and public safety data to pinpoint emerging problems (e.g., opioid overdose deaths) and develop the most cost-effective and efficient response to them (e.g., police naloxone programs). Although lauded by criminal justice reformers, implementation of harm reduction approaches has led to a number of challenges for law enforcement. It is important to understand how these changes in policing philosophies have affected police culture, training practices, officer recruitment and community relationships. This session will include discussions of these and other relevant issues, as well as presentation of promising strategies implemented by practitioners from law enforcement and public health. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Discuss some of the social, cultural and political forces that led to a shift in policing philosophies. - Describe specific harm reduction strategies that have been implemented in various law enforcement agencies. - Identify some of the barriers and challenges law enforcement have faced when implementing these programs.

Sean Goodison

PhD, Deputy Director and Senior Research Criminologist

Police Executive Research Forum

Dr. Sean Goodison is a Deputy Director and Senior Research Criminologist at the Police Executive Research Forum (PERF). His work focuses on quantitative research, research methodology, program evaluation, police use of technology and national data collection efforts. He is a member of the FBI’s Use of Force Data Task Force and National Institute of Justice (NIJ) LEADS Agencies Coordinating Council. Prior to joining PERF, he was an analyst and civilian researcher for the Washington, D.C., Metropolitan Police Department. Goodison has been the Primary Investigator on a number of studies, including a randomized controlled trial assessing the impact of body-worn cameras on citizen perceptions, and a project to collect and analyze 15 years of homicide data from official records in Washington, D.C. He has worked on numerous other policing-related grants. Goodison has published and presented on various criminological issues, such as firearms, homicide and the history of criminological thought. He received his doctorate in criminology and criminal justice from the University of Maryland and has two master’s degrees, one in forensic science and another in criminal justice, from The George Washington University.

Hope Smiley-McDonald

Director, Investigative Science Program

RTI International

Dr. Hope Smiley-McDonald is a research sociologist with nearly 20 years of research experience in the areas of corrections, substance use, drug offenders and substance abuse treatment. Her research interests include health, social and justice issues in the context of substance use, including opioid use. She has published in the areas of drug courts, reentry, employment, offender health and mental health, inmate mortality, and women and substance abuse. Smiley-McDonald has worked on several community-based and corrections-based program evaluations of substance abuse treatment programs designed for women and drug offenders and has directed the outcome evaluations of an adult drug court and an offender reentry project. She has published in the areas of drug courts, HIV risk behaviors, employment, health and mental health, women and substance abuse, and community corrections populations. Her current research is focused on the collection and reporting of solid dosage drug analyses results from local, state and federal crime laboratories and harm reduction strategies used by law enforcement to address the opioid epidemic.

Nick Richardson

Public Health Analyst

RTI International

Nick Richardson is a Research Public Health Analyst in the Policing Research Program of the Center for Justice, Safety & Resiliency at RTI International. He has several years of research experience in the areas of substance abuse and addiction, homicide and policing. His recent research explores the role of law enforcement in addressing the opioid epidemic and the innovative strategies they have implemented, including harm reduction approaches. Richardson has several years of experience working with substance-using populations as both a researcher and counselor.

Jeremy Barnum

MA, Research Associate

Police Executive Research Forum

Jeremy Barnum is a Research Associate at the Police Executive Research Forum (PERF). He specializes in geographic information science (GIS), spatial data analysis, policing and crime prevention. Prior to joining PERF, he was a Project Manager for the Rutgers Center on Public Security, where he worked in partnership with local police agencies to implement and manage basic and applied research projects. He has presented his work at practitioner and academic conferences and has published in peer-reviewed journals in the fields of criminology, criminal justice and geography. Barnum is currently completing his doctorate in criminal justice at Rutgers University – Newark. In addition, he holds a master's degree in criminal justice from Rutgers University – Newark and a bachelor's degree in criminal justice from Michigan State University.

Courtland

Tuesday, April 3, 2018

2018-04-03

Problematic Patterns: Overlapping Opioid/Benzodiazepine Prescriptions

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: Jim Huizenga, MD, Chief Clinical Officer, Appriss Health CE Certified By: AMA,AAFP,ACPE,ADA,ANCC In this session, researchers will present findings with important implications for policies aimed at curbing the opioid overdose epidemic through improved prescribing. Their research will highlight the importance of adherence to guidelines for prescribing opioids, as well as the review of prescription drug monitoring programs (PDMPs) by providers prior to prescribing to mitigate risk and improve care coordination among providers. Concurrent prescribing of opioid and benzodiazepine medications is strongly discouraged by clinical guidelines, including the Centers for Disease Control and Prevention’s Guideline for Prescribing Opioids for Chronic Pain. Analysis of controlled substance prescribing can elucidate patterns of opioid and benzodiazepine co-prescribing. For this presentation, researchers analyzed opioid/benzodiazepine co-prescribing using the 2015 Prescription Behavior Surveillance System (PBSS) in 10 states. PBSS data come from state PDMPs and can be used to characterize the use and misuse of prescribed controlled substances by measuring rates, doses and patterns of risky prescribing. The researchers identified prescriptions for opioids and benzodiazepines which overlapped for seven or more days for a given patient (an overlapping event), and characterized these occurrences by demographics, frequency, dosage, duration of overlap, and whether they were from a single provider or multiple providers. They will present their findings, such as the percentage of patients prescribed both opioids and benzodiazepines, the percentage of patients having at least one overlapping event during the year, and the number of providers involved in an overlapping event. In addition, participants will hear Rhode Island’s perspective regarding its recent implementation of various clinical alerts with the PDMP and preliminary effects on prescribing. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify the frequency of concurrent opioid/benzodiazepine prescriptions. - Describe the demographics of those who have been co-prescribed opioids and benzodiazepines. - Describe the average dose and duration of overlap for opioid/benzodiazepine co-prescriptions. - Discuss Rhode Island’s experience with various clinical alerts with the PDMP and connection to prescribing regulations.

Gery Guy

PhD, MPH, Senior Health Economist

Centers for Disease Control and Prevention

Dr. Gery P. Guy, Jr., is a Senior Health Economist in the Division of Unintentional Injury Prevention at the Centers for Disease Control and Prevention (CDC). He conducts health economics and health services research focusing on the prevention of opioid overdose. His research focuses on the patterns of Rx drug use, the impact of state policies and health system interventions on prescribing patterns and opioid-related morbidity and mortality, and the economic burden of opioid and heroin overdoses in the United States. Guy received his doctorate in health services research and health policy with a concentration in economics from Emory University, and his Master of Public Health in health policy from the Rollins School of Public Health at Emory University. He also completed a two-year postdoctoral fellowship in prevention effectiveness at the CDC. Guy has authored over 80 scientific publications and book chapters.

James V. McDonald

MD, MPH, Chief Administrative Officer of the Board of Medical Licensure and Discipline

Rhode Island Department of Health

Dr. James V. McDonald has served at the Rhode Island Department of Health (RIDOH) since 2012 as the Chief Administrative Officer of the Board of Medical Licensure and Discipline and the Center for Customer Services Medical Director. He is also a member of the Governor’s Task Force on Preventing Overdose Deaths and leads the Prevention Strategy Work Group. McDonald is also the Medical Director of the overdose prevention program, as well as Medical Director for the Center for Health Systems and Policy at RIDOH. McDonald earned his medical degree from Loyola Stritch School of Medicine in Chicago, his pediatric residency in the U.S. Navy, and his preventive medicine residency from the State University of New York. He earned is master's degree in public health from the University of North Carolina in Chapel Hill. McDonald is board certified in pediatrics and preventive medicine. His diverse career includes officership in the U.S. Navy, as well as private practice in rural areas and in the Navajo Nation. McDonald lives in North Kingstown with his wife and three children.

Baker

Tuesday, April 3, 2018

2018-04-03

Community Pharmacists and Harm Reduction: Evidence and Opportunities

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: Anne L. Burns, RPh, Vice President, Professional Affairs, American Pharmacists Association, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ANCC,NAADAC,NASW,NBCC Harm reduction is a concept that has gained momentum as it relates to prevention of negative consequences of drug use. Some harm reduction approaches, such as naloxone provision, have garnered significant support, whereas others, such as providing access to clean syringes, are the exception as opposed the rule. Evidence suggests there is significant variation in harm reduction behaviors among providers, including community pharmacists. Community pharmacies are one of the most accessible points for healthcare; approximately 90% of U.S. residents live within five miles of a pharmacy. Therefore, pharmacies have a great opportunity to promote and engage their communities in harm reduction approaches. This session will examine evidence-based harm reduction approaches that can be employed in community pharmacies. The presenters will use their syringe dispensing research conducted across three states to describe the current harm reduction climate in community pharmacies. During this interactive session, participants will discuss scenarios in which they are encouraged to evaluate their own attitudes and beliefs toward non-Rx syringe sales, naloxone dispensing and other harm reduction strategies while taking a look at the impact of state level policies on these approaches. The session will be targeted to practicing pharmacists, coalition leaders and harm reduction stakeholders. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Explain harm reduction approaches that can be implemented in community pharmacy settings. - Describe the perceptions and behaviors of pharmacists related to non-Rx syringe sales and other harm reduction approaches. - Evaluate the feasibility of implementing harm reduction approaches in a pharmacy and/or partnering with one or more community pharmacies to engage in harm reduction approaches.

Nicholas Hagemeier

PharmD, PhD, Associate Professor and Research Director

Gatton College of Pharmacy, East Tennessee State University

Nicholas “Nick” Hagemeier, PharmD, PhD, is an Associate Professor of Pharmacy Practice in the East Tennessee State University (ETSU) Gatton College of Pharmacy and Research Director of ETSU's Center for Prescription Drug Abuse Prevention and Treatment. He earned his Doctor of Pharmacy, master's and doctorate degrees from Purdue University. He has nine years of experience in community pharmacy settings. Hagemeier is Co-Investigator of ETSU’s $2.2 million Diversity-Promoting Institutions Drug Abuse Research Program, which is funded by the National Institutes of Health (NIH), and is Principal Investigator for a core project focused on Rx drug abuse-related communication. He is also Director of a Community Pharmacy Practice Research Fellowship. He has obtained over $2.3 million in NIH and state funds to conduct Rx drug abuse research. He has published 30 peer-reviewed manuscripts and has given multiple invited research presentations. He received the Tennessee Pharmacists Association GenerationRx Champions Award in 2016 for his efforts to engage community pharmacists in Rx drug abuse prevention.

KariLynn Dowling

PharmD, Community Pharmacy Practice Research Fellow

Gatton College of Pharmacy, East Tennessee State University

KariLynn Dowling, PharmD, is a Community Pharmacy Practice Research Fellow and adjunct faculty member at East Tennessee State University (ETSU) Gatton College of Pharmacy. She is a 2014 graduate of the University of Montana Skaggs School of Pharmacy. She completed residency training at Penobscot Community Health Care in Bangor, Maine, as a member of the 2014-15 PGY1 Community Pharmacy and 2015-16 PGY2 Health-Systems Pharmacy Administration residency classes. As a resident, Dowling focused on controlled substance stewardship and program implementation for intranasal naloxone and medication assisted therapy initiatives. Her career interests include Rx drug abuse research, addiction treatment, and academia. Dowling is pursuing a Master of Public Health (community health concentration) from ETSU.

Regency VII

Tuesday, April 3, 2018

2018-04-03

Colorado AmeriCorps Community Opioid Response Program

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: Nancy Hale, MA, President and Chief Executive Officer, Operation UNITE, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,APA,MCHES,NAADAC,NASW,NBCC The Colorado AmeriCorps Community Opioid Response Program (CORP) is a statewide initiative utilizing 12 AmeriCorps members assigned to six regional Area Health Education Centers (AHECs) to provide support to local communities that are implementing strategies to reduce the impact of opioid abuse. This project links together the existing infrastructures of the AHECs, Rise Above Colorado, the Colorado Consortium for Prescription Drug Abuse Prevention, and the legislatively mandated Colorado Substance Abuse Trend and Response Task Force that is chaired by the state's attorney general, to the work of local community coalitions, primarily through a constellation model approach that has been identified as a best practice. The presentation will discuss the evidence-based strategies that are used. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the Colorado AmeriCorps Community Opioid Response Program. - Identify the evidence-based strategies being used in this project. - Explain how AmeriCorps members can be utilized in their community to help respond to the opioid crisis.

Lin Browning

MA, Executive Director

Central Area Health Education Center

Lin Browning currently serves as the Executive Director for Central Colorado Area Health Education Center (CCAHEC), which focuses on health careers and workforce diversity, health professions student education, health professions continuing education, and public health and community education. With degrees in education (master's) and psychology (bachelor's), certification in economic development and nonprofit management, along with experience in real estate, investing, business development and human resources, Browning feels that leading CCAHEC utilizes her strengths and allows for continued progression. Her dual passions for education and workforce development lend themselves nicely to the current projects at CCAHEC, particularly the Colorado AmeriCorps Community Opioid Response Program. As a true collaborator, Browning is grateful for the strong partnerships between the Colorado Regional AHEC Offices, Colorado Consortium for Prescription Drug Abuse Prevention, the Colorado Attorney General’s Office and Rise Above Colorado. This unique structure allows for a holistic approach to the current opioid epidemic facing the nation.

Kent MacLennan

MA, Executive Director

Rise Above Colorado

Kent MacLennan is proud to lead the organization into its next phase as the Executive Director of Rise Above Colorado. As the founding Executive Director for the Colorado Meth Project, he has overseen local public service messaging, public policy, fundraising and community outreach efforts to reduce first-time meth use. In May 2009, Colorado was the sixth of eight states to adopt the Meth Project, which as been nationally recognized for its extensive research, integrated media campaign and proven results. MacLennan has more than 20 years of progressive leadership experience in the nonprofit sector. He spent nearly 15 years in the development field for youth-serving and educational organizations, including Young Amercias Center for Financial Education, the University of Denver and Up With People. He has direct experience working with the teenage demographic targeted by the Colorado Meth Project, having taught social studies for two years at Pomona High School in Arvada. MacLennan holds a bachelor's degree in foreign service from Georgetown University and a master's degree in education from the University of Denver.

Jose' Esquibel

Director, Office of Community Engagement

Colorado Office of the Attorney General

Since 2013, José Esquibel has served as the Vice Chair of Prevention for the Colorado Statewide Substance Abuse Trend and Response Task Force, a legislatively mandated task force chaired by Attorney General Cynthia H. Coffman. His role includes active participation in a collaborative and comprehensive approach to addressing multiple issues related to Rx drug abuse through the Colorado Consortium for Prescription Drug Abuse Prevention. The consortium serves as the official Rx drug abuse prevention committee of the task force and is focused on implementing the goals of the Colorado Plan to Reduce Prescription Drug Abuse Prevention Plan related to public awareness, provider and prescriber education, the prescription drug monitoring program, and disposal of unused household medications. Esquibel's experience in substance abuse prevention includes work at the community level and within state government.

Gina Olberding

MBA, Operations Manager

Colorado Consortium for Prescription Drug Abuse Prevention

Gina Olberding is the Operations Manager for the Colorado Consortium for Prescription Drug Abuse Prevention. Created by Gov. Hickenlooper in 2013, the consortium addresses Rx drug abuse with a collaborative, statewide approach, serving as the convener for 10 work groups with over 400 members. Prior, Olberding spent nearly 12 years in patient safety and risk management at COPIC Insurance, managing a nationally recognized communication and reimbursement program designed to address unanticipated medical outcomes. She is a volunteer and past board secretary for the Colorado nonprofit Kids in Need of Dentistry. She has a Master of Business Administration in healthcare administration.

Learning Center

Tuesday, April 3, 2018

2018-04-03

Heroin and Healthcare: Identifying Opportunities for Intervention Prior to Overdose

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: Amy G. Griffin, JD, Corporate Counsel, Kentucky Employers’ Mutual Insurance CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,APA,MCHES,NAADAC,NASW,NBCC Little is known about trends in non-fatal heroin overdose, patients’ healthcare utilization preceding overdose, or prior Rx opioid use, an important consideration given the association between Rx opioid abuse and heroin use. Such information could inform prevention strategies and tailor interventions. Presenters will offer an analysis of MarketScan® Medicaid and commercial claims data, 2010-2014, which found heroin-involved overdose rates increased more among the commercially-insured than Medicaid patients (270% vs. 94.3%). Nearly all patients had a healthcare encounter in the six months prior to their first overdose, with two-thirds of commercially-insured patients having outpatient visits. In the month prior to the first overdose, 24.5% of Medicaid and 8.6% of commercially insured patients had opioid prescriptions. Healthcare utilization patterns suggest that opportunities exist for interventions at the point of care prior to the first overdose, noting differences in where patients access care by insurance type. Outpatient settings are of particular importance for the emerging cohort of young commercially insured patients aged 15-24 years with opioid use disorder. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Explain how non-fatal drug overdose trends and healthcare utilization histories can inform prevention. - Describe differences in healthcare utilization patterns by insurance type for heroin overdose. - Identify strategies to support interventions at the point of care prior to the first heroin overdose.

Alexander Y. Walley

MD, MSc, Associate Professor of Medicine

Boston University School of Medicine

Alexander Y. Walley, MD, MSc, is an Associate Professor of Medicine at Boston University School of Medicine and a general internist and addiction medicine specialist at Boston Medical Center. He is the director of the Boston Medical Center Addiction Medicine Fellowship program. His research focus is on the medical complications of substance use, specifically HIV and overdose. He provides primary care and office-based addiction treatment for patients with HIV at Boston Medical Center and methadone maintenance treatment at Health Care Resource Centers. He is the medical director for the Massachusetts Department of Public Health’s Opioid Overdose Prevention Pilot Program. Since 2007, that program has trained more than 60,000 people in Massachusetts’s communities, including people who use opioids, people in recovery and their social networks. Walley graduated from Harvard College, received his medical degree from Johns Hopkins School of Medicine and received his master's degree in epidemiology from Boston University School of Public Health.

Lindsey Bridwell

MPH, CHES, Evaluation Fellow, Opioid Overdose Health Systems Team

Centers for Disease Control and Prevention

Lindsey Bridwell is as an Evaluation Fellow on the Prescription Drug Overdose Health System Team in the Division of Unintentional Injury Prevention at the Centers for Disease Control and Prevention (CDC). Her primary role as an evaluation scientist involves conducting impact assessments of CDC’s Guideline for Prescribing Opioids for Chronic Pain and providing technical assistance to states in responding to the opioid epidemic. She has a bachelor's degree in neuroscience from the College of William & Mary and an master's degree in public health in behavioral science and health education with a certificate in mental health from Rollins School of Public Health at Emory University. Lindsey is also a Certified Health Education Specialist and has coordinated, evaluated and developed programmatic curriculum in the areas of tuberculosis research training, literacy, noncommunicable disease, neurodegenerative disease, youth alcohol and substance use prevention programs, and opioid misuse and overdose.

Michele K. Bohm

MPH, Health Scientist

Centers for Disease Control and Prevention

Michele Bohm received her master’s degree in epidemiology from Emory University and is a Health Scientist with the National Center for Injury Prevention and Control at the Centers for Disease Control and Prevention (CDC). She has worked on issues related to opioid abuse since 2012, including tracking trends in opioid prescribing and conducting analyses to understand how health services data can inform prevention efforts. She also works with other centers and divisions at CDC as the opioid epidemic now impacts multiple public health issues including infectious disease risk among people who inject drugs, self-harm and suicide among people with chronic pain, neonatal abstinence syndrome and adolescent misuse of prescriptions.

Dunwoody

Tuesday, April 3, 2018

2018-04-03

Improving Addiction Outcomes: Lessons from the Physician Health Program Model

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: Julie Miller, Editor in Chief, Behavioral Healthcare Executive and Addiction Professional CE Certified By: AMA,AAFP,ADA,ACPE,ANCC,APA,NASW Physician health programs (PHPs) focus on the rehabilitation and monitoring of physicians with substance use disorders as well as mental and physical illnesses. Data confirm that PHPs are very effective: participants with opioid use disorder have a 75% or greater documented abstinence rate at five years. Using similar long-term disease monitoring and contingency management, this model has been extended to other cohorts with impressive results, including airline pilots, DUI offenders, drug-court participants, healthcare and other licensed professionals. These programs have been shown to be very effective and, at the same time, cost-effective. This session introduces participants to the central elements of these evidence-based chronic disease management programs exemplified by PHPs, comparing and contrasting them with current treatment methods. The presentation will extract the crucial components into a cohesive model — a model that can shift addiction care from its focus on acute care to where it belongs, effective, measured and lifelong disease management. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify the basic components of physician health and similar disease management programs. - Apply components from the physician health program model that have broad application to addiction management. - Recognize how each of these identified components improve outcomes.

P. Bradley Hall

MD, FASAM, DABAM, MROCC, AAMRO, President, Federation of State Physician Health Programs

Executive Medical Director, West Virginia Medical Professionals Health Program

In 2005, Dr. P. Bradley Hall became involved in the establishment of the West Virginia Medical Professionals Health Program, serving as Founding Medical Director. He serves as President/Executive Director of the West Virginia Society of Addiction Medicine. He is a certified Medical Review Officer by the American Association of Medical Review Officers and the Medical Review Officer Certification Council and a Board Registered Interventionist with the Association of Intervention Specialists. Hall is President of the Federation of State Physician Health Programs. He was one of the co-authors of the American Society of Addiction Medicine’s 11 policies on physician health. He served on the Federation of State Medical Board's Impaired Physicians Committee in the updating of the impaired physicians policy. Hall is a member of the West Virginia Governor’s Advisory Council on Substance Abuse. He is a co-author of the Chapter on Physician Health Programs in the soon to be published “Physician Mental Health and Well-Being - Research and Practice.” Hall chairs the Planning Committee of the Appalachian Addiction and Prescription Drug Abuse Conference. He serves as the Executive Medical Director of the West Virginia Medical Professionals Health Program, the license board(s) designated Physicians Health Program.

Paul Earley

MD, Georgia Professionals Health Program, Inc.

President-Elect, Federation of State Physician Health Programs

Dr. Paul Earley has been an addiction medicine physician for over 30 years. He specializes in the assessment, treatment and management of healthcare professionals with addictive disorders. He also works with patients already in recovery, providing long-term therapy. He is the author of two books and numerous articles on addiction and its treatment. He is a contributing author to the American Society of Addiction Medicine (ASAM) textbook, "The ASAM Principles of Addiction Medicine," and the ASAM criteria. His most recent book, "RecoveryMind Training," is an innovative and comprehensive process designed to reengineer addiction treatment. His work was featured in the documentary series on addiction entitled "Close to Home" by Bill Moyers. Earley is the Medical Director of the Georgia Professionals Health Program, Inc., the Physicians Health Program for the state of Georgia, and the President-elect of the Federation of State Physician Health Programs. He is the President-elect of ASAM. Earley is the recipient of the ASAM Annual Award in 2015.

Doris Gundersen

MD, Colorado PHP Medical Director

Federation of State Physician Health Programs

Dr. Doris Gundersen is board certified in both general adult and forensic psychiatry. She is an Assistant Clinical Professor in the Department of Psychiatry at the University of Colorado, where she teaches medical students residents and fellows. Additionally, she maintains a private practice in general adult and forensic psychiatry. In 2000, Gundersen was invited to join the Colorado Physician Health Program (CPHP) team and for 15 years, has been dedicated to assisting physicians with serious illnesses and providing education to medical communities locally, nationally and internationally concerning physician health. She has been CPHP’s medical director since 2009. She has collaborated with her CPHP colleagues on physician health research and coauthored articles accepted for publication. She currently chairs the Colorado Medical Society’s committee on physician well-being. Gundersen is the past-President of the Federation of State Physician Health Programs.

Grand Hall

Tuesday, April 3, 2018

2018-04-03

Networking Break

3:15 PM - 3:45 PM

3:15 PM

3:45 PM

Networking break in the Exhibit Hall

Piedmont

Tuesday, April 3, 2018

2018-04-03

United We Stand: Georgia’s Comprehensive Plan and Colorado’s Collective Impact Model

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: Jackie L. Steele, Jr., JD, Commonwealth Attorney, Kentucky 27th Judicial Circuit, and and Member, Operation UNITE Board of Directors CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,APA,MCHES,GA Bar,NAADAC,NASW,NBCC Since 1999, the number of overdose deaths involving opioids has quadrupled, according to the Centers for Disease and Control. Given the magnitude of the crisis, entities find they are overwhelmed when they fight back alone. As a result, diverse stakeholders have joined forces to present a united front in some states. This session's presentations will feature Georgia’s “firewall” — a comprehensive plan to hold back the epidemic — and Colorado’s collective impact model. From Georgia, the presentation will lay out the statewide strategic plan for dealing with the opioid epidemic. They will explain the plan’s creation and implementation. In 2016, the Georgia Prevention Project created the Substance Abuse Research Alliance (SARA) — a consortium of more than 100 researchers at universities, schools of public health, medical schools, state agencies, nonprofits and the CDC. SARA’s “Prescription Opioids and Heroin Epidemic in Georgia: A White Paper,” defined the scope of the problem and proposed a legislative agenda. Two key recommendations became law in 2017: making naloxone available over the counter and strengthening the PDMP. From there, SARA updated its white paper and assisted the Georgia Department of Public Health to create a statewide strategic plan. The plan takes advantage of other states’ experiences to set up budgets, legal mechanisms, programs and goals to be implemented by many players — governmental, nonprofit and corporate. Presenters will share a case study of the Colorado Consortium for Prescription Drug Abuse Prevention, and its use of the Collective Impact model to develop, coordinate and implement state level policies and programs to address the opioid crisis. Launched in 2013, the consortium has evolved into a prototypical Collective Impact system, involving nine work groups, more than 450 participating members statewide, and a number of affiliated local and regional coalitions. Examples of policy and programmatic successes will be presented, including: public awareness, provider education, naloxone access, safe disposal, heroin response, PDMP enhancements, treatment access, improved data systems, and advocacy for affected families and friends. Advice and lessons learned will be shared with other state, regional or local coalitions that may be interested in using the Collective Impact model for opioid misuse prevention. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe a process for achieving an effective statewide plan for reducing deaths from opioid addictions. - Identify methods for evaluating progress against goals and for crafting and implementing changes to a statewide strategic plan. - Compare key components of various state plans in order to find the right plan for another individual state. - Identify the five conditions for Collective Impact. - Explain how Collective Impact can be used to address the opioid crisis. - Select measures for objectively evaluating the success of state-level responses.

Robert Valuck

PhD, RPh, Director

Colorado Consortium for Prescription Drug Abuse Prevention

Dr. Robert J. Valuck is a Professor in the Departments of Clinical Pharmacy, Epidemiology, and Family Medicine at the University of Colorado Schools of Pharmacy, Public Health, and Medicine at the Anschutz Medical Campus in Aurora, Colorado. He is Director of the Colorado Consortium for Prescription Drug Abuse Prevention, created by Gov. John Hickenlooper to address the Rx drug abuse problem with a collaborative, statewide approach. The donsortium has evolved over the past four years to include 10 work groups, with over 450 members across the state, focusing on key areas relating to education, prevention, intervention, treatment and recovery. The consortium has gained recognition as a model for the development of collaborative, coordinated responses to the opioid overdose epidemic in the United States.

Gina Olberding

MBA, Operations Manager

Colorado Consortium for Prescription Drug Abuse Prevention

Jim Langford

Executive Director

Georgia Prevention Project

Jim Langford, Executive Director and Co-founder of the Georgia Prevention Project (GPP), brings many years of business, public service and nonprofit experience to the organization. He has been appointed by five Georgia governors to a variety of commissions and boards in the state. He also is the founder of multiple other nonprofit organizations and initiatives. GPP — a statewide prevention program aimed at reducing the use of dangerous substances among teens and young adults — evolved from its roots as the Georgia Meth Project and accomplishes its work through awareness campaigns, educational programming and strategic partnerships with national and community based organizations. In his business life, Langford founded and managed successful high technology companies over a 20-year period. Prior to his high technology career, he was an executive of The Coca-Cola Company in Atlanta, New York, Puerto Rico and Argentina. He is a member of the Board of Councilors of the Carter Presidential Center and a former member of the Georgia Board of Natural Resources and the Georgia Humanities Council. Langford earned his undergraduate degree in journalism from the University of Georgia and his Master of Business Administration from the Harvard Business School.

Hanover AB

Tuesday, April 3, 2018

2018-04-03

Safe Alprazolam Prescribing and Benzodiazepine Monitoring Program

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: Kelly Clark, MD, MBA, DFAPA, DFASAM, Chief Medical Officer, Clean Slate Centers, President, American Society of Addiction Medicine, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ANCC Deaths resulting in accidental overdoses related to benzodiazepines has been rising in Ventura County, California. Of all benzodiazepines, alprazolam is the most commonly prescribed, misused and diverted; however, it is no longer the drug of first choice for most conditions. To help reduce morbidity, mortality and drug diversion, Ventura County Behavioral Health focused on incorporating good practices into its medical decision-making regarding controlled substances. The project dealt with multifaceted challenges: a growing epidemic of Rx drug abuse in the community, consumers’ lack of awareness of the dangers these substances pose, providers’ lack of awareness of evidenced-based practices, and resistance to change on the part of both patient and prescriber. The project used data to design report cards, offered providers feedback about their prescribing practices, and provided them data that reflected how their practice compared to peers and the organization as a whole. As of May 2017, the number of patients with an active alprazolam prescription had decreased by 84% since project inception (November 2014). This presentation will define the scope of the problem; offer evidence-based practices for prescribing and monitoring controlled substances and the development of a clinical practice guideline; review indications for using benzodiazepines and alternatives; and discuss resistance to change, integrating non-pharmacologic approaches in treatments, and successful interventions and challenges. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify current guidelines and practices that reflect those guidelines in order to provide optimal and safe care to patients. - Identify safe practices to minimize the long-term use of benzodiazepines when other treatment approaches are best practices. - Outline procedures for safe practices to implement them in clinical practice.

Brian Taylor, MD

MD, Medical Director, Adult Services and ADP

Ventura County (California) Behavioral Health

A Diplomate of the American Board of Psychiatry and Neurology, Dr. Brian S. Taylor graduated from Stanford University School of Medicine in 1991, completed his internship in general surgery at University of California, San Francisco, and then returned to Stanford University Hospital to train in psychiatry where he served as Chief Resident. In addition to his private practice, Taylor is the current Behavioral Health Medical Director for Ventura County Behavioral Health (VCBH), Secretary of Sterling Care Psychiatric Group, Inc. and Past Chief of Staff at Ventura County Medical Center (VCMC). He has previously served as Quality Medical Director at VCBH, Medical Director for both Hillmont House MHRC and Anka-Ventura Crisis Residential Treatment center, and, for four years, VCMC Department of Psychiatry Chief. Taylor is a recipient of the prestigious 2015 David Fainer, MD, and Leo Tauber, MD, Behavioral Health Professional of the Year Award and has also been recognized by the Consumers' Research Council of America as one of America's Top Psychiatrists 2015.

Celia Woods

MD, Quality Medical Director

Ventura County (California) Behavioral Health

Dr. Celia Woods, President of Sterling Psychiatric Group, Inc., is passionate about quality care and evidence-based approaches to opioid risk, and currently serves as the Quality Medical Director for Ventura County Behavioral Health. She is a board-certified psychiatrist with both administrative and clinical experience serving a diagnostically and demographically diverse population, including out-patient mental health and clinics, partial psychiatric hospitals, in-patient psychiatric hospitals, group homes and nursing homes, and extensive experience with substance use disorders.

Hanover FG

Tuesday, April 3, 2018

2018-04-03

Do the Next Right Thing: A Family-Centered and Multidisciplinary Approach to Substance Use Disorder Treatment among Perinatal Women

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: Mark Birdwhistell, MPA, Vice President for Administration and External Affairs, University of Kentucky HealthCare CE Certified by: AMA, AAFP, ANCC, NAADAC, NASW, NBCC Opioid abuse has ravaged the American healthcare landscape, and the Commonwealth of Kentucky is no exception. Kentucky ranks third in the U.S. in overdose deaths. Families residing in Kentucky’s rural communities are disproportionately impacted by the opioid crisis. Although evidence-based medication assisted treatment for opioid dependence exists, resources needed to treat opioid use disorders for women in rural areas are lacking. Between 2000 and 2016, the number of Kentucky babies born with neonatal abstinence syndrome soared exponentially, from 19 to 1,172. This presentation will describe how UK HealthCare uses family-centered care to treat opioid use disorder as a chronic illness affecting pregnant women and their families during the perinatal period through its’ PATHways Prenatal and Beyond Birth clinic. Patients’ stories will be woven throughout the presentation, highlighting the human aspect of their journeys through a complex healthcare system. UK HealthCare’s program incorporates the best practices in the field, adhering to federal guidelines for office-based buprenorphine treatment across the spectrum of care for women. The perinatal program provides a comprehensive treatment program for a highly vulnerable subset of the population with substance use disorders. Women and their families are supported and advocated for through continuous levels of care ranging from intensive medical care to sustained recovery. UK HealthCare has office-based opioid treatment programs, which link patients hospitalized with infections related to infectious diseases and chronic infections such as HIV. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe how a family-centered approach to substance use disorder treatment can be operationalized across the continuum of care. - Outline the key components of substance use disorder treatment as it pertains to pregnant and parenting women. - Identify opportunities for family and stakeholder advocacy in the context of family-centered care.

Laura Fanucchi

MD, MPH, Assistant Professor of Medicine

University of Kentucky

Laura Fanucchi, MD, MPH, is a general internist with additional board certification in addiction medicine. She obtained her medical degree from Emory University School of Medicine, completed internal medicine residency at New York Presbyterian Hospital Weill Cornell Medical College, and is currently Assistant Professor of Medicine at the University of Kentucky. Fanucchi’s clinical and research focus is on improving the care of hospitalized and medically complex patients with substance use disorders. She is currently providing treatment for opioid use disorder in HIV primary care at the University of Kentucky Bluegrass Care Clinic.

Seth S. Himelhoch

MD, MPH, Chair of the Department of Psychiatry

University of Kentucky College of Medicine

Seth S. Himelhoch, MD, MPH is a board-certified psychiatrist and a graduate of the University of Michigan School of Medicine and the Johns Hopkins School of Public Health. Himelhoch completed his internship and residency at the University of California, San Francisco School of Medicine, and completed a fellowship in health services research at Johns Hopkins School of Medicine under the auspices of the Robert Wood Johnson Clinical Scholars Program (2001-2003). He is currently a Professor and Chairman of the Department of Psychiatry at the University of Kentucky. Himelhoch’s program of research focuses on developing and testing interventions to improve access and outcome of care for people with co-occurring psychiatric and drug use disorders. This work has been funded by The National Institutes of Mental Health, Drug Abuse, and Heart, Lung and Blood grants, among others. Throughout his career, he has published extensively in high impact journals, including the American Journal of Psychiatry, AIDS, JAIDS, American Journal of Addictions, and Psychiatric Services. Of note, he is currently a Fellow of the Robert Wood Johnson Clinical Scholars Program (2017-2020), where he and his team are working to develop interventions to assist rural communities suffering from the consequences of the opiate epidemic.

Michael G. Kindred

MD, Beyond Birth Medical Director, Surgeon and Addiction Medicine, Assistant Professor, Department of Psychiatry

University of Kentucky College of Medicine

Dr. Michael G. Kindred's interest in addiction medicine started during his surgical residency when he observed that a large percentage of his trauma patients who presented with penetrating and blunt injuries were intoxicated. His interest continued as he developed an elective practice in general surgery, where he found that the majority of his patients had co-morbid substance use problems. In pursuing this career interest, he completed a fellowship in addiction medicine at the University of Kentucky and then transitioned to faculty. Currently, 90% of his effort is dedicated to treating patients with opioid use disorder using buprenorphine across multiple outpatient clinics. He also treats other primary substance use disorders, and manage complex addictions in the inpatient setting with follow up after discharge. His approach to managing substance use disorders is to implement evidence-based treatment strategies. He is also involved in the development of novel interventions. His strategy recognizes the biological and psychosocial aspects of addiction and therefore emphasizes interventions that incorporate those critical aspects of the disease.

Alice Thornton

MD, Professor of Medicine, University of Kentucky College of Medicine

Chief of the Division of Infectious Diseases, Medical Director, Bluegrass Care Clinic, University of Kentucky Medical Center

Dr. Alice Thornton completed her medical degree at Marshall University in Huntington, West Virginia. She completed her residency at Wake Forest University School of Medicine in Internal Medicine. She then completed her fellowship training with the Division of Infectious Diseases at Indiana University Purdue University, where she studied the pathogenesis of chancroid. She was recruited to assist in the development of an Infectious Diseases Fellowship Program at the University of Kentucky in 1998. Thornton has successfully acquired four grants funded by the Health Resources and Services Administration (HRSA) – Ryan White Part B, C and D and the Local Performance Site grant of the Southeast AIDS Training and Education Center. She serves as Medical Director of the Blue Grass Care Clinic. She is Principal Investigator of the National Institutes of Health (NIH)-funded Reprieve Study – Randomized Clinical Trial to Prevent Vascular Events in HIV. Thornton is a clinical site visitor for HRSA, and also serves as a grant reviewer for HRSA, NIH and the Centers for Disease Control and Prevention (CDC). She recently was elected to the HIV Medicine Association Board of Directors. She is a Professor of Medicine in the University of Kentucky Department of Internal Medicine and Chief of the UK Division of Infectious Diseases.

Nancy Jennings

BSN, RN, Beyond Birth Nurse Navigator

University of Kentucky HealthCare

Nancy Jennings has more than 24 years of OB/GYN nursing experience. She earned her bachelor's degree in nursing from the University of Kentucky in 1986. Jennings currently serves as the lead Perinatal Recovery Facilitator for the PATHways Beyond Birth program at University of Kentucky HealthCare. The program provides women a treatment model to improve skills to actively manage their recovery and engage in attachment-based parenting, while also providing opportunities for continuing education and job training. These are all critical to long-term recovery and improving psychosocial and physical health.

Holly Dye

MRC, Beyond Birth Program Director

University of Kentucky HealthCare

Holly Dye, MRC, is a nationally recognized expert on addiction and the impact on children. After 20 years of work with foster children, in-patient and out-patient drug treatment settings, Dye created a model program for medical and behavioral health interventions with families impacted by substance abuse that utilized telehealth networks, a basic online training program and a 16-hour training curriculum for professionals. She has authored numerous publications, many specific to substance use disorders and child development, and has developed programs for parents with addiction. She is the recipient of the 2012 Bluegrass Alliance for Women, Impact Award; 2011 Department of Homeland Security Service Award; 2008 Victim Impact Program Service Award; 2006 Champion for Children Award, presented by Prevent Child Abuse Kentucky; and the 2007 Recognition Award by the Federal Medical Center for work done for the Victim Impact Program. She was featured in the A&E Special A Question of Life or Meth, which received the Daytime Emmy Award for Outstanding Special, June 14, 2007. Dye currently works as the Program Manager of the Beyond Birth at University of Kentucky HealthCare and the University of Kentucky, College of Nursing Perinatal Research Center in Lexington, Kentucky.

Regency V

Tuesday, April 3, 2018

2018-04-03

Hope In Action: Partnering with Faith-Based Communities to Address the Opioid Epidemic

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: Elizabeth Nichols, MS, Manager, Department of Specialty Courts, Kentucky Administrative Office of the Courts, and Member, Operation UNITE Board of Directors CE Certified By: AMA,AAFP,ANCC,APA,MCHES,NAADAC,NASW,NBCC Religious and faith-based organizations are essential health assets with unique expertise that is crucial to advancing the mission of the U.S. Department of Health and Human Services (HHS) to enhance and protect the health and well-being of the American people. Because so many people live their lives through their faith commitments, faith-based organizations are uniquely positioned to understand and serve their neighbors and communities in culturally competent ways. These organizations are often driven by faith to serve people of all faiths or none with compassion and commitment, and to provide them with food, housing, health care, family support, mental health support, addiction recovery, counseling, education and other essential services. This session will review the strategies for partnering with faith communities in response to the opioid epidemic as outlined in the HHS Partnership Center’s Opioid Epidemic Practical Toolkit, which is available at http://hhs.gov/opioid-practical-toolkit. Participants will learn how faith leaders and community leaders, as well as concerned citizens, can support prevention efforts, reduce risk and provide support to those who are in and seeking recovery. Presenters also will address the particular challenges faith-based service delivery organizations experience as they seek to deliver essential services. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe how faith leaders and their community members are currently responding to the opioid epidemic. - Recognize what faith communities need to understand in order to reduce the stigma associated with substance use disorders. - Explain how to partner with faith communities to strengthen the community’s response to the opioid epidemic.

Greg Delaney

Outreach Coordinator

Woodhaven Ohio

Pastor Greg Delaney who serves as the Outreach Coordinator at Woodhaven, which is a treatment center known as “a safe place to recover.” Delaney is a frequent Faith Collaborator with/for the Ohio Attorney General Mike DeWine's Statewide Outreach on Substance Use, as well as Attorney General Patrick Morrisey of West Virginia’s Combating Addiction with Grace initiative. Delaney has been instrumental in a number of initiatives, such as The CHAMPIONS NETWORK, a coordinated and collaborative network of qualified individuals, community-based services, ministries and churches ministering to the addicted in our local communities, and an ongoing weekday BLOG called “Opportunities for Hope,” which offers messages of encouragement and recovery to its readers and subscribers. He also hosts a weekly radio show of the same name broadcast on 90.9 in Lancaster, Ohio.

Jeffrey A. Allen

MDiv, Executive Director

West Virginia Council of Churches

Rev. Jeffrey S. Allen is a United Methodist pastor currently appointed to the West Virginia Council of Churches as the Executive Director. He holds a bachelor's degree in biology and a bachelor's degree in religious studies from West Virginia University and a Master of Divinity degree from Emory University. He previously served as Project Director for the West Virginia Healthy Kids and Families Coalition and as the Community and Families Development Director at Community Development Outreach Ministries (CDOM) for 13 years. He also has served as pastor at the Keystone and Northfork United Methodist Churches in McDowell County, West Virginia, and the College Hill United Methodist Church in Waco, Kentucky. He is married to Laura Harbert. They have a golden retriever named Miles and four cats: Dora, Little Cat, Samantha, and Thomas.

Heidi Christensen

MTS, Public Affairs Specialist, Center for Faith-based and Neighborhood Partnerships

U.S. Department of Health and Human Services

Heidi Christensen, MTS, is the Public Affairs Specialist at the Center for Faith-based and Neighborhood Partnerships at the U.S. Department of Health and Human Services (the HHS Partnership Center). Her efforts focus on strengthening the capacity of national faith and community organizations to respond to critical public health issues. During her tenure at the Partnership Center, Christensen has coordinated coalitions of multi-sector community-based partners to address childhood obesity, chronic disease, and the social and economic issues challenging the health of our nation’s communities. She also has coordinated partner-based social media events, educational and training web series, and communications that equip community-level health leadership. Previously, at the Center for Interfaith Action on Global Poverty, she supported U.S. based faith leaders and their communities on collaborative efforts addressing malaria and other health issues affecting the developing world. She also managed communications and event production for the Cathedral College of Washington National Cathedral. Christensen holds a master’s degree in systematic theology from Virginia Theological Seminary.

Shannon Royce

JD, Director, Center for Faith-based and Neighborhood Partnerships

U.S. Department of Health and Human Services

Shannon Royce brings a wealth of experience to her role as Director of the Center for Faith-based and Neighborhood Partnerships at the U.S. Department of Health and Human Services (the HHS Partnership Center). The HHS Partnership Center was formed in 2001, under the George W. Bush administration, to ensure that faith partners and nonprofits faced no barriers and were engaged as full partners in serving the poor and helping the vulnerable. Royce's professional background includes both government and private sector experience. In government, she worked for over seven years on Capitol Hill, including serving as Counsel to Sen. Chuck Grassley (now Chairman of Senate Judiciary Committee). In the private sector, Royce worked in several faith-based nonprofit organizations. Early on, she led the D.C. office of the Southern Baptist Ethics & Religious Liberty Commission, a group focused on issues such as sex trafficking, global hunger and protecting religious liberty. Most recently, she served as Chief of Staff and Chief Operating Officer at the Family Research Council (FRC), managing day-to-day operations for a team of 80 in fulfilling the FRC mission of promoting “a culture in which all human life is valued, families flourish and religious liberty thrives.” She received her Juris Doctor from the George Washington University School of Law.

Regency VI

Tuesday, April 3, 2018

2018-04-03

Fentanyl and the Overdose Epidemic: The NYC Public Health Response

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: Grant T. Baldwin, PhD, MPH, Director, Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ANCC,APA,GA Bar,GA POST,NAADAC,NASW,NBCC The rate of unintentional drug overdose death in New York City (NYC) increased for the sixth consecutive year, from 8.2 per 100,000 residents in 2010 to 19.9 per 100,000 residents in 2016, constituting a 143% increase. In 2016, there were 1,374 unintentional drug overdose deaths in NYC compared with 937 unintentional drug overdose deaths in 2015, an increase of 437. Similar to other jurisdictions, fentanyl is driving the increase in overdose deaths. In response, the NYC Department of Health and Mental Hygiene has implemented timely and innovative actions. To better assess the presence of fentanyl in the NYC illicit drug market, a research team collected 358 used syringes from 11 syringe exchange programs throughout NYC that were laboratory tested for heroin, fentanyl, cocaine and other substances. In another study, in-depth interviews are ongoing with people who use drugs (PWUD) to assess: 1) knowledge of fentanyl; 2) how participants learned about fentanyl; 3) perceptions of risk related to fentanyl; and 4) adoption of drug use behavior changes (e.g., risk reduction practices) in response to awareness of the presence of non-pharmaceutical fentanyl in the NYC. In this session, presenters will: 1) provide an overview of 2016 overdose mortality data in NYC; 2) present results from the syringe testing study to assess the presence of fentanyl in NYC; and 3) share findings from interviews conducted with PWUD around fentanyl knowledge and behavior adaptation. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe mortality surveillance methods using death certificates and toxicology to enumerate fentanyl-involvement in overdose deaths. - Discuss syringe testing study findings and describe immediate and ongoing responses to observed increases in overdose deaths in New York City. - Identify how people who use drugs learn about and adapt to the increased presence of fentanyl in the drug market, including suggestions for harm reduction messaging.

Denise Paone

EdD, Senior Director of Research and Surveillance

New York City Department of Health and Mental Hygience

Dr. Denise Paone is the Senior Director of Research and Surveillance in the Bureau of Alcohol and Drug Use Prevention, Care and Treatment at the New York City Department of Health and Mental Hygiene. She received her master's and doctoral degrees from Columbia University and has more than 25 years of experience in the fields of public health, harm reduction and substance use research. Before joining city government, Paone served as Director of Research at Beth Israel Chemical Dependency Institute, where she conducted several local, national and international drug and syringe exchange program evaluation studies. Paone is currently leading city-wide substance use and overdose surveillance, as well as conducting drug-related morbidity and mortality studies with an emphasis on overdose deaths and the fentanyl-driven opioid epidemic. She co-leads the real-time drug surveillance project RxStat, an innovative collaboration between public health and public safety that serves as a national model for jurisdictions struggling with high rates of drug overdose. Paone is a Distinguished Scholar affiliated with the CUNY School of Public Health, and the former chair of the National Council of State and Territorial Epidemiologists overdose subcommittee. She has published numerous research papers and peer-reviewed articles.

Nisha Beharie

DrPH, MPH, Senior Research Associate

New York City Department of Health and Mental Hygiene

Dr. Nisha Beharie works as Senior Research Associate within the Bureau of Alcohol and Drug Use Prevention, Care and Treatment at the New York City Department of Health and Mental Hygiene. She received her bachelor's degree from Fordham University (1999), before completing a master's degree in public health (2014) at Columbia University, and a doctorate degree in public health (2015) from the City University of New York (CUNY) Graduate Center. She has extensive research, teaching and program experience in the fields of health policy, harm reduction, behavioral health, mental health and qualitative studies. Beharie has worked in a range of capacities with public-facing programs geared toward helping high-risk youth, individuals with mental illness and other marginalized populations. She has held teaching positions at CUNY and New York University and contributed to over 10 peer-reviewed publications. In 2014, Beharie was awarded the American Public Health Association Student Assembly Conference Scholarship. She has widely presented her work to public health audiences across the country.

Alexandra Harocopos

PhD, MS, Director of Qualitative Research, Bureau of Alcohol and Drug Use Prevention, Care and Treatment

New York City Department of Health and Mental Hygiene

Dr. Alex Harocopos is the Director of Qualitative Research at the Bureau of Alcohol and Drug Use Prevention, Care, and Treatment at the New York City Department of Health and Mental Hygiene. She has been conducting substance use research for more than 15 years both in the United Kingdom and the United States. Her work includes studies of drug markets, drug use in post-Katrina New Orleans, and behavioral health and drug use practices, particularly as related to the use of opioids. Harocopos has an master's degree in research methods from London South Bank University and her doctorate in criminal justice from the CUNY Graduate Center.

Hanover CDE

Tuesday, April 3, 2018

2018-04-03

Changing Attitudes: Law Enforcement, Public Health and Naloxone

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: Nancy Hale, MA, President and Chief Executive Officer, Operation UNITE, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,APAGA Bar,GA POST Objections exist to law enforcement carrying naloxone in some jurisdictions. In this session, presenters will make the case for naloxone programs as effective partnerships between law enforcement and public health and identify strategies to overcome barriers to the programs. The creator of the Quincy Model in Massachusetts will explain the value of officers carrying and administering naloxone. Attendees will travel from inception in 2010 to present day and experience best practices — a direct result of the collaboration of law enforcement and the Department of Public Health. The presenter will discuss proven steps to reduce opioid overdose deaths while ensuring officers safety. Other topics will include safe prescribing, dispensing and proper disposal of unused medications. The presenter will reflect on how a local issue evolved into a national initiative to streamline access to naloxone, amend local laws, save lives, restore families and return people with substance use disorders to the community. From Delaware and New Jersey, presenters will outline strategies to convince law enforcement to carry naloxone. The Camden County Addiction Awareness Task Force in New Jersey and atTAcK Addiction in Delaware successfully developed and employed these methodologies, including: providing scientific evidence of the changes in the brain’s neurochemistry, structure and function; demonstrating the genetic predisposition to the disease of addiction; and addressing senior officers as well as academy recruits. The presenters also will review solutions to mitigate the cost of naloxone along with the message of “protect our own” in law enforcement. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Recognize the impact of the opioid crisis on the family and society. - Describe a mindset change of substance use disorder from the officer’s perception: the person. - Discuss the public’s perception of the changing role of law enforcement. - Identify objections to law enforcement officers carrying naloxone. - Explain solutions used to overcome barriers to law enforcement carrying naloxone. - Outline solutions to enable law enforcement to carry naloxone in your community.

Harry Earle

MA, Chief of Police

Gloucester Township (New Jersey) Police Department

Harry Earle, MA, is the Chief of Police of the Gloucester Township Police Department in Camden County, New Jersey. He has served with the department since 1988 and been Chief since 2010. Earle has implemented numerous community and problem-solving policing models with a focus on overall crime prevention through new programs targeting at-risk youth and early victimization identification. Earle holds a bachelor's degree in criminal justice, a master’s degree in human resource development, and is a graduate of the FBI National Academy. Earle is the President of the Camden County Chiefs of Police Association, and serves on numerous boards and committees including the Camden County College Police Academy Advisory Board, the New Jersey Council on Juvenile Justice System Improvement, and the New Jersey Human Trafficking Commission. Earle has lectured on the topics of police professionalism, bullying, peer mediation, violence prevention in schools, community policing, addiction and prevention of child sexual exploitation.

Patrick Glynn

MA, NREMT, Lieutenant Detective-Commander

Special Investigations and Narcotics Units, Quincy (Massachusetts) Police Department

Lieutenant Detective Patrick Glynn is a 32-year veteran of the Quincy (Massachusetts) Police Department and the Commander of the Special Investigations and Narcotics Units and the Director of the South Shore Drug Task Force. He has been training police officers for the past 25 years. He is a Senior Staff Instructor for the Municipal Police Training Committee, presenter for numerous community groups and adjunct faculty for Eastern Nazarene College. He is a founding member of the Norfolk County Prescription Monitoring Program. In addition, he is the Director of the the Quincy Naloxone Program and has spoken throughout the country on the “Quincy Model." He received the 2013 President’s Advocate for Action Award, presented by Office of National Drug Control Policy, the 2014 Gary P. Hayes Award, presented by the Police Executive Research Forum, and the 2012 Quincy Community Hero Award. Glynn holds a bachelor's degree in human services from New Hampshire College and a master's degree in criminal justice from Anna Maria College.

William Lynch

RPh, BPharm, Clinical Staff Pharmacist

Jefferson Health System, atTAcK addiction and Camden County (New Jersey) Addiction Awareness Task Force

William Lynch, RPh, BPharm, received his pharmacy degree from Rutgers University and is a practicing Clinical Staff Pharmacist with Kennedy University Hospital (KUH), the major core teaching affiliate with the Rowan School of Osteopathic Medicine (RSOM), where he serves as Adjunct Clinical Faculty. His pharmacy background includes more than 30 years of clinical practice at KUH/RSOM and as a clinical preceptor for Rutgers University, Ernest Mario School of Pharmacy, along with being a healthcare professional partner of the Delaware Prevention Coalition and State of Delaware Substance Abuse Epidemiological Working Group. Lynch is a member of the Camden County New Jersey Addiction Awareness Task Force (CCAATF), where he co-chairs the Education and Prevention Committee, and he is an Advisory Board Member with atTAcK addiction. Lynch is a certified New Jersey Department of Law and Public Safety Division of Criminal Justice Police Training Commission Instructor. He is the overnight clinical staff pharmacist at KUH, which specializes in behavioral medicine providing pediatric, adolescent, and adult psychological care, 24/7 crisis intervention, and drug and alcohol detoxification and treatment services.

Courtland

Tuesday, April 3, 2018

2018-04-03

Improving Clinician PDMP Interventions: Unsolicited Reports, Provider Report Cards and Mandated Use

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: John J. Dreyzehner, MD, MPH, FACOEM, Commissioner, Tennessee Department of Health, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ANCC In this interactive session, practicing clinicians — who have expertise in prescription drug monitoring programs (PDMPs) and clinical interventions — will discuss the ideal use of clinical decision tools that provide feedback and/or decision support to improve medical decision-making. PDMP-based interventions to improve prescribing decisions for controlled medications are recognized as best practices and are being implemented nationwide. Interventions such as unsolicited reports, provider report cards and mandated use hold promise as mechanisms to improve patient safety, inform providers and decrease high-risk prescribing. Unfortunately, thus far, providers have not been part of the development or implementation of these interventions and outcome data evaluating the impact is sparse. The presenters will provide recommendations, as well as explore the outcomes that should be considered in order to evaluate the utility of these interventions so risk and reward can be examined. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the characteristics of ideal interventions to change provider decisions. - Identify barriers to using PDMP feedback tools (unsolicited reports and report cards) and mandated use in the clinical setting. - Explain how to evaluate outcomes associated with PDMP provider interventions including unsolicited. reporting, provider report cards and mandated use.

Scott Weiner

MD, MPH, Director, Brigham Comprehensive Opioid Response and Education Program

Brigham and Women’s Hospital

Scott G. Weiner, MD, MPH, FACEP, FAAEM, is an Attending Emergency Physician and Assistant Clinical Director in the Department of Emergency Medicine at Brigham and Women’s Hospital in Boston. He is the Director of B-CORE: The Brigham Comprehensive Opioid Approach and Education Program. Weiner completed his residency training at the Harvard-Affiliated Emergency Medicine Program at Beth Israel Deaconess Medical Center and his master's degree in public health at Harvard School of Public Health. He is the President-Elect of the Massachusetts College of Emergency Physicians. His research focuses on technological innovations that improve the care of emergency department patients presenting with pain, including usage and optimization of online prescription drug monitoring programs and tablet-based screening tools.

Jason Hoppe

DO, Associate Professor, Department of Emergency Medicine

University of Colorado

Dr. Jason Hoppe is an emergency physician and medical toxicologist at the University of Colorado and Rocky Mountain Poison and Drug Center with a career focus on Rx opioid safety and maximizing the utility of prescription drug monitoring programs (PDMPs). He serves as co-chair for Colorado’s statewide PDMP task force and is a founding member of the coordinating committee for the Colorado Consortium for Prescription Drug Abuse Prevention. Through these groups he has worked extensively to improve Colorado’s PDMP. His research using PDMPs has resulted in several published projects linking PDMP and clinical data. These projects have lead to further grant funding for three additional large scale PDMP implementation and evaluation projects. He has worked extensively with the Colorado Board of Pharmacy and the Department of Public Health to improve and evaluate the Colorado PDMP.

Baker

Tuesday, April 3, 2018

2018-04-03

Pharmacy-Based Naloxone: Strategies from Massachusetts, Rhode Island, Oregon and Washington

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: Anne L. Burns, RPh, Vice President, Professional Affairs, American Pharmacists Association, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AAFP,ACPE,APA Policies allowing for pharmacy-based distribution of naloxone are being implemented across the United States to mitigate the still staggering numbers of opioid-related overdose deaths. To maximize the impact of these policies, this session will outline strategies to help community pharmacists implement them fully. Oregon and Washington allow patients and laypersons direct access to naloxone through community pharmacies. Presenters will explore their differing policy and implementation approaches, including an overview of current trainings and outreach materials. They also will present findings from an online survey distributed to pharmacists through listservs operated by the Oregon Board of Pharmacy and the Washington State Pharmacy Quality Assurance Commission. Results provide insight into the implications of policy and personal efficacy on naloxone distribution practices and attitudes. Naloxone access through pharmacies has expanded to every state. However, due to under-implementation, this rapid policy expansion has failed to show an impact on overdose rates or fatalities. Researchers will present novel evidence of passive and active collaborations, interventions, strategies and materials that optimized and expanded pharmacy-based naloxone implementation, resulting in significant increases in naloxone dispensing in Rhode Island and Massachusetts. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe different policy and implementation strategies for pharmacy-based naloxone distribution. - Identify current strategies for naloxone-based trainings for pharmacists and patients. - Outline the behavioral and psychological barriers and facilitators to pharmacy-based naloxone distribution. - Compare and contrast effectiveness of posters, tear-offs, syringe bag stickers and register tear-offs to increase patient and caregiver engagement with pharmacy staff about naloxone. - Discuss the increase in naloxone dispensing related to academic detailing and active application of scripted language used to initiate naloxone conversations. - Apply data obtained from fidelity checks to the interventions discussed.

Jeffrey Bratberg

PharmD, Clinical Professor

University of Rhode Island College of Pharmacy

Dr. Jeffrey Bratberg is well acquainted with the challenges community pharmacists and pharmacies face regarding opioid dispensing, safety, overdose and addiction. In 2012, Bratberg, along with a University of Rhode Island student pharmacist, co-developed an overdose education and naloxone training program for pharmacists in the first-in-nation statewide Collaborative Pharmacy Practice Agreement for naloxone. He is an unpaid consultant for prescribetoprevent.org, a website devoted to opioid overdose education and naloxone training, which hosts an online continuing professional education program that has trained over 10,000 pharmacists nationwide. In 2015, he was selected to serve as a member of the Rhode Island Governor’s Overdose Prevention and Intervention Task Force. He is a consultant or co-investigator on federal grants from the National Institute on Drug Abuse, Centers for Disease Control and Prevention, and Agency for Healthcare Research and Quality. Bratberg is the 2016 NASPA National Cardinal Health Generation Rx Award winner. The Generation Rx Champions Award honors a pharmacist who has demonstrated outstanding commitment to raising awareness of the dangers of Rx drug misuse among the general public, as well as the pharmacy community. Finally, Bratberg is the guest editor of the first ever special issue on Opioid Safety and Naloxone of the Journal of the American Pharmacists Association (Mar/April 2017).

Traci Green

PhD, MSc, Deputy Director, Boston Medical Center Injury Prevention Center

Associate Professor of Emergency Medicine and Epidemiology, Warren Alpert School of Medicine, Brown University

Nicole O'Kane

PharmD, Clinical Director

HealthInsight Oregon

Nicole O’Kane, PharmD, is a pharmacist and the Clinical Director at HealthInsight Oregon. Her expertise includes the evaluation and reporting of medical data, as well as the design and measurement of person-centered interventions to improve the safety and effectiveness of medication use. O’Kane has extensive experience collaborating with communities across Oregon to evaluate the incidence of harm related to adverse drug events, and support the integration of processes to improve medication safety. She works directly with providers and pharmacists across healthcare settings to provide leadership and project management to improve coordination of care for people taking high-risk medication combinations, including opioids and other controlled substances. O’Kane is a serving member of the Oregon Health Authority naloxone workgroup and the Tri-county opioid safety coalition, supporting the development of effective policies and monitoring for safer opioid prescribing and the expanded distribution of naloxone. She also serves as Co-Investigator on a project funded by Agency for Healthcare Research and Quality to develop and evaluate a toolkit aimed at community pharmacists to facilitate use of the Oregon Prescription Drug Monitoring Program and enhance supportive, effective communication between patients, pharmacists and prescribers around opioid management.

Lindsey Alley

MS, Senior Research Associate

HealthInsight Oregon

Lindsey Alley, MS, is a Research Associate and Project Manager at HealthInsight Oregon. She received her master's degree in applied psychology at Portland State University, where she gained advanced training in the psychosocial facets of health behavior and health outcomes. Her work involves a variety of qualitative and quantitative methods. Her research focuses on patient experiences and relationship implications (e.g., spouse-patient, provider-patient and pharmacist-patient), regarding both treatment facilitation and adherence for individuals living with chronic illness and chronic pain. She has successfully coordinated seven research projects through which she has collected, analyzed and disseminated data regarding psychosocial determinants of various health-related behaviors, including safe patient handling, exercise, drinking, obesity, work-related injuries and psychological well-being. She is managing an Agency for Healthcare Research and Quality-funded project to develop and evaluate a toolkit aimed at community pharmacists to facilitate use of the Oregon Prescription Drug Monitoring Program and enhance supportive, effective communication between patients, pharmacists and prescribers around opioid management.

Regency VII

Tuesday, April 3, 2018

2018-04-03

#IRiseAbove: Social Media and Engagement Strategies for Youth Substance Misuse Prevention

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: Tom Valentino, Senior Editor, Addiction Professional and Behavioral Healthcare Executive CE Certified By: AMA,AAFP,ADA,ACPE,ANCC,APA,CHES,NASW In this session, Rise Above Colorado will illustrate how to use survey data and social media to disseminate a social-norming campaign that helps close the gap in teens’ perceptions of their peers’ use of substances compared to actual, self-reported teen use. The social-norming approach is based on research that behavior is influenced by perceptions of the norm, or how we believe our peers think and act. By closing this gap in perception versus reality, the campaign is designed to reduce — or eventually prevent — teen substance use. In order to be relevant and meet teens where they are, Rise Above Colorado is actively engaged in promoting these messages through social media. Presenters will share lessons learned and best practices for promoting prevention campaigns through social media, highlighting tools for social media management and youth engagement. Additionally, following a best practice in prevention, the social-norming campaign messages are reinforced across the social ecological model by community-based partners in targeted geographies. These partners engage youth directly through specifically designed educational resources that incorporate skill-building and relationship-building opportunities to complement and reinforce the social-norming campaign. Finally, employing a Positive Youth Development framework, Rise Above Colorado prioritizes a strengths-based message, correcting the general public perception and normalizing the reality that most teens are in fact making positive, healthy choices every day. Bringing visibility to this positive norm helps to create a context in which young people are supported in their personal decision-making as they navigate their adolescent years. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Explain the role of social norming in youth substance misuse prevention. - Identify the current trends in youth utilization of social media platforms. - Apply Positive Youth Development principles to initiatives.

Jonathan Judge

MA, Program Director

Rise Above Colorado

Jonathan Judge is the Director of Youth Engagement at Rise Above Colorado. He brings significant curriculum design and program management experience to his role leading youth outreach efforts for the organization. As director for the International Towne program at Young Americans Center for Financial Education from 2003-2008, Judge led curriculum creation, as well as overall program management of a middle-school, hands-on education program in global economics. Moving on to become the Program Manager for the Colorado Meth Project, he developed and led the organization’s volunteer network, oversaw statewide outreach to schools and youth serving agencies, and led an initiative to design and pilot a nationally utilized meth prevention curriculum. Judge designs, implements and monitors the organization’s social media activity and leads large-scale community art projects across Colorado.

Mae Thompson

Student, Board Member

Rise Above Colorado

Mae Thompson serves on the Board of Directors for Rise Above Colorado. Her role is to provide youth voice and input through the cultivation of youth-adult partnerships. For the past five years Thompson has been an advocate for youth voice, in various capacities, at both local and state levels. Most recently she served two years as the Youth Partner for Rise Above Colorado where she focused on youth engagement across the state. She is passionate about creating environments where young people feel comfortable to speak up and share their opinions in order to create a more informed community. Thompson is currently a student at the University of Denver, graduating June 2018 with degrees in International Studies and Strategic Communication.

Kavitha Kailasam

MA, Director of Community Partnerships

Rise Above Colorado

Kavitha Kailasam is the Director of Community Partnerships and Capacity Building at Rise Above Colorado. She has worked in youth development programs for the last 12 years in a variety of capacities and locations, spanning the private and public sectors. At Rise Above Colorado, Kailasam is responsible for supporting community partners in implementing youth engagement and Rx drug misuse prevention strategies. Prior to joining Rise Above Colorado, she directed a youth violence and substance misuse prevention funding program for the State of Colorado. Kailasam received undergraduate and graduate degrees in international development from the University of Denver.

Learning Center

Tuesday, April 3, 2018

2018-04-03

Coverage of Addiction Benefits in ACA Plans

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: Amy G. Griffin, JD, Corporate Counsel, Kentucky Employers’ Mutual Insurance CE Certified By: AMA,AAFP,ACPE,ANCC,APA,NAADAC,NASW The National Center on Addiction and Substance Abuse conducts comprehensive reviews of the addiction benefits offered in each state’s individual marketplace health insurance plans. Plans are evaluated for compliance with the Affordable Care Act’s requirements to cover addiction benefits and the adequacy of coverage for the full range of critical benefits to treat and manage addiction. This presentation will provide an overview of the requirements to cover addiction treatment and present findings from the Center’s new review of 2017 ACA plans which will detail the specific benefits offered in each state. There will be a particular focus on coverage of medication assisted treatment for opioid addiction. The presenter will discuss recommendations developed by the Center to improve insurance coverage of evidence-based treatment and provide an update on federal healthcare reform to describe how any proposed or actual changes will impact insurance coverage for addiction treatment. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify the federal requirements to cover addiction benefits. - Recognize the critical benefits needed for evidence-based addiction treatment and identify where coverage gaps typically occur. - Describe actions that states can take to ensure comprehensive coverage of addiction benefits by plans sold in their state.

Lindsey Vuolo

JD, MPH, Associate Director of Health Law and Policy

The National Center on Addiction and Substance Abuse

Dunwoody

Tuesday, April 3, 2018

2018-04-03

A Review of TIP #63: Medications for Opioid Use Disorder

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: Stephanie McCladdie, MPA, Regional Administrator, Region 4, Substance Abuse and Mental Health Services Administration CE Certified by: AMA, ACPE, ADA, ANCC, APA This session will provide an overview of the Substance Abuse and Mental Health Services Administration's Treatment Improvement Protocol (TIP) #63 on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder (OUD) — methadone, naltrexone and buprenorphine — and the other strategies and services needed to support recovery. An expert panel developed the TIP’s content based on a review of the literature and on their extensive experience in the field of addiction treatment. The five sections of the TIP include (1) laying the groundwork for understanding treatment concepts; (2) guidance on OUD screening, assessment, treatment and referral; (3) information and tools for healthcare professionals who prescribe, administer or dispense OUD medications or treat other illnesses in patients who take these medications; (4) ways that addiction treatment counselors can collaborate with healthcare professionals to support client-centered, trauma-informed OUD treatment and recovery; and (5) a glossary and list of audience-segmented resources. TIP #63 is a key resource for healthcare and addiction professionals, policymakers, administrators, peer support specialists, patients and families. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the different forms of medications to treat OUD and the evidence behind them. - Identify engagement strategies that can be used in various treatment settings. - Outline strategies for clear communication with prescribers and creation of supportive environments for clients who take OUD medication.

Steve Daviss

MD, DFAPA, Senior Medical Advisor, Office of the Chief Medical Officer and Center for Substance Abuse Treatment

Substance Abuse and Mental Health Services Administration

Dr. Steve Daviss currently serves as Senior Medical Advisor to the Office of the Chief Medical Officer and to the Center for Substance Abuse Treatment at the Substance Abuse and Mental Health Services Administration within the U.S. Department of Health and Human Services (HHS). He is double-boarded in psychiatry and in psychosomatic medicine, with expertise in the intersections of psychiatry, addiction, primary care, health information technology and healthcare policy. Prior to beginning his service to HHS in September 2017, he served in numerous leadership positions in clinical, policy and medical informatics areas, including clinical assistant professor of psychiatry at University of Maryland, chair of the Department of Psychiatry at University of Maryland Baltimore Washington Medical Center, founding president at Fuse Health Strategies, Chief Medical Informatics Officer at M3 Information, chair of the Parity Accreditation Committee of ClearHealth Quality Institute, and election to Recorder of the Assembly at the American Psychiatric Association in 2017.

Centennial Ballroom

Tuesday, April 3, 2018

2018-04-03

Plenary Session

5:30 PM - 7:15 PM

5:30 PM

7:15 PM

Deputy Assistant Secretary James A. Walsh for the U.S. Department of State’s Bureau of International Narcotics and Law Enforcement Affairs (INL) will moderate a panel highlighting the international response to the opioid crisis. Panelists may discuss efforts related to regulating, monitoring, and enforcing opioid and synthetic drug production and controls. Presentations will focus on information sharing, best practices, and coordination on illicit opioid and heroin trafficking. Panelists will include: - Mauricio Ibarra, General Director for North America Affairs, Ministry of Foreign Affairs, Mexico - Raymond Donovan, DEA Special Agent in Charge for the Special Operations Division - Justice Tettey, UN Office on Drugs and Crime (UNODC) Chief of the Laboratory and Science Section

James A. Walsh

Deputy Assistant Secretary

International Narcotics and Law Enforcement Affairs Bureau

James A. Walsh has served as Deputy Assistant Secretary of State in the Bureau of International Narcotics and Law Enforcement Affairs (INL) since January 2015. In his capacity as Senior Bureau Official since December 2017, he is responsible for State Department programs and policies combating drugs and organized crime around the world, as well as support for law enforcement and rule of law. INL currently manages a portfolio of more than $4 billion in more than 90 countries. From 2015 to 2017, he directed State Department law enforcement and rule of law assistance activities in Europe and Asia (excluding Pakistan and Afghanistan) and oversaw the Department's Air Wing and INL's resources. He previously served as the Executive Director/Controller for the bureau where he led several efforts to strengthen criminal justice assistance programs including the development of an inter-agency Criminal Justice Sector Rating Tool. Prior to joining the Department, Mr. Walsh worked in the private sector for five years supporting Fortune 500 companies. He also served nearly eight years in the U.S. Army where he had several overseas deployments leading aviation units. James Walsh was born and raised in Northern Indiana. He is a career member of the Senior Executive Service, has a bachelor's degree from West Point, and a master's degree in business administration from Bowie State University. Mr. Walsh received the Presidential Meritorious Rank Award in 2017.

Dunwoody

Tuesday, April 3, 2018

2018-04-03

Open Meeting

8:00 PM - 10:00 PM

8:00 PM

10:00 PM

Open Meeting

Grand Hall

Wednesday, April 4, 2018

2018-04-04

Coffee in the Exhibit Hall

7:00 AM - 8:00 AM

7:00 AM

8:00 AM

Coffee in the Exhibit Hall

Terrace Foyer

Wednesday, April 4, 2018

2018-04-04

Conference Registration

7:00 AM - 6:00 PM

7:00 AM

6:00 PM

Conference Registration

Centennial Ballroom

Wednesday, April 4, 2018

2018-04-04

Plenary Session: The Role of Science in Addressing the Opioid Crisis

8:15 AM - 9:30 AM

8:15 AM

9:30 AM

The Role of Science in Addressing the Opioid Crisis

Francis Collins

MD, PhD, Director

National Institutes of Health (NIH)

Francis S. Collins, MD, PhD, was appointed the 16th Director of the National Institutes of Health (NIH) by President Barack Obama and confirmed by the Senate. He was sworn in on August 17, 2009. On June 6, 2017, President Donald Trump announced his selection of Dr. Collins to continue to serve as the NIH Director. In this role, Dr. Collins oversees the work of the largest supporter of biomedical research in the world, spanning the spectrum from basic to clinical research. Dr. Collins is a physician-geneticist noted for his landmark discoveries of disease genes and his leadership of the international Human Genome Project, which culminated in April 2003 with the completion of a finished sequence of the human DNA instruction book. He served as director of the National Human Genome Research Institute at NIH from 1993-2008. Before coming to NIH, Dr. Collins was a Howard Hughes Medical Institute investigator at the University of Michigan. He is an elected member of the National Academy of Medicine and the National Academy of Sciences, was awarded the Presidential Medal of Freedom in November 2007, and received the National Medal of Science in 2009.

Nora Volkow, MD

Director,

National Institute on Drug Abuse/National Institutes of Health

Nora D. Volkow, MD, became Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH) in May 2003. NIDA supports most of the world's research on the health aspects of drug abuse and addiction. Dr. Volkow's work has been instrumental in demonstrating that drug addiction is a disease of the human brain. As a research psychiatrist and scientist, Dr. Volkow pioneered the use of brain imaging to investigate the toxic effects and addictive properties of abusable drugs. Her studies have documented changes in the dopamine system affecting, among others, the functions of frontal brain regions involved with motivation, drive, and pleasure in addiction. She has also made important contributions to the neurobiology of obesity, ADHD, and aging. Dr. Volkow was born in Mexico, attended the Modern American School, and earned her medical degree from the National University of Mexico in Mexico City, where she received the Robins award for best medical student of her generation. Her psychiatric residency was at New York University, where she earned the Laughlin Fellowship Award as one of the 10 Outstanding Psychiatric Residents in the USA. Dr. Volkow spent most of her professional career at the Department of Energy's Brookhaven National Laboratory (BNL) in Upton, New York, where she held several leadership positions including Director of Nuclear Medicine, Chairman of the Medical Department, and Associate Director for Life Sciences. In addition, Dr. Volkow was a Professor in the Department of Psychiatry and Associate Dean of the Medical School at the State University of New York (SUNY)-Stony Brook. Dr. Volkow has published more than 680 peer-reviewed articles and written more than 100 book chapters and non-peer-reviewed manuscripts, and has also edited four books on neuroimaging for mental and addictive disorders. During her professional career, Dr. Volkow has been the recipient of multiple awards. In 2013, she was a Samuel J. Heyman Service to America Medal (Sammies) finalist and was inducted into the Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) Hall of Fame. She was elected to membership in the Institute of Medicine in the National Academy of Sciences, received the International Prize from the French Institute of Health and Medical Research for her pioneering work in brain imaging and addiction science, and was awarded the Carnegie Prize in Mind and Brain Sciences from Carnegie Mellon University. She has been named one of Time magazine's "Top 100 People Who Shape Our World," "One of the 20 People to Watch" by Newsweek magazine, Washingtonian magazine's "100 Most Powerful Women" in both 2015 and 2017, "Innovator of the Year" by U.S. News & World Report, and one of "34 Leaders Who Are Changing Health Care" by Fortune magazine. Dr. Volkow was the subject of a 2012 profile piece by CBS's 60 Minutes and was a featured speaker at TEDMED 2014.

Piedmont

Wednesday, April 4, 2018

2018-04-04

Knowledge and Agility: Pivoting in Response to Federal and State Health Policy Changes

9:45 AM - 11:00 AM

9:45 AM

11:00 AM

Moderator: Michael Barnes, JD, Chairman, Center for Lawful Access and Abuse Deterrence, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,APA,GA Bar,NAADAC,NASW,NBCC Rx Summit participants are squarely in the middle of two of the nation’s top policy issues: healthcare reform and reducing drug overdoses. Naturally, we must do our best to share our real-world recommendations with policymakers in a way that reflects practical and political realities. We must also prepare to adjust to new laws, regulations and enforcement efforts that may not be all that we had hoped. This session will address the impact that healthcare reform and overdose reduction policies can have on healthcare providers, patients, prevention leaders, and the public at large. The speakers — a physician, a legislator, and an attorney, all of whom work daily to improve healthcare policy — will discuss current legislative, regulatory, and enforcement initiatives, and analyze their potential impacts on communities. They will provide an inclusive, matter-of-fact overview of how health and safety leaders can respond to contingencies, whether we live in red or blue states. This session’s topics will be drawn from some of the most timely federal and state health policy debates, and will likely include the following: - Healthcare reform, including state insurance marketplaces; - Private insurance and Medicaid coverage of treatment; - Federal block grants; - State treatment guidelines for pain and addiction; and - Law enforcement and prosecutions. To account for the practical and political realities of making policy in 2018, the presenters’ analyses and recommendations will encompass commonly debated concerns, such as budget, the roles of government and the private sector, and privacy. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify two national issues that could have major impacts on efforts to reduce substance use, addiction and overdoses. - Recognize current legislative, regulatory and enforcement initiatives that could affect substance use prevention and treatment efforts. - Formulate potential responses to policy changes.

Kelly Clark

MD, MBA, DFAPA, DFASAM, Chief Medical Officer, Clean Slate Centers

President, American Society of Addiction Medicine, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board

Kimberly Moser

RN, BSN, State Representative

Kentucky, 64th District

Rep. Kim Moser is a Registered Nurse, with many years of experience in Neonatal Intensive Care Units and flight nursing on the University of Kentucky Neonatal Transport Team. She has dedicated her professional career to advocating for positive healthcare legislation and public health issues. Moser chaired the Kentucky Physician’s PAC, and worked with the Kentucky Medical Association Alliance on medical legislative issues. She is a past-president of the Kentucky Medical Association Alliance and is the current President of the AMA Alliance. She serves as Director of Drug Control Policy in northern Kentucky. In 2016, she was elected to the Kentucky legislature, where she serves on the Health and Family Services, Education, Licensing and Occupation, and Judiciary Committees and chairs the Medicaid Oversight and Advisory Committee. In her first legislative session, Moser successfully passed important legislation to limit opioid prescribing. She works to stem the tide of addiction through furthering best-practice policies in education and prevention, expanding addiction treatment, criminal justice reform and building model continuums.

Michael Barnes

JD, Chairman

Center for Lawful Access and Abuse Deterrence, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board

Michael C. Barnes, JD, is a Founder and the Chairman of the Board of Directors of the Center for Lawful Access and Abuse Deterrence. He also is a practicing attorney and the managing partner at DCBA Law & Policy in Washington, D.C. Barnes has been a member of the Advisory Board for the National Rx Drug Abuse & Heroin Summit since 2012, has authored more than 10 scholarly articles, and presents frequently at conferences nationwide. He provides analysis for TV networks including CNBC, CNN, FOX Business, FOX News, and MSNBC. Barnes previously served as Confidential Counsel in the White House Office of National Drug Control Policy. He is a member of the National Rx Drug Abuse & Heroin Summit Advisory Board.

International North

Wednesday, April 4, 2018

2018-04-04

VA Data about Rx Opioids and Overdose and Suicide: Clinical Implications

9:45 AM - 11:00 AM

9:45 AM

11:00 AM

NEW LOCATION: INTERNATIONAL NORTH TITLE & SESSION DESCRIPTION UPDATED 3/30/18 Moderator: John L. Eadie, MPA, Coordinator, Public Health and Prescription Drug Monitoring Program Project, National Emerging Threat Initiative, A National HIDTA Initiative, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,APA,NAADAC,NASW,NBCC Despite recommendations within recent guidelines for patient-centered evaluation of the risks and benefits for prescribing opioids for chronic pain, there are concerns regarding the effectiveness of initiatives solely focused on opioids that do not consider co-morbid conditions, such as initiatives from some state regulators, insurers, payers and healthcare organizations that encourage blanket opioid dose reduction or discontinuation. These concerns are especially pronounced for patients with mental health or substance use disorders (MH/SUD) for whom risk for overdose or suicide still exist even when opioids are no longer prescribed. Due to these concerns, the Department of Veterans Affairs (VA) is analyzing national data and have found: 1. Limitations of using morphine equivalent daily dose (MEDD) as a singular population-based risk mitigation strategy given that in fiscal year 2013, VA patients prescribed less than 90 MEDD accounted for 93% of patients and 79% of overdose/suicide-related deaths. 2. A significant decrease in follow-up year overdose mortality between FY2011 and FY2014 among VA patients prescribed opioids in FY2010 and FY2013 (no significant change in suicide mortality). Presenters will offer practical suggestions to treat patients prescribed opioids for chronic pain and discuss future analyses. These findings underscore that patients at risk for overdose/suicide tend to be complex patients with multiple comorbidities — especially MH/SUD conditions — and that a multifaceted risk mitigation approach is needed to improve patient safety. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Recognize that most patients who are prescribed opioids who end up dying from overdose or suicide are below 90 mg morphine equivalent daily dose and have a mental health or substance use disorder. - Identify strategies for addressing opioid prescribing among complex patients on long-term opioids for chronic pain.

Ajay Manhapra

MD, Physician, Research Scientist, Lecturer

Hampton VA Medical Center, New England Mental Illness Research, Education and Clinical Center, Yale School of Medicine

Dr. Ajay Manhapra was a practicing hospitalist managing complexly ill patients for over a decade before he made a career transition to addiction medicine and research. After a two-year VA-funded fellowship at Yale University, he started a primary care based clinic for patients with severe chronic disabling pain who have failed several treatment interventions. The clinic follows a whole-person approach to help these patients recover their functional life. In the clinic, they focus on multimorbidity as the main target of pain treatment, combining medical and psychiatric care, treatment of dependence and addiction, and polypharmacy management with behavioral treatment of pain. He also continues his research related to addiction and comorbidities through his affiliations at Yale School of Medicine and VA New England MIRECC.

Stefan Kertesz

MD, MSc, Professor, University of Alabama at Birmingham

Director of Homeless Patient-Aligned Care Team, Birmingham VA Medical Center

Dr. Stefan Kertesz serves at the Birmingham Veterans Affairs (VA) Medical Center and as Professor at the University of Alabama at Birmingham Schools of Medicine and Public Health. Since 1996, he has focused his clinical care and research on the medical and addiction care of vulnerable populations, notably persons who are homeless. Starting at Boston Health Care for the Homeless Program in 1996, he transitioned to Birmingham in 2002, and currently runs the Homeless Patient-Aligned Care Team at Birmingham VA Medical Center. His research, funded by the National Institute on Drug Abuse and the Veterans Administration Health Services Research Merit program, has focused on natural history of illicit drug use, addiction treatment services and design of patient-centered care for homeless individuals. He serves on the Opioid Safety Initiative and the Opiate Advisory Team for the Birmingham VA Medical Center. In addition to briefing Surgeon General Vivek Murthy in January 2016, his popular commentaries on opioids have appeared in Slate.com, The Hill, STATNews and The Huffington Post. His recent work highlights the patient-level outcomes associated with incautious termination of opioid prescriptions. His views do not represent positions of any federal agency or the state of Alabama.

Elizabeth Oliva

PhD, VA National Opioid Overdose Education and Naloxone Distribution Coordinator

Department of Veterans Affairs, Veterans Health Administration

Friedhelm Sandbrink

MD, VA Acting National Director for Pain Management

Department of Veterans Affairs, Veterans Health Administration

Hanover FG

Wednesday, April 4, 2018

2018-04-04

Faith-Based Recovery Support: What Works in Tennessee

9:45 AM - 11:00 AM

9:45 AM

11:00 AM

Moderator: J. Kevin Massey, Health Administrator, Correct Care Solutions, Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ANCC,APA,MCHES,NAADAC,NASW,NBCC This session will present the innovative ways that Tennessee has approached partnering with the faith-based community to combat addiction and mental health issues. The Tennessee Department of Mental Health and Substance Abuse Services (TDMHSAS) designed the Tennessee Community Faith Based Initiative to connect the state's faith-based community with its recovery courts, prevention coalitions, recovery programs, treatment programs, jail and prison programs, and lifeline peers around the state to increase access to resources and, ultimately, to become resources. The approach is to help the faith-based community volunteers build recovery support services/ministry work by using a best practice model that directly connects them with state and local initiatives. The goal is to build more recovery-conducive communities utilizing natural/organic resources. The TDMHSAS recognizes willing volunteer organizations, across all belief systems, as Certified Recovery Congregations when they use a developed best practice model. Moreover, the TDMHSAS connects the organizations with each other, statewide, through networking and training opportunities so partnerships can be built with more local accessibility. As a result, there are 270 Certified Recovery Congregations across Tennessee, working hand in hand with the TDMHSAS to deliver a consistent message and share information with their immediate community. The presenters will share lessons learned and data. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Explain how the Tennessee Community Faith Based Initiative and the Lifeline Peer Project connect the continuum of care across the state. - Describe the Tennessee Community Faith Based Initiative’s best practice model and its successful implementation. - Recognize the benefits of building strong partnerships with the faith community as well as helping the faith community increase its capacity to combat addiction.

Allen Burnette

CPRS, Project Lifeline Recovery Coordinator - Region 5 South

Tennessee Department of Mental Health and Substance Abuse Services

Allen Burnette contracts with the Tennessee Department of Mental Health and Substance Abuse Services as a Lifeline Recovery Coordinator for 13 counties, reducing the stigma of addiction and increasing community support for those who struggle with addiction. He has served as a Certified Peer Recovery Specialist for the Franklin County Prevention Coalition for the past eight years in multiple capacities. Burnette was instrumental in the development of the Moral Reconation Therapy Program for juveniles in the Franklin County Court System. Over the past eight years, Burnette has facilitated at least one class per week and witnessed the change in cognitive behavior of over 800 juveniles. He serves on the Juvenile Recovery Court in Franklin County and is a team member for the Tennessee Alliance of Drug Endangered Children. Burnette is a person in long-term recovery, 11 years clean. As a person in long-term recovery he is a better father, son, productive member of his community and understands the true meaning of being responsible. His purpose in life is to help others have the same opportunities that he’s had ... to truly live life. His motto “Recovery Is the New High" became the slogan in the prevention, treatment and recovery communities across the entire state of Tennessee.

Monty Burks

PhD, CPRS, Director of Faith-Based Initiatives

Tennessee Department of Mental Health and Substance Abuse Services

Monty Burks, CPRS, PhD, serves as the Director of Faith-Based Initiatives for the Tennessee Department of Mental Health and Substance Abuse Services, where his role is engaging and connecting Tennessee’s faith communities with the goal of expanding addiction recovery support services across the state. He also oversees the Tennessee Lifeline Peer Project, a state program aimed at reducing the stigma associated with people who suffer from addiction. Burks earned his master’s degree in criminal justice from Middle Tennessee State University and his doctorate in theology from Heritage. Burks has more than 16 years’ experience working with the criminal justice system in various roles, including adjunct criminal justice professor at Motlow State Community College, Criminal Justice Research Analyst at Middle Tennessee State University, and Criminal Justice Program coordinator at Tennessee State University, where he still serves as an adjunct professor of criminal justice.

Regency V

Wednesday, April 4, 2018

2018-04-04

SAMHSA Opioid STR: State-Specific, Evidenced-Based Approaches to Prevention, Treatment and Recovery Support to Reduce Opioid Related Deaths

9:45 AM - 11:00 AM

9:45 AM

11:00 AM

MODERATOR: Tonia M. Schaffer, MPH, Public Health Advisor, Center for Substance Abuse Prevention, Substance Abuse and Mental Health Administration Presenters will highlight effective strategies of two Substance Abuse and Mental Health Administration (SAMHSA) Opioid State Targeted Response (STR) states to reduce opioid-related deaths. They will include successful efforts to engage hard-to-reach populations. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Outline SAMHSA’s Opioid STR programmatic goals and objectives. - Explain how to develop a needs assessment and strategic plan align to achieve the state level Opioid STR goals. - Describe the two different Opioid STR state practices utilizing evidenced-based practices.

Kim Thierry English

MEd, NCAC II, MAC, Public Health Advisor, Center for Substance Abuse Treatment

Substance Abuse and Mental Health Services Administration

Kim Thierry English has been a Public Health Advisor with the Center for Substance Abuse, Division of Services Improvement, Substance Abuse and Mental Health Services Administration (SAMHSA) since 2007 and has been in the behavioral health/substance use disorder field for over 30 years. Currently, she is Program Lead for the MAT-PDOA (Medication Assisted Treatment- Prescription Drug Opioid Abuse) Program and is an assigned Government Project Officer for Opioid STR grants. She has many years of clinical work in substance use disorders and mental health, and she has worked extensively in community outreach, business development, strategic planning and grant writing. She has worked as a peer reviewer with SAMHSA on various grant initiatives. She is the Founding President of the District of Columbia Addictive Disorders Services Providers Consortium and has served on the Board of Directors for the Center for Creative Non-Violence in Washington, D.C. She attended St. Gregory’s College in Shawnee, Oklahoma, graduated with a bachelor's degree in Sociology from Cameron University, in Lawton, Oklahoma, completed coursework toward a master's degree in business administration at Oklahoma City University Meinders School of Business, and received a master's degree in education in counseling from Boston University. Additionally, she has NCAC II and MAC Certifications.

Kim Nesbitt

MA, Public Health Advisor/West Team, Center for Substance Abuse Prevention

Substance Abuse and Mental Health Service Administration

Kim Nesbitt is currently a Government Project Officer with the Substance Abuse and Mental Health Service Administration (SAMHSA), Center for Substance Abuse Prevention. At SAMHSA, Nesbitt is responsible for development of Funding Opportunity Announcements, oversees several discretionary grant programs and serves as Contract Officer Representative. She provides program expertise and guidance on public health programs in the field of substance abuse prevention. She previously worked as a Program Analyst with the Administration for Children and Families, Office of Community Services, Division of State Assistance, where she provided oversight and management of the Social Service Block Grant Hurricane Sandy program. She is a former Health Specialist at the National Institutes of Health, National Center for Complementary and Alternative Medicine, where she conducted portfolio analysis of programs and coordinated many facets of the extramural research office grant programs. Nesbitt has over 15 years of experience in the public health sector with expertise in research study coordination, grant monitoring and program development. She holds a master's degree in community health education from Adelphi University, a bachelor's degree in psychology from the State University of New York, and an associate’s degree in nursing from Howard Community College.

Tonia M. Schaffer

MPH, Public Health Advisor, Center for Substance Abuse Prevention

Substance Abuse and Mental Health Services Administration

Tonia M. Schaffer, MPH, Public Health Advisor/Government Project Officer, is responsible for monitoring and guiding the substance abuse prevention activities of 17 states including the Virgin Islands. Schaffer coordinates the development of program policies, the creation of monitoring tools and evaluation protocols, and the provision of training and technical assistance to grantees. Recently, Schaffer was assigned the responsibility of addressing the opioid crisis across three centers to assist states to implement prevention, treatment and recovery interventions, as well as develop monitoring tools, facilitate technical assistance strategies and document best practices. She is responsible for organizing training sessions for the division staff and state grantees. Schaffer has extensive experience in substance abuse/misuse, HIV/AIDS, behavioral health, health policy, health equity and organizational development. Schaffer has assisted a multitude of entities including state and local governmental agencies, minority colleges/universities, criminal justice institutions, community based organizations, Congressional representatives and federal agencies.

Regency VI

Wednesday, April 4, 2018

2018-04-04

Fentanyl Analogues Causing the Convergence of Science and Law: The Truth of the Evolving Fentanyl Analogue Epidemic

9:45 AM - 11:00 AM

9:45 AM

11:00 AM

Moderator: Rita Noonan, PhD, Branch Chief, Division of Unintentional Injury Prevention, Centers for Disease Control and Prevention CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,APA,GA Bar,GA POST,NAADAC,NASW,NBCC “Why can’t we fix this fentanyl crisis? What is the government doing?” The media and public often discuss fentanyl as a single, unified drug. While “fentanyl” is a single drug listed as a Schedule II controlled substance, fentanyl analogues are an ever-evolving and multiplying number of illicit compounds that evade detection, identification and understanding. Embracing the critical distinction between fentanyl, illicit fentanyl and fentanyl analogues is a vital step in understanding the scope of the fentanyl problem. In this session, a forensic toxicologist will explain this distinction with understandable scientific principles. Once the sophistication of the methodologies of fentanyl core structure adaptation is understood, then the immense potential for fentanyl creation is visible. When that understanding is married with explanation of complexities posed by illicit market importation, expense of equipment and expertise needed for identification, and challenges in testing for substances, then the whole of the fentanyl analogues crisis comes into stark contrast and view. An Assistant United States Attorney will discuss the legal challenges of prosecuting new fentanyls compared to those inherent in prosecution of diverted pharmaceutical fentanyls (and opioids). Topics will include the availability and sources for illicit fentanyl analogues, the difficulties in their detection and identification, and the current status of fentanyl scheduling under the United States Code and under the laws of constituent states. Together, the presenters will provide a legally and scientifically accurate — yet practical and comprehensible — summary of the fentanyl analogues from evolution, to identification, to prosecution. Their goal is that participants will gain a new fearlessness of approach, grounded in fact and common sense, that can be applied to working toward interventions in public health and public safety response to meet the deadly scourge of the fentanyl analogues. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Discuss the characteristics of fentanyls, particularly in regard to their rapid evolution, and the currently identified fentanyls in the United States and the world. - Outline strategies for staying abreast of the evolution of new fentanyls. - Identify the legal challenges of prosecuting new fentanyls compared to those inherent in prosecution of diverted pharmaceutical fentanyls (and opioids).

M.J. Menendez

JD, National Opioid Coordinator

Organized Crime Drug Enforcement Task Forces, U.S. Department of Justice

M.J. Menendez is the National Opioid, Heroin and Fentanyl Efforts Coordinator for the U.S. Department of Justice's Organized Crime Drug Enforcement Task Forces (OCDETF). She has been on detail to the OCDETF Executive Office since May 2015, on loan from the District of Colorado where she serves an Assistant United States Attorney in the Department of Justice. Menendez has been a prosecutor for 19 years, and she also served as a District Court Judge in Jefferson County, Colorado, for three years. Her passion for advocacy caused her to step down from the bench and return to a leadership role in whole-of-government, public health and public safety collaborations in the fight against the opioid epidemic.

Barry Logan

PhD, F-ABFT, Sr. Vice President of Forensic Science Initiatives, Chief Scientist

NMS Labs

Dr. Barry K. Logan is Sr. Vice President of Forensic Science Initiatives, Chief Scientist, at NMS Labs in Willow Grove, Pennsylvania, where his responsibilities include management of toxicology resources, new test design and development, and expert testimony in forensic toxicology and chemistry. Logan is a Fellow of the American Board of Forensic Toxicologists (ABFT), and has over one 100 publications and 400 presentations in forensic toxicology and analytical chemistry, including work on the effects of methamphetamine, cocaine and marijuana on drivers, drug caused and related death. His recent work has focused on the analytical and interpretive toxicology of emerging recreational and designer drugs. Logan’s other appointments include Executive Director of the Robert F. Borkenstein course at Indiana University, and Executive Director at the Center for Forensic Science Research and Education (CFSRE) at the Fredric Rieders Family Foundation in suburban Philadelphia. He holds academic appointments at Indiana University, Arcadia University and Thomas Jefferson University. In recognition of his work and contributions, Dr. Logan has received numerous national and international awards, and in 2013-14 served as President of the American Academy of Forensic Sciences (AAFS).

Hanover CDE

Wednesday, April 4, 2018

2018-04-04

Treatment Matters: Best Practices for Treatment in Drug Courts and the Criminal Justice System

9:45 AM - 11:00 AM

9:45 AM

11:00 AM

Moderator: David Tapp, JD, MS, Judge, 28th Judicial Circuit of Kentucky, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ANCC,APA,GA Bar,GA POST,NAADAC,NASW,NBCC Due to lack of treatment resources and inadequate service coordination in most communities, those with substance use disorders experience high rates of continued use, relapse and sometimes overdose while involved in community supervision and after release from jails and prisons. Drug treatment courts are an alternative to incarceration that identifies and provides treatment to justice system-involved individuals with substance use disorders. Because drug treatment courts place more individuals in addiction treatment than anywhere else in the justice system, it is important that criminal justice professionals understand that there is no one-size-fits-all approach to treatment to ensure the implementation of evidence-based practices as consistent with the requirements of the Americans with Disabilities Act. In this session, the American Society of Addiction Medicine (ASAM) and the National Association of Drug Court Professionals (NADCP) will discuss the current evidence base for the treatment of substance use disorders, including use of telehealth for underserved communities, and outline how to apply effective treatment research in drug treatment courts and throughout the justice system continuum. Participants will leave with an understanding of how to implement these best practices, as well as with increased knowledge of the simple tools available to them through ASAM and NADCP to assist with improving outcomes. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the role of drug courts in diversion and treatment. - Identify best practices for drug courts in treatment of substance use disorders. - Recognize how to access American Society of Addiction Medicine and the National Association of Drug Court Professionals resources for best practices.

Cara Poland

MD, MEd, FACP, FASAM, Medical Director, Spectrum Health's GREAT MOMs

Assistant Professor of Medicine and Psychiatry, Michigan State University

Cara Poland, MD, MEd, FACP, FASAM, was trained in internal medicine at St. Joseph Mercy Hospital in Ann Arbor, Michigan, and in addiction medicine at Boston Medical Center. She has an interest in educating physicians and physicians-in-training to improve care for patients with substance use disorders and alcohol use disorders. She is interested in medical student curriculum development and assessment, student well-being and identifying ways to improve the process of medical training. She is professionally active in multiple societies, including acting as the current President of the Michigan Society of Addiction Medicine. She is currently the medical director of a program for treatment of pregnant women with substance use disorders and has a general addiction practice. She is an assistant professor at Michigan State University, where she acts as a Learning Society Chief.

Terrence Walton

MSW, Chief Operating Officer

National Association of Drug Court Professionals

Terrence D. Walton, Chief Operating Officer for the National Association of Drug Court Professionals (NADCP), is among the nation’s leading experts in providing training and technical assistance to drug courts and other treatment courts internationally. Prior to being named COO in October 2015, he was the NADCP Chief of Standards. In addition to being responsible for the daily operation of NADCP and planning the national conference, he retains his responsibility for establishing and implementing best practice standards nationwide. Previously, Walton was Director of Treatment for the Pretrial Services Agency for the District of Columbia (PSA). During his 15 years at PSA, he directed operations that provide substance use disorder and mental health assessment, treatment and social services for all adults released under PSA supervision in the District of Columbia. Walton holds a bachelor's degree in psychology and a master's degree in social work, with specializations in program administration and substance abuse. Noted for his practical strength-based approaches to complex issues, Walton is actively sought out for insight on facilitating long-term recovery for justice system involved individuals who are living with substance use and mental health disorders.

Hanover AB

Wednesday, April 4, 2018

2018-04-04

Advancing Science Into Action: Enhancing PDMPs and EHRs

9:45 AM - 11:00 AM

9:45 AM

11:00 AM

NEW LOCATION: HANOVER AB Moderator: Jan Losby, PhD, MSW, Team Lead, Prescription Drug Overdose Health Systems Team, Centers for Disease Control and Prevention CE Certified By: AMA,AAFP,ACPE,ANCC Inappropriate prescribing is a key driver of the opioid crisis. To ensure the safer use of opioid therapy for patients, approaches for integrating prevention strategies into healthcare systems have been developed and implemented. In this session, speakers will highlight strategies used to operationalize the Centers for Disease Control and Prevention (CDC) Guideline for Prescribing Opioids for Chronic Pain recommendations into clinical practice through prescription drug monitoring programs (PDMPs). Reducing barriers to accessing PDMP data within clinical workflow, through PDMP-Electronic Health Record (EHR) integration is considered a promising state-level intervention for both informing clinical practice and improving patient care. CDC will share lessons learned from a nine-state evaluation on how PDMP-EHR integration promotes judicious opioid prescribing and facilitates communication between providers and patients about the risks and benefits of opioid therapy for chronic pain. Further, Illinois will highlight its new PDMP application, which calculates and reports patients’ current daily Morphine Milligram Equivalents (MMEs), within clinical workflow. This application uses color-coded MME numbers and trend graphs to alert prescribers when patients’ current daily MMEs are approaching a level that is associated with increased risks. Last, New York will discuss enhancements of its PDMP, including mandated use (requirements for initial and subsequent PDMP checks for controlled substances) and timely submission of data. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe how PDMP integration with electronic health records promotes judicious prescribing and improves patient outcomes. - Identify health information technology strategies that support operationalization of the Centers for Disease Control and Prevention Prescribing Guideline. - Explain how applications within the PDMP and/or EHR can support clinical decision-making.

Wesley M. Sargent, Jr.

EdD, EdS, MA, Health Scientist

Centers for Disease Control and Prevention

Joshua Vinciguerra

JD, Director of Bureau of Narcotic Enforcement

New York State Department of Health

Joshua Vinciguerra is the Director of the Bureau of Narcotic Enforcement at the New York State Department of Health. He is a member of Gov. Andrew Cuomo’s Task Force to Combat Heroin. He currently serves on the Executive Committee of the National Association of State Controlled Substance Authorities and is a member of the National Alliance for Model State Drug Laws Resource Group on Novel Psychoactive Substances. Vinciguerra is a former federal prosecutor in the U.S. Attorney’s Office for the Northern District of New York. He has served as an Assistant Attorney General in the New York State Attorney General’s Criminal Enforcement and Financial Crimes Bureau and as an Assistant District Attorney in the New York County District Attorney’s Office under Robert Morgenthau, where he prosecuted narcotics and weapons crimes in the Office of Special Narcotics and white-collar crime in the Frauds Bureau. He clerked in the New York State Supreme Court, Appellate Division, Fourth Department, in Rochester, New York. He is a volunteer firefighter.

Stanley Murzynski

MS, Clinical Website Administrator

Illinois Prescription Monitoring Program

Stanley Murzynski is the Clinical Website Administrator for the Illinois Prescription Monitoring Program. He received both his bachelor's and master's degrees in computer science from the University of Illinois, Springfield. He currently is pursuing a master's degree in healthcare informatics at the University of Illinois, Chicago. He has been with the Illinois Prescription Monitoring Program for six years and has held various I.T. positions during that time.

Lindsey Bridwell

MPH, CHES, Evaluation Fellow, Opioid Overdose Health Systems Team

Centers for Disease Control and Prevention

Baker

Wednesday, April 4, 2018

2018-04-04

DEA Update for Pharmacists

9:45 AM - 11:00 AM

9:45 AM

11:00 AM

Moderator: Julie Miller, Editor in Chief, Behavioral Healthcare Executive and Addiction Professional CE Certified By: AAFP,ACPE,GA POST This session is designed as an opportunity for the U.S. Drug Enforcement Administration (DEA) to share developments and guidance to pharmacists to inform their efforts to respond to the nation’s Rx drug abuse and heroin epidemics. The presenter will describe the nation’s current opioid abuse and diversion trends, the basic responsibilities for pharmacists under federal law and regulations, the checks and balances of the Controlled Substances Act, the legal obligations of DEA registrants, and DEA’s response to the current opioid epidemic. He also will address new regulations, such as the Comprehensive Addiction and Recovery Act. The presentation will demonstrate how the current public health epidemic has impacted society and provide tips for pharmacists to respond, such as measures for preventing Rx drug misuse and securing pharmacies from drug theft and robberies. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Explain the corresponding responsibility of pharmacists. - Describe “red flags” that may indicate pharmaceutical diversion. - Identify Effective Controls and Preventative Measures against pharmacy diversion.

James Arnold

MA, Chief, Liaison and Policy Section, Office of Diversion Control

U.S. Drug Enforcement Administration

James Arnold currently serves as Chief of the Policy and Liaison Section, Office of Diversion Control, Drug Enforcement Administration (DEA) at DEA Headquarters in Washington, D.C. He has served as the Chief of the Policy Unit and the Chief of the Regulatory Unit at DEA Headquarters, as well as in various other investigative and supervisory positions at the DEA New Jersey Field Division, Newark, New Jersey. His efforts in the New Jersey Field Division focused on administrative, civil, and criminal investigations of DEA registrants and other individuals and organizations who were engaged in violations of the Controlled Substances Act and/or with other illegal activities with legitimate, and illegal, controlled substances and listed chemicals. With over 28 years of experience with the DEA, Arnold spoken nationwide on numerous regulatory subjects; has coordinated and spearheaded investigations on various regulatory issues of nationwide importance for DEA and the Department of Justice; was intimately involved with various investigations and prosecutions of DEA registrants at the height of the opioid Rx drug problem in south Florida in 2011 and 2012; and has been an Instructor at the DEA Justice Training Center in Quantico, Virginia, for Intelligence Research Specialists, Special Agents of Tactical Diversion Squads, and new Basic Diversion Investigator Classes since July of 1999. He is a proud graduate of West Chester State University, and Drew University, where he received a master's degree. Arnold has been the recipient of numerous awards and commendations throughout his DEA career, in recognition of many successful investigations and prosecutions, and for his leadership, performance and commitment to public service.

Regency VII

Wednesday, April 4, 2018

2018-04-04

Opioid Prevention 2.0: Innovative Strategies for Staying Ahead of the Trends

9:45 AM - 11:00 AM

9:45 AM

11:00 AM

Moderator: Dale Stephenson, PhD, CIH, Dean, College of Health Professions, Northern Kentucky University CE Certified By: AMA,AAFP,ACPE,ANCC,APA,CHES,NAADAC,NASW,NBCC Recent prevention efforts have focused on the distribution of naloxone to prevent fatal opioid overdoses. While these efforts help reduce overdose deaths, the negative impact of opioid misuse continues to plague people who use opioids and their families. A group of experts will discuss predicted trends and innovative strategies — that move beyond prevention of fatal overdose with naloxone — that states and communities can implement to stay ahead of these challenges. The following prevention approaches will be explained: psycho-educational family-based interventions designed to prevent adverse childhood experiences including trauma associated with parental substance use disorders; improvements in public health surveillance and response; and the “knock and talk” approach to providing current users knowledge and resources to reduce the risk of overdoses. The presenters will discuss how these innovative strategies can augment current prevention efforts with a focus on addressing emerging trends and improving health outcomes for opioid users and their families. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify emerging opioid misuse trends and their potential impact on the U.S. population. - Explain three innovative prevention efforts that directly address emerging opioid misuse trends. - Identify the benefits associated with the implementation of innovative prevention efforts.

Shai Fuxman

EdD, Senior Research Scientist

Education Development Center

Dr. Shai Fuxman, a Senior Research Scientist with the Education Development Center, is an experienced researcher in the fields of public health and education. He serves as a Senior Training and Technical Assistance Associate for the Substance Abuse and Mental Health Services Administration's Center for the Application of Prevention Technologies (CAPT), a training and technical assistance center supporting the substance abuse prevention efforts of the country’s states, tribes and jurisdictions. At the CAPT, Fuxman leads the opioid response team, providing research and technical support to states and communities regarding best practices for reducing opioid misuse and overdoses. He has presented to various audiences on risky and protective factors related to opioid misuse, as well as effective strategies for reducing opioid misuse. His subject and skill expertise include positive and healthy youth development, program evaluation, and culturally responsive approaches to health promotion. He has published articles on efforts to engage parents and youth in efforts to reduce risky behaviors among youth. He earned his doctorate and master’s degrees in education from Harvard University’s Graduate School of Education and his bachelor’s degree from Brandeis University.

Corey Davis

JD, MSPH, EMT-B, Deputy Director

Network for Public Health Law

Corey Davis is a Senior Attorney at the National Health Law Program and Deputy Director at the Network for Public Health Law (NHeLP). His work focuses on public health, particularly identifying and leveraging opportunities in the Affordable Care Act and Medicaid to improve public health. Prior to joining NHeLP, Davis was a health policy consultant at Temple University’s fledgling Center for Health Law, Policy, and Practice, where his work focused on improving access to essential medications, particularly opioids for the treatment of cancer and AIDS pain. He also served as an employment rights attorney at Equality Advocates Pennsylvania, where he represented lesbian, gay, bisexual and transgender (LGBT) individuals and provided education, outreach and strategic support to the LGBT community. Before joining Equality Advocates, Davis was a New Voices fellow at Prevention Point Philadelphia, where he oversaw a street-based legal clinic sited at the city’s only syringe exchange program. He is the recipient of the International AIDS Society’s Young Investigator Award and has been published numerous times in the lay and academic press.

Gary Langis

Technical Assistance Specialist

Education Development Center/MassTAPP

Gary Langis’s work began in the late 1980s volunteering as part of an independent group providing underground needle exchange on the North Shore. In 1990, he began working as an outreach educator for the Healthy Streets Outreach Program in Lynn, Massachusetts. In 1991 he accepted a position as Program Manager at Noddles Island Multi Service Agency working for the HIV Benefits Advocacy Program for persons who were HIV+. In 1997, he became the HIV Program Manager for CAB Health and Recovery Services HIV program in Lynn and is currently an independent consultant. Over his 13 years working at CAB, Langis helped to develop cutting-edge HIV prevention programs that encompassed principles of harm reduction and served as a model for other programs. In 1997, he was a founding member and Board President of the New England Prevention Alliance (NEPA), a group of activists that provide independent syringe exchange and Naloxone distribution to underserved communities. Langis collaborated with the state sharing data, forms, training methods and tools that were created and developed by NEPA that contributed to the foundation of the Opioid Overdose Education and Naloxone Distribution program. NEPA has conducted civil disobedience to highlight the disparities of HIV prevention in communities including Brockton, Lawrence, Worcester and Lynn.

Karina Forrest-Perkins

MHR, LADC, Chief Executive Officer

The Wayside House, Inc.

Karina A. Forrest‐Perkins is a national speaker and consultant on systems improvement and primary care integration within the behavioral health field. Forrest-Perkins also serves as the Chief Executive Officer for The Wayside House, a women’s chemical dependency and co-occurring treatment center in Minneapolis, St. Louis Park, and St. Paul, Minnesota. Prior to this appointment, she served as the President and CEO of Prevent Child Abuse Minnesota and Minnesota Communities Caring for Children. Forrest-Perkins has served as a staff member or task force appointee in three Oklahoma governors’ administrations and is a current appointee to the Minnesota Governor’s Task Force on Medical Cannabis Research. In addition to her position as CEO of The Wayside House, she has served in executive roles in residential adolescent co-occurring treatment, outpatient co-occurring treatment and substance abuse prevention. She currently consults as a subject matter expert for the National Addiction Technology Transfer Center, Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Excellence on Opioid Abuse for Pregnant and Postpartum Women, and SAMHSA’s Center for the Application of Prevention Technologies. Forrest-Perkins is a 2017 Bush Foundation Leadership Fellow and lives in Robbinsdale with her husband, Jack, and cat, Gus.

Learning Center

Wednesday, April 4, 2018

2018-04-04

The Role of Third-Party Payers in Promoting Multi-Disciplinary Care

9:45 AM - 11:00 AM

9:45 AM

11:00 AM

Moderator: Daniel Blaney-Koen, JD, Senior Legislative Attorney, American Medical Association, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified by: AMA, AAFP, ACPE, ANCC, NASW With the move to reduce opioid prescriptions, what are the options for patients who suffer from chronic pain? Payers can play important roles in improving quality of care for these patients. This session is designed as a guide for payers to improve their services in this area by discussing the challenges to overcome and sharing examples of successful strategies. To emphasize the value of working together toward solutions, participants will hear from a provider and a payer. Topics to be covered will include: - Federal policies and initiatives developed to help increase access to comprehensive pain management - Public policy initiatives aimed to limit harm from Rx opioids. - Goals and treatment approaches in an interdisciplinary pain management program that coordinates physical and occupational therapy, behavioral health, pain education, and medication management, including opioid weaning, to restore patients to a greater quality of life and give them the tools to better self-manage their pain condition. - Roles and responsibilities of payers in ensuring individuals who suffer from chronic pain and/or opioid use disorder get the right care at the right time in the right setting. - Current challenges and opportunities in assuring access to appropriate, evidence-based care. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Outline federal policies and initiatives aimed to increase access to comprehensive pain management and public policy initiatives to limit harm from Rx opioids. - Describe the goals and treatment approaches in an interdisciplinary pain management program. - Discuss payers’ roles and responsibilities in ensuring appropriate, timely care for individuals who suffer from chronic pain and/or opioid use disorder. - Identify challenges and opportunities in assuring access to appropriate, evidence-based care.

Steven Stanos

DO, Medical Director, Swedish Pain Services, Swedish Health System

President, American Academy of Pain Medicine

Dr. Steven Stanos is Medical Director of Swedish Pain Services for Swedish Health System in Seattle, Washington. Stanos is board certified in Physical Medicine and Rehabilitation and Pain Medicine. Stanos presently serves as President of the American Academy of Pain Medicine and on the Board of Directors of the American Board of Pain Medicine. He is active with the American Academy of Physical Medicine and Rehabilitation. He served as a panel member on the National Pain Strategy and an invited consultant to the Centers for Disease Control and Prevention (CDC) for the CDC Opioid Guideline published in 2016.

Kim Holland

MBA, Vice President, State Affairs

Blue Cross Blue Shield Association

Kim Holland is Vice President, State Affairs, for the Blue Cross and Blue Shield Association (BCBSA), a national federation of 36 independent, community-based and locally operated Blue Cross and Blue Shield companies. The Blue System is the nation's largest health insurer covering more than 106 million people – one-in-three Americans – providing coverage to individuals in every ZIP code across all 50 states, the District of Columbia and Puerto Rico. In her role with BCBSA, Holland is responsible for ensuring that Blue Cross Blue Shield Plan interests are represented in the development of federal and state legislative and regulatory positions and priorities involving commercial insurance and Medicaid. Additionally, Kim she is BCBSA’s corporate lead in the association’s response to the nation’s opioid epidemic. Prior to joining BCBSA, Holland spent over 20 years as an employee benefit consultant and independent agency executive. In 2005, she was appointed Oklahoma Insurance Commissioner by Gov. Brad Henry to fill an unexpired term, and in 2006 became the first woman elected to the post. Holland resides in Ft. Worth, Texas, with her husband Jim and near her son, daughter-in-law and two grandchildren.

Dunwoody

Wednesday, April 4, 2018

2018-04-04

Expanding Access to OUD Treatment: The Role of Telehealth

9:45 AM - 11:00 AM

9:45 AM

11:00 AM

Moderator: Anne L. Burns, RPh, Vice President, Professional Affairs, American Pharmacists Association, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ANCC,APA,NAADAC,NASW,NBCC In rural and economically challenged areas, the healthcare workforce is not adequately sized or trained to handle the opioid epidemic. Telehealth shows promise to relieve these strains by expanding access to critical expertise and resources. This is of particular importance for medication assisted treatment (MAT) of opioid use disorders, which requires a specialized skill set that may not be available in a primary care setting. However, there are policy issues and implementation challenges associated with telehealth that must be considered if it is to be fully utilized and scaled up for wider diffusion. Policies and innovative programs are being implemented to address some of these considerations, yet more needs to be done to understand the opportunities and barriers for telehealth in MAT for opioid use disorders. This presentation will lay out recent findings from the field, as well as clinical experience on the use of telehealth within behavioral healthcare and, in particular, for the use with MAT. It will discuss current practices in using teleheath for treatment of opioid use disorders, facilitators and barriers to implementing telehealth for behavioral health providers, and ways in which telehealth may affect access to and delivery of treatment for opioid use disorders. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify current strategies that are being implemented for telehealth within behavioral healthcare, and specifically in medication assisted treatment for opioid use disorder, including types of telehealth being used and for whom. - Describe best practices, barriers and facilitators in using telehealth for opioid use disorder treatment. - Explain ways in which telehealth may affect access to and delivery of medication assisted treatment for opioid use disorders, especially in rural areas.

Judy Bartlett

PhD, MPH, Program Operations Director, Project ECHO

University of New Mexico Health Sciences Center

Judy Bartlett, MPH, PhD, Program Operations Director with Project ECHO at the University of New Mexico, is focused on using the ECHO model to support knowledge dissemination and capacity building among primary care teams in rural and underserved areas, particularly in the area of substance use disorders. Prior to her work at ECHO, Bartlett spent nearly 10 years with the U.S. Department of Health and Human Services (HHS), leading evaluations of national HHS programs; as well as 6 years at a federally-qualified health center, leading their quality improvement projects.

Patrick Marshalek

MD, Associate Professor, Clinical Faculty

School of Medicine, West Virginia University

Dr. Patrick Marshalek is a psychiatrist and Associate Professor at West Virginia University (WVU) School of Medicine with specialties in behavioral medicine and psychiatry. He is board certified in psychiatry and has multiple clinical appointments at WVU and within the surrounding community, including the Chestnut Ridge Center West Virginia University, a leading regional referral center for treatment of mental health and addiction disorders. Through these appointments, Marshalek directs multiple teams, including telepsychiatry and pain resource management. His expertise includes use of telehealth and delivery of substance abuse treatment, including office-based medication assisted treatment. Marshalek has presented and published extensively on addiction medicine.

Laura Dunlap

PhD, Senior Director, Behavioral Health Services, Policy and Economics Research

RTI International

Laura J. Dunlap, PhD, is Senior Director of RTI International’s Behavioral Health Services, Policy, and Economics Research Program. She has over 20 years of experience conducting evaluations of substance abuse treatment programs and the systems in which they provide services, including medication assisted treatment for opioid use disorders (OUDs). She currently serves as the Project Director for the Centers for Disease Control and Prevention-funded Evaluation of Medication Assisted Treatment. She recently led the Office of The Assistant Secretary for Planning and Evaluation-funded Telehealth study, which examined use of telehealth for expanding access to treatment of OUDs. She has led numerous research studies in the field of behavioral health on multiple federal contracts and grants, including for the Substance Abuse and Mental Health Services Administration and the National Institutes of Health. Dunlap has published her findings in numerous journals.

Peter Yellowlees

MD, MBBS, Vice Chair for Faculty Development and Professor of Psychiatry at the University of California Davis

University of California Davis

Dr. Peter Yellowlees lives in Sacramento, California, where he is Vice Chair for Faculty Development and Professor of Psychiatry at the University of California Davis. He is President of the American Telemedicine Association, a member of the National Academy of Sciences review committee evaluating the national VA mental health services for veterans, a member of the American Psychiatric Association workgroup on telepsychiatry, and co-founder of HealthLinkNow, Inc. An experienced speaker and media commentator, Yellowlees has written and produced over 180 video editorials on psychiatry for Medscape. He has multiple research interests and is presently working on the development and validation of asynchronous telepsychiatry, automated translation and clinical interpreting systems, internet e-mail and video consultation services and assessment and treatment protocols to improve physician health and wellness. Yellowlees is an expert in physician health and telepsychiatry. He chairs the UC Davis Health System Wellbeing Committee and has many physicians as patients. He has provided clinical consultations to patients on Indian health reservations via telemedicine for over a decade. He has worked in public and private sectors in the United States, Australia and the United Kingdom, including rural settings. He has published five books and over 200 scientific articles and book chapters.

Grand Hall

Wednesday, April 4, 2018

2018-04-04

Lunch in the Exhibit Hall

11:00 AM - 2:00 PM

11:00 AM

2:00 PM

Lunch in the Exhibit Hall

Piedmont

Wednesday, April 4, 2018

2018-04-04

Syringe Services Programs in Rural, At-Risk Areas: Lessons Learned and Future Prospects

11:15 AM - 12:30 PM

11:15 AM

12:30 PM

Moderator: Tom Valentino, Senior Editor, Addiction Professional and Behavioral Healthcare Executive CE Certified By: AMA,AAFP,ACPE,ANCC,MCHES,NAADAC,NASW,NBCC The consequences of the opioid epidemic (e.g., HIV and HCV outbreaks, overdose fatalities) have caused state and local governments to implement syringe services program in suburban and rural areas throughout the United States. National experts will discuss the intertwined and synergistic roles policymakers, law enforcement, implementers of syringe service programs, and community stakeholders have in confronting the opioid epidemic and highlight opportunities and best practices for program implementation. Speakers also will highlight the guidebook developed for rural, at-risk areas that provides practical information on how to establish syringe services programs. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify how to establish a syringe services program in rural and suburban areas. - Explain how to work with community members to establish a syringe services program. - Apply evidence-based solutions to address the consequences of injection drug use in at-risk areas.

Regina LaBelle

JD, Public Affairs Strategist, LaBelle Strategies

Visiting Fellow, Duke Margolis Center for Health Policy

Regina LaBelle, JD, is a Principal with LaBelle Strategies, advising governments and nonprofit organizations on effective strategies to address today's opioid epidemic. She also is a Visiting Fellow with the Duke-Margolis Center for Health Policy. A frequent commentator on the opioid issue, LaBelle has appeared on MSNBC and is a regular contributor to The Hill. Until January 2017, she was Chief of Staff in the White House Office of National Drug Control Policy (ONDCP), where she served for eight years as a political appointee. While at ONDCP, she co-authored and helped to implement the administration's plan to address the opioid epidemic. She represented ONDCP before Congress, at national conferences and with the media. Skilled at public speaking, writing and strategy development, her previous work as Legal Counsel to the Mayor of Seattle, as well as in the federal government, provides a unique perspective on today's public policy challenges. A graduate of Georgetown University Law Center and magna cum laude graduate of Boston College, LaBelle lives with her husband and son in Maryland.

Sean Allen

DrPH, Assistant Scientist

Johns Hopkins, Bloomberg School of Public Health

Dr. Sean T. Allen is a faculty member at the Johns Hopkins Bloomberg School of Public Health in the Department of Health, Behavior and Society. He has conducted research on a number of harm reduction policy initiatives, including the cost-effectiveness of syringe services program implementation. He has published extensively on geospatial aspects of injection drug use and service utilization among people who inject drugs. Allen completed his post-doctoral training at Johns Hopkins University in the Drug Dependence Epidemiology Training Program. During his post-doctoral training, he served as a Senior Policy Advisor at the White House Office of National Drug Control Policy. Allen completed his doctoral training at The George Washington University, where he received his doctorate in public health - health behavior. He also holds a master's degree in public health and dual bachelor's degrees in biology and agriculture - entomology from the University of Kentucky.

International North

Wednesday, April 4, 2018

2018-04-04

Drug Testing in Clinical Practice: When, What, Who and How

11:15 AM - 12:30 PM

11:15 AM

12:30 PM

NEW LOCATION: INTERNATIONAL NORTH Moderator: Robert DuPont, MD, President, Institute for Behavior and Health, Inc., and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,APA There has been inconsistent clinical practice and unethical and/or fraudulent activities related to drug testing, such as healthcare settings testing with unnecessary frequency and payers creating restrictive policies that have no evidentiary basis in research or clinical expertise. American Society of Addiction Medicine (ASAM) recognized that balance must be made between clinical outcomes and utility costs to improve the quality of care that patients receive and developed national guidance. In this session, presenters will discuss the ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document in relation to improving clinical outcomes and standardizing payment models for drug testing. While all testing has pros and cons, its clinical and economic value is supreme. Participants should leave with an awareness and understanding of how to utilize the ASAM Drug Testing consensus document to determine when, where and how often it is appropriate to perform drug testing to treat their patient populations. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Recognize the importance of the guidance needed around drug testing today. - Explain the duality between clinical outcomes/quality of care and utility costs. - Summarize the ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document's recommendations and how they should be used in practice.

Frank James

MD, JD, FASAM, FACLM, Vice Chair, Payer Relations Committee

American Society of Addiction Medicine

Dr. Frank James earned his law and medical degrees at Southern Illinois University. He is board certified in general, child and adolescent, and forensic psychiatry, as well as addiction medicine. James spent his clinical years providing inpatient and outpatient psychiatric services in underserved areas in the Ohio Valley. He developed a specialty outpatient clinic for opioid use disorder (OUD). His treatment model focused on the integration of group therapy and psychotropic medication management with the use of urine drug screens (UDS) and medication assisted treatment (MAT). For the last seven years, James has worked in managed care. He provides large behavioral health organizations guidance in drafting evidenced-based benefit guidelines specific to OUD treatment and service, including level of care determination, MAT prior authorizations, and UDS coverage determination. His current focus is medical/behavioral integration and alternative payment model development substance use disorder services. James is a member of the American Society of Addiction Medicine (ASAM) Finance Committee, Vice Chair of ASAM’s Payer Relations Committee, and Alternate to ASAM’s Board of Directors for Region III. He helped develop ASAM’s Public Policy on Hepatitis C treatment, including recommendations for integrating Hepatitis C treatment in SUDs treatment programs, as well as looking at alternative payment models.

Margaret Jarvis

MD, DFASAM, Director of the Division of Addiction Medicine

Neurosciences Institute at Geisinger Health System

Margaret Jarvis, MD, DFASAM, is the Director of the Division of Addiction Medicine in the Neurosciences Institute at Geisinger Health System. She began her work at Geisinger by being the Medical Director for Marworth Treatment center, which she has done from 1999 to the present. She has worked extensively with the American Society of Addiction Medicine, serving on the board of directors (currently as Vice President) and on many committees. She also chairs the Quality Improvement Council and, in that capacity, has overseen the creation of the recent publication, “Appropriate Use of Drug Testing in Clinical Addiction Medicine.”

Regency V

Wednesday, April 4, 2018

2018-04-04

Update from the DEA Diversion Control Division

11:15 AM - 12:30 PM

11:15 AM

12:30 PM

Moderator: Jackie L. Steele, Jr., JD, Commonwealth Attorney, Kentucky 27th Judicial Circuit, and Member, Operation UNITE Board of Directors CE Certified by: ACPE, GA Bar, GA POST Participants will be presented with the latest information on the opioid crisis from the perspective of the U.S. Drug Enforcement Administration (DEA). The session will include an overview of steps that the DEA Diversion Control Division is taking to address the crisis, as well as free, science-based opioid misuse prevention resources available to communities. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Discuss the latest statistics and trends in opioid diversion from the DEA Diversion Control Division. - Explain the upcoming DEA Rx drug take back effort and upcoming practitioner diversion awareness conferences. - Describe the free, science-based Operation Prevention opioid awareness program for schools and families, as well as opioid-specific drug education materials available at no cost from DEA.

James Arnold

MA, Chief, Liaison and Policy Section, Office of Diversion Control

U.S. Drug Enforcement Administration

Sean T. Fearns

Chief, Community Outreach Section, Office of Congressional and Public Affairs

U.S. Drug Enforcement Administration

Sean Fearns has served as the Chief of Community Outreach for the U.S. Drug Enforcement Administration (DEA) since 2015, a position that includes management of the DEA Museum, as well as the DEA Community Outreach and Prevention Support section. In this capacity, Fearns is responsible for guiding a diverse and creative staff to develop and implement strategic national partnerships with other organizations that help educate the public on the current drug threats facing the country, communicate key Administration drug prevention messages, and reduce the demand for those drugs, including implementing the DEA 360 Strategy.

Regency VI

Wednesday, April 4, 2018

2018-04-04

“Naloxone Plus”: Exploring Effective Response Methods After Opioid Overdose Reversal

11:15 AM - 12:30 PM

11:15 AM

12:30 PM

Moderator: Tina Messer, MA, Manager, Department of Specialty Courts, Kentucky Administrative Office of the Courts, and Member, Operation UNITE Board of Directors CE Certified By: AMA,AAFP,ACPE,ANCC,APA,GA Bar, GA POST,NAADAC,NASW,NBCC Across the country, first responders are carrying and administering naloxone and successfully reversing countless overdoses. However, some are frustrated with the repeated revival of individuals, as well as continued, frequent police contacts and arrests. Some communities are exploring better ways to respond after naloxone administration, which can be an important intervention point. This session will explore states’ overdose response teams that reach out to individuals to discuss treatment options; connect them to treatment, including immediate induction of buprenorphine during post-naloxone withdrawal; and provide take-home naloxone. Some local response teams have had success in getting a majority of individuals to enter treatment post-overdose. A crisis of this magnitude requires innovative and multiple intervention points, including post-overdose, as a part of a comprehensive strategy to reduce opioid dependency and aid in treatment and recovery from opioid use disorders. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify key components of models of opioid overdose response teams operating in several states. - Describe the benefits of employing opioid overdose response teams. - Identify ways to establish linkage to treatment for opioid use disorders including immediate induction into medication assisted treatment, particularly buprenorphine.

Jessica Reichert

MS, Manager, Center for Justice Research and Evaluation

Illinois Criminal Justice Information Authority

Jessica Reichert is the Manager of the Center for Justice Research and Evaluation at the Illinois Criminal Justice Information Authority. Recently, she conducted a study of police referrals to treatment programs for opioid use disorders, and she is working on a process and outcome evaluation on the second police-treatment program in the country. Reichert has published over 50 articles and reports including in scholarly, peer-reviewed journals. She has recently published articles on Medication Assisted Treatment for Criminal Justice Populations and An Overview of the Opioid Crisis in Illinois, as well as was an author of the state's opioid plan. Reichert sits on Illinois' State Opioid Crisis Response Council, Cook County Opioid Task Force and the National PTAC (Police, Treatment, and Community) Collaborative. She has presented at national and state forums on the criminal justice response to the opioid crisis. In addition, Reichert is an adjunct instructor at Loyola University Chicago. She earned her master’s degree in criminal justice from University of Wisconsin-Milwaukee.

Jac Charlier

MPA, National Director for Justice Initiatives, Center for Health and Justice

TASC, Inc.

Jac Charlier is the National Director for Justice Initiatives for the Center for Health and Justice (CHJ) at TASC. He specializes in solutions to reduce crime and drugs by successfully bridging the criminal justice and behavioral health systems from police to prosecutors to courts to probation to parole. Charlier is a nationally recognized expert in deflection and pre-arrest police diversion, and is the co-founder of the Police, Treatment and Community (PTAC) Collaborative. The mission of PTAC is to strategically widen community behavioral health and social service options available through law enforcement — including probation and parole — deflection and diversion. Charlier is a leader in our nation’s battle against opioids and has developed criminal justice opioid overdose (OD) prevention and post-OD response strategies. Charlier served as Deputy Chief in the Illinois State Parole Division. He earned his master’s degree in public policy from The Ohio State University. Charlier is a father of three (mostly) great kids. Charlier is an accomplished civic and community leader in his home city of Chicago. He is a military veteran, recipient of the Outstanding Eagle Scout Medal, and played rugby for far too long.

Hanover CDE

Wednesday, April 4, 2018

2018-04-04

Correctional-Based Interventions: Treating Criminal Justice Involved Populations

11:15 AM - 12:30 PM

11:15 AM

12:30 PM

Moderator: Richard W. Sanders, MSCJ, Commissioner, Kentucky State Police, and Member, Operation UNITE Board of Directors CE Certified By: AMA,AAFP,ANCC,APA,NAADAC,NASW,NBCC,GA Bar,GA POST This session features two programs that are treating criminal justice involved populations in the corrections setting, as well as assisting with their transition back into the community. The Kenton County Detention Center (KCDC) Jail Substance Abuse Program (JSAP) treats individuals involved with the criminal justice system, as a key component of Northern Kentucky’s Collective Response to the Heroin Epidemic. The eight-county region, just across the Ohio River from Cincinnati, has been described as Kentucky’s “heroin ground zero.” The presenter will explain processes aimed at solving the ongoing issues surrounding opiate and other substance-use in communities. The JSAP consists of a comprehensive biopsychosocial treatment model for men and women incarcerated at KCDC. JSAP includes multi-tiered interventions with varying levels of intensity and commitment. All treatment tiers include, at a minimum: addiction education, introductions to support systems, overdose prevention and response training, relapse prevention, pre-release preparation, post-release networking, a living-risk assessment, therapeutic community living environment, and a voluntary option for a naltrexone injection with referral to community mental health and health care providers for consecutive naltrexone injections and behavioral therapy prior to release. The Hollywood Impact Studios Rehabilitation and Vocational Training Center has a unique approach to helping men mainstream from jail, prison and longer-term drug recovery programs back into society through mentoring, recovery and vocational/education training in a Christ-centered environment. The center’s In-Jail Program at the Los Angeles County Jail allows incarcerated men to begin building relationships with Christian Hollywood professionals as they learn about careers in the television and film industry. This relationship continues as the men are met “at the gate” upon their release. Then, the center’s Alumni-Continuum Support Groups helps them with recovery, like skills, housing, work, etc. The third component is the Hollywood Impact Studios Rehabilitation and Vocational Training Center, known as Miracle Mountain, which opened in early 2018. Topics will include breaking the cycle of incarceration and drug/alcohol abuse through a holistic, faith-based approach; the importance of building real relationships with people working through recovery; how to bring down recidivism rates in jails and prisons by implementing this type of program; and how best to utilize volunteers to fulfill your mission. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the components of a comprehensive regional approach to addressing addiction-related issues aimed at mitigating stressors on correctional, medical and judicial systems. - Apply various evidence-based treatment models to their specific populations, facilities and regions. - Recognize the monetary, safety and systematic benefits to presenting the best evidence-based programing in a correctional setting. - Outline challenges faced by secular and nonsecular programs for treating criminal justice involved populations. - Explain the importance of relationships with those in recovery. - Identify the benefits of a holistic approach. - Discuss how the Kenton County Detention Center’s Jail Substance Abuse Program and Hollywood Impact Studios’ programs are replicable and scalable to meet the needs of other communities.

Jason Merrick

MSW, CADC, Director of Addiction Services

Kenton County (Kentucky) Detention Center

Gary Hall

President and Co-Founder

Hollywood Impact Studios Rehabilitation and Vocational Corp.

Gary Skeen Hall has been a writer and producer in television for more than 20 years, writing and producing for “21 Jump Street,” “The A-Team” and Pensacola: Wings of Gold,” to name only a few. He also wrote and produced the HBO feature, “Stringer.” The son of a U.S. Naval officer, Hall graduated from UCLA with a degree in motion picture/television. He began his career at 20th Century Fox as an assistant director trainee prior to moving to Stephen J. Cannell Productions and Warner Bros. He returned to 20th Century Fox in 1998 as a Senior Vice President, heading up post production for 20th Century Fox Television. His department was in charge of an average of 30 television series and pilots per year and had an annual operating budget of over $40 million. Among the series he oversaw were, “24,” “The Simpsons,” “Bones,” “Empire” and “Homeland.” Hall is a current member of the Producer’s Guild of America, Writer’s Guild of America and Academy of Television Arts and Sciences. Hall also has worked part time as a police officer for the Los Angeles Police Department for over 35 years, with multiple commendations for bravery and service. He has worked such assignments as gangs, narcotics and homicide, as well as several special assignments, including the infamous Night Stalker case. Hall currently is assigned to patrol. Police work, a side of life most of us rarely see, has brought realism to his writing and compassion to his life. In 2009, Hall combined his two passions, law enforcement and television, when he and his wife, Cyndi, founded their prison ministry Hollywood Impact Studios. This vocational program teaches the careers of the television industry to inmates inside the Los Angeles County Jail.

Hanover FG

Wednesday, April 4, 2018

2018-04-04

Empowering Families: How to Address a Loved One’s Opioid Use and Become a Family Advocate

12:30 PM - 1:45 PM

12:30 PM

1:45 PM

Moderator: Karen H. Perry, Co-Founder and Executive Director, Narcotics Overdose Prevention and Education (NOPE) Task Force, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: APA,CHES,NAADAC,NASW,NBCC An estimated 2 million families are confronted with helping loved ones engage in treatment. This session will feature two presentations designed to empower family members of a loved one who has an opioid use disorder, first by navigating treatment and then by becoming an advocate within their community. The first presentation will address the challenges that a family faces when realizing a loved one has an opioid use disorder. Confronted with judgment and stigma, family members often are fearful and too paralyzed to do anything. If they choose to help a loved one get into treatment, family members face the difficult task of navigating a system typically with voluntary participation, unclear protocols, extensive wait lists, insurance gatekeepers, disparity, patient brokering and daunting financial challenges. The presenters will explain how families can be empowered using Community Reinforcement and Family Training, Motivational Interviewing, and other resources to help a loved one get the care, supports and treatment they need and deserve. Case examples will be utilized. The second presentation will discuss how to equip parents and families with critical information on how to become effective advocates within their own community. The presenter will share the latest updates on federal efforts related to programs and funding, as well as provide an understanding of the current laws that exist to help navigate the treatment system (such as the Mental Health Parity and Addiction Equity Act). The presenter will encourage family members to act on specific issues related to addiction and provide tools for action, such as how best to tell personal narratives around addiction. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Recognize the challenges families face in identifying opioid misuse by loved ones. - Identify the various obstacles families encounter when seeking treatment. - Explain resources and tools that can empower families to take action to engage loved ones in treatment. - Inform parents and families of support and critical information they need to become effective advocates. - Describe what families can do to help remedy inadequacies with enforcement of the Mental Health Parity and Addiction Equity Act. - Persuade other parents and families to act on specific issues related to addiction and provide guidance on how best to tell personal narrative around addiction.

Courtney Hunter

MPA, Director, Advocacy and Government Affairs

Partnership for Drug-Free Kids

Courtney Hunter joined the Partnership for Drug-Free Kids, a national nonprofit that supports families struggling with their son or daughter's substance use, in 2009. She has worked in various roles at the Partnership, with the media relations department, state alliance program and the program department, managing The Meth Project. In her current role as Director, Advocacy and Government Affairs, Hunter works closely with families to advocate for more resources at the federal level and increased access to addiction treatment. Hunter graduated cum laude with a degree in political science and Spanish studies from the University of Minnesota. She received her Master in Public Administration degree from the School of International and Public Affairs at Columbia University in 2013.

Patricia Aussem

LPC, MAC, MBA, Consultant

Partnership For Drug Free Kids

After a successful career as an executive in the communications industry with an Master of Business Administration in finance, Patricia Aussem earned her master's degree in counseling psychology in 2010, completing clinical training as a counselor on the adolescent, co-occurring, detox and rehab units of a New Jersey-based psychiatric hospital. Licensed in both New York and New Jersey and certified as a Master Addictions Counselor, Aussem provides clinical oversight and educational materials for the Partnership for Drug-Free Kids’ Parent Support Network.

Denise Mariano

Consultant and Parent Coach

Partnership for Drug-Free Kids

Denise Mariano’s work and advocacy efforts spread far and wide, however, her focus remains on advocating for and supporting families impacted by substance use disorder. She has been a strong voice for families at the national and state levels since, 2011. Mariano was selected and honored at the White House as an Advocate for Action, where she was recognized as one of the leaders across the country making a difference. She also was selected as a National Council on Alcoholism and Drug Dependence Advocacy Leader for her efforts in New Jersey. Mariano is a Peer Parent Coach at the Partnership for Drug-Free Kids and works within the Parent Support Network, where she helps develop and promote programs to support families struggling with substance use disorders and to encourage healthier behaviors and improve family cohesion. This work is based upon Community Reinforcement and Family Training, or CRAFT, and Motivational Interviewing, evidence-based models. She also serves as an Ambassador for the Partnership. Mariano is a member of her County Task Force on Opiates, a member of Faces and Voices, D.C. Program Outreach Committee and a member of New Jersey’s Experience, Hope and Strength Recovery High School Fund Raising Committee.

Hanover AB

Wednesday, April 4, 2018

2018-04-04

States with Fast Data: Lessons Learned from Kentucky, New Mexico and Wisconsin

12:30 PM - 1:45 PM

12:30 PM

1:45 PM

NEW LOCATION: HANOVER AB Moderator: Puja Seth, PhD, Lead, Overdose Epidemiology and Surveillance Team, Centers for Disease Control and Prevention CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,GA Bar,GA POST In 2016, 11 states received Enhanced State Opioid Overdose Surveillance grants from the Centers for Disease Control and Prevention. Kentucky, New Mexico and Wisconsin will share experiences with using enhanced data sources to track fatal and nonfatal opioid overdoses. They have found that the overlay of traditional and enhanced data provides a more complete picture of opioid overdoses. Their experiences show how the epidemic is shifting in different states. The presenters will compare traditional and enhanced monitoring of opioid overdoses at state and local levels. Traditional data sources, including hospital discharge records and death certificates, lack timeliness and information about overdose risk factors. Enhanced data sources include ambulance runs, emergency department syndromic surveillance data, prescription drug monitoring programs, toxicology, and coroner/medical examiner reports. Linkages among these systems can further enhance overdose surveillance. In Kentucky, rapid data systems are highly correlated with traditional monitoring systems. Sources show increases in nonfatal opioid and heroin overdoses, further confirmed by similar increases in fatal overdoses. In New Mexico, there were 168 unintentional-and undetermined-intent drug overdose deaths in the latter half of 2016. Of the fentanyl overdose deaths (14.9% of all overdose deaths), 48% were due to illicitly manufactured fentanyl. In Wisconsin, enhanced data sources suggest a continuous climb in nonfatal opioid overdoses. However, traditional sources do not support this, suggesting Wisconsin is seeing an increase in suspected (rapid data sources) but not confirmed (traditional data sources) cases. Fatal overdoses show decreasing Rx opioid deaths but increasing heroin and multiple-drug deaths. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify enhanced surveillance systems available to public health. - Explain the caveats related to these enhanced systems. - Describe how three different states have implemented these enhanced systems.

Jennifer Broad

MPH, Research Analyst-Advanced

Wisconsin Department of Health Services

Jennifer Broad is a Research Analyst-Advanced at the Wisconsin Department of Health Services, Division of Public Health. The Office of Health Informatics was awarded the Enhanced State Opioid Overdose Surveillance Grant from the Centers for Disease Control and Prevention, and Broad’s role is the Dissemination Coordinator for that grant. She has a Master of Public Health in epidemiology from the University of Illinois-Chicago and has worked at city, state and military public health agencies, as well as academia.

Luigi F. Garcia Saavedra

MPH, Substance Use Epidemiologist Supervisor

New Mexico Department of Health

Luigi F. Garcia Saavedra was born and raised in Lima, Peru. His undergraduate studies were made at Universidad Peruana Cayetano Heredia, from where he graduated with a major in Science with focus in Biology. In Lima, he undertook advanced studies in Biochemistry and Molecular Biology and worked as teacher and researcher. In 2013 he graduated from the Masters in Public Health program at University of New Mexico, with a concentration in Epidemiology. In 2014 he joined the New Mexico Department of Health as Substance Abuse Epidemiologist, where he focused on surveillance, epidemiology translation, and data analysis on substance abuse. In May 2017 became the Substance Use Epidemiologist Supervisor under the NM Enhanced State Opioid Overdose Surveillance grant.

Michael Singleton

PhD, Assistant Professor, Biostatistics

University of Kentucky

Dr. Michael Singleton is an Assistant Professor in the Department of Biostatistics at the University of Kentucky and a faculty member in the Kentucky Injury Prevention and Research Center. He received his doctorate in epidemiology and biostatistics from the University of Kentucky. His current research interests include rapid surveillance for drug overdoses, and applications of probabilistic record linkage in public health. He is the Principal Investigator for Kentucky’s Enhanced State Surveillance of Opioid-Involved Morbidity and Mortality project, which is funded through a cooperative agreement with the Centers for Disease Control and Prevention.

Baker

Wednesday, April 4, 2018

2018-04-04

Pharmacists and Physicians: Strategies for Effective Collaboration in Pain Management and MAT

12:30 PM - 1:45 PM

12:30 PM

1:45 PM

Moderator: Anne L. Burns, RPh, Vice President, Professional Affairs, American Pharmacists Association, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA, AAFP, ACPE, ADA, ANCC, APA, MCHES, NAADAC, NASW, NBCC Opioid medications have been a common treatment for chronic pain in the past decade. However, a dramatic rise in opioid misuse and overdoses is leading to new approaches to pain management, more rigorous monitoring of opioid use, and an increase in medication assisted treatment (MAT) for substance use disorder. Careful medication selection and monitoring are crucial components of chronic pain management and MAT, which can be enhanced through collaborations between pharmacists and physicians. In this session, successful strategies for pharmacists to collaborate with physicians and the rest of the health care team will be explored. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify mechanisms for collaboration between pharmacists and prescribers in providing chronic pain management and medication assisted treatment services. - Describe effective communication strategies between pharmacists and prescribers to optimize care and minimize patient risk. - Outline policies around PDMP use and other mechanisms being used to manage risk and diversion and support appropriate medication use. - Discuss involvement of pharmacists and physicians in community coalitions.

Kathryn Cunniff

PharmD, Primary Care Pharmacist

Penobscot Community Health Care

Dr. Katie Cunniff is a Hepatitis C Primary Care Pharmacist at Penobscot Community Health Care (PCHC), a Federally Qualified Health Center based in Bangor, Maine. Cunniff graduated from the University of New England’s College of Pharmacy in 2016 and subsequently completed a Community Pharmacy Residency Program at PCHC. Highlights of her work at PCHC throughout residency and her current position include participating in pharmacist role expansion into the transitions of care arena, pioneering a pharmacist-managed hepatitis C testing and treatment initiative, and integrating pharmacists into Medication Assisted Recovery in the greater Bangor area. She is passionate about expanding services to provide higher quality, more comprehensive care for the underserved.

Trip Gardner

MD, Chief Psychiatric Officer and Medical Director of Homeless Health Services

Penobscot Community Health Care

Dr. Trip Gardner is the Chief Psychiatric Officer and Medical Director of Homeless Health Services at Penobscot Community Health Care (PCHC), a Federally Qualified Health Center in Bangor, Maine. PCHC provides 350,000 patient visits a year to 65,000 individuals, in 16 locations. In 2004, Gardner created a model that fully integrates mental health services including addiction into primary care. He has presented about integration more than 25 times throughout the country and has served on expert panels for HRSA, SAMHSA and NACHC. Gardner was the project director of the 2005 “Integrated Medical, Mental Health and Substance Abuse Services for People Who are Homeless” Robert Wood Johnson Foundation grant that helped establish the first homeless health center in the country to receive level 3 Patient Centered Medical Home certification. This homeless health center was featured in the Agency for Healthcare Research and Quality’s “A Guidebook of Professional Practices for Behavioral Health and Primary Care Integration.” Gardner previously served for three years as a regional Medical Director for the State of Maine Department of Behavioral and Developmental Services.

Regency VII

Wednesday, April 4, 2018

2018-04-04

Changing Prescribing Practices to Prevent Opioid Addiction

12:30 PM - 1:45 PM

12:30 PM

1:45 PM

Moderator: John L. Eadie, MPA, Coordinator, Public Health and Prescription Drug Monitoring Program Project, National Emerging Threat Initiative, A National HIDTA Initiative, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ANCC For many years, prevention efforts were focused almost entirely on reducing “non-medical” abuse of prescription opioids by adolescents. More recently, policymakers have shifted their focus to overprescribing by clinicians, a root cause of the opioid crisis. Some states have recently passed laws limiting first-time opioid prescriptions and mandating prescriber education. Healthcare systems are also implementing interventions to reduce exposure to opioids in emergency rooms and other settings. The presenter will provide an overview of strategies for preventing opioid addiction and will recommend policies and interventions that clinicians, healthcare administrators, payers, health officials and legislators can utilize to most effectively prevent new cases of opioid addiction. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Outline strategies for preventing inappropriate opioid prescribing. - Identify pathways for development of addiction in patients exposed to opioids. - Prepare interventions to promote more cautious prescribing.

Andrew Kolodny

MD, Co-Director, Opioid Policy Research

Brandeis University

Andrew Kolodny, MD, is one of the nation's leading experts on the Rx opioid and heroin crisis devastating families and communities across the country. He is a the Co-Director of Opioid Policy Research at the Heller School for Social Policy and Management at Brandeis University. He previously served as Chief Medical Officer for Phoenix House, a national nonprofit addiction treatment agency and Chair of Psychiatry at Maimonides Medical Center in New York City. Kolodny has a long-standing interest in public health. He began his career working for the New York City Department of Health and Mental Hygiene in the Office of the Executive Deputy Commissioner. For New York City, he helped develop and implement multiple programs to improve the health of New Yorkers and save lives, including city-wide buprenorphine programs, naloxone overdose prevention programs and emergency room-based screening, brief intervention and referral to treatment (SBIRT) programs for drug and alcohol misuse.

Learning Center

Wednesday, April 4, 2018

2018-04-04

The Lock-In Loophole: Intended and Unintended Effects of Patient Review and Restriction Programs

12:30 PM - 1:45 PM

12:30 PM

1:45 PM

Moderator: Greg Hamlin, Director of Claims, Kentucky Employers’ Mutual Insurance CE Certified By: AMA,AAFP,ACPE,ANCC,NASW Patient review and restriction programs, also known as lock-in programs (LIP), are proliferating across public and private payers to combat the opioid crisis. LIPs identify patients demonstrating potential overutilization of controlled substances and generally require patients to use a single prescriber and pharmacy. While widely implemented, there has been little research examining the complete impacts of LIPs. In this session, presenters offer results from analyses evaluating the immediate and sustained effects of a state Medicaid LIP on a variety of healthcare utilization and health outcomes. Additionally, they discuss the extent of and reasons behind circumvention of the LIP, wherein patients obtain controlled substance prescriptions through out-of-pocket cash purchases. Data analyzed includes North Carolina Medicaid claims linked to records from the state's Prescription Drug Monitoring Program from October 2009 through June 2013, as well as qualitative interviews with North Carolina Medicaid LIP pharmacists. Findings from this work provide an important foundation for bolstering the design and operation of LIPs with an eye toward improving patient and public health outcomes. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Outline the effects of a Medicaid lock-in program on key utilization and health outcomes. - Describe patterns and drivers of Rx opioid cash payments in a lock-in program patient population. - Identify strategies for improving the design and public health benefit of lock-in programs moving forward.

Rebecca Naumann

PhD, MSPH, Epidemiologist

University of North Carolina at Chapel Hill

Becky Naumann, PhD, is an Injury Epidemiologist at the University of North Carolina at Chapel Hill. She has a bachelor's degree in environmental health (University of Georgia) and a master's degree in public health (Emory University). Prior to beginning her doctoral training in injury epidemiology, she worked as an epidemiologist in the National Center for Injury Prevention and Control at the Centers for Disease Control and Prevention. Naumann has engaged in injury prevention research for more than 10 years. She has published 25 articles in the field of injury prevention and co-authored four book chapters. She works as an Epidemiologist at the University of North Carolina's Injury Prevention Research Center, where she is involved in a variety of research projects related to opioid overdose prevention.

Andrew Roberts

PharmD, PhD, Assistant Professor of Preventive Medicine and Public Health

University of Kansas Medical Center

Andrew Roberts, PharmD, PhD, serves as Assistant Professor of Preventive Medicine and Public Health at the University of Kansas Medical Center. He is a pharmacist and pharmaceutical health services researcher focused on examining the design and outcomes of policies intended to reduce unsafe opioid use and expand opioid use disorder treatment. He received his doctorate in pharmaceutical outcomes and policy from the University of North Carolina at Chapel Hill in 2015 and his Doctor of Pharmacy from Drake University in 2011.

Dunwoody

Wednesday, April 4, 2018

2018-04-04

A True Continuum of Care: Incorporating Workforce Development and Education into Addiction Treatment

12:30 PM - 1:45 PM

12:30 PM

1:45 PM

Moderator: Elizabeth Nichols, MS, Manager, Department of Specialty Courts, Kentucky Administrative Office of the Courts, and Member, Operation UNITE Board of Directors CE Certified By: AMA,AAFP,ACPE,ANCC,APA,NAADAC,NASW,NBCC In response to the drug epidemic in central and eastern Kentucky, Addiction Recovery Care has developed a continuum of addiction treatment that includes workforce development and education in order to lead to meaningful employment. By partnering with Sullivan University and developing The Peer Support Specialist Academy (PSSA), the program helps people who suffer from substance use disorders to begin moving from hopeless to purposeful and from Medicaid to private insurance. This presentation will explain the development and outcomes of the PSSA and highlight lessons learned for others who want to replicate the program. Topics will include: the need for workforce development and education in addiction treatment, return on investment in regard to public investment in addiction treatment, the importance of Medicaid reimbursement for addiction treatment, and barriers to successful employment. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Recognize the importance of combining workforce development and education into addiction treatment. - Identify the major barriers to successful employment for people in addiction treatment. - Explain the role of a peer support specialist in addiction treatment. - Discuss return on investment (ROI) in regard to public investment in addiction treatment, including the factors that influence ROI and the ROI for the most common interventions. - Recognize the importance of Medicaid reimbursement for addiction treatment (including peer support services).

Tim Robinson

JD, Chief Executive Officer and Founder

Addiction Recovery Care

Tim Robinson is the Chief Executive Officer and Founder of Addiction Recovery Care, LLC, a company that strives to provide world-class, holistic care to people suffering with substance abuse disorder. The company integrates medical, clinical/behavioral, spiritual and vocational rehabilitation services to provide an innovate continuum of care. Addiction Recovery Care's mission is personal to Robinson, who states, "It was never my dream to grow up and become an alcoholic, so getting sober and starting an addiction recovery organization was never in my life plan." He founded the organization after an eight-year battle with alcoholism. He celebrated 11 years sober in December 2017. With Robinson at the helm, Addiction Recovery Care is pioneering addiction treatment and has expanded its footprint throughout central and eastern Kentucky with nine residential and four outpatient treatment centers. Robinson resides in Louisa, Kentucky, with his wife, Lelia, and two young sons, Russ and Kent.

Piedmont

Wednesday, April 4, 2018

2018-04-04

A Parity Framework

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: Daniel Blaney-Koen, JD, Senior Legislative Attorney, American Medical Association, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA, AAFP, ACPE, ADA, ANCC, APA, MCHES, NAADAC, NASW, NBCC Where do we stand 10 years after passage of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008? Has this (and subsequent) federal and state laws succeeded in preventing limitations on mental health and substance use disorder benefits? What should the next steps be to improve enforcement? To answer these questions, this session will feature the work of the Parity@10 Compliance Campaign — a collaboration of the National Center on Addiction and Substance Abuse, the Legal Action Center, Partnership for Drug-Free Kids, TRI@Public Health Management Corporation, and The Kennedy Forum working in partnership with state advocates — which aims to ensure that (1) private and public health plans offer parity compliant mental health and substance use disorder benefits and (2) regulators end complaint-driven enforcement models that place the onus on consumers to fight for evidence-based care. The presenters will: - Share the research analysis underlying the Parity@10 Campaign on current enforcement gaps within public and private insurance coverage for substance use disorders. - Outline recommendations and policies to improve Parity Act compliance and access to care. - Identify strategies that key state players, including treatment providers, consumers, and representatives from the recovery community, are pursuing to ensure Parity Act compliance by health plans and more robust enforcement by state Medicaid offices, insurance departments and Attorneys General. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Define the obstacles for Parity Act enforcement on the state level. - Identify solutions to overcome obstacles to the enforcement of the Parity Act. - Outline actions to help enforce the Parity Act and promote increased access to addiction treatment.

Ellen Weber

JD, Vice President, Health Initiatives

Legal Action Center

Ellen Weber is the Vice President for Health Initiatives at the Legal Action Center (LAC). She helps lead LAC’s efforts to expand access to substance use treatment. Weber worked previously at the center from 1985-2002, during which time she conducted disability rights litigation, established the center’s office in Washington, D.C., and led the center’s national policy work. She led the field’s efforts to obtain protections for persons with substance use disorders under the Americans With Disabilities Act, participated in the first round of national healthcare reform legislation and advocated for a more balanced federal budget for the prevention and treatment of substance use disorders. Weber held an appointment as Professor of Law at the University of Maryland Carey School of Law. She established and directed the Drug Policy and Public Health Strategies Clinic, in which she worked on implementation of the Affordable Care Act and Parity Act in public and private insurance in Maryland, and adoption of harm reduction legislation to address the opioid epidemic. Weber started her career in 1980 as a trial attorney in the Civil Rights Division of the U.S. Justice Department. She graduated from Dickinson College and New York University School of Law.

Sara Howe

MS, CHES, Chief Executive Officer

Illinois Association for Behavioral Health

Sara Moscato Howe, MS, CHES, is Chief Executive Officer of the Illinois Association for Behavioral Health (IABH). Her responsibilities include state and federal policy analysis and advocacy efforts on behalf of the IABH's membership. Howe also oversees the planning and implementation of IABH’s substance abuse prevention programs: Operation Snowball and the Cebrin Goodman Teen Institute. She is Chair of the Illinois Department of Human Services Social Services Advisory Council, a member of Illinois’ Human Services Commission, and serves as Public Policy Chair of the National Council for Behavioral Health. Howe holds a master's degree in health promotion with a research emphasis in collegiate peer alcohol abuse prevention and a bachelor's degree in health promotion from Purdue University. She is currently pursuing a Master of Business Administration degree from the Krannert School of Management at Purdue University.

Rocky Schwartz

Co-Chair

New Jersey Behavioral Health Planning Council

Rocky Schwartz is a woman in long-term recovery from alcoholism and addiction for 36 years. She naively believed that she would be able to prevent her children from suffering from substance abuse. However, both of her sons have been struggling with substance abuse and mental health issues. Seven years and $300,000 later, she has lost six insurance appeals. She gave up the first few appeals due to emotional fatigue. With each insurance denial, she became more and more outraged. Schwartz has become a passionate advocate for parity enforcement. She is the Co-Chair of the New Jersey Behavioral Health Planning Council, member of the New Jersey Parity Coalition and National Alliance on Mental Illness. She was recognized by the New Jersey legislature as an Advocacy Leader. She testified in the New Jersey legislature in support of the proposed parity bill. She spoke at the New Frontier of Mental Health and Addiction Event on Capitol Hill. Most recently, she testified before the President's Commission on Combating Drug Addiction and Opioid Crisis in the White House.

International North

Wednesday, April 4, 2018

2018-04-04

A Rural Primary Care Clinic's Successful Response to the Opioid Epidemic

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

NEW LOCATION: INTERNATIONAL NORTH Moderator: John J. Dreyzehner, MD, MPH, FACOEM, Commissioner, Tennessee Department of Health, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,APA,MCHES,NAADAC,NASW,NBCC In rural Minnesota, CHI St. Gabriel's Health clinic serves a community of 8,700 people and county of 33,000. The Morrison County Drug Task Force and the clinic's Controlled Substance Care Team work collaboratively to reduce narcotics in their community. Key components of the model include a thorough evaluation by the clinic’s nurse and social worker of each situation and person for additional social or medical needs, treating the whole person. Also, the clinic works closely with community organizations and law enforcement to gain insight into its patients in efforts to keep the community safe and healthy. Finally, the clinic has two buprenorphine-naloxone prescribers, reaching an often neglected and underserved patient population. The comprehensive program addresses the needs of addicted individuals presenting to the clinic, as well as the emergency room and county jail. Presenters will explain their narcotic reducing model, which they believe is reproducible and necessary to address and treat the narcotic epidemic. They will review the statistics and results associated with implementation, which drew the attention of state and national agencies and leaders. Presenters will explain how they are now utilizing Project ECHO to reach other rural communities in Minnesota and will outline plans to replicate the program with $1 million in legislative funding, giving participating communities the model and tools needed to reduce opioid prescribing and treat addiction. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe a patient-centered model to reduce opioid prescriptions in the community. - Explain how to use medication assisted treatment as part of a normal primary care clinic in a rural community to treat patients with opioid use disorder. - Identify local and state resources to engage in order to address the opioid epidemic collectively.

Heather Bell

MD, Family Physician

Family Medical Center, CHI St Gabriel's

In 2012, Dr. Heather Bell began her family medicine practice in rural Minnesota. With her visionary leadership, she has been influential in redesigning the primary care delivery model across the clinic by adopting whole-person centered care and instituting guiding principles that led to the clinics earned recognition by the state of Minnesota as a Patient Certified Medical Home. As an emancipated minor, Bell’s childhood faced many challenging times. Losing a mother as an early teen and coping through family chemical abuse and addiction instilled the strength of perseverance, courage and desire to make a difference through the practice of medicine. As opioid use and issues became increasingly apparent, Bell identified that the whole-person centered care approach of the medical home model was most appropriate for reengineering the approaches to care. She became very active in the Controlled Substance Care Team within the clinic setting and introduced medication assisted addiction treatment. Her leadership perseverance is transforming the clinic practice with demonstrated outcomes in both cost savings and patient care.

Kurt DeVine

MD, Family Physician

Family Medical Center, CHI St Gabriel's

Dr. Kurt Devine has been a full spectrum family medicine physician for more than 26 years. As a practicing physician in rural Minnesota, he has faced many unique challenges caring for patients in the primary care setting amid evolving care delivery models demanded forward thinking and creative strategies for change. As opioid use and its attributing issues became increasingly apparent, he became more engaged and involved with the local community task force assembled to address concerns of opioid use and dependency within the county. He quickly discovered the importance of guiding change with a strong provider championship and building impactful community partnerships. His leadership has enabled grant funding to be put to practical use and demonstrate positive outcomes from both the financial and patient care perspectives. Over the last year he has provided medication assisted treatment. It is his exemplary leadership, Devine created a culture shift within his own practice and other practices throughout the state. The program model he created has shown significant impact on opioid prescribing, as well as treatment of patients and will be reproduced in other communities with the help of recent legislative funding.

David Baker

Minnesota State Representative

Chief Executive Officer, Baker Hospitalities, Inc.

Rep. Dave Baker is in his second term in the Minnesota House of Representatives. A resident of Wilmar, Baker represents District 17B, which covers much of Kandiyohi County. In the legislature, he serves as Chair of the Select Committee on Technology and Responsive Government and is a member of the Rules and Legislative Administration, Health and Human Services Reform, Job Growth and Energy Affordability, Transportation Finance, and Ways and Means Committees. After Baker and his wife Mary lost their son Dan to opioid addiction, he became a leading advocate for reforms to curb opioid-related overdoses and deaths. During his time as an elected official, he's authored and passed bills to provide first responders with the life-saving drug naloxone, help doctors and dentists be more diligent when prescribing very powerful pain medication, limit dental patients to four days of opioids when a tooth is extracted, create new labeling on bottles to remind patients of the addictive nature of opioids, and increase funding for treatment centers to help individuals recover from this disease. Outside the legislature, he is a small business owner and well-known volunteer in Willmar. He and his wife have lived in the city for 26 years and have had three children.

Hanover FG

Wednesday, April 4, 2018

2018-04-04

Using What We Know: Helping Teachers, Families and Communities Respond Systematically to Children Affected by Familial SUD

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: Tom Valentino, Senior Editor, Addiction Professional and Behavioral Healthcare Executive CE Certified by: AMA, ANCC, APA The effects of familial substance use disorder (SUD) are best understood within the context of a dynamic biopsychsocial model that is developmental in nature. Such a model helps to highlight the interaction of factors that can affect cognitive, social emotional and behavioral outcomes for children at various stages of development and their families. When these are better understood, effective supportive, prevention and intervention practices can be implemented. However, it is not necessary to invent new services when many current services can be adapted to better assist these families. This presentation will focus on presenting original and published research on the types of effects that have been documented for children from families where substance use disorder is present, including school, community and family-based interventions that are effective and evidence based. Presenters will place specific emphasis on understanding how missed intervention opportunities contribute to cognitive emotional and behavioral issues before and at school entry, as well as the types of interventions that are effective in addressing these issues and supporting the family structure. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Recognize the interactive nature of factors that place children from homes affected by SUD at risk for poor academic and developmental outcomes at different points in development. - Describe school-based interventions that have been shown to be effective with the specific behaviors that most often present at school age. - Explain the importance of utilizing existing evidence-based practices rather than reinventing the wheel each time a new substance epidemic occurs. - Distinguish the role of the family, the importance of family therapy, and opportunities for intervention within a family system that occur at different points in time.

Conrae Lucas-Adkins

PsyD, MA, Assistant Professor, Department of School Psychology

Marshall University

Dr. Conrae Lucas-Adkins is an Assistant Professor of school psychology in the College of Education and Professional Development at Marshall University. She earned her undergraduate, graduate and specialist degrees from Marshall University. Lucas worked as an outpatient and school-based therapist for a local community mental health agency for four years and as a full-time school psychologist in West Virginia for 14 years, prior to joining the faculty at Marshall University. Lucas is licensed as a school psychologist by the West Virginia Board of Examiners of Psychologists and continues to practice school psychology on a contractual basis in West Virginia public schools. Her current research interests include examining the long-term effects of neonatal abstinence syndrome on the cognitive, behavioral and emotional development of children and building supports within the schools to support this population.

Marianna Footo-Linz

PhD, Professor of Psychology

Marshall University

Dr. Marianna Footo-Linz is a native of southern West Virginia. She received her bachelor’s and master's degrees in psychology from Marshall University (1981, 1986) and her doctoral degree in developmental psychology from the University of North Carolina at Chapel Hill (1992). She completed her pre-doctoral clinical internship in pediatric psychology at the Children’s Hospital in Columbus, Ohio (1991). She is a Professor of Psychology at Marshall University, Huntington, West Virginia, and is a licensed psychologist in West Virginia. Footo-Linz is the director of the American Psychological Association-accredited doctoral program in clinical psychology (PsyD) at Marshall University. She has been the director since the program’s inception in 2001 and has completed two successful accreditation reviews, the most recent being in 2011 when the program was awarded a full seven years' accreditation. Footo-Linz teaches graduate courses in developmental psychology and psychological assessment. She also teaches undergraduate courses in child development and research. Footo-Linz is a representative of the National Council of Schools and Programs in Professional Psychology, a member of the Federal Education Advocacy Campus and a campus ambassador for the National Health Service Corps. She has provided and supervised mental health consultation services for both urban and rural Head Start programs for 12 years and presents frequently to local groups on topics related to child behavior and development. She has presented regularly at the Appalachian Studies Conference and most recently at the annual conference for the National Association for Rural Mental Health in the Summer of 2010. She also wrote a successful Health Resources and Services Administration grant for the Graduate Psychology Education program in 2007 and received a mid-year award in 2014.

Todd Davies

PhD, Director of Research Development and Translation

Marshall University

Dr. Todd Davies directs and manages the Marshall Clinical Research Center, a newly developed hub for clinical trial activity at Marshall University. The Marshall Clinical Research Center is dedicated to bringing cutting-edge clinical research and advanced care to Marshall and throughout rural West Virginia. Davies assists with building translational protocols for research at Marshall and developing a rural research network throughout Central Appalachia. This research network brings together advanced care, community outreach and healthcare informatics. His background is diverse and includes a time in the military and assisting in the creation and development of 22 medical technology (predominantly pharmaceutical and healthcare IT) start-up companies before running a start-up, ADS Biotechnology, as its CEO. Davies specializes in program planning, trial development, data collection and trial operations.

Amy Saunders

MA, Director of MU Wellness Center

Marshall University

Amy Saunders is the director of the MU Wellness Center at Marshall University, where she oversees health and wellness initiatives on campus and serves as Co-Chair for the Marshall University Substance Use Recovery Coalition. She received a master's degree in psychology from Marshall University and has over 20 years of experience working in the fields of mental health and public health. She is currently working on a doctorate degree in education at Marshall University. Saunders served as the supervisor for a school-based mental health program overseeing services to students in five middle schools. She has authored and received over 20 public health related grants. Saunders serves as the Principal Investigator (PI) for an interdisciplinary health professionals training grant from the Substance Abuse and Mental Health Services Administration (SAMHSA) to provide Screening, Brief Intervention, and Referral to Treatment (SBIRT) for individuals with mental health and substance use concerns. She is serving as a Co-PI on a Behavioral Health Workforce Education and Training grant from the Health Resources and Services Administration (HRSA). Saunders has assisted with strategic planning and coalition development on campus and within the local community and state. She is a founding member of the Cabell County Substance Abuse Prevention Partnership and the West Virginia Collegiate Initiative to Address to Address High Risk Drinking and Substance Use, coalitions working to provide substance use education and prevention in West Virginia.

Lyn Moore O’Connell

PhD, IMFT, SBIRT Clinical Coordinator

Marshall University

Dr. Lyn O’Connell is the Clinical Coordinator of the Screening, Brief Intervention and Referral to Treatment (SBIRT) grant at Marshall University. The SBIRT grant trains Marshall faculty and students along with community members on universal screening, motivational interviewing techniques, and evidence-based interventions to improve referrals to effective treatment. She received her doctorate from Virginia Tech in marriage and family therapy and her research focuses on barriers to accessing mental health treatment, stigma, motivation to change and substance use disorders in families.

Regency V

Wednesday, April 4, 2018

2018-04-04

Opioid Use Disorders and the Americans with Disabilities Act: Eliminating Discriminatory Barriers to Treatment and Recovery

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: Tina Messer, MA, Manager, Department of Specialty Courts, Kentucky Administrative Office of the Courts, and Member, Operation UNITE Board of Directors CE Certified by: AMA, ACPE, ADA, ANCC, APA, GA Bar This presentation will provide information on the Americans with Disabilities Act (ADA) and its applicability to individuals in treatment for or recovery from addition to opioids. In addition to providing a general review of the law and cases that have interpreted the ADA’s protections for these individuals, this presentation will specifically discuss the issue of current illegal drug usage and how it affects protection under the ADA. The presenters will provide examples of instances when a person may or may not be covered, and will discuss how healthcare providers, advocates, attorneys and others who provide assistance to individuals with opioid use disorders can support these individuals. This will include a discussion of who may have a complaint under the ADA and where to file complaints if it appears that an individual’s rights under the ADA have been violated. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the Americans with Disabilities Act’s protections for people with opioid use disorder. - Identify potential discrimination under the ADA that people in treatment and recovery may be experiencing. - Explain where to reach out to assist individuals in filing complaints of discrimination (DOJ or other appropriate federal agency).

Erin Meehan Richmond

JD, Trial Attorney, Disability Rights Section, Civil Rights Division

U.S. Department of Justice

Erin Meehan Richmond is a Trial Attorney in the Disability Rights Section of the Civil Rights Division at the U.S. Department of Justice (DOJ). Prior to joining the Disability Rights Section in 2013, she served as a Trial Attorney in the Housing and Civil Enforcement Section of the Civil Rights Division at DOJ for 12 years. At DOJ, she has worked on a range of disability-rights related issues, including physical accessibility in housing, and enforcement of the rights of students with mental health related disabilities. She holds a bachelor's degree from Boston University and a juris doctorate from New England School of Law.

Charlotte Lanvers

JD, Trial Attorney, Disability Rights Section, Civil Rights Division

U.S. Department of Justice

Charlotte Lanvers is a Trial Attorney in the Disability Rights Section of the Civil Rights Division at the U.S. Department of Justice (DOJ), where she enforces the Americans with Disabilities Act (ADA). From 2012-2014, Lanvers worked as a Staff Attorney at the Department of Education, Office for Civil Rights (OCR), where she helped develop Section 504 and title II guidance about Section 504 obligations to respond appropriately to the bullying of students with disabilities. Prior to joining OCR, Lanvers worked at Disability Rights Education and Defense Fund as a Skadden Fellow and Staff Attorney on cases enforcing the rights of students with diabetes to receive insulin administration at school and in class action litigation against the Social Security Administration for failing to provide effective communication to blind and visually impaired recipients and beneficiaries. Lanvers holds a bachelor's degree from Princeton University and a juris doctorate from Cornell Law School.

Regency VI

Wednesday, April 4, 2018

2018-04-04

Stamp Out Heroin: One County's Three-Pronged Approach

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: David Hamby, National Coordinator, National Emerging Threats Initiative, A National HIDTA Initiative, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,APA,GA Bar,GA POST,NAADAC,NASW,NBCC In this session, participants will learn lessons from a three-pronged response to the rising tide of opiate overdoses in Carroll County, Maryland, launched in 2015 by State’s Attorney Brian DeLeonardo. First, the Stamp Out Heroin program provided further intervention for people who were treated for overdose by emergency responders. The program began by police, hospitals and first responders distributing resource cards to all overdose victims. By mid-2017, Stamp Out Heroin cards had linked more than 200 individuals to treatment services. In addition, through a partnership with a local nonprofit organization, Rising above Addiction, the state’s attorney’s office can request funds for immediate detoxification treatment at any time. Next, the Major Overdose Initiative identifies people who experience multiple overdoses. Through information provided by local law enforcement, the office found that 35 individuals accounted for more than 100 overdoses in 2016. With this information, the office proactively worked to get these individuals into treatment through direct contact to prevent fatal overdoses. As a result of this initiative, burglaries and thefts combined for a 33% decrease in one jurisdiction. Finally, the Early Intervention Program targets new opiate users who enter the criminal justice system. In the post-trial, pre-disposition diversion program, participants are required to get an evaluation and follow treatment recommendations, while being monitored by pretrial services. If participants are successful, they are able to get a new trial in one year, avoid serving time in the criminal justice system, and, the end result, they are granted an expungement of charges. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the role of the Stamp Out Heroin card in addressing the rising tide of opiate overdoses in Caroll County, Maryland. - Explain how to use charts and reports to identify individuals at most risk for overdoses. - Identify overdose strategies that reduce fatal overdoses, crime and recidivism.

Brian DeLeonardo

JD, State's Attorney

Carroll County, Maryland

State’s Attorney Brian DeLeonardo has served since 2014 as the chief law enforcement officer for Carroll County, Maryland, and oversees an office of 43 prosecutors, investigators and support staff. He previously served as an Assistant Attorney General for Maryland, and as the managing partner in a law firm where he represented hundreds of clients facing criminal charges as a result of their battle with drug addiction. He served as an Adjunct Law Professor at the University Of Baltimore School Of Law and as instructor for both state and federal law enforcement agencies for over 15 years, including the Maryland State Police, Department of Homeland Security, Federal Bureau of Investigations, and Bureau of Alcohol, Tobacco, Firearms and Explosives. He was appointed in 2016 by Maryland Gov. Larry Hogan to serve on Maryland’s Criminal Sentencing Commission. He participated in the Law Enforcement Subcommittee for the Maryland Governor’s Heroin Task Force, which was formed to discuss innovative ways to address the rise in opioid overdoses. DeLeonardo is the elected Vice President of the Maryland State’s Attorney’s Association and is the head of the Legislation Committee for the association.

Tim Weber

APS, Drug Treatment and Education Liaison

Office of the State's Attorney, Carroll County, Maryland

Tim Weber is the Drug Treatment and Education Liaison for the States Attorney’s Office in Carroll County, Maryland. He is on the Carroll County Behavioral Health and Addictions Planning Committee, Opioid Response team and is the founding board member of the Triangle Recovery Club. He also founded The Weber Addiction Group and Weber Sober Homes. He is a published author of Gutters and Roses with notes from a sober home. Weber is certified through the Maryland Association of Prevention Professionals and Advocates as a prevention specialist and is completing his bachelor's degree in business studies. Weber was the 2011 Risky Business Award winner for substance abuse prevention and the DEA's Light of Hope Award winner in 2014, and in 2017, he received a governor's citation for his work in the field of prevention and treatment for substance use disorders. Most importantly, he is in long-term recovery since 2003 from heroin and all drugs and alcohol.

Brittney Sabock

Treatment and Outreach Specialist

Office of the State's Attorney, Carroll County, Maryland

Brittney Sabock is currently the Outreach and Treatment Specialist for the Carroll County State’s Attorney’s Office in Maryland. Previously, she was a recovery coach at the Carroll County Health Department assisting individuals with substance use and mental health disorders. Sabock has been an advocate for treatment and recovery in Carroll County for over three years. She is also active in the Special OPTS Program, which is a high school opioid prevention program. Sabock was presented the Message of Hope Award from State’s Attorney Brian DeLeonardo in 2016. She did the Discovery Education Operation Prevention Program in conjunction with the U.S. Drug Enforcement Administration, which was shared virtually with high schools all across the country. More than 200,000 students were reached by her personal testimony. Sabock is one of the lead coordinators for the Heroin Overdose Response Team, as well as an active member of the Opioid Prevention Collation. She is dedicated to outreach, prevention and educating the community on the disease of addiction and opioid crisis. More importantly, she is a person in long-term recovery from drug and alcohol addiction.

Hanover CDE

Wednesday, April 4, 2018

2018-04-04

Expanding Access to Treatment for Justice-Involved Populations: Lessons Learned from States

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: David Tapp, JD, MS, Judge, 28th Judicial Circuit of Kentucky, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ANCC,APA,GA Bar,GA POST,NAADAC,NASW,NBCC According to the National Center on Addiction and Substance Abuse, 65% of the U.S. prison population meets the medical criteria for drug or alcohol addiction, but less than 11% receive treatment for that addiction. As a result of the opioid crisis and the chronic, relapsing nature of opioid use disorder, more prisons and jails are turning to medication assisted treatment (MAT) to help stabilize individuals within the corrections system and ease their transition back into community. States are implementing evidence-based MAT programs along with rehabilitation programs for individuals while incarcerated and improved access to case management and recovery services in the community setting following release. With support from the Centers for Disease Control and Prevention, the National Governor’s Association (NGA) analyzed different ways states are improving access to opioid use disorder treatment for justice-involved populations to identify innovative strategies to be shared with peer states and other stakeholders. In this session, NGA will discuss the national landscape of treatment programs in corrections and key lessons learned. The session also will feature two innovator states piloting MAT programs in correctional settings, highlighting their promising practices in improving health outcomes and reducing recidivism rates. Discussion topics will include: educating prison staff and addressing stigma regarding MAT; designing protocols for the administration of medications; strengthening networks for follow-up care in the community setting; and connecting individuals with case management and recovery support services. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the use of medication assisted treatment in state correctional institutions - Describe supportive programming and services to improve success of medication assisted treatment in correctional institutions. - Explain how to address challenges to implementing medication assisted treatment programs in correctional institutions.

Benjamin Watts

MBA, Health Services Administrator

Vermont Department of Corrections

Ben Watts is the Health Services Administrator for the Vermont Department of Corrections (DOC), an expert in performance-based contracting for correctional jurisdictions, and has led the development of Vermont’s correctional medication assisted treatment program. Prior to joining DOC, he was a Research Associate for Community Oriented Correctional Health Services, focusing on the implications of the Affordable Care Act to address the needs of justice-involved individuals. Watts has 15 years of experience in the mental health and social service fields, both in delivering services directly to clients and in managing the administrative aspects of programs. He has a bacherlor's degree in psychology from the University of Vermont and a master's degree in business administration with a concentration in organizational change leadership from Norwich University.

Jeffrey Locke

MPP, JD, Program Director

National Governors Association

Jeffrey Locke serves as Program Director for the National Governors Association (NGA) Center for Best Practices Homeland Security and Public Safety Division, where he focuses on issues that include criminal justice reform, public safety, juvenile justice, heroin and Rx drug abuse. Prior to joining NGA, Locke served as a volunteer in the Peace Corps in Togo, West Africa, and has worked in various capacities at the local and federal government levels. Locke holds a master’s degree in public policy from Harvard Kennedy School and a Juris Doctor from Boston College Law School. Locke originally hails from New York.

Jennifer Clarke

Medical Program Director

Rhode Island Department of Corrections

Jennifer Clarke is an associate professor of medicine at the Alpert Medical School of Brown University. She has been working as an internist at the Rhode Island Department of Corrections since 1998, and became the department's medical programs director in November 2015. Her research interests include incarcerated populations, women's health, substance misuse and reproductive health.

Joann Kang

JD, Lead for Policy and Partnerships, Division of Unintentional Injury Prevention

Centers for Disease Control and Prevention

Joann Kang serves as the Team Lead for Policy and Partnerships within Center for Disease Control and Prevention (CDC) Division of Unintentional Injury Prevention. Within this capacity, she oversees partnership engagement and policy activities related to the public health topics that fall within the division’s purview, including opioid overdose prevention. Prior to joining CDC, Joann practiced as a public interest lawyer and also worked as a policy analyst/lobbyist on children’s health issues for a nonprofit organization. Kang received her bachelor's degree in advertising from the University of Illinois at Urbana-Champaign and her law degree from Emory University School of Law.

Hanover AB

Wednesday, April 4, 2018

2018-04-04

Implementation and Evaluation of New Mexico’s PDMP Mandate Legislation in Context

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

NEW LOCATION: HANOVER AB Moderator: Sarah Bacon, PhD, Team Lead, State Opioid Overdose Prevention State Support Team, Centers for Disease Control and Prevention CE Certified By: AMA,AAFP,ACPE,ANCC,ADA In March 2016, legislation was passed in New Mexico requiring providers to obtain a prescription drug monitoring program (PDMP) report before initially prescribing an opioid and check established patients quarterly. Although the PDMP mandate did not take effect until January 2017, quarterly data shows that PDMP enrollments and activity have increased substantially since providers became aware of impending changes to their licensing board rules. These data also show marked declines in the percent of overlapping opioid prescriptions from different providers (down 13%) and overlapping opioid and benzodiazepine prescriptions (down 11%). Provider engagement with the PDMP was further enhanced by the introduction of prescriber feedback reports (PFRs) in November 2016. Presenters will share New Mexico's initial 2017 evaluation findings triangulating multiple sources: PFR surveys, PDMP usage statistics and surveillance data supplemented by interviews with key stakeholders. An unexpected benefit of the PDMP mandate legislation on opioids was the addition of benzodiazepines to reporting requirement rules promulgated by all state licensing boards. Presenters will outline next steps as the state continues to evaluate the impact of the policy change through PDMP user surveys (pharmacists, prescribers, law enforcement) and compare pre/post mandate PDMP data plus drug overdose morbidity and mortality data to create a comprehensive state assessment. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe how New Mexico findings relate to previous studies of PDMP mandates in Kentucky, Ohio, Tennessee and New York. - Explain how the New Mexico mandatory PDMP use legislation was passed and how it is being implemented. - Identify the strategies New Mexico is using to evaluate the impact of the prescriber mandate legislation in context.

Michael Landen

MD, MPH, State Epidemiologist

New Mexico Department of Health

Dr. Michael Landen is the State Epidemiologist with the New Mexico Department of Health. His principal areas of professional interest include tribal epidemiology, substance abuse epidemiology and injury prevention. He has worked as a family physician and clinical director for the Indian Health Service in Arizona and New Mexico, and as a volunteer physician in Belize. In 1995, he began work as an Epidemic Intelligence Service Officer assigned to the Alaska Department of Health and Social Services. He has been with the New Mexico Department of Health since 1997. He served as a Council of State and Territorial Epidemiologists Executive Board member from 2007-2010.

Kathryn Lowerre

PhD, MPH, Evaluator

New Mexico Department of Health

Dr. Kathryn Lowerre joined the New Mexico Department of Health (NMDOH) in 2014 as the Bureau Evaluator for Environmental Health Epidemiology, working with multiple Centers for Disease Control and Prevention-funded programs engaging stakeholders and presenting evaluation findings to a range of audiences. In April 2016 she moved to NMDOH’s Prescription Drug Overdose Prevention Program. Previous positions include college and university teaching appointments, as well as work at county and regional health departments on health impact assessments and population health indicators and in drug regulatory affairs as a consultant. Her first health-related position, in clinical trials coordination, was at the Duke AIDS Research and Treatment Center, where she volunteered and worked part-time while completing her doctorate.

Baker

Wednesday, April 4, 2018

2018-04-04

Safe Rx Opioid and Naloxone Dispensing Toolkit: Pilot Study Results

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: CeCe Spitznas, PhD, Senior Science Policy Advisor, Office of National Drug Control Policy, and Member, National Rx Drug Abuse & Heroin Summit CE Certified By: AAFP,ACPE This presentation will provide results from the RESPOND Toolkit pilot study, which was introduced at the 2017 National Rx Drug Abuse & Heroin Summit. Results highlight the importance of training tailored to community pharmacists to promote psychological and behavioral shifts supporting greater opioid safety for patients. The RESPOND Toolkit, which is funded by the Agency for Healthcare Quality and Research, enhances community pharmacists’ understanding of their role in addressing opioid safety; improves integration of prescription drug monitoring programs (PDMP) into daily workflow; and enhances communication between pharmacists, prescribers and patients. The toolkit consists of an online continuing education course and printed materials. Preliminary focus groups and participant interviews performed mid-study shaped the final content, flow and delivery of the toolkit. The RESPOND Toolkit was tested in six community pharmacies in Oregon using a quasi-experimental design. Pre- and post-surveys assessed RESPOND’s effectiveness in positively impacting pharmacists’ knowledge, attitudes, perceived behavioral control and self-efficacy. State PDMP data were used to examine changes in store-level PDMP query rates and opioid dispensing behavior. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe educational components of the RESPOND Toolkit. - Explain findings from the RESPOND Toolkit pilot study. - Discuss implications of RESPOND pilot study findings on community pharmacy practice.

Dan Hartung

PharmD, MPH, Associate Professor of Pharmacy

Oregon State University / Oregon Health & Science University College of Pharmacy

Dan Hartung, PharmD, MPH, is a pharmacist, Associate Professor of Pharmacy in the Oregon State University / Oregon Health & Science University College of Pharmacy, and an investigator in the Pacific Northwest Evidence-based Practice Center. Hartung received his Doctor of Pharmacy from the University of Wisconsin, Master of Public Health with emphasis biostatistics and epidemiology from OHSU, and he completed a pharmacy residency at the Portland VA Medical Center, and outcomes research fellowship at Oregon State University. His work involves pharmaceutical health services research, with a specific focus on pharmacy benefit design and delivery within state Medicaid programs. He is currently leading a Centers for Disease Control and Prevention-funded effort to explore how Medicaid policies involving Rx opioids affect high-risk opioid utilization and opioid-related health outcomes. He is also principal investigator on an Agency for Healthcare Research and Quality-funded project to develop and pilot a toolkit to help community pharmacists improve their use of state prescription drug monitoring program data and ultimately improve the safety of opioid use in the community.

Nicole O'Kane

PharmD, Clinical Director

HealthInsight Oregon

Regency VII

Wednesday, April 4, 2018

2018-04-04

Effective Early Primary Prevention for Rx Drug Abuse

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: Nancy Hale, MA, President and Chief Executive Officer, Operation UNITE, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ANCC,APA,MCHES,NASW As the need to address opiate abuse and addiction rises, so does the call for primary prevention. But what is primary prevention, and at what age is it best applied? In this interactive session, two presentations will illustrate effective primary prevention for K-12 students. The first presenter will explore the evidence‐based practices that are proven to be effective in primary prevention and the ineffective approaches to avoid. Topics will include the role of sense of self, self‐efficacy, and prosocial peer bonding and influence play on building the capacity to resist negative behavior. Examples from the Too Good for Drugs program will illustrate how to develop these skills to foster healthy decision-making and a resistance to substance use. Through hands‐on activities, participants will experience primary prevention in action and in the context of how a comprehensive prevention program is designed to work. Participants will link social emotional competency skills to the risk factors for substance use, understand the relationship between self‐efficacy and resistance and resiliency, and identify effective strategies to promote skill development through age‐appropriate and developmentally appropriate methods. The second presentation will demonstrate a primary prevention program targeting Rx drug abuse for some of our youngest community members (2nd graders) and, through them, prevention skills and education for local families. Presenters will share their expertise and experience in teaching medication safety principles to elementary school students. Sample materials, curricula and lessons learned will be shared with participants. Presenters will reveal how this fun and innovative strategy is both a developmentally appropriate intervention for children, as well as local families. Participants will learn how they can implement this strategy as a collaborative effort between coalitions, school departments, pharmacists and public safety agencies. Finally, presenters will discuss how this program fits in to a community-wide strategy to address opiates and overdose prevention. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Differentiate effective and ineffective prevention strategies. - Explain the benefits of implementing a consistent, comprehensive prevention program. - Describe how social emotional competency builds protection against risky behavior, including preventing substance use. - Outline the effects of experiential learning strategies on the development of social emotional competency and resilience. - Identify key Rx drug abuse prevention messages for young elementary school students. - Describe interactive techniques and materials for providing Rx drug abuse prevention messages to young children and their families. - Recognize how this program advances a larger community-wide strategy to address Rx drug misuse and overdose prevention.

Stephanie M. Patton

MPH, Prevention Coordinator

Town of Stoughton, Massachusetts

Stephanie Patton, MPH, has been identified by her peers as a prevention leader in Massachusetts. She has been the Prevention Coordinator for the Organizing Against Substances in Stoughton (OASIS) Coalition since 2012, but involved with the coalition since its inception in 2004. A primary focus of her work is policy change at the local, regional and state level. Prior to this role, Patton served as the Program Director for the Southeast Center for Healthy Communities, where she provided technical assistance to prevention coalitions throughout Southeastern Massachusetts. Stephanie has over 15 years of experience in public health, substance abuse prevention and coalition development. She has presented at numerous national, state and regional conferences and has extensive experience developing and leading engaging workshops and trainings. atton has a master's degree in public health from the University of Massachusetts, Amherst and a bachelor's degree from Wellesley College.

Sally Borges

MSN, RN, Supervisor of Health Services

Stoughton (Massachusetts) Public Schools

Sally Borges has been a licensed registered nurse in Massachusetts since 1995 and has a master's degree in nursing. She has worked in a variety of settings within the community, concentrating on pediatrics starting in 2006 when she began working in the Fall River School Department as a school nurse. Currently, she holds the position of Supervisor of Health Services for Stoughton Public Schools and has held that position since 2015. Concurrently, Borges still is employed for a pediatrician's office in the city of Fall River.

Cindy Swartzwelder

Vice President of Training and Implementation

C.E. Mendez Foundation

Cindy Swartzwelder is the Vice President of Training and Implementation at the C.E. Mendez Foundation, Inc., a Florida nonprofit foundation that specializes in the field of drug and violence prevention education. In addition to delivering the Too Good programs in local schools, she also designs and facilitates the national training program for the Too Good programs. In the 10 years she has been with the foundation, Swartzwelder has trained more than 6,500 teachers and facilitators at more than 400 training events nationwide. She presents at state and national conferences about the impact of social emotional skill development on risky behavior and how to develop those skills in children and adolescents. Swartzwelder holds a bachelor's degree from the University of South Florida and has volunteered with both the No More Orphans and I Matter Too (mentoring/tutoring) programs. She currently serves as a Guardian ad Litem for children in dependency court in Hillsborough County and resides near Tampa.

Learning Center

Wednesday, April 4, 2018

2018-04-04

Improving the Quality of Substance Use Disorder Treatment through Payer-Driven Change

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: Gary Enos, MS, Editor, Addiction Professional CE Certified By: AMA,AAFP,AAFP,ANCC,APA Historically, the delivery of substance use disorder (SUD) treatment has occurred outside of the traditional healthcare system. Misconception and stigma surrounding this chronic disease have resulted in limited access to, and lack of insurance coverage for, evidence-based medical treatments. In some instances, this gap has been filled with treatment approaches that lack significant evidence, resulting in poor outcomes and significant costs for patients and families seeking help for SUDs. Science has shown that evidence-based treatments for SUD can improve health outcomes and reduce the risk of overdose. Yet, only one in ten people in the United States with an SUD receive any form treatment. How then, are families, payers and policymakers to recognize and support quality SUD treatment? The SUD Treatment Task Force, a national public-private partnership, is taking on this challenge. The group, which includes representatives from across the insurance industry working in consultation with subject matter experts, is working to develop and implement a strategic plan to ensure alignment with evidence-based principles for quality SUD treatment. This session will provide an overview of the principles and describe the task force’s efforts to raise the standard of SUD treatment to the highest quality through payer-driven solutions. These strategies may include changes in reimbursement, coverage, certification or other innovative programs. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify the general principles of quality substance use disorder treatment. - Discuss how payer-driven reform can improve the quality of substance use disorder care. - Explain the SUD Treatment Task Force’s strategic plan, including baseline assessments by payers and plans to implement policy changes and their potential impact.

Cynthia Reilly

MS, BSPharm, Project Director, Substance Use Prevention and Treatment Initiative

The Pew Charitable Trusts

As Director of The Pew Charitable Trusts' substance use prevention and treatment initiative, Cynthia Reilly works on federal and state initiatives to reduce the inappropriate use of Rx opioids while ensuring patients have access to effective pain management. She also focuses on expanding access to effective treatment for substance use disorders and serves as a member of the SUD Treatment Task Force. Prior to joining Pew, Reilly worked on issues related to the safety and quality of medication use for the American Society of Health-System Pharmacists in Bethesda, Maryland. In this role, she coordinated the society’s work in support of rescheduling hydrocodone combination products from Schedule III to Schedule II to improve the safe and appropriate use of those therapies. In addition, she led development of policy that called on clinicians to increase efforts to combat Rx drug abuse while also ensuring patient access to needed pain therapies. Reilly received her bachelor’s degree in pharmacy from Temple University, and her master’s degree in global health and medical policy from George Mason University.

Samantha Arsenault

MA, Manager of National Treatment Quality Initiatives

Shatterproof

Douglas (Doug) Nemecek

Chief Medical Officer

Cigna

Dunwoody

Wednesday, April 4, 2018

2018-04-04

Buprenorphine Use and Cost Trends

2:00 PM - 3:15 PM

2:00 PM

3:15 PM

Moderator: Elizabeth Nichols, MS, Manager, Department of Specialty Courts, Kentucky Administrative Office of the Courts, and Member, Operation UNITE Board of Directors CE Certified By: AMA,AAFP,ACPE,ANCC,APA,NAADAC,NASW,NBCC Expanding medication assisted treatment (MAT) of OUD with buprenorphine is a major goal of national efforts to combat the opioid crisis. Cost of treatment is an important factor that may determine utilization of buprenorphine. Increasingly, private insurers include buprenorphine in their formulary, yet little is known about overall cost and cost-sharing. Using MarketScan Rx claims data from 2003 to 2015, presenters will share new data on buprenorphine use and cost trends among privately insured adults. This evidence is crucial for informing future efforts to increase the uptake of and adherence to OUD treatment. Their findings show that private insurer spending on buprenorphine has not increased since the first buprenorphine product approved to treat OUD entered the market in 2003. Patient out-of-pocket buprenorphine costs also have declined steadily across the study period, likely owing to new generic buprenorphine product entries and the positive effects of the Mental Health Parity and Addiction Equity Act on MAT insurance coverage. The number of total buprenorphine users increased dramatically from 2003 to 2013 but has since plateaued; the number of patients newly starting buprenorphine has declined since 2013. The presenters build on this new evidence to highlight existing concerns affecting buprenorphine access and affordability and discuss potential opportunities to increase the uptake of buprenorphine moving forward. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe historical trends in the use and cost of buprenorphine. - Identify the underlying policy and market changes contributing to these trends. - Explain the implications of recent buprenorphine use and cost trends on future efforts to expand opioid use disorder treatment.

Andrew Roberts

PharmD, PhD, Assistant Professor of Preventive Medicine and Public Health

University of Kansas Medical Center

Grand Hall

Wednesday, April 4, 2018

2018-04-04

Networking Break

3:15 PM - 3:45 PM

3:15 PM

3:45 PM

Networking break in the Exhibit Hall

Piedmont

Wednesday, April 4, 2018

2018-04-04

Gender Differences and Substance Abuse: Eliminate Discrimination, Improve Treatment and Save Lives

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: Michael Barnes, JD, Chairman, Center for Lawful Access and Abuse Deterrence, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ANCC,APA,NAADAC,NASW,NBCC Women face unique issues when it comes to Rx drug abuse and other substance use. For example, according to the National Institute on Drug Abuse, women are less likely to misuse or abuse Rx pain medicines but are more likely to misuse sleep medications than men. Women may develop a substance use disorder (SUD) more quickly than men, and women with SUD may experience more physical effects on their heart and blood vessels. Women may also be more likely to relapse after completing addiction treatment. Yet, women are also uniquely positioned to influence policies and practices to reduce substance abuse. For example, women utilize healthcare services more frequently than men and make up 57% of all expenses incurred at doctors' offices. Women also make 80% of their families’ healthcare decisions. This session will address genetic distinctions of women, only recently accounted for in healthcare, and unique challenges of providing treatment to women with pain, addiction and other conditions for which controlled medications may be medically necessary. The presenters will provide evidence-based practice recommendations and examine policy proposals in the areas of substance-related education and prevention; screening, diagnosis, and intervention; treatment; and chronic care management. They will emphasize the importance of eliminating laws that punish women for having the disease of addiction and other institutionalized forms of discrimination against women with SUDs. Finally, the presenters will discuss ways women can bring about meaningful change to reduce substance abuse. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe how gender differences play an important role in addiction and other disease progression, effects of medications, and barriers to treatment. - Identify laws and other institutionalized sanctions that are levied against people with SUDs — especially against women with addiction. - Recommend practical solutions that can help improve treatment and reduce discrimination and societal costs.

Behshad Sheldon

Chair, Board of Directors

Female Opioid-Addiction Research and Clinical Experts

Behshad Sheldon is the founder and chairwoman of the board of directors for Female Opioid-addiction Research and Clinical Experts (FORCE). She is the former President and CEO of Braeburn and, through this role, came to be a passionate defender of the rights of people with opioid use disorder. Sheldon began her career in the pharmaceutical industry as a sales representative and has held positions in sales, training, and domestic and global marketing. She spent 10 years at Otsuka Pharmaceuticals and co-founded the Otsuka Princeton office in 2002. Sheldon also served as a member of the board of directors of the Otsuka R&D organization, contributing to the oversight of 18 pre-approval programs for 13 products in CNS, cardio-renal, pain, dermatology and oncology. Prior to joining Otsuka, she served as a Senior Director in Global Marketing at Bristol-Myers Squibb, where she was responsible for the marketing of Plavix and Glucophage. Sheldon's other commercial experiences have included managing successful marketing initiatives at SmithKline Beecham, including Bactroban. She has been a Director of Cerecor Inc. since July 11, 2014. Sheldon holds a bachelor's degree in neuroscience from the University of Rochester.

Shruti Kulkarni

JD, Policy Director

Center for Lawful Access and Abuse Deterrence

Shruti Kulkarni is the Policy Director for the Center for Lawful Access and Abuse Deterrence (CLAAD). She offers policy insight on the prevention of diversion, misuse, and abuse of controlled Rx medications and treatment of substance use disorders. In this capacity, she proposes and analyzes policies and legislation; drafts legislative language, testimony, white papers, and scholarly articles; and educates state and federal legislators and policymakers. Kulkarni has over a decade of experience in the healthcare industry, including government affairs and sales positions in the pharmaceutical industry, and at the Food and Drug Adminstration’s Office of Policy in the Office of the Commissioner. She also is an Associate Attorney at DCBA Law & Policy, a Washington, D.C., law firm that focuses on healthcare law and policy. Kulkarni obtained her Juris Doctor degree from George Mason University School of Law. She received her bachelor’s degree magna cum laude from Saint Joseph’s University.

Andrea Barthwell

MD, DFASAM, Founder and Director

Two Dreams Treatment Centers

International North

Wednesday, April 4, 2018

2018-04-04

Treating Chronic Pain in a Non-Opiate-Based Format

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

NEW LOCATION: INTERNATIONAL NORTH Moderator: Gary Ozanich, PhD, Director of Health Informatics, Associate Director of Research, Health Innovation Center, Northern Kentucky University CE Certified By: AMA,AAFP,ACPE,ANCC In this session, the presenter will outline options based on his experience treating patients who have become physically dependent on opiate-based medications because of chronic pain. He will cover how to diagnose pain and refer patients to the appropriate specialist for care. He will present several modalities of treatment, including injections, non-addictive medications and physical therapy. For patients with chronic refractory pain, he will explain spinal cord stimulation — a relatively new technology that is essentially a pacemaker for pain. Participants will take away information on techniques, medications and procedural therapy available to help patients with chronic pain. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify patients with chronic pain and addiction. - Describe other modalities in treating pain outside of narcotic therapy. - Recognize when and how to refer patients to the appropriate specialist so they get the care they deserve.

John Dombrowski

MD, FASA, DABAM, Chief Executive Officer

Washington Pain Center

Dr. John Dombrowski has 25 years of experience in anesthesiology and pain medicine. With the rise of addiction in the United States, he became board certified in addiction medicine to treat these patients. He is a frequent lecturer across the country to discuss techniques that anesthesiologists can use to limit the amount of opiates provided patients. Also, he is frequently on national television, such as FOXNews, Good Morning America and Today.

Hanover FG

Wednesday, April 4, 2018

2018-04-04

Long-Term Recovery: The Essential Roles of Families and Addiction Treatment Providers

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: Gary Enos, MS, Editor, Addiction Professional CE Certified By: AMA,ACPE,ANCC,APA,MCHES,NAADAC,NASW,NBCC Making sustained, stable recovery — including no use of any alcohol, marijuana, opioids or other drugs — the expected outcome of treatment can be achieved as demonstrated by four decades of work in the state physician health programs (PHPs). These programs provide a system of intensive care management that includes treatment, random testing for drugs and alcohol, and peer recovery support. Inspired by the PHP care management system, and in the face of the nation’s overdose epidemic, Caron Treatment Centers made substantial changes in its programs to improve long-term patient outcomes. At the root of these changes is the engagement of families who are in a position to fulfill many of the care management roles used in the PHP care system. Working hand in hand with treatment programs, engaged families can provide the necessary support to achieve recovery. This presentation will describe a new vision for engaging families in addiction treatment to improve long-term outcomes and outline practical steps based on the experiences of this distinguished program. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify sustained recovery as the principal goal of addiction treatment, including abstinence. - Summarize the core elements of the state physician health programs and long-term outcomes. - Describe practical steps for providers to harness this care management strategy and include families.

Robert DuPont

MD, President

Institute for Behavior and Health, Inc., and Member, National Rx Drug Abuse & Heroin Summit Advisory Board

Douglas Tieman

President and Chief Executive Officer

Caron Treatment Centers

Douglas Tieman has been the President and CEO of Caron Treatment Centers since 1995. Under his direction, Caron has taken leadership roles in treating addiction in young adults and adolescents, sponsoring research, and participating in national conferences on addiction and recovery. Tieman has spent 30 years in the addiction treatment field in treatment center and industry leadership positions. He began his career with the Hazelden Foundation, and has served as Chairman of the National Association of Addiction Treatment Providers and a member of the American College of Addiction Treatment Administrators. He is currently a board member of the National Council on Alcoholism and Drug Dependence and the American Foundation for Addiction Research, and serves on the Behavioral Healthcare Editorial Advisory Board.

Regency V

Wednesday, April 4, 2018

2018-04-04

Update from the Office of National Drug Control Policy (ONDCP)

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: Cece Spitznas, PhD, Senior Science Policy Advisor, Office of National Drug Control Policy, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board

CeCe Spitznas

PhD, Senior Science Policy Advisor

Office of National Drug Control Policy, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board

Cece Spitznas, PhD, is Senior Science Policy Advisor in the Office of National Drug Control Policy (ONDCP), a component of the Executive Office of the President. She provides policy analysis and scientific advice to the ONDCP Director and Chief of Staff on special matters of concern to ONDCP, such as emerging drug trends and demand reduction, and helps to develop legislative responses to problems of national scope, particularly on Rx drugs, heroin and fentanyl. In 2012, she organized a National Leadership Meeting for ONDCP on Maternal Substance Use and Neonatal Abstinence Syndrome. From 2000-2012, Spitznas was a program official at the National Institute on Drug Abuse (NIDA), where her research portfolio concerned developing and testing new screening, brief interventions and treatments for people with substance use disorders, including pregnant women, and developing provider training. She received her clinical and research training in psychology at the University of New Mexico and the University of Alabama at Birmingham (UAB) School of Medicine. She worked as a research professor at UAB, conducting research on relapse and treatment for crack cocaine use in homeless cocaine users prior to joining the NIH.

Charmaine Yoest

PhD, Associate Director

Office of National Drug Control Policy

Dr. Charmaine Yoest is an Associate Director of the Office of National Drug Control Policy in the Executive Office of the President. Yoest has a track record serving in many facets of political life — in the White House, on a presidential campaign, and leading a national nonprofit. She is also the author of Mother in the Middle, a book on childcare policy (HarperCollins). Yoest began her career working in the West Wing of the White House for President Ronald Reagan in the Office of Presidential Personnel, and later served as a Senior Advisor to the 2008 Huckabee for President Campaign. Previously, she led Americans United for Life as the President and CEO for over seven years. Most recently, Yoest served as the Assistant Secretary for Public Affairs at the Department of Health and Human Services. Yoest received her bachelor's degree political science from Wheaton College and, after the White House, studied ethics and philosophy at Oxford University. Later, she earned a doctorate degree from the Department of Politics at the University of Virginia. While there she directed a national study on paid parental leave in academia funded by the Alfred P. Sloan Foundation. She also received Mellon, Olin, Bradley and Kohler fellowships. Yoest and her husband are the parents of five children. Their oldest daughter is an NCAA champion and four-time ACC champion. Their next son is a CAA champion and currently is a 2nd Lieutenant, serving in Army Aviation. Their next daughter is also a Division 1 athlete.

Jacqueline Hackett

Office of National Drug Control Policy

Christine Kourtides

Office of National Drug Control Policy

Regency VI

Wednesday, April 4, 2018

2018-04-04

Opioid and Fentanyl Overdoses: Rapid Surveillance and Regional Patterns

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: Christopher M. Jones, PharmD, MPH, Director, National Mental Health and Substance Use Policy Laboratory, Substance Abuse and Mental Health Services Administration, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ANCC,APA,GA Bar,GA POST The Centers for Disease Control and Prevention (CDC) partnered with states to develop groundbreaking surveillance programs to provide timely, in-depth examination of opioid overdoses. In this session, CDC researchers will present results from analysis of data collected using the Enhanced State Opioid Overdose Surveillance (ESOOS) program. States submit emergency department (ED) visit data on nonfatal overdoses on a quarterly basis and medical examiner/coroner data on fatal overdoses within eight months of death. An overview of regional patterns of opioid overdose morbidity and mortality, 2016 to 2017, will be presented. Researchers have documented regional changes in opioid overdoses as well as the drugs most frequently involved in opioid overdoses. Preliminary data suggest overall increases in opioid overdose morbidity and mortality in ESOOS states represented in the Northeast, South, Midwest and West; however, specific drugs and overdose circumstances vary across regions. Presenters also will examine the role of fentanyl and fentanyl analogs, which are often mixed with heroin or cocaine, or pressed into counterfeit pills. Data for nonfatal opioid overdoses were analyzed from states sharing ED data through the National Syndromic Surveillance Program. Fentanyl overdose death characteristics were examined, including presence of fentanyl or fentanyl analogs, route of drug administration, combinations of drugs involved and suspected fentanyl source. Presenters will outline their findings to date, including the proportion of opioid overdose deaths caused by fentanyl and the proportion of ED visits in which fentanyl was suspected to be involved. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Recognize regional patterns in opioid overdose morbidity and mortality. - Identify drugs that are involved in opioid overdose morbidity and mortality regionally. - Describe the epidemiology of fentanyl overdose deaths in 12 states. - Identify the characteristics of fentanyl overdose deaths, including route of administration. - Describe estimates of suspected nonfatal fentanyl overdose in several states.

Christine Mattson

PhD, MS, Health Scientist

Centers for Disease Control and Prevention

Dr. Christine Mattson works at the Centers for Disease Control and Prevention (CDC) on the Overdose Epidemiology and Surveillance Team as a Health Scientist. Dr. Mattson has a doctorate in epidemiology and joined CDC in 2007 as an Epidemic Intelligence Service Officer working in the Global AIDS Program. She has worked in the field of HIV prevention and surveillance domestically and internationally for over 15 years. She has a strong interest in epidemiology methods and surveillance and most of her previous publications focused on behavioral and clinical outcomes of people living with HIV. Since joining the Overdose Epidemiology and Surveillance Team, she has co-authored the first annual "Surveillance Report of Drug-Related Risks and Outcomes — United States, 2017," and she serves as a science officer on the Enhanced State Opioid Surveillance program.

Julie O'Donnell

PhD, MPH, Epidemiologist

Centers for Disease Control and Prevention

Lawrence Scholl

PhD, MPH, Epidemic Intelligence Service Officer

Centers for Disease Control and Prevention

Dr. Lawrence Scholl is an Epidemic Intelligence Service (EIS) Officer working on the Overdose Epidemiology and Surveillance Team in the Division of Unintentional Injury Prevention (DUIP) at the Centers for Disease Control and Prevention (CDC). As an EIS Officer, he completed an evaluation of the Prescription Behavior Surveillance System (PBSS), analyzed Rx histories of overdose decedents, and is conducting an analysis of PBSS prescribing data and an investigation of substance use during pregnancy. Prior to arriving at DUIP, Scholl worked with the North Carolina Division of Public Health to analyze deaths from overdoses and data collected in the North Carolina Violent Death Reporting System. He also worked with the North Carolina Division of Mental Health to examine data collected by the state’s prescription drug monitoring program. At the University of North Carolina, his research and evaluation work focused on youth suicide prevention and young driver safety.

Hanover CDE

Wednesday, April 4, 2018

2018-04-04

Fentanyl Analogues: Investigation and Prosecution in the New World

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: Rita Noonan, PhD, Branch Chief, Division of Unintentional Injury Prevention, Centers for Disease Control and Prevention CE Certified by: GA Bar, GA POST The rapid evolution of fentanyl analogues necessitates that the related deaths be understood in the context of fentanyl supply, importation and structure. Importation of fentanyl analogues through express shipping and direct mail is a contributory factor in many such deaths, and the linkage of distribution networks and chains to the resultant deaths from fentanyl deliveries presents opportunity to leverage efforts to dismantle and disrupt drug trafficking organizations. This session will equip law enforcement and prosecutors to target the dealers that knowingly distribute opioids causing death. From Homeland Security Investigations, participants will gain understanding of the fentanyl, fentanyl analogues, counterfeit pills and other harmful substances entering through the ports of entry. They will learn methodologies for monitoring, assessing and attacking such threats, in an unclassified, non-law enforcement sensitive setting. An Assistant U.S. Attorney will present on federal prosecutions under the Burrage v. United States “but for causation” standard, and how that standard has required integration between science and law in novel fashions to achieve such prosecutions. This will include a “checklist” for investigative thoroughness, as well as prosecution hurdles, such as poly-drug overdose and post-mortem identification challenges inherent in the ever-changing world of fentanyl analogues. The presenter will explain how information gleaned in federal and state investigations can be shared among state and federal agencies to contribute to dismantlement and disruption of drug trafficking organizations. A forensic toxicologist will discuss the importance of rapid identification of fentanyl analogues in his toxicology work with the medical examiner community, highlighting a particular identification instance that led to federal and state partnership and success. He also will overview the challenges presented by the evolution of fentanyl analogues, highlighting the number of fentanyl analogues in existence and how the challenges in identification provide hurdles to be overcome in investigation and prosecution. Participants will gain insight into a unique partnership among federal agencies and NMS Labs, which is valuable to the whole-government approach to address the fentanyl epidemic. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Recognize the challenges presented by the rapid evolution of fentanyl analogues. - Identify approaches to investigate and prosecute fentanyl, fentanyl analogues and other opioids causing serious bodily injury or death. - Use more complex methodologies and systems to build complex investigations and partnerships to dismantle and disrupt major fentanyl analogue distribution rings operating in the United States. - Describe a partnership among federal agencies and a lab that is responding to the fentanyl epidemic.

M.J. Menendez

JD, National Opioid Coordinator

Organized Crime Drug Enforcement Task Forces, U.S. Department of Justice

Barry Logan

PhD, F-ABFT, Sr. Vice President of Forensic Science Initiatives, Chief Scientist

NMS Labs

Hanover AB

Wednesday, April 4, 2018

2018-04-04

The Intersection of Law Enforcement and Healthcare: Increased Utilization of California's PDMP

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

NEW LOCATION: HANOVER AB Moderator: John L. Eadie, MPA, Coordinator, Public Health and Prescription Drug Monitoring Program Project, National Emerging Threat Initiative, A National HIDTA Initiative, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,GA Bar,GA POST This presentation about the California prescription drug monitoring program (PDMP) — which is known as CURES — is designed to deliver useful information to participants from all 50 states. Presenters will discuss CURES in a national context and draw from literature that examines multiple states’ PDMPs. They will discuss prescriber use of CURES and the value of CURES to law enforcement and dispensers. California maintains CURES as one method to mitigate harms caused by opioids. Use of this system by physicians has been shown to decrease their writing of opioid medication prescriptions, potentially reducing the amount of fatal overdoses of both Rx opioids and heroin. Additional benefits of PDMP utilization include physicians being more aware of the criminal act of patient “doctor shopping,” potentially irresponsible prescribing by fellow healthcare professionals, or other forms of pharmaceutical diversion such as fraud and forgeries. This presentation will highlight findings from an academic project that aimed to understand physician underutilization of CURES and evaluate an opioid reduction workgroup’s progress toward its goal of 100% of physicians in its geographical area using CURES. The project identified a performance gap and offered solutions to close this gap, as well as an evaluation plan to assess solution effectiveness. This project will be presented in the context of the workgroup’s diverse efforts at reducing death by overdose through a multi-disciplinary approach involving key stakeholders from behavioral health, public health, law enforcement, education and the community. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe how, when and why physicians in the geographical area of the workgroup were not using CURES. - Identify the knowledge, motivation and organizational influences facilitating or impeding physicians’ utilization of the CURES database. - Outline the recommendations for practice of physicians in the areas of knowledge, motivation and organizational resources.

Victor Fazio

EdD, MACJ, Detective Sergeant

Ventura County (California) Sheriff’s Office

Victor Fazio has 23 years of law enforcement experience and has been assigned to the Narcotics Bureau at the Ventura County (California) Sheriff’s Office for over 15 years. He is considered an expert throughout the country in pharmaceutical drug diversion and heroin investigations. He began investigating criminally operating physicians and the unlawful practices of pharmaceutical companies in 2002. He was the architect and task force commander of the Ventura County Interagency Pharmaceutical Crimes Unit, which investigates any crime involving a pharmaceutical drug or heroin including drug dealing resulting in death. He supervises the Major Narcotics Violator team for the Ventura County Narcotics Task Force known as VCAT. Fazio has investigated and supervised many multi-jurisdictional / international cases involving both Rx drugs and heroin. He has instructed thousands of law enforcement officers, doctors, nurses, pharmacists and attorneys for the California Narcotics Officers Association, the National Association of Drug Diversion Investigators, and other agencies and organizations throughout the country. Fazio has a bachelor's degree in political science from the University of California, Los Angeles, a master's degree in criminal justice from Arizona State University, and a doctorate in education from the University of Southern California. His research interests are focused on reducing harms caused by opioids through physician education.

Daniel Hicks

Manager, Prevention Services

Ventura County Behavioral Health

Dan Hicks is Manager of Prevention Services for Ventura County Behavioral Health Department. A graduate of Princeton University, Hicks has been an alcohol and drug policy advocate more than 20 years, working closely with city and county governments, public safety agencies and retail establishments. He has facilitated policy discussions of among elected officials, police officers, parents groups and regional media; led policy change efforts to address underage and binge drinking and youth marijuana abuse; and has advanced Rx drug and heroin prevention strategies in cooperation with schools and law enforcement to achieve common goals. Physician outreach and education, direct mail and e-marketing, and paid media placement have all been employed to destigmatize overdose response and facilitate local action. Since October 2014, Hicks has co-led Ventura County’s Overdose Prevention and Rescue Project, reaching thousands of county residents with potentially life-saving information. The project places a heavy focus on quality data collection and analysis in order to target precious prevention resources. Today, fatal and nonfatal overdose data are combined with other community indicators to systematically expand and target overdose prevention efforts for this community of 850,000 residents.

Baker

Wednesday, April 4, 2018

2018-04-04

Safe Disposal in Colorado: A State-Led Approach

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: Richard W. Sanders, MSCJ, Commissioner, Kentucky State Police, and Member, Operation UNITE Board of Directors CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,APA,MCHES,GA POST,NAADAC,NASW,NBCC Proper medication disposal is widely recognized as a key strategy to combat the Rx drug epidemic. The State of Colorado is taking a novel approach to the safe disposal of Rx medications. This discussion will focus on the state’s approach to safe disposal, and the process to develop the program. Topics to be reviewed include stakeholder engagement, rules and regulations, responsibilities of engaged parties (the state, contractor, host site), and accompanying materials to educate the public. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the state-funded safe disposal program in Colorado. - Identify the benefits and challenges of engaging stakeholders in the development and implementation of a statewide safe disposal program. - Apply the presented model of community drug disposal to other states.

Greg Fabisiak

Environmental Integration Coordinator

Colorado Department of Public Health and Environment

Greg Fabisiak joined the Colorado Department of Public Health and Environment in 2009 following a 27-year career in water and wastewater utility management. As the department’s Environmental Integration Coordinator, he provides leadership in formulating and implementing approaches to address emerging environmental issues and those that fall outside of traditional, media-specific regulatory programs. This includes developing the department’s strategy to reduce impacts to public health and the environment from improperly disposed pharmaceuticals. In this role, Fabisiak manages the Colorado Household Medication Take-Back Program and works with a diverse group of stakeholders to expand and promote this program statewide, so that all residents have may access to safe and environmentally-sound options for medication disposal. Fabisiak also serves as co-chair of the Safe Disposal Work Group at the Colorado Consortium for Prescription Drug Abuse Prevention.

Sunny Linnebur

PharmD, FCCP, FASCP, BCPS, BCGP, Professor

Skaggs School of Pharmacy and Pharmaceutical Services, University of Colorado

Sunny Linnebur, PharmD, FCCP, FASCP, BCPS, BCGP, is a Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences. She received her Doctor of Pharmacy degree from the University of Kansas. She completed a PGY1 residency at the Veterans Affairs Medical Center in Denver and a PGY2 Primary Care Residency at the University of Colorado. Linnebur’s clinical practice area is in geriatrics at the University of Colorado Hospital Seniors Clinic, where she precepts pharmacy students and residents. Her research and clinical areas of interest include medication therapy management, osteoporosis, vitamin D, dementia and urologic disorders. She is an active member of the American College of Clinical Pharmacy and the American Geriatrics Society, where she serves as a member of the Board of Directors. She is a certified geriatric pharmacist. Linnebur co-chairs the Safe Disposal Work Group at the Colorado Consortium for Prescription Drug Abuse Prevention.

Whit Oyler

Program Manager

Colorado Consortium for Prescription Drug Abuse Prevention

Whit Oyler is the Program Manager for the Colorado Consortium for Prescription Drug Abuse Prevention, a statewide collaborative of over 300 participants from state agencies, universities, professional associations, treatment centers and stakeholder groups. He is pursuing a Master of Public Health at the University of Colorado and is an alumnus of the Substance Abuse and Mental Health Services Administration Prevention Fellowship and was housed in the Colorado Department of Human Services – Office of Behavioral Health.

Regency VII

Wednesday, April 4, 2018

2018-04-04

Using EHR-Based Clinical Decision Supports to Affect Opioid Prescribing Behavior

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: Jan Losby, PhD, MSW, Team Lead, Prescription Drug Overdose Health Systems Team, Centers for Disease Control and Prevention CE Certified By: AMA,AAFP,ACPE,ADA,ANCC Evidence-based clinical guidelines hold promise for improving care to ensure the safer use of long-term opioid therapy for patients. With this goal in mind, the Centers for Disease Control and Prevention (CDC) released the Guideline for Prescribing Opioids for Chronic Pain in March 2016. To help encourage uptake and use of the guideline, CDC developed a comprehensive implementation plan to move science into action. This session will describe health system opportunities to support guideline-concordant care and showcases how one system integrated the guideline through clinical decision support (CDS) embedded in an electronic health record (EHR). Presenters will share a real-world example of how they developed, tested and launched CDS tools at the point of care in an outpatient primary care setting. Analysis of prescriber response to an alert designed to flag at-risk patients found that prescribers typically acknowledged the alert yet continued the prescription (85%). In 15% of cases, the prescriber cancelled the Rx. In 38% of these cancellations, the patient left the encounter without receiving an opioid. Additionally, the platform alerts prescribers to: co-prescriptions of opioids and benzodiazepines; the need to complete a pain agreement and urine drug screens for patients on opioids more than 90 days; and the use of short-acting opioids for patients not currently on opioids. This approach lays the groundwork for health systems to integrate evidence-based clinical decision-making to support more judicious opioid prescribing. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify health system opportunities to support guideline-concordant care. - Explain how to integrate clinical decision supports into electronic health records. - Describe how provider behavior has been affected by electronic health records alerts.

Meghan Wally

MSPH, Project Manager

Carolinas HealthCare System

Meghan Wally is a Project Manager in the Department of Orthopaedic Surgery at Carolinas HealthCare System. She manages a body of research focused on Rx drug abuse, misuse and diversion and interventions to impact prescribing behavior, improve pain management and optimize patient safety. Wally is a certified health education specialist and a doctoral student in the Department of Public Health Sciences at University of North Carolina at Charlotte.

Jan Losby

PhD, MSW, Team Lead, Prescription Drug Overdose Health Systems Team

Centers for Disease Control and Prevention

Joseph Hsu

MD, Orthopaedic Trauma Surgeon

Carolinas HealthCare System

Joseph Hsu, MD, is Professor of Orthopaedic Trauma Surgeon at Carolinas HealthCare System and has over 10 years of experience as an orthopaedic traumatologist. He has clinical expertise in surgical interventions, limb salvage, orthopaedic infections and fragility fractures. His current research interests are in lower extremity disability, Rx drug overdoses and fall prevention. Hsu has several peer-reviewed publications in the field of orthopaedic trauma and hip fractures, and he has experience working within clinical consortiums at a national and international level. He has extensive experience in the military and civilian organizations with creating and implementing clinical practice guidelines.

Learning Center

Wednesday, April 4, 2018

2018-04-04

Tackling the Opioid Epidemic in Tennessee: Third-Party Payer and Provider Perspectives

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: Amy G. Griffin, JD, Corporate Counsel, Kentucky Employers’ Mutual Insurance CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,APA,NAADAC,NASW,NBCC Effectively addressing the overdose epidemic will require a coordinated effort by all stakeholders, including practitioners and third-party payers. It is imperative that third-party payers and practitioners work together to ensure access to addiction treatment in a manner that reduces patient discrimination, allows for quality care and decreases opportunities for waste, fraud and abuse. In this session, two presentations will demonstrate these dynamics at work in Tennessee — which has one of the nation’s highest rates of Rx painkiller use, with a record number of people dying from opioid overdoses in 2014. Representatives of the state’s largest health insurance carrier, BlueCross BlueShield of Tennessee (BCBST), will explain how the company is demonstrating results through a clinical and social approach to combat the misuse and unintentional overuse of Rx painkillers. To assist lawmakers, regulators, providers, and, most importantly, its members in providing measured solutions to the Rx drug abuse epidemic, BCBST began a focused investigation into Rx drug utilization in the state in 2014. BCBST initiated a multi-prong approach to address this critical issue, and pain management was one of the disciplinary concentration areas. In 2015, BCBST began evaluating its Medicaid population by contracting an organization that specializes in alternatives ways to address pain management. Presenters will outline the Pain Management and Care Improvement Program that has been implemented for BCBST Medicaid members. They will discuss outcome measurements and lessons learned from the pilot program, as well as results of various prescriber education and outreach initiatives. A Tennessee physician, with over a decade of experience, will examine coverage and payment issues that impede access to valuable treatment for individuals with opioid use disorder. He will explain the urgent need for laws and regulations to be up-to-date and flexible to allow the use of new, innovative products, including practitioner-administered medications approved by the U.S. Food and Drug Administration to treat opioid use disorder, as well as to allow new policies and programs to take effect and make a meaningful impact. The speaker will propose practical solutions, including current legislative and regulatory initiatives and reimbursement models that ensure proper care for individuals with opioid use disorder. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe health plan strategies to implement safe prescribing efforts. - Identify the components of the health plan’s Pain Management and Care Improvement Program pilot and various prescriber education initiatives. - Explain outcomes collected and lessons learned from the Pain Management pilot and provider outreach initiatives. - Describe current reimbursement methods and how they are affecting access to addiction treatment. - Explain how some legislative and regulatory efforts have either aimed to, or unintentionally resulted in, a decrease in access to quality, evidence-based addiction treatment. - Outline legislative and regulatory initiatives that could improve care and coverage of treatment for individuals with opioid use disorder.

Cheryl McClatchey

MS, LSPE, Vice President, Behavioral Health Programs

BlueCross BlueShield of Tennessee

Cheryl McClatchey is the Vice President of Behavioral Health for BlueCross BlueShield of Tennessee. She is responsible for management and oversight of the behavioral health product line for all lines of business including the BlueCare Tennessee state government business and the BCBST commercial business. Additionally, she is responsible for developing medical-behavioral integration strategies and appropriate coordination between behavioral health and medical products. McClatchey led BlueCare’s efforts to address the issues of substance use disorders and opioid misuse. Efforts included collaboration with community health providers to bring the Mothers and Infants Sober Together program to a rural Appalachian community, where a large percentage of babies have been born with neonatal abstinence syndrome. This program provided integrated substance abuse services at the rural health clinic. This effort led to the plans for a regional detox center for women addicted to Rx drugs housed at the local hospital. Prior to joining BlueCare Tennessee in 2009, McClatchey spent 23 years in behavioral health positions with various organizations as a clinician, executive and entrepreneur. She earned a bachelor’s degree in psychology from Buena Vista College in Iowa and a master’s degree in clinical psychology from the University of Tennessee at Chattanooga.

Timothy Smyth

President

Catalyst Health Solutions

Dr. Timothy S. Smyth is triple boarded in Addiction Medicine, Pain Medicine and Anesthesiology. He practiced interventional and medical management of chronic pain for 23 years. For the past five years, he has focused exclusively on helping those with addiction to opioids with an emphasis on medically assisted treatment. Smyth is the Medical Director at Overmountain Recovery (OMR), one of the few not-for-profit methadone clinics in the country. OMR is a joint project between East Tennessee State University and Ballad Healthcare (formerly Mountain States Health Alliance). Smyth is also the Medical Director and a founding partner of Catalyst Health Solutions (CHS). CHS is an addiction clinic focusing on the outpatient treatment of addiction using MAT in the form of Buprenorphine. CHS includes among its staff two board-certified addiction psychiatrists and four masters-level addiction counsellors. CHS is one of the first clinics in the area to be licensed by the State of Tennessee Department of Mental Health and Substance Abuse Services.

Robin Cruise

Project Manager, Behavioral Health

BlueCross BlueShield of Tennessee

Robin Cruise is a Behavioral Health Project Manager for BlueCross BlueCross BlueShield of Tennessee (BCBST). She is responsible for managing behavioral health improvement projects related to all lines of business including the BlueCare Tennessee state government business and the BCBST commercial business. Prior to joining BCBST in 2008, she was Program Director at a transitional housing program for homeless women with co-occurring substance use and mental health disorders. She has worked as a clinician at various organizations, including an outpatient substance abuse treatment facility, a residential substance abuse treatment facility and the Louisiana Correctional Institute for Women, a prison housing 1,000-plus female felony offenders. She earned a bachelor’s degree in political science and a master’s degree in social work from Louisiana State University and is a Licensed Clinical Social Worker.

Dunwoody

Wednesday, April 4, 2018

2018-04-04

Extended-Release Naltrexone vs. Buprenorphine-Naloxone: A Comparative Effectiveness Trial

3:45 PM - 5:00 PM

3:45 PM

5:00 PM

Moderator: David Tapp, JD, MS, Judge, 28th Judicial Circuit of Kentucky, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ANCC Extended-release naltrexone (XR-NTX), an opioid antagonist, and buprenorphine-naloxone (BUP-NX), a partial opioid agonist, are medications available for office-based treatment that represent divergent approaches to opioid relapse prevention, i.e. opioid-free versus opioid-maintenance therapies. With respect to the choice between these widely used treatment options, important comparative effectiveness issues — e.g., questions regarding the relative feasibility of initiating treatment, rates of relapse to illicit opioid use, retention in treatment, and overdose and other safety concerns — have not been rigorously addressed. To fill this critical knowledge gap, the National Institute on Drug Abuse National Drug Abuse Treatment Clinical Trials Network conducted a multi-site comparative effectiveness trial with 570 adults admitted to inpatient opioid detoxification centers were randomly assigned to receive monthly XR-NTX or daily BUP-NX for 24 weeks of outpatient treatment. In this session, the presenters will provide an overview of the trial's design and its main treatment effectiveness and safety outcomes. They will describe key secondary findings, including the results of analyses of predictors of treatment success and their implications for patient-treatment matching. Discussion will place the trial's findings in the context of the broader scientific evidence base that supports the use of XR-NTX and BUP-NX and describe how the cumulative evidence might inform the decisions of patients, clinical providers, and healthcare policymakers weighing a choice between these treatment approaches. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe how extended-release naltrexone and buprenorphine differ as opioid use disorder treatments. - Explain the primary and key secondary findings of the National Institute on Drug Abuse National Drug Abuse Treatment Clinical Trials Network comparative effectiveness trial. - Apply lessons learned from the National Institute on Drug Abuse National Drug Abuse Treatment Clinical Trials Network trial and related studies to clinical decision-making.

Joshua Lee

MD, MSc, Professor, Department of Population Health

New York University School of Medicine

Joshua D. Lee, MD, MSc, is an Associate Professor of Population Health and Medicine/General Internal Medicine and Clinical Innovation at the NYU School of Medicine. He is a clinician researcher focused on addiction pharmacotherapies, and is Director of the NYU ABAM Fellowship in Addiction Medicine. His research models the use of addiction pharmacotherapies in primary care as and criminal justice populations. He has conducted multiple National Institutes of Health and other clinical trials examining the use of extended-release naltrexone and buprenorphine opioid treatments in outpatient criminal justice involved-adults, in soon-to-be released jail inmates and in community detox settings.

Edward Nunes

MD, Professor of Psychiatry

Columbia University Medical Center / New York State Psychiatric Institute

Dr. Edward Nunes is a Professor of Psychiatry, and Principal Investigator of the Greater New York Node of the National Institute on Drug Abuse (NIDA) Clinical Trials Network, as well as other NIDA-funded studies on behavioral and medication treatments for substance dependence and related psychiatric disorders. Interests and ongoing studies include treatments for cocaine dependence in general, heroin and other opioid dependence, for nicotine dependence in general, and for addicted patients with co-occurring psychiatric disorders including depression, and post-traumatic stress disorder. Types of treatment under study include medication treatments (naltrexone, buprenorphine, mirtazapine), as well as behavioral and psychotherapeutic approaches and computer-delivered treatments. Nunes also studies the challenges involved in implementing evidence-based treatments for substance use disorders in real-world community-based treatments settings. Nunes serves on the American Board of Addiction Medicine, co-chairs the Columbia/New York State Psychiatric Institute’s Institutional Review Board, and has been appointed to the National Advisory Council on Drug Abuse.

Centennial Ballroom

Wednesday, April 4, 2018

2018-04-04

Plenary Session: Agency Update

5:15 PM - 6:30 PM

5:15 PM

6:30 PM

Representatives from government agencies will provide an update on key initiative and programs.

Anne Hazlett

Assistant to the Secretary for Rural Development

U.S. Department of Agriculture (USDA)

Anne Hazlett serves as the Assistant to the Secretary for Rural Development at the United States Department of Agriculture. An Indiana native, she has a deep and lifelong passion for rural America, small towns and the people who call them home. Anne has worked on agriculture and rural issues for over fifteen years. Serving as legal counsel for the Agriculture Committees in both the U.S. House and Senate, Anne has been an advocate for rural communities on many issues important to rural America from Farm Bill legislation to broadband and nutrition programs. In addition to her service on Capitol Hill, Anne also served as Director of Agriculture for her home state of Indiana and Chief of Staff for Indiana Lt. Governor Becky Skillman. In these key leadership roles, she worked to ensure that Indiana's agriculture industry and rural business sector were a significant part of the state's economic revitalization. At USDA, Anne is leading the Rural Development mission area to create an environment for rural prosperity, from greater access to broadband connectivity and medical care to workforce training through distance learning. In this work, she is particularly passionate about helping families and community leaders touched by the opioid epidemic find hope and partnership in building a brighter future. Hazlett is a graduate of Kansas State University and the Indiana University School of Law. She also holds a master's degree in agricultural law from the University of Arkansas.

Anne Schuchat

MD, (RADM, USPHS), Principal Deputy Director

Centers for Disease Control and Prevention (CDC)

Anne Schuchat, MD, is the acting director for the Centers for Disease Control and Prevention (CDC) and acting administrator of the Agency for Toxic Substances and Disease Registry (ATSDR). Dr. Schuchat has been CDC's principal deputy director since 2015, and she also led CDC as acting director from January-July of 2017. She began her public health career in 1988 when she came to CDC as an Epidemic Intelligence Service officer. She served as the director of CDC's National Center for Immunization and Respiratory Diseases from 2006-2015. Other CDC leadership posts include: acting director of the Center for Global Health (2012-13), acting director of the National Center for Infectious Diseases (2005), and chief of the Respiratory Diseases Branch (1998-2005). Dr. Schuchat was the initial medical director of ABCs – the Active Bacterial Core surveillance of the Emerging Infections Program Network – and spearheaded prevention of newborn infection from group B streptococcal disease in the 1990s. She was promoted to Rear Admiral in the Commissioned Corps of the United States Public Health Service in 2006 and earned a second star in 2010. Dr. Schuchat was elected to the National Academy of Medicine (formerly the Institute of Medicine) in 2008. Dr. Schuchat has played key roles in a number of CDC emergency responses. Most notably, she served as Chief Health Officer for CDC's 2009 H1N1 pandemic influenza response; led the CDC team responding to the SARS outbreak in Beijing in 2003; and supported the Washington D.C. field team during the 2001 bioterrorist anthrax response. Globally, Dr. Schuchat has worked in West Africa on meningitis, pneumonia, and Ebola vaccine trials; in South Africa on surveillance and prevention projects, and represented technical and health research institutes on the GAVI Alliance board. She has authored or co-authored more than 230 scientific articles, book chapters, and reviews. Her contributions have been recognized by receipt of USPHS Meritorious Service Medals, the American Public Health Association's Maternal and Child Health Young Investigator Award, the USPHS Physician Research Officer of the Year, and an Honorary Doctorate in Science from Swarthmore College. Dr. Schuchat graduated with highest honors from Swarthmore College and with honors from the Geisel School of Medicine at Dartmouth and completed her residency and chief residency in internal medicine at NYU's Manhattan VA Hospital.

Elinore F. McCance-Katz

MD, PhD, Assistant Secretary

Substance Abuse and Mental Health Services Administration (SAMHSA)

Elinore McCance-Katz, MD, PhD, is the first Assistant Secretary for Mental Health and Substance Use. She obtained her PhD from Yale University with a specialty in Infectious Disease Epidemiology and is a graduate of the University of Connecticut School of Medicine. She is board certified in General Psychiatry and in Addiction Psychiatry. She is a Distinguished Fellow of the American Academy of Addiction Psychiatry with more than 25 years as a clinician, teacher, and clinical researcher. Most recently she served as the Chief Medical Officer for the Rhode Island Department of Behavioral Healthcare, Developmental Disabilities and Hospitals and as the Chief Medical Officer for the Eleanor Slater Hospital system which is Rhode Island's state resource for patients with the most serious mental illnesses and medical illnesses requiring long term, inpatient care. She was also Professor of Psychiatry and Human Behavior at Brown University. Previously, she served as the first Chief Medical Officer for the Substance Abuse and Mental Health Services Administration (SAMHSA). Prior to coming to SAMHSA, she served at the University of California, San Francisco as a Professor of Psychiatry, as the Medical Director for the California Department of Alcohol and Drug Programs, and as the Medical Director of SAMHSA's Clinical Support Systems for Buprenorphine (PCSS-B) and Opioids (PCSS-O). Dr. McCance-Katz has published extensively in the areas of clinical pharmacology, medications development for substance use disorders, drug-drug interactions, addiction psychiatry, and treatment of HIV infection in drug users. She served on the World Health Organization (WHO) committee that developed guidelines on the treatment of drug users living with HIV/AIDS. She has been a national leader in addressing the overprescribing of opioid analgesics and in providing consultation on management of patients with chronic pain and opioid overuse. She was a participant in the development of SAMHSA TIP 40 which provided the initial guidance to physicians utilizing buprenorphine in the treatment of opioid use disorder, contributed to the development and maintenance of the legislatively required 8 hours of physician training for prescribing buprenorphine products and has continued to be actively involved in the development and delivery of physician training on office-based treatment of opioid use disorders. She has been one of the architects of Rhode Island's plan for addressing the opioid epidemic including new approaches to treatment in the form of a statewide system of Centers of Excellence in the treatment of opioid use disorder, new approaches to training in the utilization of DATA 2000 (Drug Abuse Treatment Act of 2000) to bring DATA waiver training to medical students, and going forward, nurse practitioner and physician assistant students, and legislative/regulatory work addressing safe use of opioids in acute pain.

Scott Gottlieb

MD, Commissioner

Food and Drug Administration (FDA)

Scott Gottlieb, MD, was sworn in as the 23rd Commissioner of Food and Drugs on May 10, 2017. Dr. Gottlieb is a physician, medical policy expert, and public health advocate who previously served as the FDA's Deputy Commissioner for Medical and Scientific Affairs and before that, as a senior advisor to the FDA Commissioner. He also worked on implementation of the Medicare drug benefit as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he supported policy work on quality improvement and the agency's coverage process, particularly as it related to new medical technologies. In 2013 Dr. Gottlieb was appointed by the Senate to serve on the Federal Health Information Technology Policy Committee, which advises the Department of Health and Human Services on healthcare information technology. Dr. Gottlieb was previously a Resident Fellow at the American Enterprise Institute, and a Clinical Assistant Professor at the New York University School of Medicine in Manhattan, where he also practiced medicine as a hospitalist physician. He completed a residency in internal medicine at the Mount Sinai Medical Center in New York, New York and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University, in Middletown, Connecticut, where he studied Economics.

Centennial Ballroom

Wednesday, April 4, 2018

2018-04-04

Bill Clinton, 42nd President of the United States

6:30 PM - 7:30 PM

6:30 PM

7:30 PM

President Bill Clinton will be addressing the Rx Summit at 6:30 pm on April 4, 2018. William Jefferson Clinton, the first Democratic president in six decades to be elected twice, led the United States to the longest economic expansion in American history, including the creation of more than 22 million jobs. After leaving the White House, President Clinton established the Clinton Foundation in order to continue working on the causes he cared about. Since its founding, the Foundation has endeavored to help build more resilient communities by developing and implementing programs that improve people’s health, strengthen local economies, and protect the environment. President Clinton and the Clinton Foundation have been at the forefront of the fight against the opioid epidemic since 2012. The Clinton Health Matters Initiative works to save lives, alleviate suffering and reduce the stigma facing victims and families of opioid use disorder. The Foundation provides training and resources to communities to fight addiction; brings partners together to discuss and implement solutions; and works to prevent overdose deaths by making the life-saving opioid-reversal drug, naloxone, more widely accessible and at a lower cost. Above all, President Clinton has always believed that we can do more together than any of us can do on our own. In 2005, he founded the Clinton Global Initiative to foster partnerships among governments, businesses, nongovernmental organizations and private citizens to turn good ideas into measurable results. To date, over 3,600 CGI commitments have already improved the lives of more than 435 million people in more than 180 countries. CGI’s work continues through these ongoing commitments and through the Clinton Global Initiative University which this year, celebrates 10 years of bringing together college and university students from every corner of the globe to turn good ideas into action. President Clinton was born on August 19, 1946, in Hope, Arkansas. He and his wife Secretary Hillary Rodham Clinton have one daughter, Chelsea; two grandchildren, and live in Chappaqua, New York.

Dunwoody

Wednesday, April 4, 2018

2018-04-04

Open Meeting

8:00 PM - 10:00 PM

8:00 PM

10:00 PM

Open Meeting

Terrace Foyer

Thursday, April 5, 2018

2018-04-05

Conference Registration

7:00 AM - 12:00 PM

7:00 AM

12:00 PM

Conference Registration

Thursday, April 5, 2018

2018-04-05

Coffee

7:00 AM - 8:00 AM

7:00 AM

8:00 AM

Coffee

Centennial Ballroom

Thursday, April 5, 2018

2018-04-05

Plenary Session

8:15 AM - 9:30 AM

8:15 AM

9:30 AM

Jerome Adams

MD, MPH, VADM Surgeon General

U.S. Department of Health & Human Services

Jerome M. Adams, MD, MPH, the 20th Surgeon General of the United States, was sworn into office by Vice President Mike Pence on September 5, 2017. Dr. Adams, a board-certified anesthesiologist, served as Indiana State Health Commissioner from 2014 to 2017. Dr. Adams, a Maryland native, has bachelor's degrees in both biochemistry and psychology from the University of Maryland, Baltimore County, a master of public health degree from the University of California at Berkeley, and a medical degree from Indiana University School of Medicine. Dr. Adams was also an associate professor of clinical anesthesia at Indiana University School of Medicine and a staff anesthesiologist at Eskenazi Health, where he was Chair of the Pharmacy and Therapeutics Committee. He has served in leadership positions at a number of professional organizations, including the American Medical Association, the Indiana State Medical Association and the Indiana Society of Anesthesiologists. He is the immediate past Chair of the Professional Diversity Committee for the American Society of Anesthesiologists. As Health Commissioner, Dr. Adams presided over Indiana's efforts to deal with the state's unprecedented HIV outbreak. In this capacity, he worked directly with the Centers for Disease Control and Prevention, as well as with state and local health officials and community leaders, and brought the widest range of resources, policies and care available to stem the epidemic affecting that community. He also helped with the successful launch of Indiana's state-based, consumer-driven alternative to Medicaid expansion and worked with the state legislature to secure more than $10 million to combat infant mortality in high-risk areas of the state. Dr. Adams' motto as Surgeon General is "better health through better partnerships." As Surgeon General, Dr. Adams is committed to maintaining strong relationships with the public health community and forging new partnerships with non-traditional partners, including business and law enforcement. He has pledged to lead with science, facilitate locally led solutions to the nation's most difficult health problems, and deliver higher quality healthcare at lower cost through patient and community engagement and better prevention. As Surgeon General, Dr. Adams oversees the operations of the U.S. Public Health Service Commissioned Corps, which has approximately 6,500 uniformed health officers who serve in nearly 600 locations around the world to promote, protect and advance the health and safety of our nation and our world.

Thursday, April 5, 2018

2018-04-05

The 5th Annual SAM (Smart Approaches to Marijuana) Marijuana Education Summit

8:15 AM - 5:00 PM

8:15 AM

5:00 PM

Project SAM’s leaders are among the world’s most prominent voices calling for science-based marijuana education and awareness.

International South

Thursday, April 5, 2018

2018-04-05

SAM President's Opening Keynote

9:00 AM - 9:30 AM

9:00 AM

9:30 AM

Details TBA

Kevin Sabet

President and CEO

Smart Approaches to Marijuana (SAM)

Kevin A. Sabet, PhD, is an author, consultant, former advisor to three U.S. presidential administrations and assistant professor, and he serves as the President and CEO of SAM, which he founded with former Congressman Patrick Kennedy in 2013. He has studied, researched, written about and implemented drug policy for almost 20 years. He has worked in the Clinton (2000) and Bush (2002-2003) administrations, and in 2011 he stepped down after serving more than two years as the senior advisor to President Obama's drug control director, having been the only drug policy staffer to have ever served as a political appointee in a Democrat and Republican administration. He since has appeared at the Aspen Ideas and New Yorker festivals, on the Organization of American States blue ribbon commission advising hemispheric drug policy, and in hundreds of forums and discussions promoting the ideas outlined in his first book, "Reefer Sanity: Seven Great Myths About Marijuana," published by Beaufort. He has been featured on the front page of the New York Times and in virtually every major media publication and news channel on the subject of drug policy.

International South

Thursday, April 5, 2018

2018-04-05

Bishop Jethro James - Community Impacts from the Front Lines

9:30 AM - 9:50 AM

9:30 AM

9:50 AM

Details TBA

International South

Thursday, April 5, 2018

2018-04-05

Federal Keynote

9:50 AM - 10:30 AM

9:50 AM

10:30 AM

Details TBA

Piedmont

Thursday, April 5, 2018

2018-04-05

How to Talk to the Media About Heroin

10:00 AM - 11:15 AM

10:00 AM

11:15 AM

Moderator: Julie Miller, Editor in Chief, Behavioral Healthcare Executive and Addiction Professional CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,APA,MCHES,GA Bar, GA POST, NAADAC,NASW,NBCC Chances are you are already doing great work -- work that’s even news worthy. Chances are also good it’s not getting the media coverage you’re expecting. Even worse, sometimes your “good news story” may be dwarfed by tragic headlines or negative stats. Let an award-winning team of journalists help you focus your media message to spotlight the positive efforts your group is working to achieve.  Jeremy Campbell and Erin Gutierrez of WXIA, the Atlanta NBC affiliate, are creators of “The Triangle,” a documentary news series that exposed the dramatic increase in heroin-related deaths in Atlanta’s suburbs and investigated potential solutions to the crisis. The series was viewed more than 10 million times in one year. This session will be a rare opportunity for Rx Summit participants to gain insights from media representatives. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify the types of stories journalists will cover.  - Design your pitch to help get coverage when you need it. - Explain ways to connect with the media in a positive way for the community.

Jeremy Campbell

Reporter

WXIA Tegna, Inc.

Jeremy Campbell is a reporter with a decade’s worth of experience at small and large market stations.  He and Erin Gutierrez are the creators of “The Triangle,” a documentary news series that exposed the dramatic increase in heroin related deaths in Atlanta’s suburbs and investigated potential solutions to the crisis.  Their work together has been honored with six Emmy Awards, a Murrow Award for Innovation and the National Association of Broadcaster’s President’s Award. 

Erin Gutierrez

Executive Producer

WXIA Tegna, Inc.

Erin Gutierrez is a producer whose background spans from overseeing local newscasts to crafting coverage for CNN. Gutierrez and Jeremy Campbell are the creators of “The Triangle,” a documentary news series that exposed the dramatic increase in heroin related deaths in Atlanta’s suburbs and investigated potential solutions to the crisis.  Their work together has been honored with six Emmy Awards, a Murrow Award for Innovation and the National Association of Broadcaster’s President’s Award. 

Hanover AB

Thursday, April 5, 2018

2018-04-05

Hospitals in Action: Creating Safer Post-Operative Management to Reduce Opioid-Related Harm

10:00 AM - 11:15 AM

10:00 AM

11:15 AM

Moderator: Carla S. Saunders, DNP, APRN, NNP-BC, Advance Practice Coordinator, Pediatrix Medical Group, Neonatal Nurse Practitioner, East Tennessee Children’s Hospital, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ADA,ANCC A recent study found 5% to 6% of patients who did not use opioids prior to surgery continued to fill prescriptions for opioids long after what would be considered normal surgical recovery. This session will feature a groundbreaking, national opioid safety pilot with hospitals to make care safer and reduce patient harm from opioid misuse, dependence and addiction. Presenters will explain the program and share challenges and best practices gleaned from the pilot and highlight key results. The American Society of Anesthesiologists and Premier, Inc., collaborated to launch the pilot through Premier’s Hospital Improvement Innovation Network, which is part of the Centers for Medicaid and Medicare Services Partnership for Patients program. The effort has enlisted around 30 hospitals and is focused on measurably improving post-operative opioid pain management. The pilot’s focus is on adult patients undergoing elective hip and knee arthroplasty and colectomy surgical procedures. Participants have worked to redesign their existing best practices/workflows with new pain management strategies in effort to ensure safer patient care when using opioid medications. This includes partnering with patients and families on pain management expectations and education on the safe use, storage and disposal of opioids, and prevention of opioid misuse and abuse post discharge. Clinicians at participating hospitals were educated on appropriate opioid screening, prescribing, dispensing and administration. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe a unique program geared toward hospitals and health systems to decrease opioid use in the post-surgical setting for patients undergoing common surgeries. - Summarize the preliminary findings related to the pilot program and what this means to hospitals and the overall impact on the national opioid epidemic. - Explain the systematic planning, data collection, use of standardized processes/outcomes, harm and cost avoidance measures, peer-to-peer learning, and continuous monitoring, evaluation and refinement of implemented strategies that drove the results of this program.

Roshni Ghosh

MD, MPH, Vice President and Chief Medical Information Officer

Premier, Inc.

Dr. Roshni Ghosh had more than 15 years of experience in healthcare, with a focus on the delivery of care, health outcomes, health quality and population health management, with a focus on change management, clinical workflow design and business process reengineering skills and overall quality improvement. Ghosh has extensive experience analyzing trends in health information technology development and health informatics to increase efficiencies in patient care as well as improve quality and access to care while decreasing costs. Prior to joining Premier, Ghosh served as the Chief Medical Information Officer for Deloitte’s federal health practice. There she drove health analytics and reform, care coordination and population health across all major federal health agencies, the Military Health System and Veteran’s Affairs, as well as in the commercial marketplace. As a SME and a certified Project Management Professional, she also managed the development and deployment of the Department of Defense’s global electronic health record system, as well as the Joint Interagency Program’s clinical informatics and requirements department. At Premier, Ghosh is a VP, Chief Medical Information Officer, as well as Premier’s Government Services Lead. She is also the Program Director for Premier’s Hospital Improvement Innovation Network for the Centers for Medicaid and Medicare Services. In addition, Ghosh is spearheading numerous opioid focused pilots and initiatives at Premier focusing on different aspects of the crisis, specifically around pharmacy data and quality, safety and quality outcomes, and the patient experience. Ghosh, an adjunct professor at George Washington University, earned her medical degree from Rutgers University and her master’s in public health from Columbia University.

Lynda Martin

RN, BSN, MPA, Senior Director Clinical Operations, Government Services

Premier, Inc.

Lynda Martin is a registered nurse with more than 25 years of senior leadership and management experience in the healthcare quality, patient safety, performance improvement, infection prevention, pay-for-performance, federal contracting, regulatory and accreditation arenas. She has experience with developing innovative quality, patient safety and performance improvement programs to drive advances across the care continuum, as well as directing large-scale initiatives and engaging cross-functional teams to achieve safe, quality, cost-effective outcomes. She is skilled at establishing strategic relationships. At Premier, Martin is the director of clinical operations and the director of Premier’s Hospital Improvement Innovation Network (HIIN), a prime contractor HIIN for the Centers for Medicaid and Medicare Services Partnership for Patients program. She has responsibilities for leadership, development and execution of the clinical assessment and quality improvement strategy for the Premier HIIN program. This includes oversight of the clinical and technical assistance provided to hospitals for improving clinical processes, culture, patient safety and infection prevention and for the engaging of senior leaders, patients and families to reduce preventable harm and readmissions and improve the patient experience across the care continuum.

Asokumar Buvanendran

MD, Professor, Department of Anesthesiology, Rush University Medical Center

Committee on Pain Medicine Chair, American Society of Anesthesiologists

Dr. Asokumar Buvanendran is an anesthesiologist specializing in pain medicine, Chair of the American Society of Anesthesiologists Pain Committee, and President of the American Society of Regional Anesthesia and Pain Medicine. He dedicates time to research and teaching, including clinical duties in the Rush University Department of Anesthesiology and national advocacy for advancement in pain care. He was a reviewer of the CDC Guideline for Prescribing Opioids for Chronic Pain. At Rush, Buvanendran is William Gottschalk, Endowed Chair of Anesthesiology, Vice Chair of Research, Director of Orthopedic Anesthesia, and Professor in the Department of Anesthesiology. He brings a unique perspective, with a very busy clinical practice of acute and chronic interventional pain medicine with research. While a large focus of his practice is on chronic pain patients, his department also has a collaborative agreement with the Department of Orthopedics, where they foster treatment modalities before patients have surgery—improving both postoperative pain for patients and outcomes. He was one of the early pioneer researchers in multimodal analgesia for orthopedic surgery with key publications in JAMA. Buvanendran has also served as Medical Director for Enhanced Recovery After Surgery and Co-Director of the Anesthesiology Research Clerkship at Rush.

International North

Thursday, April 5, 2018

2018-04-05

Addressing the Opioid Crisis Begins at the Border

10:00 AM - 11:15 AM

10:00 AM

11:15 AM

Moderator: Richard W. Sanders, MSCJ, Commissioner, Kentucky State Police, and Member, Operation UNITE Board of Directors CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,APA,CHES,GA Bar,GA POST,NAADAC,NASW,NBCC The increase in opioid-related deaths in the United States in the last three years has largely been driven by the rapid proliferation of illicit synthetic opioids such as fentanyl and various fentanyl analogs. This session features two presentations about the federal government’s response, particularly at the nation’s borders. The first presenter will provide the big picture. The federal government is pursuing a broad range of public health interventions to track and mitigate this crisis. In addition, the federal government is engaging in multilateral and bilateral international engagements in the pursuit of controlling the production and flow of synthetic opioids. This presentation will briefly describe the latest epidemiology and trends, the economic drivers of illicit fentanyl, international control efforts, and the federal public health response. The next presenter will address that the majority of illegal opioids consumed in the United Stated are smuggled into the country via the southwest border or come in through mail or express consignment hubs. U.S. Customs and Border Protection (CBP) is the federal agency responsible for securing the border and protecting the public from dangerous people and materials. The opioid epidemic is a threat to the American people; as such, CBP is fully engaged in stemming the flow of illicit drugs into the county. The presenter will explain that CBP’s efforts to combat this crisis has three main components: international engagement with the countries from which these drugs originate and with other countries experiencing this epidemic; counter network operations using sound data and tracking; and border interdiction driven by intelligence and enhanced technology. Essential to the fight against opioids is also the responsibility to keep CBP officers and agents safe through training and equipment. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe current epidemiological trends related to synthetic opioids. - Discuss the economics of illicit fentanyl. - Outline international control efforts. - Identify federal public health strategies to address this growing threat. - Explain the critical role of the U.S. Customs and Border Protection (CBP) in combating illegal opioid smuggling. - Identify the major elements of CBP strategy to combat the flow of illicit drugs. - Discuss how can state and local partners and CBP work together to stem the opioid crisis.

Stephen D. McConachie

Chief Operations Manager

U.S. Customs and Border Protection

Stephen D. McConachie is a Chief Operations Manager at U.S. Customs and Border Protection Headquarters in Washington, D.C. He manages programs involving Counternarcotics, Weapons of Mass Destruction, and Medical Countermeasures. He also serves as the Senior Liaison to the White House Office of National Drug Control Policy. McConachie became a U.S. Customs Inspector in 1999. He has been a volunteer firefighter since he was 16, and has served as Captain of an engine company and as Commander of the Allegheny County Hazardous Materials “Silver Team.” He has also served as President of the Pennsylvania Association of HazMat Technicians. McConachie has developed and taught courses for the Allegheny County Fire Academy, and had articles published in Firehouse Magazine and the Journal of Emergency Medical Services. A native of Pittsburgh, Pennsylvania, McConachie is a graduate of West Liberty University and is a certified Master Exercise Practitioner.

Christopher M. Jones

PharmD, MPH, Director, National Mental Health and Substance Use Policy Laboratory

Substance Abuse and Mental Health Services Administration, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board

Dr. Christopher M. Jones currently serves as the Director of the National Mental Health and Substance Use Policy Laboratory at the Substance Abuse and Mental Health Services Administration (SAMHSA). Prior to joining SAMHSA, he served as Acting Associate Deputy Assistant Secretary for Science and Data Policy and Director of the Division of Science Policy in the Office of the Assistant Secretary for Planning and Evaluation (ASPE) at the U.S. Department of Health and Human Services. The Office of Science and Data Policy is the HHS focal point for policy research, analysis, evaluation, and coordination of public health, science, and data policy activities, and provides authoritative advice and analytical support to HHS leadership on public health, science, and data policy issues and initiatives. Jones also has served as Senior Advisor in the Office of the Commissioner at the U.S. Food and Drug Administration (FDA) and led the Centers for Disease Control and Prevention’s (CDC) drug abuse and overdose activities, where he focused on strategic policy development and implementation, engaging national and state partners, and conducting research to improve policy and clinical practice. During his career, Jones has served as Senior Public Health Advisor to the White House Office of National Drug Control Policy, led the FDA’s Drug Safety and Risk Communication team, and served on the Science Team in the CDC’s Strategic National Stockpile. He received his bachelor's degree from Reinhart College, his doctorate degree in pharmacy from Mercer University, and his master's degree in public health from New York Medical College, and he is currently completing his doctorate degree in public health at The George Washington University Milken Institute School of Public Health. Jones has authored more than 50 peer-reviewed publications on the topic of drug abuse and overdose. Jones is a member of the National Rx Drug Abuse & Heroin Summit Advisory Board.

Hanover FG

Thursday, April 5, 2018

2018-04-05

Best Treatment Practices in Correctional Settings: From Pre-Diversion to Parole

10:00 AM - 11:15 AM

10:00 AM

11:15 AM

Moderator: J. Kevin Massey, Health Administrator, Correct Care Solutions CE Certified By: ACPE,AAFP,AMA,ANCC,APA,GA Bar,GA POST,NAADAC,NASW,NBCC One part of all communities with high potential to impact the opioid death rates is the correctional system. Last year in Connecticut, 52% of people who died of an overdose had been through the state’s correctional system. Substance use affects more than 50% of people entering New York City’s correctional facilities, and from 2011 until 2016, approximately 30,000 individuals were diagnosed with active opioid use disorder. In this session, physician members of the American Society of Addiction Medicine (ASAM) and the American Correctional Association (ACA) will discuss the challenges and opportunities in implementing best practices in correctional systems, based on their knowledge and experience providing addiction medical care within these systems. In addition, the presenters will discuss ASAM and ACA’s joint initiative of delineating the pillars of appropriate cost-effective interventions for treatment that cover the whole continuum from pre-diversion to parole. Participants should leave with an understanding of: 1) the pillars of what evidence-based care looks like for the chronic disease of addiction; 2) the current treatment landscape in our correctional system; and 3) how to move forward in addressing opioid addiction in their community’s correctional system. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the current treatment landscape of opioid addiction in the correctional system. - Outline evidence-based practices in correctional settings. - Identify the challenges and opportunities in implementing best practices in the correctional system.

Kathleen Maurer

MD, MPH, MBA, Medical Director and Director of Health Services

Connecticut Department of Correction

Dr. Kathleen Maurer is the Connecticut Department of Correction (DOC) Director of Health and Addiction Services and Medical Director. Before assuming her current post in 2011, she was Assistant Medical Director at Correctional Managed Health Care, a division of the University of Connecticut Health Center, which contracts with the state corrections department for offender medical care. During her career, Maurer has provided hands-on clinical care and medical program management in the private sector. In the realm of correctional care, she is particularly interested in the role of correctional healthcare in the broader scope of public health, such as in the treatment of Hepatitis C Virus in offender-patients. Her recent initiatives include working to expand Medicaid access to halfway house residents and integrate Medicaid utilization management with the correctional system. She is developing a system-wide medication assisted treatment program for the Connecticut DOC. Maurer earned her medical degree from Yale University School of Medicine. She earned an master's in public health degree from Yale. She holds an master's in business administration degree from the University of Connecticut and is board-certified in internal medicine, occupational and environmental medicine, and addiction medicine. She recently was awarded the Coalition of Correctional Health Authorities national award for Leadership in Correctional Healthcare.

Lipi Roy

Medical Director

Kingsboro Addiction Treatment Center, New York State Office of Alcoholism and Substance Abuse Services

Dr. Roy is a physician board certified in addiction medicine and clinical assistant professor at NYU School of Medicine. She is currently the Medical Director of New York City’s Kingsboro Addiction Treatment Center, operated by New York State Office of Alcoholism and Substance Abuse Services. As the former Chief of Addiction Medicine for NYC jails including Rikers Island, Dr. Roy oversaw substance use treatment and recovery services for the city’s incarcerated men and women. Previously, she was a primary care doctor to Boston's vulnerable homeless population, among whom the leading cause of death was drug overdose; served as an attending physician at Massachusetts General Hospital; and faculty at Harvard Medical School. She completed her MD and MPH degrees at Tulane University, followed by internal medicine training at Duke University. A longtime advocate for public service, she served the underserved in Nicaragua and India; New Orleans residents affected by Hurricane Katrina; and provided medical relief to earthquake victims in Haiti and Boston Marathon runners.

Courtland

Thursday, April 5, 2018

2018-04-05

I’ve Got 99 Problems and a Centralized Medical Examiner System Isn’t One: Partnering with C/MEs

10:00 AM - 11:15 AM

10:00 AM

11:15 AM

Moderator: Sarah Bacon, PhD, Team Lead, State Opioid Overdose Prevention State Support Team, Centers for Disease Control and Prevention CE Certified By: AMA,AAFP In 2016, Missouri began participating in two surveillance programs funded by the Centers for Disease Control and Prevention: Enhanced State Opioid Overdose Surveillance (ESOOS) and National Violent Death Reporting System (NVDRS). While the overall goals of the two programs are different, both require the identification of deaths due to specific causes via death certificates, followed by the acquisition and linkage to data from coroners and medical examiners (C/MEs). In the first year of ESOOS and NVDRS implementation, the Missouri Department of Health and Senior Services encountered lessons learned that would be valuable to share as ESOOS is expanded and other states begin participating. Presenters will identify barriers related to hiring staff, writing a contract for C/ME reimbursement, C/ME outreach and obtaining records in a timely fashion to meet CDC deadlines. They will explain how the obstacles were overcome as ESOOS and NVDRS staff worked closely together, along with other department staff, C/MEs, and the Missouri Coroners’ and Medical Examiners’ Association. Now in the second year, the department plans to expand participation throughout the state and follow through on lessons learned. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Describe the coroner/medical examiner system in Missouri, provide brief descriptions of ESOOS and NVDRS, and list the requirements to participate in each of these programs. - Describe the process and activities MODHSS conducted in order to implement both programs simultaneously and garner support within the C/ME community. - Identify activities completed, lessons learned and next steps in implementation of ESOOS and NVDRS.

Tanner Turley

Research Analyst

Missouri Department of Health and Senior Services

Tanner Turley is a Research Analyst II with the Bureau of Health Care Analysis and Data Dissemination within the Department of Health and Senior Services for the State of Missouri. He’s been in his current position since April 2017, but has been with the state of Missouri since January 2016, having worked as a Research Analyst I with the Department of Economic Development on the Occupational Employment Statistics program. In his current role, Turley abstracts various data elements from Coroner/Medical Examiner Narratives, toxicology reports and death certificates for deaths that are ruled as opioid overdoses. He enters that information into a Centers for Disease Control and Prevention web-based application as part of the Enhanced State Opioid Overdose Surveillance program.

Evan Mobley

MS, Research Analyst

Missouri Department of Health and Senior Services

Evan Mobley is the Project Manager for the Enhanced Surveillance of Opioid-Involved Morbidity and Mortality grant for the state of Missouri. In this position, he oversees data abstraction into the Centers for Disease Control and Prevention database, writes grant reports and responds to opioid-related data requests. He has worked as a research analyst at Missouri Department of Health and Senior Services since 2013 analyzing birth, death, hospital and home visiting data. He received a master's degree in criminal justice from the University of Central Missouri in 2013.

Centennial Ballroom

Thursday, April 5, 2018

2018-04-05

Prevention for Youth, by Youth

10:00 AM - 11:15 AM

10:00 AM

11:15 AM

Moderator: Karen H. Perry, Co-Founder and Executive Director, Narcotics Overdose Prevention and Education (NOPE) Task Force, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: ACPE,AAFP,ADA,AMA,ANCC,APA,MCHES,NASW,NBCC By the 12th grade, about half of adolescents have abused an illicit drug at least once, according to the annual Monitoring the Future national survey. Since young people have a strong influence on their peers, shaping that influence in a positive way can bring powerful and lasting change. This session will feature two presentations about raising up youth leaders to be vital players within prevention efforts. The Georgia Prevention Project’s Teen Advisory Council (TAC) program is modeled after Community Anti-Drug Coalitions of America's National Youth Leadership Initiative. The TAC aims to strengthen the skills and capacity of young people to effect positive change in their communities. The presentation will discuss how to use evidenced-based strategies that empower youth to make healthy decisions and take the lead on prevention efforts. Presenters will highlight how TAC members lead “Not Prescribed” — an innovative, evidenced-based online Rx drug abuse prevention lesson — with their peers. A TAC member will share personal experiences and tips for adult supporters. The second presentation is designed for professionals who work with students in the prevention of substance abuse, bullying and other adolescent problem behaviors. Information will be shared on the blending of three prevention models: 40 Developmental Assets, Youth Survey data and Positive Community Social Norms (Positive Messaging Campaigns). The session will share best practices on how to develop student leadership councils, facilitate student leadership, and organize schoolwide events and activities designed to reduce substance abuse and create a more positive school climate. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Distinguish among communication styles and appropriateness for different audiences. - Describe youth voices and how social media can be utilized in prevention messaging. - Identify the influences that impact youth decisions. - Explain how to engage youth in the prevention planning process. - Recognize how youth data, protective factors and social norms work together in prevention. - Use planning templates and other materials to engage youth in prevention planning.

Kaitlin Merchen

MSW, Director of Programs

Georgia Prevention Project

Kaitlin Merchen is the Director of Programs for the Georgia Prevention Project. She provides oversight of the Georgia Meth Project, Georgia Rx Abuse Project and all community outreach programs. The Teen Advisory Council program and the College Prevention Partnership program are two such programs, both focusing on peer-to-peer education. Before joining the Georgia Prevention Project, Merchen was a Peace Corps Volunteer. She spent two years in Mozambique, Africa, working on education and community development projects that emphasized sustainability and community empowerment. She has many years of experience working with teens and young adults. Merchen earned her master's degree in social work from Georgia State University at the Andrew Young School of Policy Studies and her undergraduate degree in English from the University of Georgia.

Joe Markiewicz

Senior Consultant

Building Stronger Communities

Joe Markiewicz is the Senior Consultant at Building Stronger Communities. Recently, he was the Program Coordinator for the Statewide Prescription Drug Overdose Reduction Initiative at the University of Kentucky. He has over 20 years' experience as a community coalition trainer, prevention planner, evaluator and youth trainer. He has been a presenter at national conferences on the subject of risk and protective factors, evidenced-based prevention strategies, youth data, community planning and positive social norming. In 2012, Markiewicz received the Erie County Award for Youth Violence Reduction and as Chair of the Erie County Collaborative Board he received the Statewide Community Coalition of the Year Award in Pennsylvania. In his previous employment, Markiewicz was a statewide planner and trainer with the Center for Juvenile Justice Training & Research, Pennsylvania Commission on Crime and Delinquency, and Juvenile Court Judge’s Commission, as well as many other youth-serving organizations. He is also a national technical assistant for the Office of Juvenile Justice Training & Research (OJJTR).

Cydney Maddox

Member, Teen Advisory Council

Georgia Prevention Project

Cydney Maddox is a senior at Lassiter High School, and she is President of the school's Teen Advisory Council (TAC) chapter. In her own words: "In TAC, we implement community level change strategies to combat the growing rate of prescription drug abuse and addiction in our community. Ever since I first got involved in TAC during my sophomore year, I have been able to make a tremendous difference in the lives of my neighbors and peers. My passion for prevention stems from Kaitlin Merchan’s and Connor Nettels’s belief that individual students can be leaders and make a difference. Drug prevention is so important to me personally, that is the subject of my Gold Award. Outside of school, I like to serve my community in Girl Scouts and learn about languages and cultures. I hope to attend Hampton University this fall, majoring in international studies and minoring in Spanish."

Learning Center

Thursday, April 5, 2018

2018-04-05

Workers’ Comp: Opioid Use Trends and Effective Population Health Management

10:00 AM - 11:15 AM

10:00 AM

11:15 AM

Moderator: Greg Hamlin, Director of Claims, Kentucky Employers’ Mutual Insurance CE Certified By: AMA,AAFP,ANCC,NASW This session features two presentations to inform the workers’ compensation industry in its responses to the opioid epidemic. The Workers Compensation Research Institute will present its latest findings on interstate variations and trends in opioid use among injured workers across 26 state workers compensation systems. The presentation will explore how often injured workers across these states received opioids on a chronic basis, at daily doses exceeding guideline recommendations, and concomitantly with other sedating drugs such as benzodiazepines. These high-risk utilization patterns may be potential markers of likelihood of physician dependence, addiction and overdose deaths. The presentation also will highlight injury, worker and employer characteristics associated with higher opioid utilization. Specifically for patients who have undergone work-related injury, it is important to consider the unique characteristics, challenges and risks inherent to workers’ comp populations. Presenters will explain how aggregation and transformation of big data into smart data — combined with systematically applied innovative clinical logic — can reduce drug therapy risks, expose gaps in care and present stakeholders with a complete view of relevant information about their injured workers, dramatically increasing awareness and helping them act on what matters. Attendees will learn how clinical and business intelligence and data strategies can be applied to support the challenges of population health management and its role in improving the care and safety of injured workers. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify which state workers’ compensation jurisdictions had higher or lower opioid utilization and higher prevalence of high-risk utilization patterns. - Identify states where opioid use among injured workers decreased in the early part of this decade and discuss the policy context in which these changes occurred. - Distinguish how opioid utilization varies by different injury, worker and employer characteristics. - Define key attributes in the workers’ comp population, e.g, risk factors, conditions and gaps in care. - Explain how to tailor and apply practical strategies that will improve care delivery in the population. - Recognize how analytics can drive population health strategy to support data-driven decision-making.

Silvia Sacalis

PharmD, Vice President, Clinical Services

Healthesystems

Silvia Sacalis, PharmD, provides clinical leadership as Vice President of Clinical Services at Healthesystems. Her experience and clinical expertise span the pharmacy benefit manager (PBM), retail pharmacy and managed care environments. Leveraging her technology background, clinical skills and management expertise, she helps develop and operationalize strategic clinical initiatives to help workers’ compensation insurance payers maximize the impact of a PBM program. Throughout her career, she has held various leadership roles in which she provided oversight of the development of clinical services programs and integration of analytics technology with clinical consultative support. Sacalis received her bachelor's degree in computer science and doctorate degree in pharmacy from the University of Illinois at Chicago.

Adam Seidner

MD, MPH, Chief Medical Officer

The Hartford

Adam L. Seidner, MD, MPH, is the Global Medical Director at Travelers Insurance Company in Hartford, Connecticut. Since 1997 he has been responsible for technology assessment, pharmacy benefit development, quality assurance and improvement, as well as medical policy development. He received his medical degree from the State University of New York at Syracuse. He completed residencies and is board certified in Occupational & Environmental Medicine and Family Medicine. He has also received a Master of Public Health degree from study at the University of Connecticut. Seidner has earned numerous honors and awards throughout his career such as the Delta Omega National Honor Society, Secretary of State’s Public Service Award, ACOEM Research Award, AMA Physician Recognition Award, and the AAFP Family Practice Teaching Appreciation Certificate.

Vennela Thumula

PhD, Policy Analyst

Workers Compensation Research Institute

Dr. Vennela Thumula is a policy analyst at Workers Compensation Research Institute whose research focuses on pharmaceutical use in the workers’ compensation system. She is the author of several studies evaluating prescribing patterns of opioids, drug formularies and physician dispensing. She is conducting research examining the self-reported outcomes of injured workers, including recovery of health and functioning, speed and sustainability of return to work, and access to care. Thumula received her doctorate from the University of Mississippi School of Pharmacy.

Dunwoody

Thursday, April 5, 2018

2018-04-05

Project Warm Hand Off: From Rescue to Treatment

10:00 AM - 11:15 AM

10:00 AM

11:15 AM

Moderator: Michael Barnes, JD, Chairman, Center for Lawful Access and Abuse Deterrence, and Member, National Rx Drug Abuse & Heroin Summit Advisory Board CE Certified By: AMA,AAFP,ACPE,ANCC,APA,NAADAC,NASW,NBCC To address the significant need to connect patients to treatment following an opioid overdose or crisis, Illinois awarded a grant through 21st Century Cures Act funds to the nonprofit Gateway Foundation — the state’s largest provider of substance use disorder treatment services. The foundation partnered with four hospitals in the Chicago area to create Project Warm Hand Off. Based on an SBIRT (Screening Brief Intervention and Referral to Treatment) model, the project aims to identify persons struggling with opioid use disorder and connect them directly to treatment from the emergency department. For patients who initially decline assistance, a recovery coach continues to follow up. The project collects data on participant profiles, as well as measures outcomes using HEDIS (Healthcare Effectiveness Data and Information Set). In this session, presenters will share insights from the program development phase and the process of engaging hospital providers. As the project is in its first year, presenters will share stories of challenges and successes in moving patients through the process toward their first step toward recovery. Initial participant and outcome data will also be presented. Project Warm Hand Off is working toward sustainability that will allow the program and the impact to continue well beyond the grant funding period. UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO: - Identify the challenges of moving patients from hospitals to treatment settings. - Describe an SBIRT model and assessment tools. - Evaluate the potential for developing a program in their community.

Karen Wolownik Albert

MSW, LCSW, Executive Director

Gateway Foundation

Karen Wolownik Albert is the Executive Director of Gateway Foundation’s Lake County Treatment Services. She has more than 20 years of behavioral health experience and has worked in a variety of outpatient and residential settings throughout her career. Wolownik Albert earned her bachelor's degree and master's degree in social work from the University of Michigan, and she is a licensed clinical social worker in Illinois. She is an experienced trainer, presenting at local and national conferences on a wide array of topics. She is on the board of the Lake County Opioid Initiative, as well as a Co-Chair of the Treatment Committee, and a core member in the development of the county's law-assisted diversion program, A Way Out. Wolownik Albert is a member of the Lake County Underage Drinking and Drug Abuse Prevention Task Force, and she represented that organization at the national Community Anti-Drug Coalitions of America conference this past year. She is also on the Steering Committee and co-chairs the Treatment Committee for the Chicago Area Opioid Task Force. Additionally, Wolownik Albert is an adjunct professor at the College of Lake County.

Sally Thoren

CADC, Executive Director - Chicago

Gateway Foundation

Sally Thoren has dedicated her career to the substance use disorder treatment field. She holds a bachelor's degree in political science from Carleton College, and she studied law at DePaul University in Chicago. Thoren has served in many direct care roles during her career, and she now serves as the Executive Director for Gateway’s services in Chicago. Additionally, she manages relationships with many institutional funders in Illinois, including the Division of Alcoholism and Substance Abuse, HFS Medicaid and many local funders. Thoren notes how caring for those with substance use disorders has evolved over the past 35 years, from a fragmented, hierarchical “behavior modification” approach early in her career to our current person-centered, trauma-informed, medication-assisted, multidisciplinary approach. She has been a strident advocate for the field and client advocacy, earning her the Vince Bakeman Memorial Advocacy Award in 2010. In collaboration with the Medical Director, Thoren introduced Suboxone and medication assisted treatment to her agency when it was first available. Later, she proposed and implemented training all direct care staff in the use of naloxone at Gateway, a first in Illinois.

International South

Thursday, April 5, 2018

2018-04-05

Break

10:30 AM - 10:50 AM

10:30 AM

10:50 AM

International South

Thursday, April 5, 2018

2018-04-05

Marijuana and Driving: A Deadly Combination

10:50 AM - 11:30 AM

10:50 AM

11:30 AM

Speaker: Dr. Marilyn Huestis Details TBA

Baker

Thursday, April 5, 2018

2018-04-05

Regional Roundtable Discussion: West (AK, AZ, CA, CO, HI, ID, MT, NV, NM, OK, OR, TX, UT, WA)

11:30 AM - 12:45 PM

11:30 AM

12:45 PM

Across the United States local communities have developed their own innovative strategies designed to combat the opioid epidemic. City and state governments, law enforcement, the treatment community and grassroots organizations have created programs that provide education, support, prevention and treatment for individuals and families impacted by opioid abuse and misuse. Learn what other communities and state agencies in your region are implementing by participating in one of the Regional Roundtable Discussions at the Summit. These highly interactive, moderated sessions will provide attendees the opportunity to share effective programs and their results. Roundtable participants will have the opportunity to: • Discuss strategies and best practices in establishing programs and partnerships that comprehensively reduce Rx misuse and abuse at the state and community level. • Identify state policies that could be implemented immediately to prevent overdoses and addiction-related fatalities. • Discuss resources and tools that can empower families to take action to engage loved ones in treatment. Northeast Regional Roundtable (CT, MA, ME, NH, NY, RI, VT) - Room: Piedmont (LL3) Mid-Atlantic Regional Roundtable (DC, DE, MD, NJ, PA, VA, WV) - Room: Hanover AB (LL2) Mid-South Regional Roundtable (AR, KY, LA, MO, MS, TN) - Room: Courtland (LL3) Southeast Regional Roundtable (AL, FL, GA, NC, SC) - Room: Hanover FG (LL2) Mid-West Regional Roundtable (IA, IL, IN, KS, MI, MN, ND, NE, OH, SD, WI) - Room: Dunwoody (LL3) West Regional Roundtable (AK, AZ, CA, CO, HI, ID, MT, NV, NM, OK, OR, TX, UT, WA) - Room: Baker (LL3)

Courtland

Thursday, April 5, 2018

2018-04-05

Regional Roundtable Discussion: Mid-South (AR, KY, LA, MO, MS, TN)

11:30 AM - 12:45 PM

11:30 AM

12:45 PM

Hanover FG

Thursday, April 5, 2018

2018-04-05

Regional Roundtable Discussion: Southeast (AL, FL, GA, NC, SC)

11:30 AM - 12:45 PM

11:30 AM

12:45 PM

Dunwoody

Thursday, April 5, 2018

2018-04-05

Regional Roundtable Discussion: Mid-West (IA, IL, IN, KS, MI, MN, ND, NE, OH, SD, WI)

11:30 AM - 12:45 PM

11:30 AM

12:45 PM

Hanover AB

Thursday, April 5, 2018

2018-04-05

Regional Roundtable Discussion: Mid-Atlantic (DC, DE, MD, NJ, PA, VA, WV)

11:30 AM - 12:45 PM

11:30 AM

12:45 PM

Piedmont

Thursday, April 5, 2018

2018-04-05

Regional Roundtable Discussion: Northeast (CT, MA, ME, NH, NY, RI, VT)

11:30 AM - 12:45 PM

11:30 AM

12:45 PM

International South

Thursday, April 5, 2018

2018-04-05

Marijuana and the Emergency Room

11:30 AM - 12:00 PM

11:30 AM

12:00 PM

Details TBA

Roneet Lev

MD, FACEP, Chief, Scripps Mercy Hospital San Diego

Scripps Mercy San Diego

Dr. Roneet Lev is the Chief of the emergency department at Scripps Mercy Hospital in San Diego. She is current president of IEPC, Independent Emergency Physicians Consortium, which represents over 30 emergency departments in California. She served as President of the California Chapter of the American College of Emergency Physicians. In October 2012, she established the San Diego and Imperial County Prescription Drug Abuse Medical Task Force with the goal of reducing deaths and mortality from prescription drugs. She became involved in medical issues from marijuana by her involvement in the opioid epidemic when patients came to the emergency department with cannabis-related problems that were treated with opioids. She published a consensus treatment guideline for cannabis hyperemesis syndrome and publicized the word "scromiting" that went viral. She uses data to drive change for improved prescribing habits. She is a passionate advocate for smart approaches to marijuana.

International South

Thursday, April 5, 2018

2018-04-05

PR and Messaging in a Changing Landscape

12:00 PM - 12:30 PM

12:00 PM

12:30 PM

This session will address the drug and marijuana issues we encounter today and how to get press and media coverage. Attendees will take away tips and encouragement from an experienced professional on how to generate great press outcomes with positive messages for both local and national events, with audience comments and questions encouraged.

Robert Weiner

President

Robert Weiner, Associates News; Solutions for Change Foundation

With 30 years of top level government and political experience, Robert Weiner created and heads a Washington, D.C. based company. Mr. Weiner is a White House Correspondent, radio-TV commentator, and oped columnist (750 op-eds in major papers). His illustrious career includes being a former spokesman to Clinton and Bush White Houses (Off. of National Drug Control Policy), 4-Star Gen. Barry McCaffrey, US House Government Operations Committee, and senior staff Congressmen John Conyers, Charles Rangel (House Select Narcotics Committee), Claude Pepper, Ed Koch, and Sen. Ted Kennedy. He generates wide news coverage and develops electronic and print media for issue, political and private sector clients. Weiner consults with media on news-making issues, including aging/social security, drug policy, government operations, sports policy, national security, environment, election reform and other subjects in which he and his associates have expertise. Appearances and coverage include CNN "Crossfire," ABC "Politically Incorrect," "Today," "Good Morning America," Penn and Teller, Wall Street Journal, Washington Post, New York Times, TV Guide, AP, and network radio (including regular Radio America panelist). Recent op-eds appeared in Washington Post, New York Times, Miami Herald, Atlanta Constitution, Baltimore Sun, Boston Globe, Christian Science Monitor, New York Post, New York Daily News, Washington Times, Cleveland Plain Dealer, Adweek, Orlando Sentinel, Sacramento Bee, San Jose Mercury News, Palm Beach Post, South Florida Sun Sentinel. Weiner has assembled an experienced team of experts in media execution and issue development and analysis. His company recreated following seven-year success in 1980-87; channeled skills into senior level appointed government service before and after.

International South

Thursday, April 5, 2018

2018-04-05

Lunch

12:30 PM - 1:30 PM

12:30 PM

1:30 PM

International South

Thursday, April 5, 2018

2018-04-05

From Marijuana to Heroin: One Parent's Story

1:30 PM - 1:45 PM

1:30 PM

1:45 PM

As we face the opioid crisis how concerned should we be about marijuana? My 17-year old son, Justin, died in 2008 from a heroin overdose. I believe if it weren't for marijuana, Justin would still be with us today. Justin was an unlikely victim -- an excellent student athlete and extremely talented songwriter and musician who was on his way to completing a professionally recorded album of original songs when he died. Justin had a normal and healthy life in a loving family who provided him all the opportunities possible to pursue his passions. If you think having all these benefits would make a young person immune from the perils of substance abuse, you would be wrong. Justin's drug use began when he started smoking marijuana with some of his friends at age 14. When we found out, we employed all the resources available to make him stop. We thought we had won the war, but when he was a junior in high school we discovered he had been self-medicating with opioid painkillers. A stint in rehab brought great hope, until he spent the day with people we didn't know the Sunday before his first full week as a high school senior. After snorting heroin somewhere along the way, he never woke up on Monday morning. For Justin, we believe marijuana was a gateway to his use of heroin. I have since dedicated my life to tell Justin's story to young people, to inspire them to take better care of themselves and watch out for their friends. We must take marijuana very seriously. At the very least it causes damage to a young person's brain. And for some, like our son Justin, it can be a gateway to dangerous drugs and even lead to death from a heroin overdose.

Jeffrey Veatch

Author, Activist, Advocate

International South

Thursday, April 5, 2018

2018-04-05

Panel: Colorado's Commercialization Effects

1:45 PM - 3:00 PM

1:45 PM

3:00 PM

Justin Luke Riley, Luke Niforatos and Ben Cort will speak on Colorado's commercialization effects from first-hand experiences while living there. These "day-in-the-life" stories will culminate in how listeners can join the Marijuana Accountability Action Network to fearlessly investigate, expose, challenge and hold accountable the marijuana industry.

Ben Cort

Author, Consultant

Ben Cort, a person in recovery, left a position as a human resource director for an S&P 500 firm to help start the Colorado nonprofit Phoenix Multisport. He then joined the drug policy conversation at the national level in 2012 to craft an awareness campaign and was appointed to the board of directors of Project SAM (Smart Approaches to Marijuana) and NALGAP (the National Association of Lesbian, Gay, and Transgender Treatment Providers and their Allies). A frequent speaker, Cort’s first book, “Weed, Inc.: The Truth About the Pot Lobby, THC, and the Commercial Marijuana Industry,” was released in September 2017. He moved on from his position with the University of Colorado Hospital in 2017 to focus on marijuana education and addiction consulting services.

Luke Niforatos

Chief of Staff

Smart Approaches to Marijuana (SAM)

Luke Niforatos is the Chief of Staff and Senior Policy Advisor at SAM. Prior to SAM, he spent his career working in nonprofit community healthcare (Centura Health, Metro Community Provider Network), managing teams driving over $30 million in revenue. He also built two digital health companies (DocBuddy, Niforatos Solutions). Having lived in Colorado during legalization, he has seen first-hand the disastrous effects of marijuana. This experience inspired him to work for a smart marijuana policy free of commercialization and normalization.

Justin Luke Riley

EMBA, Founder

Marijuana Accountability Coalition

Justin Luke Riley serves as CEO of Young People in Recovery (YPR) and also leads the Marijuana Accountability Coalition, a SAM affiliate in Colorado. YPR envisions a world where everyone can access the necessary tools to recover from substance use disorder and associated high-risk behaviors. Riley is 29 years-old and has been in long-term recovery from a substance use disorder since 2007. He graduated cum laude from the Honors & Leadership Program at the University of Colorado at Denver in 2013 and recently completed his Executive MBA at the University of Colorado. He is a former organizational development consultant and a youth and community engagement pastor in Denver; former secretary of the board of Faces & Voices of Recovery in Washington, DC; and past president of the board of Advocates for Recovery in Denver. He is also a White House Champion of Change award recipient. Most recently, Riley was featured as one of the four Social Entrepreneurs Advancing The Nationwide Recovery Movement in Forbes.

International South

Thursday, April 5, 2018

2018-04-05

Break

3:00 PM - 3:15 PM

3:00 PM

3:15 PM

International South

Thursday, April 5, 2018

2018-04-05

Panel: From Victims to Advocates: Leading the Way as Change Agents

3:15 PM - 4:00 PM

3:15 PM

4:00 PM

Engaging people whose lives have been impacted by marijuana is delicate business! Our panelists have been called to turn their grief into hope and their hope into action. They have suffered unimaginable pain as a result of something that current social norms treat as benign; a substance that is being normalized and glorified; a product that is marketed as though it were a health food. Our panelists are speaking out to advocate for change. They will share their journey with you. They will describe how their stories have helped influence policy-based solutions, change communities and save lives. Attendees will gain tools they can employ in their own communities as effective change agents.

Sally Schindel

Activist/Advocate

MomsStrong.org

Retired since 2008, living in Prescott, Arizona since 2002, Sally Schindel was a self-employed financial advisor, with CFP certification. Her bachelor's degree in accounting is from Western Illinois University in 1972. Schindel's passion now is volunteering with organizations that are making a difference in the lives of young people and their education. She is a long term member of P.E.O., supporting women's education, and a volunteer with MATFORCE in Prescott, working toward a brighter future by building a healthier community, striving to eliminate substance abuse and its effects. Schindel serves as the headquarters of MomsStrong.org in Arizona, a group of Moms unmasking the marijuana charade. She also volunteers with CAALM.info, a national organization dedicated to providing the latest information on the harms of marijuana to individuals and our country and the Marijuana Victims Alliance, a project of CAALM. Schindel is the proud mother of two. She calls her daughter, "the light of my life." Her son, Andy, died in 2014. Andy's death is linked to marijuana addiction. He left a powerful message that Sally wants all to know. Andy said, "Marijuana killed my soul + ruined my brain." Sally says: "I am now working with Andy, in his memory, urging young people to not risk using marijuana or other drugs. Marijuana is not harmless. I hope Andy's message will help everyone 'Think Again' before assuming the drug marijuana is harmless."

Aubree Adams

Activist/Advocate

MomsStrong.org

Aubree Adams is a Colorado mom. Her son was exposed to marijuana and marijuana edibles in the 8th grade, soon after Colorado legalized and commercialized marijuana in 2014. He had access to these products at school and at his friends' homes. Unfortunately, he started to self-harm, and then experienced a psychotic break during his freshman year in high school, during which he tried to kill himself. After two hospitalizations, her son admitted to her that he was "dabbing" -- smoking a high THC resin heated with a butane torch. Dabs are made and sold legally by the commercialized marijuana industry. He said, "I was dabbing and it made me feel crazy so I was trying to quit, it's like crack weed." Her son continued a cycle of addiction and mental illness for the next couple of years, and even progressed to other drugs like meth and heroin. He is now in recovery, and admits marijuana almost killed him and was his gateway to other drugs. Aubree feels her son survived his suicide attempt for a reason. She spends a lot of time educating and raising awareness of the harms of marijuana. She speaks out against legalizing marijuana. She feels health and safety is more important than someone's freedom to be impaired. She also objects to an industry that makes money off the addiction and destruction of others. She is saddened that the harmful effects of marijuana are now being minimized. She wants people to know that marijuana alone can be deadly and legalizing marijuana only enhances the war on drugs and the addiction rate. Colorado's suicide rate is nearly 50% higher than that of the nation as a whole and is increasing at double the national rate of increase. Marijuana use increases the risk for suicide by seven fold.

Darryl Rodgers

Author

A Life Half Lived

At the age of 19, Darryl Rodgers began a career as a corporate pilot. He served as a medic in the Army National Guard and later became a copilot/gunner on the AH-64 Apache attack helicopter. He has owned several small businesses and had the most fun running an outdoor summer day camp for boys. Rodgers also worked with at-risk boys through a nonprofit program that he started. Darryl has been married to his wife, Kim, for 26 years. They are the proud parents of two boys, Justin and Chase. Unfortunately, their oldest son, Chase, was killed in a tragic car wreck in 2014. Rodgers wrote about his son, Chase, in his first book, "A Life Half Lived."

Dana Stevens

Coordinator

Smart Approaches to Marijuana

Dana Stevens is responsible for SAM's High Means DUI initiative. She has been a public health and safety advocate most of her adult life! She cut her policy chops serving as a volunteer for the 9th District PTA (San Diego & Imperial Counties) as Vice President of Community Concerns and then Vice President of Public Health. She also served on the state PTA Legislative Committee, where she learned to work state legislation. Volunteer policy work led to professional campaign initiatives, including the Campaign to Stop Gun Violence (including the assault weapons ban, an initiative to eliminate Saturday Night Specials and to prohibit look-a-like toy guns). In 1994, Stevens ran the San Diego County campaign organization in opposition to big tobacco's Prop 188 (to roll back California's progressive tobacco-free workplace laws). In spite of being outspent (20/1) the NO on 188 campaign trounced big tobacco with 74% of the vote. Her work to reduce binge and underage drinking in Mexico (where the drinking age is 18) was featured on CBS News programs 60 Minutes and 48-Hours, as well as the Journal of the American Medical Association. As chair of the Committee on Alcohol, Tobacco, and Other Drugs for Palomar Health, California's largest public hospital district, she led the county's fist initiative to address Rx drug abuse prevention known as Prescription for Disaster. The work was recognized with both the Gold and Silver Health Communicators Awards for Advocacy. Stevens was awarded their CommUNITY Health Hero Award for leadership in substance abuse prevention. She is the Executive Director of Community Action, Service & Advocacy (CASA), where she has successfully developed two Drug-Free Communities support programs and continues to provide technical assistance to these rural and suburban coalitions. In addition, under CASA's STOP Act grant (the Surgeon General's initiative to prevent underage & binge drinking) she led a local effort to pass San Diego County's first (and only) Deemed Approved ordinance -- a land-use regulation to reign in problematic alcohol outlets and utilize a Conditional Use Permit process for all new alcohol licensees. CASA was awarded San Diego County's Public Health Champion for 2016.

International South

Thursday, April 5, 2018

2018-04-05

States to Watch in 2018

4:00 PM - 4:15 PM

4:00 PM

4:15 PM

The States to watch in 2018 are crucial because they stretch across the Midwest and the East Coast: Illinois, New Jersey, Vermont, Delaware and Michigan. These states are becoming the next marijuana battlegrounds in the U.S. We will take a deep dive into why they have become targets and how we can combat legalization.

Mervyn L. Jones II

Director, State and Local Government Affairs

Smart Approaches to Marijuana

Prior to SAM, Mervyn Jones was a Partner at Pine Street Strategies, where he helped clients successfully navigate the legislative and regulatory landscape across the federal and state government. He strives to build strategic relationships with stakeholders and clients, so they may secure critical investments and help educate decision makers. Jones recently served as Manager of Government Affairs and Political Advocacy at the National Restaurant Association, where he lobbied the House and Senate on issues of labor, tech, agriculture, healthcare, finance, sustainability and tax. Prior to leaving the Hill, he served as Special Assistant to Congressmen Tim Ryan and Vice Chair Congressman Joseph Crowley. He was responsible for monitoring federal policy, interacting with state and local government stakeholders and briefing lawmakers and their staff on Congressional and Administration initiatives and priorities. He also served as the liaison to the Congressional Progressive Caucus, Congressional Hispanic Caucus, Congressional Alaskan Pacific Asian Caucus and has strong connections to the Congressional Black Caucus.

International South

Thursday, April 5, 2018

2018-04-05

Parental/Guardian Marijuana Use as a Threat to Children

4:15 PM - 5:00 PM

4:15 PM

5:00 PM

Parents Opposed to Pot has been tracking cases of child abuse deaths related to parental/guardian marijuana use since 2012. The results are astounding - 105 deaths over a five-year period. (These deaths are not from scientific tracking, but the stories we found through social media sharing.) Marijuana does not make people mellow, as the industry would have you believe. The session will present the problem and why marijuana is a risk, as compared to other forms of substance abuse. The session will touch on the subject of pregnant mothers using and the many reasons for concern, and conclude that not addressing the issue is great cause for concern.

Julie Schauer

Founder

Parents Opposed to Pot

Julie Schauer had been teaching college art appreciation and art history classes for a long time before running into marijuana lobbyists recruiting students. Otherwise, the issue of legislation would not have been on her radar. In 2014, realizing how pervasive the false messages sent to youth, she started the group Parents Opposed to Pot, with the intent of using social media to send messages to parents who could counter the force of marijuana advocacy.

International South

Thursday, April 5, 2018

2018-04-05

Closing Remarks

5:00 PM - 5:30 PM

5:00 PM

5:30 PM

Kevin Sabet

President and CEO

Smart Approaches to Marijuana (SAM)

2018 Agenda